ANNUAL REPORT

FY 2020 — Annual report

FY 2020PDF · 162 pages26.2 MB


-- 1 of 162 --

FINANCIAL OPERATING HIGHLIGHTS
(dollars in millions except per share data and number of associates)
* Long-Term Debt ($1,1 for  and $1,1 for 1) plus Notes Payable
and Current Portion of Long-Term Debt ($11 for  and $1 for 1)
All financial data set forth in this annual report relates solely to continuing
operations unless otherwise indicated.
2020 	2019
Sales 	$ , 	$ 	1,911
Operating Profit 	$ 	,1 	$ 	,
Net Earnings 	$ 	, 	$ 	,
Net Earnings Per Common Share
(diluted) $ 	. 	$ 	.
Operating Cash Flow 	$ 	,1 	$ 	,
Investing Cash Flow 	$ (1,) 	$ 	(1,1)
Financing Cash Flow 	$ 	1, 	$ 	1,8
Capital Expenditures 	$ 	(1) 	$ 	()
Capital Disposals 	$ 	 	$ 	1
Free Cash Flow
(Operating Cash Flow less Capital
Expenditures plus Capital Disposals)
$ 	, 	$ 	,
Number of Associates 	, 	,
Total Assets 	$ 	,11 	$ 	,8
Total Debt * 	$ 	1, 	$ 	1,
Stockholders’ Equity 	$ 	, 	$ 	,
Total Capitalization
(Total Debt plus Stockholders’ Equity) $ 	,1 	$ 	,11

-- 2 of 162 --

LIFE SCIENCES
$
10.6B
• 70% Recurring
• 30% Nonrecurring
• 37% North America
• 28% Western Europe
• 28% High-Growth Markets
• 7% Other Developed Markets
DIAGNOSTICS
$
7.4B
• 83% Recurring
• 17% Nonrecurring
• 43% North America
• 19% Western Europe
• 33% High-Growth Markets
• 5% Other Developed Markets
ENVIRONMENTAL & APPLIED SOLUTIONS
$
4.3B
• 57% Recurring
• 43% Nonrecurring
• 45% North America
• 23% Western Europe
• 29% High-Growth Markets
• 3% Other Developed Markets
MIX 	GEO
MIX 	GEO
MIX 	GEO
Segment Revenues
All pie charts represent total 2020 revenue.

-- 3 of 162 --

RAINER M. BLAIR
President and Chief Executive Officer

-- 4 of 162 --

2020 was a year that will undoubtedly be etched into our
collective memory. The COVID-19 pandemic changed our lives
and businesses, suddenly and substantially. We had to invent
new ways to support each other and serve our customers,
while safeguarding our associates’ health and safety.
Fortunately, adaptability is deeply ingrained in our culture
at Danaher and as I look back on , I am most struck by
our associates’ resilience and dedication. Since the onset of
the pandemic, our team has met the challenges presented
and turned them into impactful opportunities to help our
customers and the global community. Powered by the
Danaher Business System (DBS) and unified by our Shared
Purpose, Helping Realize Life’s Potential, we have worked
hard to navigate these unprecedented times from a position
of strength.
DEAR
SHAREHOLDERS,

-- 5 of 162 --

It is not lost on us that our financial performance
in 2020 was, in part, driven by our work to tackle a
health crisis that has had a devastating impact on
so many around the world. That said, we are proud of
our ability to continue supporting customers across
all our businesses and the global community in the
fight against COVID-19.
While 2020 was certainly a challenging year for our
teams and businesses, it was also a pivotal year for
Danaher in our pursuit to become a better, stronger
company. We closed the largest acquisition in our
history—General Electric’s Biopharma business,
now known as Cytiva—which reinforces our leading
position in bioprocessing. Our strong financial perfor-
mance enabled us to accelerate growth initiatives
across our businesses, which we believe contributed
to share gains in many of our end-markets. And in the
spirit of continuous improvement, we made signifi-
cant progress toward our sustainability goals in 2020.
Through all these efforts, we solidified our position
as a global science and technology leader, and we
are heading into 2021 as a stronger company with an
even brighter future.
I am pleased to share some of our more significant
achievements in 2020.
A Critical Role in the
Fight Against COVID-19
We are proud to support frontline healthcare providers
with much-needed diagnostic testing capabilities,
and to support the scientific community’s accelerated
pursuit of new vaccines and treatments for the virus.
IDT was an early leader in the diagnostic testing effort
with their primer and probe kits, which provide a key
detection component in COVID-19 diagnostic tests.
Cepheid launched the first rapid molecular test for
COVID-19 and a rapid 4-in-1 test for COVID-19, Flu A,
Results
• Core revenue growth of 9.%
(including Cytiva).
• Gross profit margin of %.
• Adjusted diluted net earnings
per share (EPS) growth of %.
• Core operating profit margin
expansion of 1 bps.
• Free cash flow of $. billion,
marking the 9th consecutive
year in which our free cash flow
has exceeded net income.

-- 6 of 162 --

Flu B, and RSV from a single patient sample. Beckman
Coulter Diagnostics launched several new COVID-
related antibody tests and an automated antigen test
to help make higher-volume mass testing possible.
As of March 1, 2021, our operating companies have
collectively enabled or produced approximately 100
million COVID-19-related diagnostic tests.
Cytiva and Pall Biotech have contributed significantly
to the development and production of COVID-19
vaccines and treatments around the world, helping to
accelerate manufacturing on a massive scale under
intense time pressure. As of March 1, 2021, we are
involved in most vaccine and therapeutic projects
underway globally, including all vaccines in the U.S.
that have received FDA Emergency Use Authorization
or are in late-stage clinical trials. Our teams’ efforts
will continue to directly impact the lives of billions of
people around the world, as there is still much more
work to be done to tackle this global health crisis.
A Transformational
Acquisition
Our acquisition of Cytiva is one of several, strategic
portfolio moves we have made during the last few
years that accelerated our evolution into a high-
er-growth, innovation-driven company. With the
addition of Cytiva, we doubled our annual revenue in
the highly attractive biopharmaceutical end-market,
which now represents more than 50% of our Life
Sciences platform’s annual revenue. With a more
comprehensive offering across the entire biopro-
duction workflow, we are better able to support our
customers who are working to deliver more life-im-
proving drugs faster and at a lower cost—an endeavor
made even more urgent by today’s global health crisis.
The caliber of talent at Cytiva is the business’ greatest
asset. This highly innovative, passionate team has
been working to solve its customers’ toughest
biologics development and production challenges
for over thirty years. In 2020, Cytiva achieved more
than 25% core revenue growth and over $4 billion in
revenue. We could not be more pleased with Cytiva's
early results and are excited about what we can
achieve together over the next thirty years and beyond.
Investing for
Growth
Our strong margin performance and cash flow
generation in 2020 enabled us to strengthen our
competitive advantage through high-impact growth
investments across Danaher. We expanded produc-
tion capacity at Cepheid, Cytiva and Pall to support
increasing demand for COVID-related testing and
treatments, while paving the way for sustainable
long-term growth.
Ongoing organic investments in research and
development came to fruition in 2020 with several
breakthrough product launches across our portfolio.
SCIEX’s new 7500 System is the most sensitive Triple
Quad mass spectrometer on the market, helping
scientists detect and quantify analytes at previously
undetectable levels. The Videojet 1280 Continuous
Inkjet printer was designed with simplicity and relia-
bility in mind, providing customers with a high-quality
printer that is easy to use and minimizes disruptive
downtime. And Leica Biosystems’ next-generation
digital pathology scanner, the Aperio GT 450 DX,
enables pathologists to evaluate tissue samples
remotely without compromising quality or consist-
ency—a crucial capability during the pandemic.
Inorganic investments are also a key component of
our growth strategy. Aquatic Informatics—a leading
water-focused software provider—joined our Water
Quality platform in 2020, bringing data analytics
solutions to improve customer workflow and cost
efficiencies. Since 2019, we have acquired ten

-- 7 of 162 --

businesses across all three of our segments, adding
complementary products and technologies to help us
solve our customers’ toughest challenges. Through
both organic and inorganic growth investments, we
continue to differentiate our offering and reinforce
our market leadership, while enhancing our growth
and earnings trajectory.
Committed to
Sustainability
Our pursuit of continuous improvement has always
been at the heart of everything we do. We strive to be
better every day, and the many challenges we faced in
2020 highlighted our overarching responsibility and
opportunity to do just that across our three pillars of
sustainability: The innovation that fuels advance-
ments across scientific disciplines, the people at
the heart of our teams and communities, and the
environment that sustains us.
I have already shared how our teams have innovated
to address some of the most pressing health and
safety challenges of our time. I am incredibly proud
of our fast and enterprising response to the COVID-19
crisis. Last year also highlighted the need for lead-
ership and action, particularly around our efforts
to foster a diverse and inclusive culture. In 2020 we
established two key diversity goals: to increase our
representation of women associates globally to 40%,
and People of Color among U.S. associates to 35% by
2025. Our intention is to better reflect the communi-
ties in which we live, work, and serve our customers;
and we believe that setting explicit goals provides
the transparency and accountability necessary to
drive meaningful change.
Across Danaher, we have long considered the
environmental impact of our products and opera-
tions—and we continually seek to improve on this
front. In 2020, we established five-year reduction
Environmental
Impact Goals
By , we pledge:
• 1% reduction in energy consumed*
compared to 19 levels
• 1% reduction in Scope 1 and 
greenhouse gas (GHG) emissions*
compared to 19 levels
• 1% reduction in the percentage
of non-hazardous/non-regulated
waste sent to landfills or incinerators
compared to 19 levels
* Normalized to annual revenue from continuing operations

-- 8 of 162 --

goals around our energy use, greenhouse gas emis-
sions, and waste generation. To help operationalize
these improvements, we have enhanced our DBS
toolkit with energy management and waste reduc-
tion resources. These are just a few examples of how
our deep commitment to continuous improvement
inspires actions that benefit the greater good, and
we will continue to prioritize measurable progress
across the many facets of sustainability.
A Future Full
of Potential
Reflecting on my first few months as CEO, my appre-
ciation for our exceptional team and portfolio has
deepened as I have had more opportunities to engage
with our businesses and leaders. I am inspired by
the considerable innovation happening across the
organization, by the caliber and depth of our talent,
and by our associates’ passion for their work and
commitment to continuous improvement. It is clear
the Danaher Business System is what drives us every
day—it’s our ultimate competitive advantage—and I
see it alive and well across the company. The powerful
combination of these factors certainly contributed
to making 2020 an exceptional and transformative
year for Danaher.
I am deeply honored and humbled that the Danaher
Board of Directors asked me to lead our team into the
future. I am also incredibly grateful for Tom Joyce’s
mentorship and friendship over the past decade of
working together. His strategic vision and leadership
as CEO created tremendous value for Danaher and
our shareholders, and an incredible foundation for
our next chapter. Across Danaher we will strive to
keep building an even better, stronger company and
to positively impact the world around us in mean-
ingful ways. We see tremendous opportunities to do
just that in 2021 and beyond, and I am excited about
what lies ahead for Danaher.
By investing in Danaher, you are investing in a future
full of potential. Thank you for being part of our team.
We look forward to rewarding your continued support
in the years to come.
RAINER M. BLAIR
President and Chief Executive Officer
Our pursuit of contin-
uous improvement has
always been at the heart
of everything we do at
Danaher. We will strive
to keep building an even
better, stronger com-
pany and to positively
impact the world around
us in meaningful ways.”

-- 9 of 162 --



-- 10 of 162 --

THANK YOU
This year has been unprecedented in so many ways. But
despite the many challenges we all encountered as a result
of the COVID-19 pandemic, our team faced those challenges
head-on and turned them into impactful opportunities to
help the global community. Thank you to all of our associ-
ates around the world for everything you do in support of our
customers, our shareholders and one another. Together, we
are Helping Realize Life’s Potential.

-- 11 of 162 --



-- 12 of 162 --

Every day, scientists around the world are working to under-
stand the causes of disease, develop new therapies and
vaccines, and test new drugs. Our Life Sciences businesses
make this leading-edge scientific research possible. Our
capabilities extend beyond research to power the creation
of biopharmaceuticals, cell and gene therapies and more to
advance patient health and improve treatment outcomes.
LIFE SCIENCES

-- 13 of 162 --



-- 14 of 162 --

DIAGNOSTICS
Our Diagnostics businesses provide clinical instrumentation,
test consumables and software to healthcare professionals
in order to safeguard patient health and improve diagnostic
confidence wherever health care happens—from local clin-
ics and family physician’s offices to leading trauma, cancer
and critical care centers. Our instrumentation, data access
solutions and management systems improve efficiency and
automate workflows in laboratories, helping healthcare pro-
fessionals provide better patient care.

-- 15 of 162 --



-- 16 of 162 --

WATER QUALITY
As the world’s population increases, so too does the demand
for our most precious resource: water. Our Water Quality
businesses help protect the global water supply and ensure
environmental stewardship. We deliver precision instru-
mentation, advanced purification technology, software and
treatment solutions to help analyze, disinfect and manage the
world’s water across environmental, municipal, commercial
and industrial applications.
ENVIRONMENTAL & APPLIED SOLUTIONS

-- 17 of 162 --



-- 18 of 162 --

Every day, we trust packaging to ensure freshness, consisten-
cy and authenticity of products around the world. Our Product
Identification businesses provide color management, pack-
aging design and marking and coding technologies used to
help protect the world’s food supply, secure pharmaceutical
packaging and track consumer goods. This is complemented
by our comprehensive digital tools and software solutions
that help our customers bring more products to market faster.
PRODUCT
IDENTIFICATION
ENVIRONMENTAL & APPLIED SOLUTIONS

-- 19 of 162 --

FORM 10K

-- 20 of 162 --

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended December 31, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
Commission File Number: 001-08089
DANAHER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 59-1995548
(State of Incorporation) (I.R.S. Employer Identification Number)
2200 Pennsylvania Avenue, N.W., Suite 800W 20037-1701
Washington, DC
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: 202-828-0850
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value DHR New York Stock Exchange
4.75% Mandatory Convertible Preferred Stock,
Series A, without par value DHR.PRA New York Stock Exchange
5.00% Mandatory Convertible Preferred Stock,
Series B, without par value DHR.PRB New York Stock Exchange
Floating Rate Senior Notes due 2022 DHR/22A New York Stock Exchange
1.700% Senior Notes due 2024 DHR 24 New York Stock Exchange
2.500% Senior Notes due 2025 DHR/25 New York Stock Exchange
0.200% Senior Notes due 2026 DHR/26 New York Stock Exchange
2.100% Senior Notes due 2026 DHR 26 New York Stock Exchange
1.200% Senior Notes due 2027 DHR/27 New York Stock Exchange
0.450% Senior Notes due 2028 DHR/28 New York Stock Exchange
2.500% Senior Notes due 2030 DHR 30 New York Stock Exchange
0.750% Senior Notes due 2031 DHR/31 New York Stock Exchange
1.350% Senior Notes due 2039 DHR/39 New York Stock Exchange
1.800% Senior Notes due 2049 DHR/49 New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
NONE
(Title of Class)

-- 21 of 162 --

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☒
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to
file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☒ Accelerated Filer ☐
Non-accelerated Filer ☐ Smaller Reporting company ☐
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the
effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.
7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
As of February 5, 2021, the number of shares of Registrant’s common stock outstanding was 712,204,198. The aggregate
market value of common stock held by non-affiliates of the Registrant on July 3, 2020 was $113.2 billion, based upon the
closing price of the Registrant’s common stock as quoted on the New York Stock Exchange on such date.
____________________________________
DOCUMENTS INCORPORATED BY REFERENCE
Part III incorporates certain information by reference from the Registrant’s proxy statement for its 2021 annual meeting of
shareholders to be filed pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end. With the exception of
the sections of the 2021 Proxy Statement specifically incorporated herein by reference, the 2021 Proxy Statement is not deemed
to be filed as part of this Form 10-K.

-- 22 of 162 --

In this Annual Report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its
consolidated subsidiaries or the consolidated subsidiaries of Danaher Corporation, as the context requires. Unless otherwise
indicated, all financial data in this Annual Report refer to continuing operations only.
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this Annual Report, in other documents we file with or furnish to
the Securities and Exchange Commission (“SEC”), in our press releases, webcasts, conference calls, materials delivered to
shareholders and other communications, are “forward-looking statements” within the meaning of the U.S. federal securities
laws. All statements other than historical factual information are forward-looking statements, including without limitation
statements regarding: projections of revenue, expenses, profit, profit margins, pricing, tax rates, tax provisions, cash flows,
pension and benefit obligations and funding requirements, our liquidity position or other projected financial measures;
management’s plans and strategies for future operations, including statements relating to anticipated operating performance,
cost reductions, restructuring activities, new product and service developments, competitive strengths or market position,
acquisitions and the integration thereof, divestitures, spin-offs, split-offs or other distributions, strategic opportunities, securities
offerings, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets we sell into;
new or modified laws, regulations and accounting pronouncements; future regulatory approvals and the timing and
conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future
foreign currency exchange rates and fluctuations in those rates; the potential or anticipated direct or indirect impact of
COVID-19 on our business, results of operations and/or financial condition; general economic and capital markets conditions;
the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that
address events or developments that Danaher intends or believes will or may occur in the future. Terminology such as
“believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,”
“potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking
statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based
on assumptions and assessments made by our management in light of their experience and perceptions of historical trends,
current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking
statements are subject to a number of risks and uncertainties, including but not limited to the risks and uncertainties set forth
below and under “Item 1A. Risk Factors” in this Annual Report.
Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results,
developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place
undue reliance on any such forward-looking statements. Forward-looking statements speak only as of the date of the report,
document, press release, webcast, call, materials or other communication in which they are made. Except to the extent required
by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of
new information, future events and developments or otherwise.
Investment in our securities involves risk and uncertainty and you should carefully consider all information in this Annual
Report on Form 10-K prior to making an investment decision regarding our securities. Below is a summary of material risks
and uncertainties we face, which are discussed more fully in “Item 1A. Risk Factors”:
Business and Strategic Risks
• The COVID-19 pandemic has adversely impacted, and continues to pose risks to, certain elements of our business and
our financial statements, the nature and extent of which are highly uncertain and unpredictable.
• Conditions in the global economy, the particular markets we serve and the financial markets can adversely affect our
business and financial statements.
• We face intense competition and if we are unable to compete effectively, we may experience decreased demand and
decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
• Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and
enhanced products and services based on technological innovation. Our growth can also suffer if the markets into
which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
• The health care industry and related industries that we serve have undergone, and are in the process of undergoing,
significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our
business and financial statements.
1

-- 23 of 162 --

• International economic, political, legal, compliance, social and business factors (including without limitation the
impact of the United Kingdom’s departure from the European Union) can negatively affect our business and financial
statements.
• Collaborative partners and other third-parties we rely on for development, supply and marketing of certain products,
potential products and technologies could fail to perform sufficiently.
Acquisitions, Divestitures and Investment Risks
• Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate
investments that support our long-term strategy, could negatively impact our growth rate and stock price. In addition,
our acquisition of businesses, investments, joint ventures and other strategic relationships could negatively impact our
business and financial statements and our indemnification rights may not fully protect us from liabilities we may incur
related to such transactions.
• Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that
we or our predecessors have disposed could adversely affect our business and financial statements. For example, we
could incur significant liability if any of the split-off or spin-off transactions we have consummated is determined to be
a taxable transaction or otherwise pursuant to our indemnification obligations with respect to such transactions.
Operational Risks
• Significant disruptions in, or breaches in security of, our information technology systems or data; other losses or
disruptions due to catastrophe; and labor disputes can all adversely affect our business and financial statements.
• Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof,
can adversely affect our business and financial statements.
• If we encounter problems manufacturing products, fail to adjust our manufacturing capacity or related purchases to
reflect changing conditions, or suffer disruptions due to sole or limited sources of supply, our business and financial
statements may suffer. Adverse changes with respect to key distributors and other channel partners can also adversely
affect our business and financial statements.
• Our restructuring actions can have long-term adverse effects on our business and financial statements.
Intellectual Property Risks
• Any inability to adequately protect or avoid third party infringement of our intellectual property, and third party claims
that we are infringing their intellectual property rights, can adversely affect our business and financial statements.
Financial and Tax Risks
• Our outstanding debt has increased significantly as a result of the acquisition of Cytiva, and we may incur additional
debt in the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and
negatively impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could
adversely affect our business and financial statements.
• Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in our tax
rates (including as a result of changes in tax laws) or income tax liabilities/assessments, the outcome of tax audits,
financial market risks related to our defined benefit pension plans, recognition of impairment charges for our goodwill
or other intangible assets, and fluctuations in the cost and availability of commodities.
Legal, Regulatory, Compliance and Reputational Risks
• Our businesses are subject to extensive regulation (including without limitation regulations applicable to the healthcare
industry). Failure to comply with those regulations (including without limitation by our employees, agents or business
partners) or significant developments or changes in U.S. laws or policies can adversely affect our business and
financial statements. Changes in governmental regulations can also reduce demand for our products or services or
increase our expenses.
• With respect to the regulated medical devices we offer, certain modifications to such products may require new 510(k)
clearances or other marketing authorizations and may require us to recall or cease marketing such products; off-label
marketing of such products could result in substantial penalties; and clinical trials we conduct with respect to such
2

-- 24 of 162 --

products or potential products may have results that are unexpected or are perceived unfavorably by the market, all of
which could adversely affect our business and financial statements.
• We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the
course of our business that can adversely affect our business and financial statements.
• Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and
violations that could adversely affect our business and financial statements.
PART I
ITEM 1. BUSINESS
General
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and
improving quality of life around the world. Danaher is comprised of more than 20 operating companies with leadership
positions in the life sciences, diagnostics, environmental and applied sectors, organized under three segments (Life Sciences;
Diagnostics; and Environmental & Applied Solutions). United by the DANAHER BUSINESS SYSTEM (“DBS”), our
businesses are also typically characterized by a high level of products and services that are sold on a recurring basis, primarily
through a direct sales model and to a geographically diverse customer base. Our business’ research and development,
manufacturing, sales, distribution, service and administrative facilities are located in more than 60 countries.
Danaher strives to create shareholder value primarily through three strategic priorities:
• strengthening our competitive advantage through consistent application of the DBS tools;
• enhancing our portfolio in attractive science and technology markets through strategic capital allocation; and
• consistently attracting and retaining exceptional talent.
Danaher measures its progress against these strategic priorities over the long-term based primarily on financial metrics relating
to revenue growth, profitability, cash flow and capital returns, as well as certain non-financial metrics. To further the strategic
objectives set forth above, the Company also acquires businesses and makes investments that either complement its existing
business portfolio or expand its portfolio into new and attractive markets. Given the rapid pace of technological development
and the specialized expertise typical of Danaher’s served markets, acquisitions, strategic alliances and investments provide the
Company access to important new technologies and domain expertise. Danaher believes there are many acquisition and
investment opportunities available within its targeted markets. The extent to which we identify, consummate and effectively
integrate appropriate acquisitions and consummate appropriate investments affects our overall growth and operating results.
Danaher also continually assesses the strategic fit of its existing businesses and may dispose of businesses that are deemed not
to fit with its strategic plan.
DBS is not only the set of business processes and tools our operating companies use on a daily basis, but is more broadly our
culture. As reflected in our logo, DBS features five fundamental core values:
1. The Best Team Wins
2. Customers Talk, We Listen
3. Kaizen is our Way of Life
4. Innovation Defines our Future
5. We Compete for Shareholders
3

-- 25 of 162 --

Underpinned by these five fundamental core values as well as our Shared Purpose – Helping Realize Life’s Potential, the DBS
tools are organized into three pillars that are designed to apply to every aspect of our business: Growth, Lean and Leadership.
The idea for Danaher originated in the early 1980’s when the Company’s founders, Steven M. and Mitchell P. Rales,
envisioned a business that would generate sustainable long-term value for customers, employees and shareholders. Through a
series of acquisitions and divestitures, Danaher has evolved over time from a more industrial-oriented company into the science
and technology innovator it is today. While the operating companies that make up Danaher have changed, DBS continues to be
the guiding philosophy for the Company.
Sales in 2020 by geographic destination (geographic destination refers to the geographic area where the final sale to the
Company’s unaffiliated customer is made) as a percentage of total 2020 sales were: North America, 40% (including 39% in the
United States); Western Europe, 24%; other developed markets, 6%; and high-growth markets, 30%. The Company defines
high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic
product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception
of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-
growth markets.
LIFE SCIENCES
The Company’s Life Sciences segment offers a broad range of instruments and consumables that are primarily used by
customers to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the
causes of disease, identify new therapies, and test and manufacture new drugs and vaccines. Sales in 2020 for this segment by
geographic destination (as a percentage of total 2020 sales) were: North America, 37%; Western Europe, 28%; other developed
markets, 7%; and high-growth markets, 28%.
Danaher established the life sciences business in 2005 through the acquisition of Leica Microsystems and has expanded the
business through numerous subsequent acquisitions, including the acquisitions of AB Sciex and Molecular Devices in 2010,
Beckman Coulter in 2011, Pall in 2015, Phenomenex in 2016, IDT in 2018 and Cytiva in 2020. On March 31, 2020, the
Company acquired the Biopharma business of General Electric Company’s (“GE”) Life Sciences division, now known as
Cytiva, for a cash purchase price of approximately $20.7 billion (net of approximately $0.1 billion of acquired cash) and the
assumption of approximately $0.4 billion of pension liabilities (the “Cytiva Acquisition”). Cytiva is a leading provider of
instruments, consumables and software that support the research, discovery, process development and manufacturing
workflows of biopharmaceutical drugs. Cytiva is included in the Company’s Life Sciences segment results beginning in the
second quarter of 2020. The acquisition has provided and is expected to provide additional sales and earnings growth
opportunities for the Company’s Life Sciences segment by expanding the business’ geographic and product line diversity,
including new product and service offerings that complement the Company’s current biologics workflow solutions. As a
condition to obtaining certain regulatory approvals for the closing of the transaction, the Company was required to divest
4

-- 26 of 162 --

certain of its existing product lines in the Life Sciences segment that in the aggregate generated revenues of approximately $170
million in 2019.
The Life Sciences segment consists of the following businesses:
Bioprocess —The bioprocess business is a leading provider of technologies, consumables and services that advance and
accelerate the development and manufacture of vaccines, biologic drugs, and novel cell and gene therapies. The business offers
solutions that support its customers across the pharmaceutical and biopharmaceutical value chain, from the earliest stages of
drug discovery and research, to product and process development, clinical trials, therapy manufacturing and clinical use. The
business’ workflow solutions include process chromatography instruments and consumables, cell culture media, single-use
technologies, development instrumentation, lab filtration, and genomics consumables.
Filtration—The filtration, separation and purification technologies business is a leading provider of products used to remove
solid, liquid and gaseous contaminants from a variety of liquids and gases, primarily through the sale of filtration consumables
and to a lesser extent systems that incorporate filtration consumables and associated hardware. The business’ core materials
and technologies can be applied in many ways to solve complex fluid separation challenges, and are sold across a wide array of
applications in two primary business groups:
• Life Sciences. The business’ life sciences technologies facilitate the process of drug discovery, development,
regulatory validation and production and are sold to biopharmaceutical, food and beverage and medical customers. In
the biopharmaceutical area, the business sells a broad line of filtration and purification technologies, single use
bioreactors and associated accessories, hardware and engineered systems primarily to pharmaceutical and
biopharmaceutical companies for use in the development and commercialization of chemically synthesized and
biologically derived drugs, plasma and vaccines. Biotechnology drugs, plasma and biologically derived vaccines in
particular are filtration and purification intensive and represent a significant opportunity for growth for the business in
the biopharmaceutical area. The business also serves the filtration needs of the food and beverage markets, helping
customers ensure the quality and safety of their products while lowering operating costs and minimizing waste. In the
medical area, hospitals use the Company’s breathing circuit and intravenous filters and water filters to help control the
spread of infections.
• Industrial. Virtually all of the raw materials, process fluids and waste streams that are found in industry are candidates
for multiple stages of filtration, separation and purification. In addition, most of the machines used in complex
production processes require filtration to protect sensitive parts from degradation due to contamination. The business’
technologies enhance the quality and efficiency of manufacturing processes and prolong equipment life in applications
such as semiconductor equipment, airplanes, oil refineries, power generation turbines, petrochemical plants, municipal
water plants and mobile mining equipment. Within these segments, demand is driven by end-users and original
equipment manufacturers (“OEM”) seeking to improve product performance, increase production and efficiency,
reduce operating costs, extend the life of their equipment, conserve water and meet environmental regulations.
Cellular Analysis, Lab Automation and Centrifugation—The business offers workflow instruments and consumables that help
researchers analyze genomic, protein and cellular information. Key product areas include sample preparation equipment such
as centrifugation and capillary electrophoresis instrumentation and consumables; liquid handling automation instruments and
associated consumables; flow cytometry instrumentation and associated antibodies and reagents; and particle characterization
instrumentation. Researchers use these products to study biological function in the pursuit of basic research, as well as
therapeutic and diagnostic development. Typical users include pharmaceutical and biotechnology companies, universities,
medical schools and research institutions and in some cases industrial manufacturers.
Mass Spectrometry—The mass spectrometry business is a leading global provider of high-end mass spectrometers as well as
related consumable chromatography columns and sample preparation extraction products. Mass spectrometry is a technique for
identifying, analyzing and quantifying elements, chemical compounds and biological molecules, individually or in complex
mixtures. The mass spectrometers utilize various combinations of quadrupole, time-of-flight and ion trap technologies. The
business’ mass spectrometer systems and related products are used in numerous applications such as drug discovery and clinical
development of therapeutics as well as in basic research, clinical testing, food and beverage quality testing and environmental
testing. The business’ global services network provides implementation, validation, training and maintenance to support
customer installations around the world. Typical users of these mass spectrometry and related products include molecular
biologists, bioanalytical chemists, toxicologists and forensic scientists as well as quality assurance and quality control
technicians. The business also provides high-performance bioanalytical measurement systems, including microplate readers,
automated cellular screening products and associated reagents and imaging software. Typical users of these products include
biologists and chemists engaged in research and drug discovery, who use these products to determine electrical or chemical
activity in cell samples.
5

-- 27 of 162 --

Microscopy—The microscopy business is a leading global provider of professional microscopes designed to capture,
manipulate and preserve images and enhance the user’s visualization and analysis of microscopic structures. The Company’s
microscopy products include laser scanning (confocal) microscopes, compound microscopes and related equipment, surgical
and other stereo microscopes and specimen preparation products for electron microscopy. Typical users of these products
include research, medical and surgical professionals operating in research and pathology laboratories, academic settings and
surgical theaters.
Genomics Consumables—The genomics consumables business is a leading provider of custom nucleic acid products for the life
sciences industry, primarily through the manufacture of custom DNA and RNA oligonucleotides and gene fragments utilizing a
proprietary manufacturing ecosystem. The business has developed proprietary technologies for genomics applications such as
next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. The business also manufactures products
used in diagnostic tests for many forms of cancer, as well as inherited and infectious diseases. Typical users of these products
include professionals in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical
development.
Customers served by the Life Sciences segment select products based on a number of factors, including product quality and
reliability, the product’s capacity to enhance productivity, innovation (particularly productivity and sensitivity improvements),
product performance and ergonomics, access to a service and support network and the other factors described under “—
Competition.” The businesses in Danaher’s Life Sciences segment market their products and services under key brands
including BECKMAN COULTER, CYTIVA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL,
PHENOMENEX and SCIEX. Manufacturing facilities are located in North America, Europe, Asia and New Zealand. The
business sells to customers through direct sales personnel and independent distributors.
DIAGNOSTICS
The Company’s Diagnostics segment offers analytical instruments, reagents, consumables, software and services that hospitals,
physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Sales in 2020 for this segment by geographic destination (as a percentage of total 2020 sales) were: North America, 43%;
Western Europe, 19%; other developed markets, 5%; and high-growth markets, 33%.
Danaher established the diagnostics business in 2004 through the acquisition of Radiometer and expanded the business through
numerous subsequent acquisitions, including the acquisitions of Vision Systems in 2006, Beckman Coulter in 2011, Iris
International and Aperio Technologies in 2012, HemoCue in 2013, Devicor Medical Products in 2014, the clinical
microbiology business of Siemens Healthcare Diagnostics in 2015 and Cepheid in 2016. The Diagnostics segment consists of
the following businesses:
Core Lab Diagnostics—The core lab business is a leading manufacturer and marketer of biomedical testing instruments,
systems and related consumables that are used to evaluate and analyze samples made up of body fluids, cells and other
substances. The information generated is used to diagnose disease, monitor and guide treatment and therapy, assist in
managing chronic disease and assess patient status in hospital, outpatient and physicians’ office settings. The business offers
the following products.
• Chemistry systems use electrochemical detection and chemical reactions with patient samples to detect and quantify
substances of diagnostic interest in blood, urine and other body fluids. Commonly performed tests include glucose,
cholesterol, triglycerides, electrolytes, proteins and enzymes, as well as tests to detect urinary tract infections and
kidney and bladder disease.
• Immunoassay systems also detect and quantify biochemicals of diagnostic interest (such as proteins and hormones) in
body fluids, particularly in circumstances where more specialized diagnosis is required. Commonly performed
immunoassay tests assess thyroid function, screen and monitor for cancer and cardiac risk and provide important
information in fertility and reproductive testing.
• Hematology products are used for cellular analysis. The business’ hematology systems use principles of physics,
optics, electronics and chemistry to separate cells of diagnostic interest and then quantify and characterize them,
allowing clinicians to study formed elements in blood (such as red and white blood cells and platelets).
• Microbiology systems are used for the identification of bacteria and antibiotic susceptibility testing (ID/AST) from
human clinical samples, to detect and quantify bacteria related to microbial infections in urine, blood, and other body
fluids, and to detect infections such as urinary tract infections, pneumonia and wound infections. The business’
technology enables direct testing of clinical isolates to ensure reliable detection of resistance to antibiotics.
6

-- 28 of 162 --

• Automation systems reduce manual operation and associated cost and errors from the pre-analytical through post-
analytical stages including sample barcoding/information tracking, centrifugation, aliquoting, storage and conveyance.
These systems along with the analyzers described above are controlled through laboratory level software that enables
laboratory managers to monitor samples, results and lab efficiency.
Typical users of the segment’s core lab products include hospitals, physician’s offices, reference laboratories and
pharmaceutical clinical trial laboratories.
Molecular Diagnostics—The molecular diagnostics business is a leading provider of biomedical testing instruments, systems
and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-
clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based
testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both
laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems
which commonly test for health care-associated infections, respiratory disease, sexual health and virology.
Critical Care Diagnostics—The critical care diagnostics business is a leading worldwide provider of instruments, software and
related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical
parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity
glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating
rooms, hospital emergency rooms, physician’s office laboratories and blood banks.
Anatomical Pathology Diagnostics—The anatomical pathology diagnostics business is a leader in the anatomical pathology
industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a
pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments,
reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents
and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide
scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally and minimally
invasive, vacuum-assisted breast biopsy collection instruments. Typical users of these products include pathologists, lab
managers and researchers.
Customers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the
scope of tests that can be performed, the accuracy and speed of the product, the product’s ability to enhance productivity, ease
of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors
described under “—Competition.” The businesses in Danaher’s Diagnostics segment market their products and services under
key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and
RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to
customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.
ENVIRONMENTAL & APPLIED SOLUTIONS
The Company’s Environmental & Applied Solutions segment offers products and services that help protect important resources
and keep global food and water supplies safe. Sales in 2020 for this segment by geographic destination (as a percentage of total
2020 sales) were: North America, 45%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 29%.
The Company’s Environmental & Applied Solutions segment consists of the following businesses:
Water Quality—The Company’s water quality business is a leading provider of instrumentation, consumables, software,
services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground,
source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the
water quality sector in the late 1990’s through the acquisitions of Dr. Lange and Hach Company, and has enhanced the
geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of
Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:
• a wide range of analytical instruments, related consumables, software and services that detect and measure chemical,
physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean
water;
• chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling
water and wastewater applications as well as associated analytical services, primarily in applied and industrial end
markets; and
• ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial
and consumer water every day.
7

-- 29 of 162 --

Typical users of these products and services include professionals in municipal drinking water and wastewater treatment plants,
industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and
environmental operations. Customers in these industries choose suppliers based on a number of factors including the
customer’s existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness
of the supplier’s solutions offering, after-sales service and support and the other factors described under “—Competition.” The
Company’s water quality businesses provide products under a variety of key brands, including CHEMTREAT, HACH,
MCCROMETER, OTT HYDROMET, PALL WATER, SEA-BIRD and TROJAN TECHNOLOGIES. Manufacturing facilities
are primarily located in North America, Europe and Asia. Sales are made through the business’ direct sales personnel, e-
commerce, independent representatives and independent distributors.
Product Identification—The Company’s product identification business is a leading provider of instruments, software, services
and consumables for various color and appearance management, packaging design and quality management, packaging
converting, printing, marking, coding and traceability applications for consumer, pharmaceutical and industrial products.
Danaher entered the product identification market through the acquisition of Videojet in 2002, and has expanded the product
and geographic coverage through various subsequent acquisitions, including the acquisitions of Willett International Limited in
2003, Linx Printing Technologies PLC in 2005, EskoArtwork in 2011, X-Rite in 2012, Laetus in 2015, Advanced Vision
Technology Limited (“AVT”) in 2017 and Blue Software in 2018. The product identification business designs, manufactures
and markets:
• a variety of instruments, consumables and solutions used to give products unique identities by printing date, lot and bar
codes and other information on primary and secondary packaging, applying high-quality alphanumeric codes, logos
and graphics to a wide range of surfaces at a variety of production line speeds, angles and locations on a product or
package. Its vision inspection and track-and-trace solutions also help pharmaceutical and consumer goods
manufacturers safeguard the authenticity of their products through supply chains.
• software for online collaboration, three-dimensional virtualization, workflow automation, quality approvals and
prepress processes to manage structural design, artwork creation, color and product information for branded packaging
and marketing materials. Its packaging solutions help consumer goods manufacturers improve their business
processes, shorten time to market and reduce costs across internal departments and external suppliers.
• innovative color and appearance solutions through standards, software, measurement devices and related services. The
business’ expertise in inspiring, virtualizing, selecting, specifying, formulating and measuring color and appearance
helps users improve the quality and relevance of their products and reduce costs.
• flexographic computer-to-plate imaging equipment, solutions for print process control, press control and quality
assurance systems for the packaging, labels and commercial print industries. Its automation, print process and press
control solutions help packaging manufacturers reduce lead time and satisfy their customers’ demands for smaller,
more frequent print jobs.
Typical users of these products include manufacturers of consumer goods, pharmaceuticals, paints, plastics and textiles,
retailers, graphic design firms and packaging printers and converters. Customers in these industries choose suppliers based on a
number of factors, including domain experience, speed and accuracy, ease of connection to the internet and other software
systems, equipment uptime and reliable operation without interruption, ease of maintenance, service coverage and the other
factors described under “—Competition.” The product identification business’ products are primarily marketed under key
brands including AVT, ESKO, LAETUS, LINX, PANTONE, VIDEOJET and X-RITE. Manufacturing and software
development facilities are located in North America, Europe, Latin America and Asia. Sales are generally made through the
business’ direct sales personnel, independent distributors and e-commerce.
************************************
The following discussion includes information common to all of Danaher’s segments.
Materials
The Company’s manufacturing operations employ a wide variety of raw materials, including metallic-based components,
electronic components, chemistries, OEM products, plastics and other petroleum-based products. Prices of oil and gas also
affect the Company’s costs for freight and utilities. The Company purchases raw materials from a large number of independent
sources around the world. No single supplier is material, although for some components that require particular specifications or
regulatory or other qualifications there may be a single supplier or a limited number of suppliers that can readily provide such
components. The Company utilizes a number of techniques to address potential disruption in and other risks relating to its
supply chain, including in certain cases the use of safety stock, alternative materials and qualification of multiple supply
8

-- 30 of 162 --

sources. During 2020, the Company had no raw material shortages that had a material effect on the business. For a further
discussion of risks related to the materials and components required for the Company’s operations, refer to “Item 1A. Risk
Factors.”
Intellectual Property
The Company owns numerous patents, trademarks, copyrights, trade secrets and licenses to intellectual property owned by
others. Although in aggregate the Company’s intellectual property is important to its operations, the Company does not
consider any single patent, trademark, copyright, trade secret or license (or any related group of any such items) to be of
material importance to any segment or to the business as a whole. From time to time the Company engages in litigation to
protect its intellectual property rights. For a discussion of risks related to the Company’s intellectual property, refer to “Item
1A. Risk Factors.” All capitalized brands and product names throughout this document are trademarks owned by, or licensed
to, Danaher.
Competition
Although the Company’s businesses generally operate in highly competitive markets, the Company’s competitive position
cannot be determined accurately in the aggregate or by segment since none of its competitors offer all of the same product and
service lines or serve all of the same markets as the Company, or any of its segments, does. Because of the range of the
products and services the Company sells and the variety of markets it serves, the Company encounters a wide variety of
competitors, including well-established regional competitors, competitors who are more specialized than it is in particular
markets, as well as larger companies or divisions of larger companies with substantial sales, marketing, research and financial
capabilities. The Company is facing increased competition in a number of its served markets as a result of the entry of new,
large companies into certain markets, the entry of competitors based in low-cost manufacturing locations, and increasing
consolidation in particular markets. The number of competitors varies by product and service line. Management believes that
the Company has a market leadership position in many of the markets it serves. Key competitive factors vary among the
Company’s businesses and product and service lines, but include the specific factors noted above with respect to each particular
business and typically also include price, quality and safety, performance, delivery speed, application expertise, service and
support, technology and innovation, distribution network, breadth of product, service and software offerings and brand name
recognition. For a discussion of risks related to competition, refer to “Item 1A. Risk Factors.”
Human Capital
As of December 31, 2020, the Company had approximately 69,000 employees (whom we refer to as “associates”), of whom
approximately 24,000 were employed in the United States and approximately 45,000 were employed outside of the United
States. Approximately 67,000 of the Company’s total employees were full-time and 2,000 were part-time employees. Of the
United States employees, approximately 300 were hourly-rated, unionized employees. Outside the United States, the Company
has government-mandated collective bargaining arrangements and union contracts in certain countries, particularly in Europe
where many of the Company’s employees are represented by unions and/or works councils.
Danaher is committed to attracting, developing, engaging and retaining the best people from around the world to sustain and
grow our science and technology leadership. As noted above, “Consistently attracting and retaining exceptional talent” is one
of our three strategic priorities and “The Best Team Wins” is one of our five Core Values, reflecting the critical role our human
capital plays in supporting our strategy. Our human capital strategy spans multiple, key dimensions, including the following:
• Culture and Governance
◦ Our culture is rooted in DBS and in our Shared Purpose, Helping Realize Life’s Potential. At its core, DBS
reflects a commitment to use process to continuously improve every aspect of our business. Our Shared
Purpose gives meaning and direction to our continuous improvement.
◦ Danaher’s Board of Directors reviews the Company’s human capital strategy annually and at other times
during the year in connection with significant initiatives and acquisitions, supported by the Compensation
Committee’s oversight of our executive and equity compensation programs. At the management level, our
Senior Vice President of Human Resources, who reports directly to our President and CEO, is responsible for
the development and execution of the Company’s human capital strategy.
9

-- 31 of 162 --

• Recruitment
◦ As part of our commitment to the Core Value “The Best Team Wins”, we focus on identifying, attracting and
recruiting diverse talent to meet our current and future business needs. Danaher’s talent acquisition strategy
is focused on broadening our candidate pools, which we believe will increase underrepresented talent
throughout the Company.
• Engagement
◦ General. Our engagement strategy focuses on developing the best workplace and best people leaders to meet
our associates’ needs every day. Further, we believe that better associate engagement helps enable better
retention and better business performance. We assess our engagement performance through an annual
engagement survey that addresses engagement, direct supervisor effectiveness, behavior change and
performance enablement, as well as through our voluntary turnover rate.
◦ D+I. We believe a diverse workforce and culture of inclusion is essential to drive innovation, fuel growth and
help ensure our technologies and products effectively serve a global customer base. Danaher’s Diversity +
Inclusion Council (including Danaher’s Senior Vice President of Human Resources, Vice President of
Diversity + Inclusion and multiple other executive officers) oversees the development and execution of our
diversity and inclusion (“D+I”) strategy. We focus on broadening our candidate pools, sourcing diverse
slates in the hiring process and implementing and sustaining programs (such as our U.S.-based Associate
Resource Groups for Women, Black, Latinx, LGBTQ and Asian descent associates) that offer mentorship,
support and engagement to help our associates, including those from underrepresented groups, succeed and
thrive. In support of our D+I commitment, we conduct regular pay reviews from a race (in the United States.)
and gender (globally) perspective that serve to proactively identify and address potential pay differences. As
of December 31, 2020, 36% of our total associates were female; 29% of our managerial associates were
female; 33% of our total U.S. associates were People of Color; and 25% of our U.S. managerial associates
were People of Color.
• Retention
◦ Compensation and Benefits. We are committed to offering competitive compensation and benefits, tailored
in form and amount to geography, industry, experience and performance and designed to attract associates,
motivate and reward performance, drive growth and support retention. We have a common job architecture
across our businesses to provide a standardized framework for defining jobs, job families, and career levels,
and set market-aligned pay structures for each career level (adjusted as appropriate for the particular job
family, industry, and geography) based on a range of compensation surveys.
◦ Performance Management. Our Performance for Growth process supports our high-performance culture by
seeking to ensure that high-performing associates are recognized and rewarded for their contributions.
◦ Talent Development and Career Mobility. Our talent development program (which is generally structured to
consist of 70% on-the-job learning, 20% coaching and mentoring and 10% formal training) strives to provide
every associate with appropriate development opportunities. In particular, we make available to people
leaders at every level training, coaching and developmental resources to help them be effective leaders and
advance their careers. We further encourage internal promotion and mobility through our Danaher Go
program, which makes open positions throughout the organization visible to associates and proactively
encourages our associates to seek promotional opportunities. We assess our performance in this area using
metrics including internal fill rate (which tracks the percentages of open roles at particular levels filled by our
own associates) as well as the percentage of eligible associates with talent assessments/career plans.
◦ Safety and Risk Management. Associate safety is deeply embedded in our culture. Our Environment, Health
and Safety (“EHS”) Policy establishes the core principles upon which our EHS management programs are
built, and associates use our DBS-based “4E” toolkit to identify, assess and control hazards related to
ergonomics, energetics, exposures and environment. In addition, we evaluate and manage risks relating to
our human capital strategy as part of Danaher’s enterprise risk management program. Key quantitative
measures that we use to assess performance in this category include total recordable incident rate (defined as
the number of work-related injuries or illness cases serious enough to require treatment beyond first aid, per
200,000 hours worked) and days away, restricted or transferred (defined as the number of work-related
injuries or illness cases that result in an employee working with physical restrictions, being away from work
or unable to do their job or transferring to other work, per 200,000 hours worked).
10

-- 32 of 162 --

The health and well-being of our associates has been a key area of focus in our response to the COVID-19 pandemic. We
launched a global Employee Assistance Program in March 2020 to ensure a consistent support structure for mental health and
well-being across the Company and expanded the program over the course of the year to provide enhanced support with respect
to childcare, eldercare and tutoring, among other areas. In the United States, we have provided benefits beyond the
requirements of the Families First Act, for example by extending our leave policy to cover elder care and providing for
voluntary leaves even in certain circumstances not required by the law. We have focused on implementing safety precautions
on a facility-specific basis, such as wearing appropriate protective equipment, social distancing measures, work-from-home
requirements where feasible and in many cases staggered work shifts, restricted work zones and daily temperature screenings.
The results of our 2020 Associate Engagement Survey validate the impact of these efforts: 88% of surveyed associates felt
satisfied with Danaher’s efforts to care for associates during the pandemic, while 93% of surveyed associates agreed that their
leaders took actions to maintain a safe work environment.
Research and Development (“R&D”)
The Company conducts R&D activities for the purpose of developing new products, enhancing the functionality, effectiveness,
ease of use and reliability of its existing products and expanding the applications for which uses of its products are appropriate.
The Company’s R&D efforts include internal initiatives and those that use licensed or acquired technology, and we work with a
number of leading research institutions, universities and clinicians around the world to develop, evaluate and clinically test our
products. The Company conducts R&D activities primarily in North America, Europe, and Asia and generally on a business-
by-business basis, although it does conduct certain R&D activities on a centralized basis. The Company anticipates that it will
continue to make significant expenditures for R&D as it seeks to provide a continuing flow of innovative products and services
to maintain and improve its competitive position. For a discussion of the risks related to the need to develop and commercialize
new products and product enhancements, refer to “Item 1A. Risk Factors.”
Government Contracts
Although the substantial majority of the Company’s revenue in 2020 was from customers other than governmental entities, each
of Danaher’s segments has agreements relating to the sale of products to government entities. As a result, the Company is
subject to various statutes and regulations that apply to companies doing business with governments. For a discussion of risks
related to government contracting requirements, refer to “Item 1A. Risk Factors.” No material portion of Danaher’s business is
subject to renegotiation of profits or termination of contracts at the election of a government entity.
Regulatory Matters
The Company faces extensive government regulation both within and outside the United States relating to the development,
manufacture, marketing, sale and distribution of its products and services. The following sections describe certain significant
regulations that the Company is subject to. These are not the only regulations that the Company’s businesses must comply
with. For a description of the risks related to the regulations that the Company’s businesses are subject to, refer to “Item 1A.
Risk Factors.”
Medical Device Regulations
Many of our products are classified as medical devices and are subject to restrictions under domestic and foreign laws, rules,
regulations, self-regulatory codes, circulars and orders, including, but not limited to, the U.S. Food, Drug, and Cosmetic Act
(the “FDCA”). The FDCA requires these products, when sold in the United States, to be safe and effective for their intended
uses and to comply with the regulations administered by the U.S. Food and Drug Administration (“FDA”). The FDA regulates
the design, development, research, preclinical and clinical testing, introduction, manufacture, advertising, labeling, packaging,
marketing, distribution, import and export and record keeping for such products. Many medical device products are also
regulated by comparable agencies in non-U.S. countries in which they are produced or sold.
Unless an exemption applies, the FDA requires that a manufacturer introducing a new medical device or a new indication for
use of an existing medical device obtain either a Section 510(k) premarket notification clearance or a premarket approval
(“PMA”) before introducing it into the U.S. market. The type of marketing authorization is generally linked to the
classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree
of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure the
device’s safety and effectiveness.
The process of obtaining a Section 510(k) clearance generally requires the submission of performance data and clinical data,
which in some cases can be extensive, to demonstrate that the device is “substantially equivalent” to a device that was on the
market before 1976 or to a device that has been found by the FDA to be “substantially equivalent” to such a pre-1976 device.
11

-- 33 of 162 --

A predecessor device is referred to as “predicate device.” As a result, FDA clearance requirements may extend the
development process for a considerable length of time.
Medical devices can be marketed only for the indications for which they are cleared or approved. After a device has received
510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness,
such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k)
clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a modification could
significantly affect the device’s safety or effectiveness is initially left to the manufacturer using available FDA guidance;
however, the FDA may review this determination to evaluate the regulatory status of the modified product at any time and may
require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained.
Any medical devices we manufacture and distribute are subject to pervasive and continuing regulation by the FDA and certain
state and non-U.S. agencies. These include product listing and establishment registration requirements, which help facilitate
inspections and other regulatory actions. As a medical device manufacturer, our manufacturing facilities are subject to
inspection on a routine basis by the FDA. We are required to adhere to the Current Good Manufacturing Practices (“CGMP”)
requirements, as set forth in the Quality Systems Regulation (“QSR”), which require manufacturers, including third-party
manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all
phases of the design and manufacturing process.
We must also comply with post-market surveillance regulations, including medical device reporting (“MDR”) requirements
which require that we review and report to the FDA any incident in which our products may have caused or contributed to a
death or serious injury. We must also report any incident in which our product has malfunctioned if that malfunction would
likely cause or contribute to a death or serious injury if it were to recur.
Labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade
Commission. Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses,
otherwise known as “off-label” promotion. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of off-label uses.
In the European Union (“EU”), our products are subject to the medical device and in vitro medical device laws of the various
member states, which for many years were based on Directives of the European Commission. However, in May 2017, the EU
adopted new, formal regulations to replace such Directives; specifically, the EU Medical Device Regulation (the “EU MDR”)
and In Vitro Diagnostic Regulation (the “EU IVDR”), each of which imposes stricter requirements for the marketing and sale of
medical devices and in vitro devices, including in the area of clinical evaluation requirements, quality systems and post-market
surveillance. The EU regulations were adopted with staggered transitional periods that have since been updated. The full
application of the EU MDR has been postponed until May 2021, while the EU IVDR will be fully applicable in May 2022.
Complying with the EU MDR and EU IVDR requires modifications to our quality management systems, additional resources in
certain functions and updates to technical files, among other changes, which cost approximately $30 million in 2020 and we
anticipate will cost approximately $35 million in 2021.
Other Healthcare Laws
We are also subject to the U.S. Foreign Corrupt Practices Act and various health care related laws regulating fraud and abuse,
research and development, pricing and sales and marketing practices, and the privacy and security of health information,
including the U.S. federal regulations described below. Many states, foreign countries and supranational bodies have also
adopted laws and regulations similar to, and in some cases more stringent than, the U.S. federal regulations discussed above and
below, including the UK Bribery Act and similar anti-bribery laws.
• Many of our healthcare-related products are purchased by healthcare providers that typically bill various third-party
payers, such as governmental healthcare programs (e.g., Medicare, Medicaid and comparable non-U.S. programs),
private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of
our customers to obtain appropriate reimbursement for products and services from third-party payers is critical because
it affects which products customers purchase and the prices they are willing to pay. As a result, many of our
healthcare-related products are subject to regulation regarding quality and cost by the U.S. Department of Health and
Human Services (“HHS”), including the Centers for Medicare & Medicaid Services (“CMS”), as well as comparable
state and non-U.S. agencies responsible for reimbursement and regulation of healthcare goods and services, including
laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud. Third-party payers are
increasingly reducing reimbursements for medical products and services and, in international markets, many countries
have instituted price ceilings on specific products and therapies. Price ceilings, decreases in third-party reimbursement
for any product or a decision by a third-party payor not to cover a product could reduce usage and patient demand for
the product.
12

-- 34 of 162 --

• The U.S. Federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving
or providing remuneration (including any kickback or bribe), directly or indirectly, in exchange for or to induce either
the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made in
whole or in part under a federal health care program, such as Medicare or Medicaid. A person or entity does not need
to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
• The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) prohibits knowingly and willfully (1)
executing, or attempting to execute, a scheme to defraud any health care benefit program, including private payors, or
(2) falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for health care benefits, items or services. In addition,
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, also
restricts the use and disclosure of patient identifiable health information, mandates the adoption of standards relating to
the privacy and security of patient identifiable health information and requires the reporting of certain security
breaches with respect to such information. Similar to the U.S. Federal Anti-Kickback Statute, a person or entity does
not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to
violate it in order to have committed a violation.
• The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes
to be presented, a false or fraudulent claim for payment by a federal health care program, knowingly makes, uses or
causes to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly makes a
false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. The qui tam
provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government
alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary
recovery. In addition, the government may assert that a claim including items and services resulting from a violation
of the U.S. Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims
Act.
• The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transferring of remuneration
to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s
selection of a particular supplier of Medicare or Medicaid payable items or services.
• The Open Payments Act requires manufacturers of medical devices covered under Medicare, Medicaid or the
Children’s Health Insurance Program with specific exceptions to record payments and other transfers of value to a
broad range of healthcare providers and teaching hospitals and to report this data as well as ownership and investment
interests held by the physicians described above and their immediate family members to HHS for subsequent public
disclosure. Similar reporting requirements have also been enacted on the state level, and an increasing number of
countries either have adopted or are considering similar laws requiring transparency of interactions with health care
professionals.
In addition, some of the in vitro diagnostic drugs-of-abuse assays and reagents sold by the Company’s subsidiaries contain
small amounts of controlled substances, and as a result some of the Company’s facilities are inspected periodically by the
United States Drug Enforcement Administration to ensure that the Company properly handles, stores and disposes of controlled
substances in the manufacture of those products.
Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially
harm consumers. Analogous U.S. state laws and regulations, such as state anti-kickback and false claims laws, also may apply
to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims
involving healthcare items or services reimbursed by any third-party payor, including private insurers. Further, there are state
laws that require medical device manufacturers to comply with the voluntary compliance guidelines and the relevant
compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to
healthcare providers and other potential referral sources; state laws and regulations that require manufacturers to file reports
relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided
to healthcare professionals and entities; state and local laws requiring the registration of sales representatives; and state laws
governing the privacy and security of health information in certain circumstances, many of which differ from each other in
significant ways and often are not preempted by HIPAA.
For a discussion of risks related to regulation by the FDA and comparable agencies of other countries, and the other regulatory
regimes referenced above, please refer to section entitled “Item 1A. Risk Factors.”
13

-- 35 of 162 --

Healthcare Reform
In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of
legislative and regulatory changes to the healthcare system. There is significant interest in promoting changes in healthcare
systems with the stated goals of containing healthcare costs, improving quality or expanding access. For example, in the United
States, in March 2010, the U.S. Patient Protection and Affordable Care Act (as amended by the Health Care and Education
Affordability Reconciliation Act) (collectively, the “PPACA”) was signed into law, which substantially changed the way
healthcare is financed by both governmental and private insurers and significantly affected the healthcare industry. Since its
enactment, there have been judicial, Congressional and executive challenges to certain aspects of the PPACA, and there may be
additional challenges and amendments to the PPACA in the future.
Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for
their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed,
among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs and reform government program reimbursement methodologies for medical products. Individual states in the
United States have also become increasingly active in implementing regulations designed to control product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing.
Data Privacy and Security Laws
As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in
numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of
our business. For example, in the United States, HIPAA privacy and security rules require certain of our operations to maintain
controls to protect the availability and confidentiality of patient health information, individual states regulate data breach and
security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. In
particular, the California Consumer Privacy Act (“CCPA”), which came into effect in January 2020 has some of the same
features as the GDPR (discussed below), and has already prompted several other states to consider enacting similar laws. The
EU General Data Protection Regulation that became effective in May 2018 (“GDPR”) has imposed significantly stricter
requirements in how we collect, transmit, process and retain personal data, including, among other things, in certain
circumstances a requirement for almost immediate notice of data breaches to supervisory authorities with significant fines for
non-compliance. Several other countries such as China and Russia have passed, and other countries are considering passing,
laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer
restrictions. For a discussion of risks related to these laws, refer to “Item 1A. Risk Factors.”
Environmental Laws and Regulations
For a discussion of the environmental laws and regulations that the Company’s operations, products and services are subject to
and other environmental contingencies, refer to Note 18 to the Consolidated Financial Statements included in this Annual
Report. For a discussion of risks related to compliance with environmental and health and safety laws and risks related to past
or future releases of, or exposures to, hazardous substances, refer to “Item 1A. Risk Factors.”
Antitrust Laws
The U.S. federal government, most U.S. states and many other countries have laws that prohibit certain types of conduct
deemed to be anti-competitive. Violations of these laws can result in various sanctions, including criminal and civil penalties.
Private plaintiffs also could bring civil lawsuits against us in the United States for alleged antitrust law violations, including
claims for treble damages.
Export/Import Compliance
The Company is required to comply with various U.S. export/import control and economic sanctions laws, including:
• the International Traffic in Arms Regulations administered by the U.S. Department of State, Directorate of Defense
Trade Controls, which, among other things, imposes license requirements on the export from the United States of
defense articles and defense services listed on the U.S. Munitions List;
• the Export Administration Regulations administered by the U.S. Department of Commerce, Bureau of Industry and
Security, which, among other things, impose licensing requirements on the export, in-country transfer and re-export of
certain dual-use goods, technology and software (which are items that have both commercial and military, or
proliferation applications);
14

-- 36 of 162 --

• the regulations administered by the U.S. Department of Treasury, Office of Foreign Assets Control, which implement
economic sanctions imposed against designated countries, governments and persons based on United States foreign
policy and national security considerations; and
• the import regulatory activities of the U.S. Customs and Border Protection and other U.S. government agencies.
Other nations’ governments have implemented similar export/import control and economic sanction regulations, which may
affect the Company’s operations or transactions subject to their jurisdictions.
In addition, under U.S. laws and regulations, U.S. companies and their subsidiaries and affiliates outside the United States are
prohibited from participating or agreeing to participate in unsanctioned foreign boycotts in connection with certain business
activities, including the sale, purchase, transfer, shipping or financing of goods or services within the United States or between
the United States and countries outside of the United States. If we, or certain third parties through which we sell or provide
goods or services, violate anti-boycott laws and regulations, we may be subject to civil or criminal enforcement action and
varying degrees of liability.
For a discussion of risks related to export/import control and economic sanctions laws, refer to “Item 1A. Risk Factors.”
International Operations
The Company’s products and services are available worldwide, and its principal markets outside the United States are in Europe
and Asia. The Company also has operations around the world, and this geographic diversity allows the Company to draw on
the skills of a worldwide workforce, provides greater stability to its operations, allows the Company to drive economies of
scale, provides revenue streams that may help offset economic trends that are specific to individual economies and offers the
Company an opportunity to access new markets for products. In addition, the Company believes that future growth depends in
part on its ability to continue developing products and sales models that successfully target high-growth markets.
The manner in which the Company’s products and services are sold outside the United States differs by business and by region.
Most of the Company’s sales in non-U.S. markets are made by its subsidiaries located outside the United States, though the
Company also sells directly from the United States into non-U.S. markets through various representatives and distributors and,
in some cases, directly. In countries with low sales volumes, the Company generally sells through representatives and
distributors.
For a discussion of the United Kingdom’s withdrawal from the EU (“Brexit”) and certain risks and implications thereof for the
Company, refer to “Item 1A—Risk Factors”.
Information about the effects of foreign currency fluctuations on the Company’s business is set forth in “Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) included in this Annual Report. For a
discussion of risks related to the Company’s non-U.S. operations and foreign currency exchange, refer to “Item 1A. Risk
Factors.”
Available Information
The Company maintains an internet website at www.danaher.com. The Company makes available free of charge on the website
its annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those
reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after filing
such material with, or furnishing such material to, the SEC. Danaher’s internet site and the information contained on or
connected to that site are not incorporated by reference into this Form 10-K.
ITEM 1A. RISK FACTORS
You should carefully consider the risks and uncertainties described below, together with the information included elsewhere in
this Annual Report on Form 10-K and other documents we file with the SEC. The risks and uncertainties described below are
those that we have identified as material, but are not the only risks and uncertainties facing us. Our business is also subject to
general risks and uncertainties that affect many other companies, such as market conditions, economic conditions, geopolitical
events, changes in laws, regulations or accounting rules, fluctuations in interest rates, terrorism, wars or conflicts, major
health concerns including epidemics, natural disasters or other disruptions of expected business conditions. Additional risks
and uncertainties not currently known to us or that we currently believe are immaterial also may impair our business and
financial statements, including our results of operations, liquidity, financial condition and stock price.
15

-- 37 of 162 --

Business and Strategic Risks
The COVID-19 pandemic has adversely impacted, and continues to pose risks to, certain elements of our business and our
financial statements, the nature and extent of which are highly uncertain and unpredictable.
Our global operations expose us to risks associated with public health crises, including epidemics and pandemics such as
COVID-19. The global spread of COVID-19 has led to unprecedented restrictions on, and disruptions in, business and personal
activities, including as a result of preventive and precautionary measures that we, other businesses, our communities and
governments are taking to mitigate the spread. For example, many governments have issued “stay-at-home” orders which
restrict business and personal activities, and many employers are requiring employees to work from home. In addition to
existing travel and activity restrictions, jurisdictions may continue to close borders, impose prolonged quarantines and further
restrict travel and other activities. The pandemic has caused a global recession of potentially extended duration.
The direct impact of COVID-19 and the preventive and precautionary measures implemented as a result thereof have adversely
affected, and are expected to continue to adversely affect, certain elements of our Company (including to a different degree our
operations, commercial organizations, supply chains and distribution systems) and the future impact may be material, though
the impact on our different businesses and the different elements of our businesses varies (please see “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” for a discussion of how COVID-19 impacted our
results of operations and financial position in 2020). Without limiting the foregoing, we have experienced and/or may in the
future experience:
• adverse impacts on customer orders and purchases and unpredictable reductions in demand for many of our products;
• constraints on the movement of our products through the supply chain;
• adverse impacts on our collections of accounts receivable, including delays in collections and increases in
uncollectible receivables;
• supply chain capacity constraints and price increases, including with respect to freight services;
• adverse impacts on our workforce and/or key employees;
• unpredictable increases in demand for certain products; and
• increased cybersecurity attack activity.
In an effort to optimize availability of needed medical and other supplies and products in connection with the COVID-19
pandemic, we may elect to or governments may require us or our customers to allocate manufacturing capacity (for example
pursuant to the U.S. Defense Production Act (“DPA”)) in a way that adversely affects our financial condition and results of
operations, results in differential treatment of customers and/or adversely affects our reputation and customer relationships. For
example, certain of our customers are or have been subject to DPA requirements relating to the production of COVID-19
related products and have required certain of our businesses to also comply with these requirements under our supply
agreements. Further, the Biomedical Advanced Research and Development Authority (“BARDA”) of the U.S. government has
agreed to finance an expansion of production capacity at one of our businesses for COVID-19 related products, and in
connection therewith the business has committed certain of such incremental production capacity to the U.S. government
pursuant to the DPA. In addition, unpredictable increases in demand for certain of our products can exceed our capacity to
meet such demand on a timely basis or at all, which can result in negative publicity and otherwise adversely affect our business
and financial statements. The accelerated development and production of products and services in an effort to address medical
and other requirements as a result of the pandemic also increases the risk of regulatory enforcement actions, product defects or
claims thereof. In addition, the COVID-19 vaccines that are developed may not all use Danaher’s vaccine development/
production solutions, and/or may use Danaher’s solutions to different degrees; and if the number of COVID-19 vaccines under
development declines (for example because one or a limited number of vaccines emerges as the preferred solution) the demand
for Danaher’s vaccine development/production solutions may decline. Danaher’s COVID-19 testing solutions may also not
ultimately be the preferred testing solutions for COVID-19. Any of these developments may adversely affect our business and
financial statements.
Although we successfully issued debt and equity in underwritten offerings in 2020, COVID-19 has led to disruption and
volatility in the global capital markets, which has increased the cost of, and adversely impacted access to, capital (including in
the commercial paper markets) and increased economic uncertainty. There are no assurances that the commercial paper
markets or the capital markets will be available to us in the future or that the lenders participating in our revolving credit
facilities will be able to provide financing in accordance with their contractual obligations.
16

-- 38 of 162 --

While the pandemic continues we expect to experience continued adverse impacts on our business and financial statements,
which adverse impacts are unpredictable and may be material. Even to the extent COVID-19 conditions begin to improve, the
duration and sustainability of any such improvements will be uncertain and continuing adverse impacts and/or the degree of
improvement may vary dramatically by geography and line of business. The actions Danaher’s businesses take in response to
any improvements in conditions may vary widely by geography and line of business and will likely be made with incomplete
information; pose the risk that such actions may prove to be premature, incorrect or insufficient; and could have a material,
adverse impact on our business and financial statements. In addition, any restructuring activities we undertake in light of the
COVID-19 impact may adversely affect our business and financial statements.
Conditions in the global economy, the particular markets we serve and the financial markets may adversely affect our
business and financial statements.
Our business is sensitive to general economic conditions. Slower economic growth in the domestic and/or international
markets, actual or anticipated default on sovereign debt, volatility in the currency and credit markets, high levels of
unemployment or underemployment, reduced levels of capital expenditures, changes or anticipation of potential changes in
government trade, fiscal, tax and monetary policies, changes in capital requirements for financial institutions, government
deficit reduction and budget negotiation dynamics, sequestration, austerity measures and other challenges that affect the global
economy have in the past adversely affected, and may in the future adversely affect, the Company and its distributors,
customers and suppliers, including having the effect of:
• reducing demand for our products and services (in this Annual Report, references to products and services also
includes software), limiting the financing available to our customers and suppliers, increasing order cancellations and
resulting in longer sales cycles and slower adoption of new technologies;
• increasing the difficulty in collecting accounts receivable and the risk of excess and obsolete inventories;
• increasing price competition in our served markets;
• supply interruptions, which could disrupt our ability to produce our products;
• increasing the risk of impairment of goodwill and other long-lived assets, and the risk that we may not be able to fully
recover the value of other assets such as real estate and tax assets;
• increasing the risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to
fulfill their contractual obligations which, in addition to increasing the risks identified above, could result in preference
actions against us; and
• adversely impacting market sizes and growth rates.
If growth in the global economy or in any of the markets we serve slows for a significant period, if there is significant
deterioration in the global economy or such markets or if improvements in the global economy do not benefit the markets we
serve, our business and financial statements could be adversely affected.
17

-- 39 of 162 --

We face intense competition and if we are unable to compete effectively, we may experience decreased demand and
decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
Our businesses operate in industries that are intensely competitive and have been subject to increasing consolidation. Because
of the range of the products and services we sell and the variety of markets we serve, we encounter a wide variety of
competitors; refer to “Item 1. Business—Competition” for additional details. In order to compete effectively, we must retain
longstanding relationships with major customers and continue to grow our business by establishing relationships with new
customers, continually developing new products and services to maintain and expand our brand recognition and leadership
position in various product and service categories and penetrating new markets, including high-growth markets. Our ability to
compete can also be impacted by changing customer preferences and requirements (for example increased demand for products
incorporating digital capabilities or more environmentally-friendly products and supplier practices) as well as changes in the
way healthcare services are delivered (including the movement of some care from acute to non-acute settings and increased
focus on chronic disease management). Cost containment efforts by governments and the private sector, particularly in the
healthcare industry, are also resulting in increased emphasis on products that reduce costs and improve efficiency and
effectiveness. In addition, significant shifts in industry market share have occurred and may in the future occur in connection
with product problems, safety alerts and publications about products, reflecting the competitive significance of product quality,
product efficacy and quality systems in our industry. Our failure to compete effectively and/or pricing pressures resulting from
competition may adversely impact our business and financial statements, and our expansion into new markets may result in
greater-than-expected risks, liabilities and expenses. In addition, the Company’s competitors and customers have from time to
time introduced, and may in the future introduce, private label, generic or low-cost products that compete with the Company’s
products at lower price points. Competitors’ products can capture significant market share or lead to a decrease in market
prices overall, resulting in an adverse effect on the Company’s business and financial statements.
Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and
enhanced products and services based on technological innovation.
We generally sell our products and services in industries that are characterized by rapid technological changes, frequent new
product introductions and changing industry standards. If we do not develop innovative new and enhanced products and
services on a timely basis, our offerings will become obsolete over time and our business and financial statements will suffer.
Our success will depend on several factors, including our ability to:
• correctly identify customer needs and preferences and predict future needs and preferences;
• allocate our R&D funding to products and services with higher growth prospects;
• anticipate and respond to our competitors’ development of new products and services and technological innovations;
• differentiate our offerings from our competitors’ offerings and avoid commoditization;
• innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that
may have valuable applications in our served markets;
• obtain adequate intellectual property rights with respect to key technologies before our competitors do;
• successfully commercialize new technologies in a timely manner, price them competitively and cost-effectively
manufacture and deliver sufficient volumes of new products of appropriate quality on time;
• obtain necessary regulatory approvals of appropriate scope (including with respect to medical device products by
demonstrating satisfactory clinical results where applicable, as well as achieving third-party reimbursement); and
• stimulate customer demand for and convince customers to adopt new technologies.
If we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest
heavily in R&D of products and services that do not lead to significant revenue, which would adversely affect our business and
financial statements. Even when we successfully innovate and develop new and enhanced products and services, we often incur
substantial costs in doing so, and our profitability may suffer. In addition, promising new offerings may fail to reach the market
or realize only limited commercial success because of real or perceived efficacy or safety concerns, failure to achieve positive
clinical outcomes, uncertainty over third-party reimbursement or entrenched patterns of clinical practice. Competitors may also
develop after-market services and parts for our products which attract customers and adversely affect our return on investment
for new products.
18

-- 40 of 162 --

The health care industry and related industries that we serve have undergone, and are in the process of undergoing,
significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business
and financial statements.
The health care industry and related industries that we serve have undergone, and are in the process of undergoing, significant
changes in an effort to reduce (and increase the predictability of) costs, including the following:
• many of our customers, and the end-users to whom our customers supply products, rely on government funding of and
reimbursement for healthcare products and services and research activities. The PPACA, health care austerity
measures in other countries and other potential healthcare reform changes and government austerity measures have
reduced and may further reduce the amount of government funding or reimbursement available to customers or end-
users of our products and services and/or the volume of medical procedures using our products and services. For
example, the Protecting Access to Medicare Act of 2014, or PAMA, introduced a multi-year pricing program for
services payable under the Clinical Laboratory Fee Schedule (“CLFS”) that is designed to bring Medicare allowable
amounts in line with the amounts paid by private payers. It is still unclear whether and to what extent these new rates
will affect overall pricing and reimbursement for clinical laboratory testing services, but to the extent our customers
conclude that Medicare reimbursement for these services is inadequate, it can in turn adversely impact the prices at
which we sell our products. Other countries, as well as some private payors, also control the price of health care
products, directly or indirectly, through reimbursement, payment, pricing or coverage limitations, tying reimbursement
to outcomes or (in the case of governmental entities) through compulsory licensing. Global economic uncertainty or
deterioration can also adversely impact government funding and reimbursement.
• governmental and private health care providers and payors around the world are increasingly utilizing managed care
for the delivery of healthcare services, centralizing purchasing, limiting the number of vendors that may participate in
purchasing programs, forming group purchasing organizations and integrated health delivery networks and pursuing
consolidation to improve their purchasing leverage and using competitive bid processes to procure healthcare products
and services. Payors are also seeking to improve price predictability in an effort to mitigate exposure to future price
increases.
These changes as well as other impacts from market demand, government regulations, third-party coverage and reimbursement
policies and societal pressures are changing the way healthcare is delivered, reimbursed and funded and have in the past and
could in the future cause participants in the healthcare industry and related industries that we serve to purchase fewer of our
products and services, reduce the prices they are willing to pay for our products or services, reduce the amounts of
reimbursement and funding available for our products and services from governmental agencies or third-party payors, heighten
clinical data requirements, reduce the volume of medical procedures that use our products and services, affect the acceptance
rate of new technologies and products and increase our compliance and other costs. In addition, we may be excluded from
important market segments or unable to enter into contracts with group purchasing organizations and integrated health networks
on terms acceptable to us, and even if we do enter into such contracts they may be on terms that negatively affect our current or
future profitability. All of the factors described above can adversely affect our business and financial statements.
International economic, political, legal, compliance, social and business factors can negatively affect our business and
financial statements.
In 2020, approximately 61% of our sales were derived from customers outside the United States. In addition, many of our
manufacturing operations, suppliers and employees are located outside the United States. Since our growth strategy depends in
part on our ability to further penetrate markets outside the United States and increase the localization of our products and
services, we expect to continue to increase our sales and presence outside the United States, particularly in the high-growth
markets. Our international business (and particularly our business in high-growth markets) is subject to risks that are
customarily encountered in non-U.S. operations, including:
• interruption in the transportation of materials to us and finished goods to our customers;
• differences in terms of sale, including longer payment terms than are typical in the United States;
• local product preferences and product requirements;
• changes in a country’s or region’s political, social or economic conditions, such as the devaluation of particular
currencies;
• trade protection measures, embargoes and import or export restrictions and requirements;
• unexpected changes in laws or regulatory requirements, including changes in tax laws;
19

-- 41 of 162 --

• capital controls and limitations on ownership and on repatriation of earnings and cash;
• the potential for nationalization of enterprises;
• changes in local healthcare delivery, payment and reimbursement policies and programs;
• limitations on legal rights and our ability to enforce such rights;
• difficulty in staffing and managing widespread operations;
• differing labor or employment regulations;
• difficulties in implementing restructuring actions on a timely or comprehensive basis;
• differing protection of intellectual property; and
• greater uncertainty, risk, expense and delay in commercializing products in certain foreign jurisdictions, including with
respect to product and other regulatory approvals.
International business risks have in the past and may in the future negatively affect our business and financial statements.
For example, in 2020 we generated approximately 12% of our sales from China. Accordingly, our business and financial
statements can be adversely influenced by political, economic, legal, compliance and social conditions in China generally.
Additionally, China’s government continues to play a significant role in regulating industry development by imposing industrial
policies, and it maintains control over China’s economic growth through setting monetary policy and determining treatment of
particular industries or companies. Further, considerable uncertainty exists regarding the long-term effects of the expansionary
monetary and fiscal policies adopted by the central banks and financial authorities of some of the world’s leading economies,
including the United States and China. Uncertainty or adverse changes to economic conditions in China or the policies of
China’s government or its laws and regulations can have a material adverse effect on the overall economic growth of China and
can adversely affect our business and financial statements.
In addition, our global operations expose us to risks associated with public health crises and epidemics, such as COVID-19,
which could adversely impact our supply chains and distribution systems, reduce demand for our products and services, and
otherwise adversely affect our business and financial statements.
Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or
experience cyclicality.
Our growth depends in part on the growth of the markets which we serve, and visibility into our markets is limited (particularly
for markets into which we sell through distribution). Our quarterly sales and profits depend substantially on the volume and
timing of orders received during the fiscal quarter, which are difficult to forecast. Any decline or lower than expected growth in
our served markets could diminish demand for our products and services, which would adversely affect our business and
financial statements. Certain of our businesses operate in industries that may experience periodic, cyclical downturns. In
addition, in certain of our businesses demand depends on customers’ capital spending budgets as well as government funding
policies, and matters of public policy and government budget dynamics as well as product and economic cycles can affect the
spending decisions of these entities. Demand for our products and services is also sensitive to changes in customer order
patterns, which may be affected by announced price changes, marketing or promotional programs, new product introductions,
the timing of industry trade shows and changes in distributor or customer inventory levels due to distributor or customer
management thereof or other factors. Any of these factors could adversely affect our business and financial statements in any
given period.
Certain of our businesses rely on relationships with collaborative partners and other third-parties for development, supply
and marketing of certain products, potential products and technologies, and such collaborative partners or other third-
parties could fail to perform sufficiently.
We believe that for certain of our businesses, success in penetrating target markets depends in part on their ability to develop
and maintain collaborative relationships with other companies. Relying on collaborative relationships is risky because, among
other things, our collaborative partners may (1) not devote sufficient resources to the success of our collaborations; (2) fail to
obtain regulatory approvals necessary to continue the collaborations in a timely manner; (3) be acquired by other companies
and terminate our collaborative partnership or become insolvent; (4) compete with us; (5) disagree with us on key details of the
collaborative relationship; (6) have insufficient capital resources; and (7) decline to renew existing collaborations on acceptable
terms. Because these and other factors may be beyond our control, the development or commercialization of our products
20

-- 42 of 162 --

involved in collaborative partnerships may be delayed or otherwise adversely affected. If we or any of our collaborative
partners terminate a collaborative arrangement, we may be required to devote additional resources to product development and
commercialization or we may need to cancel some development programs, which could adversely affect our business and
financial statements.
Acquisitions, Divestitures and Investment Risks
Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate
investments that support our long-term strategy, could negatively impact our growth rate and stock price.
Our ability to grow revenues, earnings and cash flow at or above our historic rates depends in part upon our ability to identify
and successfully acquire and integrate businesses at appropriate prices and realize anticipated synergies, and to make
appropriate investments that support our long-term strategy. We may not be able to consummate acquisitions at rates similar to
the past, which could adversely impact our growth rate and our stock price. Promising acquisitions and investments are
difficult to identify and complete for a number of reasons, including high valuations, competition among prospective buyers or
investors, the availability of affordable funding in the capital markets and the need to satisfy applicable closing conditions and
obtain applicable antitrust and other regulatory approvals on acceptable terms. In addition, competition for acquisitions and
investments has resulted and may result in higher purchase prices. Changes in accounting or regulatory requirements or
instability in the credit markets could also adversely impact our ability to consummate acquisitions and investments.
Our acquisition of businesses, investments, joint ventures and other strategic relationships could negatively impact our
business and financial statements.
As part of our business strategy we acquire businesses, make investments and enter into joint ventures and other strategic
relationships in the ordinary course, and we also from time to time complete more significant transactions; refer to MD&A for
additional details. For example, our acquisition of Cytiva in March 2020 is Danaher’s largest acquisition to date based on
purchase price. Acquisitions (including the acquisition of Cytiva), investments, joint ventures and strategic relationships
involve a number of financial, accounting, managerial, operational, legal, compliance and other risks and challenges, including
but not limited to the following, any of which could adversely affect our business and our financial statements:
• businesses, technologies, services and products that we acquire or invest in sometimes under-perform relative to our
expectations and the price that we paid, fail to perform in accordance with our anticipated timetable or fail to achieve
and/or sustain profitability;
• we from time to time incur or assume significant debt in connection with our acquisitions, investments, joint ventures
or strategic relationships, which can also cause a deterioration of Danaher’s credit ratings, result in increased
borrowing costs and interest expense and diminish our future access to the capital markets;
• acquisitions, investments, joint ventures or strategic relationships can cause our financial results to differ from our own
or the investment community’s expectations in any given period, or over the long-term;
• pre-closing and post-closing earnings charges can adversely impact our results in any given period, and the impact
may be substantially different from period-to-period;
• acquisitions, investments, joint ventures or strategic relationships can create demands on our management, operational
resources and financial and internal control systems that we are unable to effectively address;
• we can experience difficulty in integrating cultures, personnel, operations and financial and other controls and systems
and retaining key employees and customers;
• we may be unable to achieve cost savings or other synergies anticipated in connection with an acquisition, investment,
joint venture or strategic relationship;
• we have assumed and may assume unknown liabilities, known contingent liabilities that become realized, known
liabilities that prove greater than anticipated, internal control deficiencies or exposure to regulatory sanctions resulting
from the acquired company’s or investee’s activities and the realization of any of these liabilities or deficiencies can
increase our expenses, adversely affect our financial position or cause us to fail to meet our public financial reporting
obligations;
• in connection with acquisitions and joint ventures, we often enter into post-closing financial arrangements such as
purchase price adjustments, earn-out obligations and indemnification obligations, which can have unpredictable
financial results;
21

-- 43 of 162 --

• as a result of our acquisitions and investments, we have recorded significant goodwill and other assets on our balance
sheet and if we are not able to realize the value of these assets, or if the value of our investments declines, we are
required to incur impairment charges;
• we may have interests that diverge from those of our joint venture partners or other strategic partners or the companies
we invest in, and we may not be able to direct or influence the management and operations of the joint venture, other
strategic relationship or investee in the manner we believe is most appropriate, exposing us to additional risk; and
• investing in or making loans to early-stage companies often entails a high degree of risk, and we do not always achieve
the strategic, technological, financial or commercial benefits we anticipate; we may lose our investment or fail to
recoup our loan; or our investment may be illiquid for a greater-than-expected period of time.
The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us
and as a result we may face unexpected liabilities.
Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against
certain liabilities related to the operation of the acquired company before we acquired it. In most of these agreements, however,
the liability of the former owners is limited and certain former owners may be unable to meet their indemnification
responsibilities. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result we
may face unexpected liabilities that adversely affect our business and financial statements.
Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or
our predecessors have disposed could adversely affect our business and financial statements.
We continually assess the strategic fit of our existing businesses and may divest, spin-off, split-off or otherwise dispose of
businesses that are deemed not to fit with our strategic plan or are not achieving the desired return on investment. For example,
in 2015, Danaher separated and split-off to Danaher shareholders the majority of its former communications business in a
Reverse Morris Trust transaction with NetScout Systems, Inc. (the “Communications Disposition”), in 2016 Danaher separated
and spun-off to Danaher shareholders its former Test & Measurement segment, Industrial Technologies segment (excluding the
product identification businesses) and retail/commercial petroleum business (collectively known as Fortive Corporation) (the
“Fortive Disposition”), and in 2019 Danaher consummated the separation and initial public offering (“IPO”) and subsequent
split-off of its Dental segment, known as Envista Holdings Corporation (the “Envista Disposition”). Transactions such as these
pose risks and challenges that could negatively impact our business and financial statements. For example, when we decide to
sell or otherwise dispose of a business or assets, we may be unable to do so on satisfactory terms within our anticipated
timeframe or at all, and even after reaching a definitive agreement to sell or dispose a business the sale is typically subject to
satisfaction of pre-closing conditions which may not become satisfied. In addition, divestitures or other dispositions can dilute
the Company’s earnings per share, have other adverse financial, tax and accounting impacts and distract management, and
disputes can arise with buyers. In addition, we have retained responsibility for and/or have agreed to indemnify buyers against
some known and unknown contingent liabilities related to a number of businesses we or our predecessors have sold or disposed.
The resolution of these contingencies has not had a material effect on our business or financial statements but we cannot be
certain that this favorable pattern will continue.
Potential indemnification liabilities pursuant to the Communications Disposition, the Fortive Disposition or the Envista
Disposition could materially and adversely affect our business and financial statements.
With respect to each of the Communications Disposition, the Fortive Disposition and the Envista Disposition, we entered into a
separation agreement and related agreements to govern the separation and related transactions and the relationship between the
respective companies going forward. These agreements provide for specific indemnity and liability obligations of each party
that can lead to disputes between us and the respective counterparty. If we are required to indemnify any of the other parties
under the circumstances set forth in these agreements, we may be subject to substantial liabilities. In addition, with respect to
the liabilities for which the other parties have agreed to indemnify us under these agreements, there can be no assurance that the
indemnity rights we have against such other parties will be sufficient to protect us against the full amount of the liabilities, or
that such other parties will be able to fully satisfy their respective indemnification obligations. It is also possible that a court
could disregard the allocation of assets and liabilities agreed to between Danaher and such other parties and require Danaher to
assume responsibility for obligations allocated to such other parties. Each of these risks could negatively affect our business
and financial statements.
22

-- 44 of 162 --

We could incur significant liability if any of the Communications Disposition, the Fortive Disposition or the Envista
Disposition is determined to be a taxable transaction.
We have received opinions from outside tax counsel to the effect that each of the Communications Disposition, the Fortive
Disposition and the Envista Disposition qualifies as a transaction that is described in Sections 355(a) and 368(a)(1)(D) of the
Internal Revenue Code. These opinions rely on certain facts, assumptions, representations and undertakings regarding the past
and future conduct of the companies’ respective businesses and other matters. If any of these facts, assumptions,
representations or undertakings are incorrect or not satisfied, our stockholders and we may not be able to rely on the respective
opinion of tax counsel and could be subject to significant tax liabilities. Notwithstanding the opinion of tax counsel, the
Internal Revenue Service (“IRS”) could determine on audit that any such transactions are taxable if it determines that any of
these facts, assumptions, representations or undertakings are not correct or have been violated or if it disagrees with the
conclusions in the respective opinion. If any such transaction is determined to be taxable for U.S. federal income tax purposes,
our stockholders that are subject to U.S. federal income tax and we could incur significant U.S. federal income tax liabilities.
Operational Risks
A significant disruption in, or breach in security of, our information technology systems or data or violation of data privacy
laws can adversely affect our business and financial statements.
We rely on information technology systems, some of which are provided and/or managed by third-parties, to process, transmit
and store electronic information (including sensitive data such as confidential business information and personally identifiable
data relating to employees, customers, other business partners and patients), and to manage or support a variety of critical
business processes and activities (such as receiving and fulfilling orders, billing, collecting and making payments, shipping
products, providing services and support to customers and fulfilling contractual obligations). In addition, some of our remote
monitoring products and services incorporate software and information technology that house personal data and some products
or software we sell to customers connect to our systems for maintenance or other purposes. These systems, products and
services (including those we acquire through business acquisitions) can be damaged, disrupted or shut down due to attacks by
computer hackers, computer viruses, ransomware, human error or malfeasance, power outages, hardware failures,
telecommunication or utility failures, catastrophes or other unforeseen events, and in any such circumstances our system
redundancy and other disaster recovery planning may be ineffective or inadequate. Attacks can also target hardware, software
and information installed, stored or transmitted in our products after such products have been purchased and incorporated into
third-party products, facilities or infrastructure. Security breaches of systems provided or enabled by us, regardless of whether
the breach is attributable to a vulnerability in our products or services, or security breaches of third party systems we rely on to
process, store or transmit electronic information, can result in the misappropriation, destruction or unauthorized disclosure of
confidential information or personal data belonging to us or to our employees, partners, customers, patients or suppliers. Like
most multinational corporations, our information technology systems and data have been subject to computer viruses, malicious
codes, unauthorized access and other cyber-attacks and we expect the sophistication and frequency of such attacks to continue
to increase. Unauthorized tampering, adulteration or interference with our products may also adversely affect product
functionality and result in loss of data, risk to patient safety and product recalls or field actions. The attacks, breaches,
misappropriations and other disruptions and damage described above can interrupt our operations or the operations of our
customers and partners, delay production and shipments, result in theft of our and our customers’ intellectual property and trade
secrets, result in disclosure of personally identifiable information, damage customer, patient, business partner and employee
relationships and our reputation and result in defective products or services, legal claims and proceedings, liability and penalties
under privacy laws and increased costs for security and remediation, in each case resulting in an adverse effect on our business
and financial statements.
In addition, our information technology systems require an ongoing commitment of significant resources to maintain and
enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology,
evolving legal and regulatory standards, evolving customer expectations, changes in the techniques used to obtain unauthorized
access to data and information systems, and the information technology needs associated with our changing products and
services. There can be no assurance that we will be able to successfully maintain, enhance and upgrade our systems as
necessary to effectively address these requirements. Further, a greater number of our employees are working remotely in
response to the COVID-19 pandemic and related governmental and community responses, which exposes us to greater
cybersecurity risks.
Any inability to maintain reliable information technology systems and appropriate controls with respect to global data privacy
and security requirements and prevent data breaches can result in adverse regulatory consequences, business consequences and
litigation. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed
controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in
the course of our business. Please see “Item 1. Business—Regulatory Matters” for additional information. Entities that are
23

-- 45 of 162 --

found to be in violation of HIPAA as the result of a breach of unsecured patient health information, a complaint about privacy
practices or an audit by the HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or
additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with
HHS to settle allegations of HIPAA non-compliance. Failure to comply with the requirements of GDPR and the applicable
national data protection laws of the EU member states may result in fines of up to €20 million or up to 4% of the total
worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Several
other countries such as China and Russia have passed, and other countries are considering passing, laws that require personal
data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. There is also a
new, broad privacy law in California, the CCPA, which came into effect in January 2020. The CCPA has some of the same
features as the GDPR, and has already prompted several other states to consider enacting similar laws. Government
enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data
privacy laws can result in civil and criminal, monetary and non-monetary penalties, any of which may adversely affect our
business and financial statements. In addition, compliance with the varying data privacy regulations across the United States
and around the world has required significant expenditures and may require additional expenditures, and may require further
changes in our products or business models that increase competition or reduce revenue.
Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can
adversely affect our business and financial statements.
Manufacturing or design defects or “bugs” in, unanticipated use of, safety or quality issues (or the perception of such issues)
with respect to, “off label” use of, or inadequate disclosure of risks relating to the use of products and services that we make or
sell (including items that we source from third-parties) can lead to personal injury, death, and/or property damage and adversely
affect our business and financial statements. These events can lead to recalls or safety alerts, result in the removal of a product
or service from the market and result in product liability or similar claims being brought against us. Recalls, removals and
product liability and similar claims (regardless of their validity or ultimate outcome) result in significant costs, as well as
negative publicity and damage to our reputation that could reduce demand for our products and services. Our business can also
be affected by studies of the utilization, safety and efficacy of medical device products and components that are conducted by
industry participants, government agencies and others. Any of the above can result in the discontinuation of marketing of such
products in one or more countries and give rise to claims for damages from persons who believe they have been injured as a
result of product issues, including claims by individuals or groups seeking to represent a class.
If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or
other events, our operations could be seriously harmed.
Our facilities, supply chains, distribution systems and information technology systems are subject to catastrophic loss due to
fire, flood, earthquake, hurricane, power shortage or outage, public health crisis (including epidemics and pandemics) and the
reaction thereto, war, terrorism, riot or other natural or man-made disasters, such as the COVID-19 pandemic and the damage
caused to our facilities by Hurricane Maria in Puerto Rico in 2017. If any of these facilities, supply chains or systems were to
experience a catastrophic loss, it could disrupt our operations, delay production and shipments, result in defective products or
services, diminish demand, damage customer relationships and our reputation and result in legal exposure and significant repair
or replacement expenses. The third-party insurance coverage that we maintain varies from time to time in both type and
amount depending on cost, availability and our decisions regarding risk retention, and may be unavailable or insufficient to
protect us against such losses.
The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly
encounter problems manufacturing products, our business and financial statements could suffer.
The manufacture of many of our products is a highly exacting and complex process, due in part to strict regulatory
requirements. Problems can arise during manufacturing for a variety of reasons, including equipment malfunction, failure to
follow specific protocols and procedures, problems with raw materials or components, natural disasters and environmental
factors, and if not discovered before the product is released to market can result in recalls and product liability exposure.
Because of the time required to approve and license certain regulated manufacturing facilities and other stringent regulations of
the FDA and similar agencies regarding the manufacture of certain of our products, an alternative manufacturer is not always
available on a timely basis to replace such production capacity. Any of these manufacturing problems could result in
significant adverse impacts to our business and financial statements.
24

-- 46 of 162 --

If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect
changes in market conditions and customer demand, our business and financial statements may suffer. In addition, our
reliance upon sole or limited sources of supply for certain materials, components and services can cause production
interruptions, delays and inefficiencies.
We purchase materials, components and equipment from third-parties for use in our manufacturing operations, including
metallic-based components, electronic components, chemistries, OEM products, plastics and other petroleum-based products.
Our profitability could be adversely impacted if we are unable to adjust our purchases to reflect changes in customer demand
and market fluctuations, including those caused by seasonality or cyclicality. During a market upturn, suppliers from time to
time extend lead times, limit supplies or increase prices. If we cannot purchase sufficient products at competitive prices and
quality and on a timely enough basis to meet increasing demand, we may not be able to satisfy market demand, product
shipments may be delayed, our costs may increase or we may breach our contractual commitments and incur liabilities.
Conversely, in order to secure supplies for the production of products, we sometimes enter into noncancelable purchase
commitments with vendors, which can impact our ability to adjust our inventory to reflect declining market demands. If
demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to
incur additional charges and our business and financial statements may suffer.
In addition, some of our businesses purchase certain requirements from sole or limited source suppliers for reasons of quality
assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers
encounter financial, operating or other difficulties or if our relationship with them changes, we might not be able to quickly
establish or qualify replacement sources of supply. The supply chains for our businesses can also be disrupted by supplier
capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability of key raw materials or
commodities and external events such as natural disasters, pandemic health issues, war, terrorist actions, governmental actions
(such as trade protectionism) and legislative or regulatory changes. Any of these factors can result in production interruptions,
delays, extended lead times and inefficiencies.
Because we cannot always immediately adapt our production capacity and related cost structures to changing market
conditions, at times our manufacturing capacity exceeds or falls short of our production requirements. Any or all of these
problems can result in the loss of customers, provide an opportunity for competing products to gain market acceptance and
otherwise adversely affect our business and financial statements.
Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels
of, key distributors and other channel partners can adversely affect our business and financial statements.
Certain of our businesses sell a significant amount of their products to or through key distributors and other channel partners
that have valuable relationships with customers and end-users. Some of these distributors and other partners also sell our
competitors’ products or compete with us directly, and if they favor competing products for any reason they may fail to market
our products effectively. Adverse changes in our relationships with these distributors and other partners, reduction or
discontinuation of their purchases from us or adverse developments in their financial condition, performance or purchasing
patterns, can adversely affect our business and financial statements. The levels of inventory maintained by our distributors and
other channel partners, and changes in those levels, also impacts our results of operations in any given period. In addition, the
consolidation of distributors and customers in certain of our served industries can adversely impact our business and financial
statements.
Our financial results are subject to fluctuations in the cost and availability of commodities that we use in our operations.
As discussed in “Item 1. Business—Materials,” our manufacturing and other operations employ a wide variety of components,
raw materials and other commodities. Prices for and availability of these components, raw materials and other commodities
have fluctuated significantly in the past. Any sustained interruption in the supply of these items could adversely affect our
business and financial statements. In addition, due to the highly competitive nature of the industries that we serve, the cost-
containment efforts of our customers and the terms of certain contracts we are party to, when commodity prices rise we are not
always able to pass along cost increases through higher prices. If we are unable to fully recover higher commodity costs
through price increases or offset these increases through cost reductions, or if there is a time delay between the increase in costs
and our ability to recover or offset these costs, our margins and profitability could decline and our business and financial
statements could be adversely affected.
Our restructuring actions can have long-term adverse effects on our business and financial statements.
We have implemented significant restructuring activities across our businesses to adjust our cost structure, and we may engage
in similar restructuring activities in the future. These restructuring activities and our regular ongoing cost reduction activities
(including in connection with the integration of acquired businesses) reduce our available talent, assets and other resources and
25

-- 47 of 162 --

can slow improvements in our products and services, adversely affect our ability to respond to customers, limit our ability to
increase production quickly if demand for our products increases and trigger adverse public attention. In addition, delays in
implementing planned restructuring activities or other productivity improvements, unexpected costs or failure to meet targeted
improvements may diminish the operational or financial benefits we expect to realize from such actions. Moreover, we may not
succeed in implementing present or future restructuring activities or cost reduction activities. Realizing the anticipated benefits
from these initiatives, if any benefits are achieved at all, can take several years, and we may be unable to achieve our targeted
cost efficiencies and profit margin improvements. Additionally, we may have insufficient access to capital to fund investments
in these strategic initiatives, or our business strategy may change from time to time, which could delay our ability to implement
initiatives that we believe are important to our business. Any of the circumstances described above could adversely impact our
business and financial statements.
Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and
results of operations.
Certain of our U.S. and non-U.S. employees are subject to collective labor arrangements. We are subject to potential work
stoppages, union and works council campaigns and other labor disputes, any of which could adversely impact our business and
financial statements.
Intellectual Property Risks
If we are unable to adequately protect our intellectual property, or if third-parties infringe our intellectual property rights,
we may suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly
pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable to
the United States.
Many of the markets we serve are technology-driven, and as a result intellectual property rights play a significant role in
product development and differentiation. We own numerous patents, trademarks, copyrights, trade secrets and other intellectual
property and licenses to intellectual property owned by others, which in aggregate are important to our business. The
intellectual property rights that we obtain, however, are not always sufficiently broad and do not always provide us a significant
competitive advantage, and patents may not be issued for pending or future patent applications owned by or licensed to us. In
addition, the steps that we and our licensors have taken to maintain and protect our intellectual property do not always prevent it
from being challenged, invalidated, circumvented, designed-around or becoming subject to compulsory licensing. In some
circumstances, enforcement is not available to us because an infringer has a dominant intellectual property position or for other
business reasons. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties
to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements adequately protect
our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that
others will not independently develop substantially equivalent proprietary information or that third-parties will not otherwise
gain access to our trade secrets or other proprietary rights. Our failure to obtain or maintain intellectual property rights that
convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized
use of such property and the cost of enforcing our intellectual property rights can adversely impact our business and financial
statements.
These risks are particularly pronounced in countries in which we do business that do not have levels of protection of corporate
proprietary information, intellectual property, technology and other assets comparable to the United States. The risks we
encounter in such countries include but are not limited to the following:
• Joint ventures that we participate in can include restrictions that could compromise our control over the intellectual
property, technology and proprietary information of the joint venture;
• As we expand our operations globally, increasing amounts of our data, intellectual property and technology is used and
stored in countries outside the United States, and regulations in certain countries require data to be stored locally.
These factors increase the risk that such data, intellectual property and technology could be stolen or otherwise
compromised;
• Certain of our products have been counterfeited and we may encounter additional and/or increased levels of
counterfeiting in the future;
• Governmental entities may adopt regulations or other requirements that give them rights to certain of our intellectual
property, technology and/or proprietary information, such as through compulsory licensing or foreign ownership
restrictions or requirements;
26

-- 48 of 162 --

• In certain countries, we do not have the same ability to enforce intellectual property rights as we do in the United
States;
• Governmental regulations relating to state secrecy or other topics limit our ability to transfer data or technology out of
certain jurisdictions; and
• Risks, costs and challenges of operating in a particular jurisdiction can result in a decision to relocate or divert
operations to a different jurisdiction, potentially at higher cost.
Any of these risks can adversely impact our business and financial statements. Refer to “—International economic, political,
legal, compliance, social and business factors could negatively affect our financial statements” for a discussion of additional
risks relating to our international operations.
Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we
could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
From time to time, we receive notices from third parties alleging intellectual property infringement or misappropriation of third
parties’ intellectual property and cannot be certain that the conduct of our business does not and will not infringe or
misappropriate the intellectual property rights of others. Disputes or litigations regarding intellectual property can be costly and
time-consuming to defend due to the complexity of many of our technologies and the uncertainty of intellectual property
litigation. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response
to a claim of infringement or misappropriation. In addition, as a result of such claims of infringement or misappropriation, we
could lose our rights to critical technology, be unable to license critical technology or sell critical products and services, be
required to pay substantial damages or license fees with respect to the infringed rights, be required to license technology or
other intellectual property rights from others, be required to cease marketing, manufacturing or using certain products or be
required to redesign, re-engineer or re-brand our products at substantial cost, any of which could adversely impact our business
and financial statements. Third-party intellectual property rights may also make it more difficult or expensive for us to meet
market demand for particular product or design innovations. When we are required to seek licenses under patents or other
intellectual property rights of others, we are not always able to acquire these licenses on acceptable terms, if at all. Even if we
successfully defend against claims of infringement or misappropriation, we may incur significant costs and diversion of
management attention and resources, which could adversely affect our business and financial statements.
The U.S. government has certain rights to use and disclose some of the intellectual property that we license and could
exclusively license it to a third-party if we fail to achieve practical application of the intellectual property.
Certain technology licensed by us under agreements with third-party licensors is subject to government rights. Government
rights in inventions conceived or reduced to practice under a government-funded program can include a nonexclusive, royalty-
free worldwide license to practice or have practiced such inventions for any governmental purpose. In addition, the U.S.
government has the right to require us or our licensors (as applicable) to grant licenses which would be exclusive under any of
such inventions to a third-party if they determine that: (1) adequate steps have not been taken to commercialize such inventions
in a particular field of use; (2) such action is necessary to meet public health or safety needs; or (3) such action is necessary to
meet requirements for public use under federal regulations. Further, the government rights include the right to use and disclose,
without limitation, technical data relating to licensed technology that was developed in whole or in part at government expense.
Financial and Tax Risks
Our outstanding debt has increased significantly as a result of the Cytiva Acquisition, and we may incur additional debt in
the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively
impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect
our business and financial statements.
As of December 31, 2020, we had approximately $21.2 billion in outstanding indebtedness. In addition, we had the ability to
incur approximately $4.4 billion of additional indebtedness in direct borrowings or under our outstanding commercial paper
facilities based on the amounts available under our credit facilities which were not being used to backstop outstanding
commercial paper balances. Our debt level and related debt service obligations (as well as the dividend obligations pursuant to
our Series A and Series B Mandatory Convertible Preferred Stock (“MCPS”)) can have negative consequences, including (1)
requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt (or dividends
on our MCPS), which reduces the funds we have available for other purposes such as acquisitions and other investments; (2)
reducing our flexibility in planning for or reacting to changes in our business and market conditions; and (3) exposing us to
interest rate risk since a portion of our debt obligations are at variable rates.
27

-- 49 of 162 --

If our credit ratings are downgraded or put on watch for a potential downgrade, we may not be able to sell additional debt
securities or borrow money in the amounts, at the times or interest rates or upon the more favorable terms and conditions that
might be available if our current credit ratings were maintained.
Our credit facilities and long-term debt obligations also impose certain restrictions on us, including certain restrictions on our
ability to incur liens on our assets, and a requirement under our credit facilities to maintain a consolidated leverage ratio (the
ratio of consolidated indebtedness to consolidated indebtedness plus shareholders’ equity) of 0.65 to 1.0 or less. If we breach
any of these restrictions and cannot obtain a waiver from the lenders on favorable terms, subject to applicable cure periods, the
outstanding indebtedness (and any other indebtedness with cross-default provisions) could be declared immediately due and
payable, which would adversely affect our business and financial statements (including without limitation our liquidity). If we
add new debt in the future, the risks described above would increase.
We may be required to recognize impairment charges for our goodwill and other intangible assets.
As of December 31, 2020, the net carrying value of our goodwill and other intangible assets totaled approximately $56.7
billion. In accordance with generally accepted accounting principles, we periodically assess these assets to determine if they
are impaired. Significant negative industry or economic trends, disruptions to our business, inability to effectively integrate
acquired businesses, unexpected significant changes or planned changes in use of our assets, changes in the structure of our
business, divestitures, market capitalization declines, or increases in associated discount rates can impair our goodwill and other
intangible assets. Any charges relating to such impairments adversely affect our financial statements in the periods recognized.
Foreign currency exchange rates can adversely affect our financial statements.
Sales and purchases in currencies other than the U.S. dollar expose us to fluctuations in foreign currencies relative to the U.S.
dollar and may adversely affect our financial statements. Increased strength of the U.S. dollar increases the effective price of
our products sold in U.S. dollars into other countries, which can from time to time require us to lower our prices or adversely
affect sales to the extent we do not increase local currency prices. Decreased strength of the U.S. dollar adversely affects the
cost of materials, products and services we purchase overseas. Sales and expenses of our non-U.S. businesses are also
translated into U.S. dollars for reporting purposes and the strengthening of the U.S. dollar generally results in unfavorable
translation effects. In addition, certain of our businesses invoice customers in a currency other than the business’ functional
currency, and movements in the invoiced currency relative to the functional currency can also result in unfavorable translation
effects. The Company also faces exchange rate risk from its investments in subsidiaries owned and operated in foreign
countries.
Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In
addition, audits by tax authorities can result in additional tax payments for prior periods.
We are subject to income taxes in the United States and in numerous non-U.S. jurisdictions. On December 22, 2017, the Tax
Cuts and Jobs Act (“TCJA”) was enacted. The TCJA significantly revised the U.S. federal corporate income tax law by, among
other things, lowering the corporate income tax rate to 21.0%, implementing a quasi-territorial tax system, and imposing a one-
time tax on unremitted cumulative non-U.S. earnings of foreign subsidiaries (“Transition Tax”).
Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and
interpretations pertaining to the TCJA), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the
complexity of our intercompany arrangements, uncertainties regarding the geographic mix of earnings in any particular period,
and other factors, our estimates of effective tax rate and income tax assets and liabilities can be incorrect and our financial
statements could be adversely affected; please refer to MD&A for a discussion of additional factors that may adversely affect
our effective tax rate and decrease our profitability in any period. The impact of the factors referenced in the preceding
sentence may be substantially different from period-to-period.
In addition, the amount of income taxes we pay is subject to ongoing audits by U.S. federal, state and local tax authorities and
by non-U.S. tax authorities, such as the audits described in MD&A and the Company’s Consolidated Financial Statements. If
audits result in payments or assessments different from our reserves, our results can include unfavorable adjustments to our tax
liabilities and our financial statements can be adversely affected. For example, the Danish tax authority’s assessments
purporting to impose withholding tax relating to interest accrued in Denmark on historical borrowings from certain of the
Company’s subsidiaries (further discussed in MD&A and the Company’s Consolidated Financial Statements) could take many
years to resolve and could ultimately result in a material, adverse impact to the Company’s financial statements, including its
cash flows and effective tax rates. Any further significant changes to the tax system in the United States or in other
jurisdictions (including changes in the taxation of international income as further described below) could also adversely affect
our financial statements. Please see MD&A and the Company’s Consolidated Financial Statements for a further discussion of
the Company’s tax audits.
28

-- 50 of 162 --

Changes in tax law relating to multinational corporations could adversely affect our tax position.
The U.S. Congress, government agencies in non-U.S. jurisdictions where we and our affiliates do business, and the
Organisation for Economic Co-operation and Development (“OECD”) have focused on issues related to the taxation of
multinational corporations. One example is in the area of “base erosion and profit shifting,” for which the OECD has released
several components of its comprehensive plan that have been adopted and expanded by many taxing authorities to address
perceived tax abuse and inconsistencies between tax jurisdictions. As a result, the tax laws in the United States and other
countries in which we do business could change on a prospective or retroactive basis, and any such changes could adversely
affect our business and financial statements.
Legal, political, and economic uncertainty surrounding the exit of the United Kingdom (“UK”) from the EU could have an
adverse effect on our business and financial statements.
The UK ceased to be a member state of the EU on January 31, 2020 (commonly referred to as “Brexit”), and the transition
period provided for in the withdrawal agreement entered by the UK and the EU ended on December 31, 2020. In December
2020, the UK and the EU agreed on a trade and cooperation agreement that applies provisionally until it is ratified by the parties
to the agreement. On December 31, 2020, the UK passed legislation giving effect to the trade and cooperation agreement, with
the EU expected to formally adopt the agreement in the first half of 2021. The trade and cooperation agreement covers the
general objectives and framework of the relationship between the UK and the EU, including with respect to trade, transport,
visas, judicial matters, law enforcement and security matters, and provides for continued participation in community programs
and mechanisms for dispute resolution. Uncertainties remain regarding the application of the terms of the trade and cooperation
agreement and the other potential impacts of Brexit, such as the impact of new or different laws and regulations as the UK
determines which EU laws to replace or replicate (including potentially new or different regulations affecting clearance or
approval of products that are developed or manufactured in the UK), and trade and tax impacts as the UK negotiates its own tax
and trade treaties with countries around the world. The impacts from Brexit could add time and expense to the conduct of our
business, delay regulatory approval of products, adversely impact the manufacturing or movement of products, adversely
impact customer demand and otherwise adversely affect our business and financial statements. As of December 31, 2020, the
Company had eight manufacturing facilities in the UK and the Company’s net investment in property, plant and equipment in
the UK was $214 million. For the year ended December 31, 2020, less than 5% of our sales were derived from customers
located in the UK, however, the impact of Brexit could also impact our business and financial statements outside the UK.
Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements.
The performance of the financial markets and interest rates impact our defined benefit pension plan expenses and funding
obligations. Significant changes in market interest rates, decreases in the fair value of plan assets, investment losses on plan
assets and changes in discount rates can increase our funding obligations and adversely impact our financial statements. In
addition, upward pressure on the cost of providing health care coverage to current employees and retirees can increase our
future funding obligations and adversely affect our financial statements.
Legal, Regulatory, Compliance and Reputational Risks
Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the
reaction of other countries thereto, particularly China, can have an adverse effect on our business and financial statements.
Significant developments or changes in U.S. laws and policies (including as a result of the new U.S. administration), such as
laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries
where we or our customers operate, or governing the health care system and drug prices, can adversely affect our business and
financial statements. For example, the previous U.S. administration increased tariffs on certain goods imported into the United
States and trade tensions between the United States and China escalated, with each country imposing significant, additional
tariffs on a wide range of goods imported from the other country. The U.S. and China could impose other types of restrictions
such as limitations on government procurement or technology export restrictions, which could affect our access to markets.
These factors have adversely affected, and in the future could further adversely affect, our business and financial statements.
Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business
partners.
We cannot provide assurance that our internal controls and compliance systems, including our Code of Conduct, always protect
us from acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that
violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks
and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace
behavior, export and import compliance, economic and trade sanctions, money laundering and data privacy. In particular, the
29

-- 51 of 162 --

U.S. Foreign Corrupt Practices Act, the UK Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit
companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or
retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree.
Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal
investigations in the United States and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and
criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition,
the government may seek to hold us liable for violations committed by companies in which we invest or that we acquire. We
also rely on our suppliers to adhere to our supplier code of conduct, and material violations of such code of conduct could occur
that could have a material effect on our business and financial statements.
Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our
business and financial statements.
In addition to the environmental, health, safety, health care, medical device, anticorruption, data privacy and other regulations
noted elsewhere in this Annual Report, our businesses are subject to extensive regulation by U.S. and non-U.S. governmental
and self-regulatory entities at the supranational, federal, state, local and other jurisdictional levels, including the following:
• We are required to comply with various import laws and export control and economic sanctions laws, which may
affect our transactions with certain customers, business partners and other persons and dealings between our
employees and between our subsidiaries. In certain circumstances, export control and economic sanctions regulations
may prohibit the export of certain products, services and technologies. In other circumstances, we may be required to
obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to
our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt
our supply of imported inventory. In addition, we sell and provide products and technology to third parties, such as
agents, representatives and distributors, who may export such items to end-users, and if any of these third parties do
not comply with applicable export or import laws we may incur liability. In addition, from time to time, certain of our
subsidiaries have limited business dealings in countries subject to comprehensive sanctions. These business dealings
represent an insignificant amount of our consolidated revenues and income but expose us to a heightened risk of
violating applicable sanctions regulations. We have established policies and procedures designed to assist with our
compliance with such laws and regulations. However, there can be no assurance that our policies and procedures have
prevented and will prevent violations of these regulations and any violation can adversely affect our business and
financial statements.
• We also have agreements to sell products and services to government entities and are subject to various statutes and
regulations that apply to companies doing business with government entities (less than 5% of our 2020 sales were
made to the U.S. federal government). The laws governing government contracts differ from the laws governing
private contracts. For example, many government contracts contain pricing and other terms and conditions that are not
applicable to private contracts. Our agreements with government entities are in some cases subject to termination,
reduction or modification at the convenience of the government or in the event of changes in government
requirements, reductions in federal spending and other factors, and we may underestimate our costs of performing
under the contract. In certain cases, a governmental entity may require us to pay back amounts it has paid to us.
Government contracts that have been awarded to us following a bid process can become the subject of a bid protest by
a losing bidder, which could result in loss of the contract. We are also subject to investigation and audit for
compliance with the requirements governing government contracts.
These are not the only regulations that our businesses must comply with. The regulations we are subject to have tended to
become more stringent over time and can be inconsistent across jurisdictions. We, our representatives and the industries in
which we operate are at times under review and/or investigation by regulatory authorities. Failure to comply (or any alleged or
perceived failure to comply) with the regulations referenced above or any other regulations can result in import detentions,
fines, damages, civil and administrative penalties, injunctions, consent decrees, suspensions or losses of regulatory approvals,
recall or seizure of products, operating restrictions, refusal of the government to approve product export applications or allow us
to enter into supply contracts, disbarment from selling to certain governmental agencies or exclusion from government funded
healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight
and reporting obligations to resolve allegations of non-compliance, disruption of our business, limitation on our ability to
manufacture, import, export and sell products and services, loss of customers, significant legal and investigatory fees,
disgorgement, individual imprisonment, reputational harm, contractual damages, diminished profits, curtailment or restricting
of business operations, criminal prosecution and other monetary and non-monetary penalties. Compliance with these and other
regulations can also affect our returns on investment, require us to incur significant expenses or modify our business model or
impair our flexibility in modifying product, marketing, pricing or other strategies for growing our business. Our products and
operations are also often subject to the rules of industrial standards bodies such as the International Standards Organization, and
30

-- 52 of 162 --

failure to comply with these rules can result in withdrawal of certifications needed to sell our products and services and
otherwise adversely impact our business and financial statements. For additional information regarding these risks, refer to
“Item 1. Business—Regulatory Matters.”
We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course
of our business that can adversely affect our business and financial statements.
We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of
our business (or related to the business operations of previously owned entities), including claims or counterclaims for damages
arising out of the use of products or services and claims relating to intellectual property matters, employment matters, tax
matters, commercial disputes, breach of contract claims, competition and sales and trading practices, environmental matters,
personal injury, insurance coverage, securities matters, fiduciary duties and acquisition or divestiture-related matters, as well as
regulatory subpoenas, requests for information, investigations and enforcement. We also from time to time become subject to
lawsuits as a result of acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities
provided in connection with, businesses divested by us or our predecessors. The types of claims made in lawsuits include
claims for compensatory damages, punitive and consequential damages (and in some cases, treble damages) and/or injunctive
relief. The defense of these lawsuits can divert our management’s attention, we from time to time incur significant expenses in
defending these lawsuits, and we can be required to pay damage awards or settlements or become subject to equitable remedies
that adversely affect our business and financial statements. Moreover, any insurance or indemnification rights that we may
have may be insufficient or unavailable to protect us against such losses. Because most contingencies are resolved over long
periods of time, new developments (including litigation developments, the discovery of new facts, changes in legislation and
outcomes of similar cases), changes in assumptions or changes in the Company’s strategy in any given period can require us to
adjust the loss contingency estimates that we have recorded in our financial statements, record estimates for liabilities or assets
previously not susceptible of reasonable estimates or pay cash settlements or judgments. Any of these developments can
adversely affect our business and financial statements in any particular period. We cannot assure you that our liabilities in
connection with current and future litigation and other legal and regulatory proceedings will not exceed our estimates or
adversely affect our financial statements and business. However, based on our experience, current information and applicable
law, we do not believe that it is reasonably possible that any amounts we may be required to pay in connection with litigation
and other legal and regulatory proceedings in excess of our reserves as of December 31, 2020 will have a material effect on our
business or financial statements.
From time to time, we become aware through our internal audits and other internal control procedures, employees or other
parties of possible compliance matters, such as complaints or concerns relating to accounting, internal controls, financial
reporting, auditing or ethical matters or relating to compliance with laws. When we become aware of such possible compliance
matters, we investigate internally and take what we believe to be appropriate corrective action. Internal investigations can lead
to the assertion of claims or the commencement of legal or regulatory proceedings against us and adversely affect our business
and financial statements.
Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other
countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health
information. Failure to comply with those regulations could adversely affect our business and financial statements.
Certain of our products are medical devices and other products that are subject to regulation by the U.S. FDA, by other federal
and state governmental agencies, by comparable agencies of other countries and regions, by certain accrediting bodies and by
regulations governing hazardous materials and drugs-of abuse (or the manufacture and sale of products containing any such
materials). The global regulatory environment has become increasingly stringent and unpredictable. Several countries that did
not have regulatory requirements for medical devices have established such requirements in recent years, and other countries
have expanded, or plan to expand, their existing regulations. Please see “Item 1. Business—Regulatory Matters” for more
information. Failure to meet these requirements adversely impacts our business and financial statements in the applicable
geographies.
To varying degrees, these regulators require us to comply with laws and regulations governing the development, testing,
manufacturing, labeling, marketing, distribution and post-marketing surveillance of our products. We cannot guarantee that we
will be able to obtain regulatory clearance (such as 510(k) clearance) or approvals for our new products or modifications to (or
additional indications or uses of) existing products within our anticipated timeframe or at all, and if we do obtain such clearance
or approval it may be time-consuming, costly and subject to restrictions. Our ability to obtain such regulatory clearances or
approvals will depend on many factors, for example our ability to obtain the necessary clinical trial results, and the process for
obtaining such clearances or approvals could change over time and may require the withdrawal of products from the market
until such clearances are obtained. Even after initial regulatory clearance or approval, we are subject to periodic inspection by
these regulatory authorities, and if safety issues arise we can be required to amend conditions for use of a product, such as
31

-- 53 of 162 --

providing additional warnings on the product’s label or narrowing its approved intended use, which could reduce the product’s
market acceptance. We are also subject to various laws regulating fraud and abuse, research and development, pricing and sales
and marketing practices, the privacy and security of health information as well as manufacturing and quality standards,
including the federal regulations described in “Item 1. Business—Regulatory Matters.”
Government authorities may conclude that our business practices do not comply with current or future statutes, regulations,
agency guidance or case law. Failure to obtain required regulatory clearances or approvals before marketing our products (or
before implementing modifications to or promoting additional indications or uses of our products), other violations of laws or
regulations, failure to remediate inspectional observations to the satisfaction of these regulatory authorities, real or perceived
efficacy or safety concerns or trends of adverse events with respect to our products (even after obtaining clearance for
distribution) and unfavorable or inconsistent clinical data from existing or future clinical trials can lead to FDA Form 483
Inspectional Observations, warning letters, notices to customers, declining sales, loss of customers, loss of market share,
remediation and increased compliance costs, recalls, seizures of adulterated or misbranded products, fines, expenses,
injunctions, civil penalties, criminal penalties, consent decrees, administrative detentions, refusals to permit importations,
partial or total shutdown of production facilities or the implementation of operating restrictions, narrowing of permitted uses for
a product, refusal of the government to grant 510(k) clearance, suspension or withdrawal of approvals, pre-market notification
rescissions and other adverse effects referenced under the risk factor titled “Our businesses are subject to extensive regulation;
failure to comply with those regulations could adversely affect our business and financial statements.” Further, defending
against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if
we are successful in defending against any such actions brought against us, our business may be impaired. Ensuring that our
internal operations and business arrangements with third parties comply with applicable laws and regulations also involves
substantial costs.
Our products are subject to clinical trials, the results of which may be unexpected, or perceived as unfavorable by the
market, and could adversely affect our business and financial statements.
As a part of the regulatory process of obtaining marketing clearance for certain new products and new indications for certain
existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations and
trial endpoints. Unexpected or inconsistent clinical data from existing or future clinical trials, or a regulator’s or the market’s
perception of this clinical data, can adversely impact our ability to obtain product approvals, our position in, and share of, the
markets in which we participate and our business and financial statements.
Off-label marketing of our products could result in substantial penalties.
The FDA strictly regulates the promotional claims that may be made about approved or cleared products. In particular, any
clearances we may receive only permit us to market our products for the uses indicated on the labeling cleared by the FDA. We
may request additional label indications for our current products, and the FDA may deny those requests outright, require
additional expensive performance or clinical data to support any additional indications or impose limitations on the intended use
of any cleared products as a condition of clearance. If the FDA or any other federal, state or foreign regulator determines that
we have marketed our products for off-label use, we can be subject to exclusion from participation in government healthcare
programs and the other adverse effects referenced under the risk factor titled “Certain of our businesses are subject to extensive
regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the
healthcare industry and the privacy and security of health information. Failure to comply with those regulations could
adversely affect our business and financial statements.” Any of these events could significantly harm our business and financial
statements.
Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may
require us to recall or cease marketing our products.
Once a medical device is permitted to be legally marketed in the United States pursuant to a 510(k) clearance, a manufacturer
may be required to notify the FDA of certain modifications to the device (similar requirements apply in other jurisdictions).
Manufacturers determine in the first instance whether a change to a product requires a new 510(k) clearance or premarket
submission, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding
whether new clearances are necessary. We have made modifications to our products in the past and have determined based on
our review of the applicable FDA regulations and guidance that in certain instances new 510(k) clearances or other premarket
submissions were not required. We may make similar modifications or add additional features in the future that we believe do
not require a new 510(k) clearance. If the FDA disagrees with our determinations and requires us to submit new 510(k)
notifications, we may be required to cease marketing or to recall the modified product until we obtain clearance, and we may be
subject to civil and criminal, monetary and non-monetary penalties and damage to our reputation.
32

-- 54 of 162 --

Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and
violations that could adversely affect our business and financial statements.
Our operations, products and services are subject to numerous U.S. federal, state, local and non-U.S. environmental, health and
safety laws and regulations concerning, among other things, the health and safety of our employees, the generation, storage, use
and transportation of hazardous materials, emissions or discharges of substances into the environment, investigation and
remediation of hazardous substances or materials at various sites, chemical constituents in products and end-of-life disposal and
take-back programs for products sold. We cannot assure you that our environmental, health and safety compliance program (or
the compliance programs of businesses we acquire) have been or will at all times be effective. Failure to comply with any of
these laws can result in civil and criminal, monetary and non-monetary penalties and damage to our reputation. In addition, we
cannot provide assurance that our costs of complying with current or future environmental protection and health and safety laws
will not exceed our estimates or adversely affect our business or financial statements.
In addition, we from time to time incur costs related to remedial efforts or alleged environmental damage associated with past
or current waste disposal practices or other hazardous materials handling practices. We are also from time to time party to
personal injury, property damage or other claims brought by private parties alleging injury or damage due to the presence of or
exposure to hazardous substances. We can also become subject to additional remedial, compliance or personal injury costs due
to future events such as changes in existing laws or regulations, changes in agency direction or enforcement policies,
developments in remediation technologies, changes in the conduct of our operations and changes in accounting rules. For
additional information regarding these risks, refer to the Consolidated Financial Statements included in this Annual Report. We
cannot assure you that our liabilities arising from past or future releases of, or exposures to, hazardous substances will not
exceed our estimates or adversely affect our reputation and financial statements or that we will not be subject to additional
claims for personal injury or remediation in the future based on our past, present or future business activities. However, based
on the information we currently have we do not believe that it is reasonably possible that any amounts we may be required to
pay in connection with environmental matters in excess of our reserves as of December 31, 2020 will have a material effect on
our business or financial statements.
Changes in governmental regulations can reduce demand for our products or services or increase our expenses.
We compete in markets in which we and our customers must comply with supranational, federal, state, local and other
jurisdictional regulations, such as regulations governing health and safety, the environment, food and drugs, privacy and
electronic communications. We develop, configure and market our products and services to meet customer needs created by
these regulations. These regulations are complex, change frequently, have tended to become more stringent over time and may
be inconsistent across jurisdictions. Any significant change in any of these regulations (or in the interpretation or application
thereof) can reduce demand for, increase our costs of producing or delay the introduction of new or modified products and
services, or restrict our existing activities, products and services. For example, a number of our products and services are
marketed to the pharmaceutical and related industries for use in discovering and developing drugs and therapies. Changes in
the U.S. FDA’s regulation of the drug discovery and development process can have an adverse effect on the demand for these
products and services. In addition, in certain of our markets our growth depends in part upon the introduction of new
regulations. In these markets, the delay or failure of governmental and other entities to adopt or enforce new regulations, the
adoption of new regulations which our products and services are not positioned to address or the repeal of existing regulations,
can adversely affect demand. In addition, regulatory deadlines can result in substantially different levels of demand for our
products and services from period-to-period.
ITEM 1B. UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 2. PROPERTIES
As of December 31, 2020, the Company had facilities in over 60 countries, including approximately 239 significant
administrative, sales, research and development, manufacturing and distribution facilities. 98 of these facilities are located in
the United States in over 20 states and 141 are located outside the United States, primarily in Europe and to a lesser extent in
Asia, South America, the rest of North America and Australia. Refer to the Consolidated Financial Statements included in this
Annual Report for additional information with respect to the Company’s lease commitments.
ITEM 3. LEGAL PROCEEDINGS
For information regarding legal proceedings, refer to the section titled “Legal Proceedings” in MD&A.
33

-- 55 of 162 --

DCH>HI:CIL>I=,+:<JA6I>DC, $"I:B L:=6K::A:8I:9ID9>H8ADH:I=DH::CK>GDCB:CI6AEGD8::9>C<HL>I=6
<DK:GCB:CI6A:CI>IN6H6E6GINL=:G:I=:DBE6CNG:6HDC67AN7:A>:K:HHJ8=EGD8::9>C<LDJA9G:HJAI>CBDC:I6GNH6C8I>DCH 
:M8AJH>K:D;>CI:G:HI6C98DHIH D;B>AA>DCDGBDG:
)" "#().(!$(*'(
'DI6EEA>867A:
#$'")$#$*)$*'-*)+$'(
,:I;DGI=7:ADL6G:I=:C6B:H 6<:H EDH>I>DCH6C9:ME:G>:C8:D;6C6=:GWH:M:8JI>K:D;;>8:GH6HD;:7GJ6GN  AAD;
6C6=:GWH:M:8JI>K:D;;>8:GH=DA9D;;>8:6II=:EA:6HJG:D;6C6=:GWHD6G9D;>G:8IDGH .CA:HHDI=:GL>H:HI6I:9 I=:EDH>I>DCH
>C9>86I:96G:6C6=:GEDH>I>DCH
#0<4 	64 	%>B8C8>= 	$55824A(8=24
,I:K:C& +6A:H 	 	=6>GB6CD;I=:D6G9 	
&>I8=:AA) +6A:H 	 	=6>GB6CD;I=:M:8JI>K:DBB>II:: 	
+6>C:G& A6>G 	 	)G:H>9:CI6C9=>:;M:8JI>K:(;;>8:G 	
&6II=:L+ &8 G:L 	 	M:8JI>K:/>8:)G:H>9:CI6C9=>:;>C6C8>6A(;;>8:G 	
#:CC>;:G% !DC:N8JII 	 	M:8JI>K:/>8:)G:H>9:CI 	
#D6@>B0:>9:B6C>H 	 	M:8JI>K:/>8:)G:H>9:CI 	
G>6C0 AA>H 	 	,:C>DG/>8:)G:H>9:CIS :C:G6ADJCH:A 	
#DH: 6GADH JI>:GG:O +6BDH 	 	,:C>DG/>8:)G:H>9:CIS=>:;,8>:CI>;>8(;;>8:G 	
0>AA>6B! $>C< 	 	,:C>DG/>8:)G:H>9:CIS,IG6I:<>8:K:ADEB:CI 	
C<:A6, %6ADG 	 	,:C>DG/>8:)G:H>9:CIS!JB6C+:HDJG8:H 	
+D7:GI, %JIO 	 	,:C>DG/>8:)G:H>9:CIS=>:;88DJCI>C<(;;>8:G 	
6C>:A +6H@6H 	 	,:C>DG/>8:)G:H>9:CISDGEDG6I::K:ADEB:CI 	
,I:K:C& +6A:H>H68D ;DJC9:GD;6C6=:G6C9=6HH:GK:9DC6C6=:GWHD6G9D;>G:8IDGHH>C8: H:GK>C<6H6C6=:GWH
=6>GB6CD;I=:D6G9H>C8: !:L6H6AHD(D;I=:DBE6CN;GDBID &G +6A:H>H6AHD6B:B7:GD;I=:
7D6G9D;9>G:8IDGHD;DGI>K:DGEDG6I>DC 6C9>H67GDI=:GD;&>I8=:AA) +6A:H
&>I8=:AA) +6A:H>H68D ;DJC9:GD;6C6=:G6C9=6HH:GK:9DC6C6=:GWHD6G9D;>G:8IDGHH>C8: H:GK>C<6H=6>GB6C
D;I=:M:8JI>K:DBB>II::D;6C6=:GH>C8: !:L6H6AHD)G:H>9:CID;I=:DBE6CN;GDBID &G +6A:H>H
6AHD6B:B7:GD;I=:7D6G9D;9>G:8IDGHD;DA;6MDGEDG6I>DC6C9D;DGI>K:DGEDG6I>DC 6C9>H67GDI=:GD;,I:K:C& +6A:H
+6>C:G& A6>G=6HH:GK:96H)G:H>9:CI6C9=>:;M:8JI>K:(;;>8:GH>C8:,:EI:B7:G 6;I:GH:GK>C<6HM:8JI>K:/>8:
)G:H>9:CI;GDB#6CJ6GNIDJ<JHI6C9/>8:)G:H>9:CIS GDJEM:8JI>K:;GDB&6G8=ID#6CJ6GN
&6II=:L+ &8 G:L=6HH:GK:96HM:8JI>K:/>8:)G:H>9:CI6C9=>:;>C6C8>6A(;;>8:GH>C8:#6CJ6GN 6;I:GH:GK>C<6H
GDJE(D;6C6=:G;GDBJCI>A:8:B7:G
#:CC>;:G% !DC:N8JII=6HH:GK:96HM:8JI>K:/>8:)G:H>9:CIH>C8:#6CJ6GN6;I:GH:GK>C<6H/>8:)G:H>9:CIS GDJE
M:8JI>K:;GDB&6NJCI>A:8:B7:G )G:H>9:CID;6C6=:GWH)6AA7JH>C:HH;GDB#6CJ6GNJCI>AEG>A6C9
)G:H>9:CID;6C6=:GWH:8@B6C%>;:,8>:C8:H7JH>C:HH;GDB&6NJCI>A:8:B7:G
#D6@>B0:>9:B6C>H=6HH:GK:96HM:8JI>K:/>8:)G:H>9:CIH>C8::8:B7:G6;I:GH:GK>C<6H/>8:)G:H>9:CIS GDJE
M:8JI>K:;GDB&6G8=JCI>A:8:B7:G
G>6C0 AA>H=6HH:GK:96H,:C>DG/>8:)G:H>9:CIS :C:G6ADJCH:AH>C8:?D>C>C<6C6=:G>C#6CJ6GN 
#DH: 6GADH JI>:GG:O +6BDH=6HH:GK:96H,:C>DG/>8:)G:H>9:CIS=>:;,8>:CI>;>8(;;>8:GH>C8:?D>C>C<6C6=:G>C:8:B7:G
 )G>DGID?D>C>C<6C6=:G G  JI>:GG:O +6BDHH:GK:96H/>8:)G:H>9:CI GJ<>H8DK:GN;DG77/>: "C8 6
7>DE=6GB68:JI>86A8DBE6CN ;GDB#6CJ6GNID:8:B7:G6H)G:H>9:CI6C9(D;+:E:GID>G:"BBJC:&:9>8>C:H 6
7>DI:8=CDAD<N8DBE6CN ;GDBJ<JHIJCI>A#6CJ6GN6C96H)G:H>9:CI6C9(D;,NCAD<>8 "C8 6
7>DE=6GB68:JI>86A8DBE6CN ;GDBJ<JHIJCI>AJ<JHI
0>AA>6B! $>C<=6HH:GK:96H,:C>DG/>8:)G:H>9:CIS,IG6I:<>8:K:ADEB:CIH>C8:
C<:A6, %6ADG=6HH:GK:96H,:C>DG/>8:)G:H>9:CIS!JB6C+:HDJG8:HH>C8:?D>C>C<6C6=:G>C
+D7:GI, %JIO=6HH:GK:96H,:C>DG/>8:)G:H>9:CIS=>:;88DJCI>C<(;;>8:GH>C8:
6C>:A +6H@6H=6HH:GK:96H,:C>DG/>8:)G:H>9:CISDGEDG6I::K:ADEB:CIH>C8:


-- 56 of 162 --

PART II
ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock is traded on the New York Stock Exchange under the symbol DHR. As of February 5, 2021, there were
2,372 holders of record of Danaher’s common stock.
Any future payments of dividends on the Company’s common stock will be determined by Danaher’s Board of Directors and
will depend on business conditions, Danaher’s earnings and other factors Danaher’s Board deems relevant.
Issuer Purchases of Equity Securities
Refer to Note 19 to the Consolidated Financial Statements included in this Annual Report for a discussion of the Company’s
common stock repurchase program.
Except in connection with the Envista Split-Off in 2019, neither the Company nor any “affiliated purchaser” repurchased any
shares of Company common stock during 2020, 2019 or 2018.
Recent Issuances of Unregistered Securities
During the fourth quarter of 2020, holders of certain of the Company’s Liquid Yield Option Notes due 2021 (“LYONs”)
converted such LYONs into an aggregate of 74 thousand shares of Danaher common stock, par value $0.01 per share. In each
case, the shares of common stock were issued solely to existing security holders upon conversion of the LYONs pursuant to the
exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933, as amended.
ITEM 6. NOT APPLICABLE
35

-- 57 of 162 --

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide
material information relevant to an assessment of Danaher’s financial condition and results of operations, including an
evaluation of the amounts and certainty of cash flows from operations and from outside sources. The MD&A is designed to
focus specifically on material events and uncertainties known to management that are reasonably likely to cause reported
financial information not to be necessarily indicative of future operating results or of future financial condition. This includes
descriptions and amounts of matters that have had a material impact on reported operations, as well as matters that are
reasonably likely based on management’s assessment to have a material impact on future operations. The Company’s MD&A
is divided into five sections:
• Overview
• Results of Operations
• Liquidity and Capital Resources
• Critical Accounting Estimates
• New Accounting Standards
This discussion and analysis should be read together with Danaher’s audited financial statements and related Notes thereto as of
December 31, 2020 and 2019 and for each of the three years in the period ended December 31, 2020 included in this Annual
Report. Management's discussion and analysis of financial condition and results of operations for 2018 is included in Item 7 of
the Company’s 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission and should be referred
to for information regarding this period.
Unless otherwise indicated, all financial results in this report refer to continuing operations.
OVERVIEW
General
Refer to “Item 1. Business—General” for a discussion of Danaher’s strategic objectives and methodologies for delivering long-
term shareholder value. Danaher is a multinational business with global operations. During 2020, approximately 61% of
Danaher’s sales were derived from customers outside the United States. As a diversified, global business, Danaher’s operations
are affected by worldwide, regional and industry-specific economic and political factors. Danaher’s geographic and industry
diversity, as well as the range of its products, software and services, help limit the impact of any one industry or the economy of
any single country on its consolidated operating results. The Company’s individual businesses monitor key competitors and
customers, including to the extent possible their sales, to gauge relative performance and the outlook for the future.
As a result of the Company’s geographic and industry diversity, the Company faces a variety of opportunities and challenges,
including rapid technological development (particularly with respect to computing, automation, artificial intelligence, mobile
connectivity, communications and digitization) in most of the Company’s served markets, the expansion and evolution of
opportunities in high-growth markets, trends and costs associated with a global labor force, consolidation of the Company’s
competitors and increasing regulation. The Company operates in a highly competitive business environment in most markets,
and the Company’s long-term growth and profitability will depend in particular on its ability to expand its business in high-
growth geographies and high-growth market segments, identify, consummate and integrate appropriate acquisitions and identify
and consummate appropriate investments and strategic partnerships, develop innovative and differentiated new products and
services with higher gross profit margins, expand and improve the effectiveness of the Company’s sales force, continue to
reduce costs and improve operating efficiency and quality, and effectively address the demands of an increasingly regulated
global environment. The Company is making significant investments, organically and through acquisitions and investments, to
address the rapid pace of technological change in its served markets and to globalize its manufacturing, research and
development and customer-facing resources (particularly in high-growth markets) in order to be responsive to the Company’s
customers throughout the world and improve the efficiency of the Company’s operations.
The COVID-19 Pandemic
The global spread of a novel strain of coronavirus (COVID-19) has led to unprecedented restrictions on, and disruptions in,
business and personal activities, including as a result of preventive and precautionary measures that we, other businesses, our
communities and governments have taken and are taking to mitigate the spread of the virus and to manage its impact. The
Company continues to actively monitor the pandemic and has taken and intends to continue taking steps to identify and mitigate
36

-- 58 of 162 --

the adverse impacts on, and risks to, the Company’s business (including but not limited to its employees, customers, business
partners, manufacturing capabilities and capacity, and supply and distribution channels) posed by the spread of COVID-19 and
the governmental and community responses thereto. The Company’s businesses have activated their business continuity plans
in response to the pandemic, including taking steps in an effort to help keep our workforce healthy and safe, and are assessing
and updating those plans on an ongoing basis. As a result of COVID-19 the Company’s businesses have modified certain of
their respective business practices (including in many cases with respect to employee travel, employee work locations, and
cancellation of physical participation in meetings, events and conferences), and the Company expects to take such further
actions as may be required by government authorities or as determined to be in the best interests of our employees, customers
and other business partners. The Company has developed return-to-work protocols designed to help ensure the health and
safety of its employees, customers and business partners, for its businesses to apply as and when return-to-work is legally
permissible and deemed appropriate. We are also working with our suppliers to understand the existing and potential future
negative impacts to our supply chain and take actions in an effort to mitigate such impacts. To date we have not experienced
any significant supply chain disruptions. Given that the prevalence of COVID-19 and the nature of the response thereto
(including the degree to which restrictions are being relaxed or re-imposed) varies significantly by geography, the impact of the
pandemic on the Company’s different business locations around the world at any given time also varies significantly.
We are also deploying our capabilities, expertise and scale to address the critical health needs related to COVID-19. We have
developed and made available a diagnostic test for the rapid detection of COVID-19 and a diagnostic test that can detect
antibodies in blood to confirm current or past exposure to COVID-19. In addition, our businesses, including the recently
acquired Cytiva business (the Cytiva Acquisition is described below), are providing critical support to firms that are developing
and producing vaccines for COVID-19, among other support. Cytiva, net of the product line divestitures required for
regulatory approval of the acquisition, contributed approximately 1,800 basis points to the increase in the Company’s total sales
in 2020 compared to 2019. We estimate that COVID-19 related demand contributed between approximately 700 to 750 basis
points to the Company’s core sales growth including Cytiva in 2020 compared to 2019 (for the definition of “core sales
including Cytiva,” refer to “—Results of Operations” below). As and to the extent the COVID-19 pandemic subsides we
expect the demand for products and services related to COVID-19 will also subside. As further discussed below, while
COVID-19 has positively impacted revenues for certain of our businesses, the pandemic and response thereto had a material
negative impact on revenues and profitability in other of our businesses in 2020 and, while conditions overall improved
sequentially from the second quarter through the end of 2020, the global demand for many of our products and services may
remain depressed at least in the near-term if not longer.
As noted below and subject to the assumptions discussed below, the Company expects core sales and core sales including
Cytiva to grow in the first quarter of 2021 compared to the prior year. However, due to the speed with which the COVID-19
situation continues to evolve, the global breadth of its spread, the range of governmental and community responses thereto and
our geographic and business line diversity, its further impact on our business remains highly uncertain, but may be materially
negative and will depend on future developments including but not limited to:
• the duration of weaknesses in the macroeconomic environment and the timing and extent of recovery in the global
demand for our products and services;
• the pace at which medical providers resume patient care and testing that is not related to the COVID-19 pandemic, the
timing of when research performed by laboratories and other institutions return to normal levels, and payment and
funding dynamics related to the foregoing; and
• the development and rate of adoption of the products we are offering to help address the pandemic and the effects
thereof; competitive product launches and related pricing pressure; impacts from changes in the mix of our product
offerings; and the degree to which COVID-19 testing solutions and vaccines are made available and utilized.
For additional information on the risks of COVID-19 to the Company’s operations, refer to the “Item 1A—Risk Factors”
section of this Annual Report.
Business Performance
Consolidated sales for the year ended December 31, 2020 increased 24.5% as compared to 2019. Acquisitions, primarily
Cytiva, contributed 18.0% to the increase in sales in 2020. While differences exist among the Company’s businesses, on an
overall basis, demand for the Company’s products and services increased on a year-over-year basis in 2020 as compared to
2019. This demand, together with the Company’s continued investments in sales growth initiatives and the other business-
specific factors discussed below, contributed to year-over-year core sales growth of 6.5% and core sales growth including
Cytiva of 9.5% (for the definition of “core sales” refer to “—Results of Operations” below). From the date of Danaher’s
acquisition of Cytiva on March 31, 2020 through December 31, 2020, Cytiva’s core sales grew more than 30% (compared to
the comparable 2019 period when the Cytiva business was owned by General Electric Company (“GE”)) reflecting strength in
37

-- 59 of 162 --

its served markets and its support in helping its customers develop and produce vaccines for COVID-19. Geographically, both
high-growth and developed markets contributed to year-over-year core sales growth during 2020. Core sales in developed
markets grew at a low-double digit rate in 2020 as compared to 2019 and were driven by North America and Western Europe.
Core sales in high-growth markets grew at a mid-single digit rate in 2020 as compared to 2019 as growth in China and other
high-growth markets in the second half of 2020 more than offset declines in China during the first quarter due to the impact of
the COVID-19 pandemic. High-growth markets represented approximately 30% of the Company’s total sales in 2020.
The Company’s net earnings from continuing operations for the year ended December 31, 2020 totaled approximately $3.6
billion, compared to approximately $2.4 billion for the year ended December 31, 2019. Net earnings attributable to common
stockholders for the year ended December 31, 2020 totaled approximately $3.5 billion or $4.89 per diluted common share
compared to approximately $2.9 billion or $4.05 per diluted common share for the year ended December 31, 2019. The
increase in net earnings in 2020 as compared to 2019 was driven by net earnings from increased sales in the Company’s
existing businesses, net earnings from Cytiva, the 2020 gain on sale of product lines, and the provision for uncertain tax
positions recorded in the first quarter of 2019 discussed below in “—Results of Operations—Income Taxes”, partially offset by
the 2019 gain on the disposition of Envista Holdings Corporation. Refer to “—Results of Operations” for further discussion of
the year-over-year changes in net earnings and diluted net earnings per common share for the year ended December 31, 2020.
While the ultimate impact of COVID-19 on future periods is highly uncertain, the Company expects core sales and core sales
including Cytiva to grow in the first quarter of 2021, assuming the negative impact of the pandemic does not increase in the
United States and internationally. Demand for instruments and consumables related to COVID-19-related testing capabilities as
well as supporting customers in pursuit of new COVID-19-related treatments and vaccines are expected to continue to drive
growth in 2021 while the performance of the Company’s other businesses is expected to continue to improve. As discussed
above, an increase of the COVID-19 infection rate and the re-imposition of government required restrictions could have a
material negative impact on the Company’s financial statements.
Acquisitions and Dispositions
On March 31, 2020, the Company acquired the Biopharma business of GE’s Life Sciences division, now known as Cytiva, for a
cash purchase price of approximately $20.7 billion (net of approximately $0.1 billion of acquired cash) and the assumption of
approximately $0.4 billion of pension liabilities (the “Cytiva Acquisition”). Cytiva is a leading provider of instruments,
consumables and software that support the research, discovery, process development and manufacturing workflows of
biopharmaceutical drugs. Cytiva is included in the Company’s Life Sciences segment results beginning in the second quarter of
2020. The acquisition has provided and is expected to provide additional sales and earnings growth opportunities for the
Company’s Life Sciences segment by expanding the business’ geographic and product line diversity, including new product
and service offerings that complement the Company’s current biologics workflow solutions.
Refer to Note 3 to the Consolidated Financial Statements for discussion regarding the Company’s acquisitions.
Envista Disposition
On September 20, 2019, Envista Holdings Corporation (“Envista”), a Danaher subsidiary at the time, completed an
underwritten IPO of 30.8 million shares of its common stock, (the “IPO”), which represented 19.4% of Envista’s outstanding
shares at the time of the offering, at a public offering price of $22.00 per share. In connection with the completion of the IPO,
through a series of equity and other transactions, the Company transferred its dental businesses to Envista (the “Separation”).
On December 18, 2019, Danaher completed the disposition of its remaining 80.6% ownership of Envista common stock
through a split-off exchange offer, which resulted in Danaher’s repurchase of 22.9 million shares of Danaher common stock in
exchange for the remaining shares of Envista common stock held by Danaher (the “Split-Off”). The IPO, Separation and Split-
Off are collectively referred to as the “Envista Disposition”. As a result, the Company recognized a gain on the disposition of
$451 million in the fourth quarter of 2019 equal to the difference between the fair value of the Danaher common stock tendered
in the exchange offer and the carrying value of Envista common stock. The accounting requirements for reporting Envista as a
discontinued operation were met when the Split-Off was completed.
Refer to Note 4 to the Consolidated Financial Statements for further discussion.
UK’s referendum decision to exit the EU (“Brexit”)
For a discussion of Brexit and certain risks and implications thereof for the Company, refer to “Item 1A—Risk Factors”.
38

-- 60 of 162 --

RESULTS OF OPERATIONS
In this report, references to the non-GAAP measures of core sales (also referred to as core revenues or sales/revenues from
existing businesses) and core sales including Cytiva refer to sales from continuing operations calculated according to generally
accepted accounting principles in the United States (“GAAP”) but excluding:
• sales from acquired businesses (as defined below, as applicable); and
• the impact of currency translation.
References to sales or operating profit attributable to acquisitions or acquired businesses refer to sales or operating profit, as
applicable, from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales and
operating profit, as applicable, attributable to divested product lines not considered discontinued operations prior to the first
anniversary of the divestiture; provided that in calculating core sales including Cytiva, Cytiva’s sales (net of the sales of the
Company product lines divested in 2020 to obtain regulatory approval to acquire Cytiva, or the “divested product lines”)
(“Cytiva sales”) are excluded from the definition of sales attributable to acquisitions or acquired businesses. The portion of
revenue attributable to currency translation is calculated as the difference between:
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as applicable));
and
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as applicable))
after applying current period foreign exchange rates to the prior year period.
As noted above, beginning with results for the second quarter of 2020, the Company also presents core sales on a basis that
includes Cytiva sales. Prior to the acquisition of Cytiva, Danaher calculated core sales solely on a basis that excluded sales
from acquired businesses recorded prior to the first anniversary of the acquisition. However, given Cytiva’s significant size and
historical core sales growth rate, in each case compared to Danaher’s existing businesses, management believes it is appropriate
to also present core sales on a basis that includes Cytiva sales. Management believes this presentation provides useful
information to investors by demonstrating the impact Cytiva has on the Company’s current growth profile, rather than waiting
to demonstrate such impact 12 months after the acquisition when Cytiva would normally have been included in Danaher’s core
sales calculation. Danaher calculates period-to-period core sales growth including Cytiva by adding to the baseline period sales
Cytiva’s historical sales from such period (when it was owned by GE), net of the sales of the divested product lines, and also
adding the Cytiva sales to the current period.
Core sales growth (and the related measure of core sales including Cytiva) should be considered in addition to, and not as a
replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies.
Management believes that reporting these non-GAAP financial measures provides useful information to investors by helping
identify underlying growth trends in Danaher’s business and facilitating comparisons of Danaher’s revenue performance with
its performance in prior and future periods and to Danaher’s peers. Management also uses these non-GAAP financial measures
to measure the Company’s operating and financial performance, and uses core sales growth as one of the performance measures
in the Company’s executive short-term cash incentive program. The Company excludes the effect of currency translation from
these measures because currency translation is not under management’s control, is subject to volatility and can obscure
underlying business trends, and excludes the effect of acquisitions (other than Cytiva sales, in the case of core sales growth
including Cytiva) and divestiture-related items because the nature, size, timing and number of acquisitions and divestitures can
vary dramatically from period-to-period and between the Company and its peers and can also obscure underlying business
trends and make comparisons of long-term performance difficult.
Throughout this discussion, references to sales growth or decline refer to the impact of both price and unit sales and references
to productivity improvements generally refer to improved cost efficiencies resulting from the ongoing application of DBS.
39

-- 61 of 162 --

>A4(0;4BA>FC70=3>A4(0;4BA>FC7=2;D38=6HC8E0
EB  	 	EB  	
-DI6AH6A:H<GDLI= ) 	  	 
"BE68ID;
8FJ>H>I>DCH 9>K:HI>IJG:H 	  	 
JGG:C8N:M8=6C<:G6I:H 	T 	 
DG:H6A:H<GDLI=CDC 	) 	  	 
"BE68ID;NI>K6H6A:H<GDLI=C:ID;9>K:HI:9EGD9J8IA>C:H 	 
DG:H6A:H<GDLI=>C8AJ9>C<NI>K6CDC 	) 	 
><?0A43C> 	
-DI6AH6A:H>C8G:6H:9 DC6N:6G DK:G N:6G76H>H>CEG>B6G>AN6H6G:HJAID;6C>C8G:6H:>CH6A:H;GDB68FJ>G:9
7JH>C:HH:H C:ID;9>K:HI>IJG:H EG>B6G>AN9J:IDI=:68FJ>H>I>DCD;NI>K6 6HL:AA6H6C>C8G:6H:>C8DG:H6A:HG:HJAI>C<;GDBI=:
;68IDGH9>H8JHH:97:ADL7NH:<B:CI -=:>BE68ID;8JGG:C8NIG6CHA6I>DC9>9CDI=6K:6H><C>;>86CI>BE68IDCG:EDGI:9H6A:HDC6
N:6G DK:G N:6G76H>H>C6HI=:C:<6I>K:>BE68ID;6HIGDC<:G. , 9DAA6G>CI=:;>GHI=6A;D;L6HD;;H:I7NI=:;6KDG67A:
>BE68ID;I=:L:6@:C>C<D;I=:. , 9DAA6G>CI=:H:8DC9=6A;D; 
$?4A0C8=6%A>58C%4A5>A<0=24
(E:G6I>C<EGD;>IB6G<>CHL:G: ;DGI=:N:6G:C9:9:8:B7:G 6H8DBE6G:9ID >C -=:;DAADL>C<
;68IDGH>BE68I:9N:6G DK:G N:6GDE:G6I>C<EGD;>IB6G<>C8DBE6G>HDCH
KH DE:G6I>C<EGD;>IB6G<>C8DBE6G>HDCHL:G:;6KDG67AN>BE68I:97N
Q 	!><=:G8DG:H6A:HKDAJB:H ADL:GDK:G6AAHE:C9>C<A:K:AH;DG7JH>C:HHIG6K:A6C9DI=:G7JH>C:HH68I>K>I>:H6H6
G:HJAID;I=:E6C9:B>86C9>C8G:B:CI6AN:6G DK:G N:6G8DHIH6K>C<H6HHD8>6I:9L>I=I=:8DCI>CJ:9EGD9J8I>K>IN
>BEGDK:B:CI>C>I>6I>K:HI6@:C>C6C9 C:ID;>C8G:B:CI6AN:6G DK:G N:6G8DHIH6HHD8>6I:9L>I=K6G>DJHC:L
EGD9J8I9:K:ADEB:CI6C9H6A:H H:GK>8:6C9B6G@:I>C<<GDLI=>CK:HIB:CIH 76H>HED>CIH
Q 	-=:>C8G:B:CI6A688G:I>K::;;:8I>CD;68FJ>G:97JH>C:HH:H>C8AJ9>C<NI>K6 C:ID;EGD9J8IA>C:9>HEDH>I>DCH
L=>8=9>9CDIFJ6A>;N6H9>H8DCI>CJ:9DE:G6I>DCH 76H>HED>CIH
KH DE:G6I>C<EGD;>IB6G<>C8DBE6G>HDCHL:G:JC;6KDG67AN>BE68I:97N
Q 	8FJ>H>I>DC G:A6I:9;6>GK6AJ:69?JHIB:CIHID>CK:CIDGN6C99:;:GG:9G:K:CJ: 6C9>C8G:B:CI6AIG6CH68I>DC8DHIH
9::B:9H><C>;>86CI6C9>CI:<G6I>DCEG:E6G6I>DC8DHIH >C:68=86H:G:A6I:9IDI=:68FJ>H>I>DCD;NI>K6 76H>H
ED>CIH -=:DBE6CN9::BH68FJ>H>I>DC G:A6I:9IG6CH68I>DC8DHIH>C8JGG:9>C6<>K:CE:G>D9ID7:H><C>;>86CI
<:C:G6AANG:A6I>C<IDI=:DBE6CNWHA6G<:G68FJ>H>I>DCH>;>I9:I:GB>C:HI=6IHJ8=8DHIH:M8::9I=:G6C<:D;
68FJ>H>I>DC G:A6I:9IG6CH68I>DC8DHIHINE>86A;DG6C6=:G>C6<>K:CE:G>D9 
Q 	"BE6>GB:CI8=6G<:HG:A6I:9IDIG69:C6B:H>CI=:CK>GDCB:CI6AEEA>:9,DAJI>DCHH:<B:CI>C8JGG:9>CI=:I=>G9
FJ6GI:GD; 76H>HED>CIH
Q 	"BE6>GB:CI8=6G<:HG:A6I:9ID6;68>A>IN>CI=:>6<CDHI>8HH:<B:CI6C96IG69:C6B:6C9DI=:G>CI6C<>7A:6HH:IH>CI=:
CK>GDCB:CI6AEEA>:9,DAJI>DCHH:<B:CI>C8JGG:9>CI=:;>GHIFJ6GI:GD; 76H>HED>CIH
DB8=4BB(46<4=CB
,6A:H7N7JH>C:HHH:<B:CI;DGI=:N:6GH:C9:9:8:B7:G6G:6H;DAADLH>CB>AA>DCH
 	 	
%>;:,8>:C8:H 	 	  	 	  	 	 
>6<CDHI>8H 	 	  	 	  	 	 
CK>GDCB:CI6AEEA>:9,DAJI>DCH 	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	 
DG>C;DGB6I>DCG:<6G9>C<I=:DBE6CNWHH6A:H7N<:D<G6E=>86AG:<>DC G:;:GID'DI:IDI=:688DBE6CN>C<DCHDA>96I:9
>C6C8>6A,I6I:B:CIH


-- 62 of 162 --

!(#(
-=:DBE6CNWH%>;:,8>:C8:HH:<B:CID;;:GH67GD69G6C<:D;>CHIGJB:CIH6C98DCHJB67A:HI=6I6G:EG>B6G>ANJH:97N
8JHIDB:GHIDHIJ9NI=:76H>87J>A9>C<7AD8@HD;A>;: >C8AJ9>C<<:C:H EGDI:>CH B:I67DA>I:H6C98:AAH >CDG9:GIDJC9:GHI6C9I=:
86JH:HD;9>H:6H: >9:CI>;NC:LI=:G6E>:H 6C9I:HI6C9B6CJ;68IJG:C:L9GJ<H6C9K688>C:H 
!854(284=24B(4;42C438=0=280;0C0
 	.40A=343424<14A
>CB>AA>DCH 	 	
,6A:H 	 	  	 	  	 	 
(E:G6I>C<EGD;>I 	 	  	 	  	 	 
:EG:8>6I>DC 	 	 	 	 	 	
BDGI>O6I>DCD;>CI6C<>7A:6HH:IH 	 	 	 	 	 	
(E:G6I>C<EGD;>I6H6D;H6A:H 	  	  	 
:EG:8>6I>DC6H6D;H6A:H 	  	  	 
BDGI>O6I>DC6H6D;H6A:H 	  	  	 
>A4(0;4BA>FC70=3>A4(0;4BA>FC7=2;D38=6HC8E0
EB  	 	EB  	
-DI6AH6A:H<GDLI= ) 	  	 
"BE68ID;
8FJ>H>I>DCH 9>K:HI>IJG:H 	  	 
JGG:C8N:M8=6C<:G6I:H 	T 	 
DG:H6A:H<GDLI=CDC 	) 	  	 
"BE68ID;NI>K6H6A:H<GDLI=C:ID;9>K:HI:9EGD9J8IA>C:H 	 
DG:H6A:H<GDLI=>C8AJ9>C<NI>K6CDC 	) 	 
><?0A43C> 	
)G>8:>C8G:6H:H>CI=:H:<B:CI8DCIG>7JI:9 IDG:K:CJ:<GDLI=DC6N:6G DK:G N:6G76H>H9JG>C<6H8DBE6G:9L>I=
6C96G:G:;A:8I:96H68DBEDC:CID;I=:8=6C<:>C8DG:G:K:CJ:<GDLI= 
JG>C< IDI6AH6A:H>CI=:H:<B:CI>C8G:6H:9 EG>B6G>AN6H6G:HJAID;>C8G:6H:9H6A:H;GDB68FJ>H>I>DCH C:ID;
9>K:HI>IJG:H6C9>C8G:6H:98DG:H6A:HG:HJAI>C<;GDBI=:;68IDGH9>H8JHH:97:ADL JGG:C8N:M8=6C<:G6I:H=696C:<A><>7A:
>BE68IDCIDI6AH6A:H>C8DBE6G:9ID JG>C< >C8G:6H:99:B6C9;DG>CHIGJB:CIH6C98DCHJB67A:HJH:9;DG
(/" G:A6I:96EEA>86I>DCH>CI=:7>DEGD8:HH>C<:C9 B6G@:IL6HE6GI>6AAND;;H:I7NADL:G9:B6C9>C8:GI6>CCDC
(/" 6EEA>86I>DCH6H6G:HJAID;I=:G:HEDCH:IDI=:E6C9:B>8 -=:DBE6CNH6LADL:G9:B6C9;DG:FJ>EB:CIA6I:>CI=:
;>GHIFJ6GI:G6C9>CI=:H:8DC9FJ6GI:G6HI=:(/" E6C9:B>8HEG:696GDJC9I=:LDGA9 6869:B>8G:H:6G8=A67H8ADH:9A6I:
>CI=:;>GHIFJ6GI:GD;6C98JHIDB:GH9:;:GG:9EJG8=6H:HD;A6G<:G>CHIGJB:CIH -=:DBE6CNH6LI=:<G69J6AG:DE:C>C<D;
8:GI6>CG:H:6G8=A67HA6I:G>C6HI=:E6C9:B>8HJ7H>9:9 6AI=DJ<=I=:G:8JGG:C8:D;I=:E6C9:B>8>C8:GI6>C<:D<G6E=>:H=6H
G:FJ>G:98:GI6>CA67HIDG:B6>C8ADH:9DGDE:G6I:6I6ADL:G86E68>IN DG:H6A:H;DG;>AIG6I>DC H:E6G6I>DC6C9EJG>;>86I>DC
I:8=CDAD<>:H>C8G:6H:968GDHHBDHIB6?DG<:D<G6E=>:HDC6N:6G DK:G N:6G76H>HA:97N0:HI:GCJGDE: =>C66C9'DGI=
B:G>86 :B6C9;DG;>AIG6I>DC H:E6G6I>DC6C9EJG>;>86I>DCI:8=CDAD<>:HL6HA:97N(/" G:A6I:99:B6C9>CI=:
7>DE=6GB68:JI>86A:C9 B6G@:I E6GI>6AAND;;H:I7NL:6@:G9:B6C9>CI=:;AJ>9I:8=CDAD<N6C96HH:IEGDI:8I>DC6C96:GDHE68:
:C9 B6G@:IH DG:H6A:HD;B>8GDH8DENEGD9J8IH9:8G:6H:9DC6N:6G DK:G N:6G76H>H68GDHH6AAB6?DGEGD9J8IA>C:H EG>B6G>AN
9J:IDADL:G9:B6C9>CI=:B:9>86A >C9JHIG>6A 6C9A>;:H8>:C8:G:H:6G8=:C9 B6G@:IH  :D<G6E=>86AAN 9:B6C9;DGB>8GDH8DEN
EGD9J8IH9:8G:6H:968GDHH6AAB6?DG<:D<G6E=>:H6C9:C9 B6G@:IH 6HH=JI9DLCB:6HJG:HID8JG7(/" G:9J8:9N:6G DK:G
N:6G9:B6C9;DG:FJ>EB:CI>CE6GI>8JA6G 2:6G DK:G N:6G8DG:H6A:H;DG;ADL8NIDB:IGN6C9E6GI>8A:8DJCI>C<HDAJI>DCH
>C8G:6H:9>C68GDHH6AAB6?DG<:D<G6E=>:H6C9BDHI:C9 B6G@:IH9J:ID>C8G:6H:99:B6C9;DG<:CDB>8H6BEA:EG:E6G6I>DC
8DCHJB67A:H6C96JIDB6I>DCEGD9J8IHG:HJAI>C<;GDBI=:(/" E6C9:B>8 DG:H6A:HD;I=:7JH>C:HHW7GD69G6C<:D;
B6HHHE:8IGDB:I:GH9:8A>C:9DC6N:6G DK:G N:6G76H>H9J:IDADL:G9:B6C9>CI=:8A>C>86A6C9E=6GB68:JI>86A:C9 B6G@:IH>C
I=:;>GHI=6A;D;I=:N:6G6H6G:HJAID;I=:(/" E6C9:B>8 :B6C9;DGB6HHHE:8IGDB:I:GEGD9J8IH>BEGDK:9H:FJ:CI>6AAN
I=GDJ<=DJII=:H:8DC9=6A;D;  :D<G6E=>86AAN I=:9:8G:6H:>C9:B6C9L6HA:97N'DGI=B:G>86 0:HI:GCJGDE:6C9
=>C6 DG:H6A:H>CI=:<:CDB>8H8DCHJB67A:H7JH>C:HH>C8G:6H:968GDHH6AAB6?DG<:D<G6E=>:H6C9EGD9J8IA>C:H 9G>K:C
EG>B6G>AN7N9:B6C9;DGEG>B:G6C9EGD7:@>IHG:A6I:9ID(/" I:HI>C< 


-- 63 of 162 --

-=:68FJ>H>I>DCD;NI>K6DC&6G8= =6HEGDK>9:9 6C9>H:ME:8I:9ID8DCI>CJ:IDEGDK>9:699>I>DC6AH6A:H6C9:6GC>C<H
<GDLI=DEEDGIJC>I>:H;DGI=:DBE6CNWH%>;:,8>:C8:HH:<B:CI7N:ME6C9>C<I=:7JH>C:HHW<:D<G6E=>86C9EGD9J8IA>C:
9>K:GH>IN >C8AJ9>C<C:LEGD9J8I6C9H:GK>8:D;;:G>C<HI=6I8DBEA:B:CII=:DBE6CNWH7>DAD<>8HLDG@;ADLHDAJI>DCH J:ID
I=:EGDM>B>IND;I=:68FJ>H>I>DC96I:IDI=::C9D;I=:;>GHIFJ6GI:G I=:G:6G:CDG:HJAIHD;DE:G6I>DCH;DGNI>K6>C8AJ9:9>CI=:
%>;:,8>:C8:HH:<B:CI>CI=:;>GHIFJ6GI:GD; :<>CC>C<>CI=:H:8DC9FJ6GI:GD; NI>K6>H>C8AJ9:9>CI=:%>;:
,8>:C8:HH:<B:CIG:HJAIH "CI=:A6HIC>C:BDCI=HD; NI>K6:ME:G>:C8:9H><C>;>86CI>C8G:6H:99:B6C968GDHH6AAB6?DG
<:D<G6E=>:H6C9:C9 B6G@:IH 9G>K:C7N9:B6C9;DG>CHIGJB:CIH6C98DCHJB67A:HJH:9>CI=:G:H:6G8=6C99:K:ADEB:CID;
(/"  G:A6I:9IG:6IB:CIH6C9K688>C:H
$?4A0C8=6%A>58C%4A5>A<0=24
(E:G6I>C<EGD;>IB6G<>CH9:8A>C:976H>HED>CIH9JG>C<6H8DBE6G:9ID -=:;DAADL>C<;68IDGH>BE68I:9N:6G DK:G
N:6GDE:G6I>C<EGD;>IB6G<>C8DBE6G>HDCH
KH DE:G6I>C<EGD;>IB6G<>C8DBE6G>HDCHL:G:;6KDG67AN>BE68I:97N
Q 	!><=:G8DG:H6A:HKDAJB:H ADL:GDK:G6AAHE:C9>C<A:K:AH;DG7JH>C:HHIG6K:A6C9DI=:G7JH>C:HH68I>K>I>:H6H6
G:HJAID;I=:E6C9:B>8 >C8G:B:CI6AN:6G DK:G N:6G8DHIH6K>C<H6HHD8>6I:9L>I=I=:8DCI>CJ:9EGD9J8I>K>IN
>BEGDK:B:CI>C>I>6I>K:HI6@:C>C6C96C9I=:>BE68ID;;DG:><C8JGG:C8N:M8=6C<:G6I:H>C C:ID;
>C8G:B:CI6AN:6G DK:G N:6G8DHIH6HHD8>6I:9L>I=K6G>DJHC:LEGD9J8I9:K:ADEB:CI6C9H6A:H6C9B6G@:I>C<<GDLI=
>CK:HIB:CIH 76H>HED>CIH
Q 	-=:>C8G:B:CI6A688G:I>K::;;:8I>CD;68FJ>G:97JH>C:HH:H C:ID;EGD9J8IA>C:9>HEDH>I>DCHL=>8=9>9CDIFJ6A>;N
6H9>H8DCI>CJ:9DE:G6I>DCH 76H>HED>CIH
KH DE:G6I>C<EGD;>IB6G<>C8DBE6G>HDCHL:G:JC;6KDG67AN>BE68I:97N
Q 	8FJ>H>I>DC G:A6I:9;6>GK6AJ:69?JHIB:CIHID>CK:CIDGN6C99:;:GG:9G:K:CJ:G:A6I:9IDI=:68FJ>H>I>DCD;NI>K6 
76H>HED>CIH
:EG:8>6I>DC6C96BDGI>O6I>DC>C8G:6H:99JG>C<6H8DBE6G:9ID9J:EG>B6G>ANIDI=:>BE68ID;I=:68FJ>H>I>DCD;
NI>K6
#$()(
-=:DBE6CNWH>6<CDHI>8HH:<B:CID;;:GH6C6ANI>86A>CHIGJB:CIH G:6<:CIH 8DCHJB67A:H HD;IL6G:6C9H:GK>8:HI=6I=DHE>I6AH 
E=NH>8>6CHWD;;>8:H G:;:G:C8:A67DG6IDG>:H6C9DI=:G8G>I>86A86G:H:II>C<HJH:ID9>6<CDH:9>H:6H:6C9B6@:IG:6IB:CI9:8>H>DCH 
806=>BC82B(4;42C438=0=280;0C0
 	.40A=343424<14A
>CB>AA>DCH 	 	
,6A:H 	 	  	 	  	 	 
(E:G6I>C<EGD;>I 	 	  	 	  	 	 
:EG:8>6I>DC 	 	 	 	 	 	
BDGI>O6I>DCD;>CI6C<>7A:6HH:IH 	 	 	 	 	 	
(E:G6I>C<EGD;>I6H6D;H6A:H 	  	  	 
:EG:8>6I>DC6H6D;H6A:H 	  	  	 
BDGI>O6I>DC6H6D;H6A:H 	  	  	 
>A4(0;4BA>FC7
EB  	 	EB  	
-DI6AH6A:H<GDLI= ) 	  	 
"BE68ID;
JGG:C8N:M8=6C<:G6I:H 	  	 
DG:H6A:H<GDLI=CDC 	) 	  	 


-- 64 of 162 --

2020 Compared to 2019
Price increases in the segment did not have a significant impact on sales growth on a year-over-year basis during 2020 as
compared with 2019.
During 2020, total sales in the segment increased 13.0%, driven by the factors discussed below related to core sales growth, net
of a modest negative impact from currency exchange rates. During 2020, increased demand for molecular diagnostics and
acute care instruments and consumables to support the response to the COVID-19 pandemic was partially offset by lower
demand for instruments and consumables in the clinical lab businesses as a result of shutdowns and restrictions related to the
pandemic. While patient volumes remained down year-over-year, the Company saw sequential improvement in patient volume
from the second quarter of 2020 through the end of the year. Core sales in the segment’s clinical lab business decreased on a
year-over-year basis driven by lower demand across all major product lines. Geographically, shutdown measures to curb
COVID-19 reduced core laboratory testing volumes year-over-year across all major geographies. Core sales increased in the
molecular diagnostics business on a year-over-year basis in both developed and high-growth markets and contributed
significantly to overall segment core sales growth. The molecular diagnostics business experienced particularly strong growth
in sales of instruments and consumables in the infectious disease product line driven by the development and commercialization
of diagnostic test solutions for COVID-19. Core sales in the acute care diagnostic business increased year-over-year primarily
due to higher demand for blood gas instruments and consumables, driven in part by increased hospitalizations as a result of the
COVID-19 pandemic. Geographically, demand was strong across all major geographies. Core sales in the pathology business
grew year-over-year driven by increased demand for advanced staining consumables and pathology imaging products.
Geographically, core sales growth in the pathology business was led by North America and Western Europe, partially offset by
soft demand in China.
Operating Profit Performance
Operating profit margins increased 350 basis points during 2020 as compared to 2019. The following factors impacted year-
over-year operating profit margin comparisons.
2020 vs. 2019 operating profit margin comparisons were favorably impacted by:
• Higher 2020 core sales volumes, lower overall spending levels for business travel and other business activities as a
result of the pandemic and incremental year-over-year cost savings associated with the continued productivity
improvement initiatives taken in 2020 and 2019, net of incremental year-over-year costs associated with various new
product development and sales and marketing growth investments and the impact of foreign currency exchange rates
in 2020 - 355 basis points
2020 vs. 2019 operating profit margin comparisons were unfavorably impacted by:
• Impairment charges related to a facility incurred in the first quarter of 2020 - 5 basis points
Depreciation and amortization as a percentage of sales decreased during 2020 as compared with 2019 largely due to the impact
of increased sales in 2020.
ENVIRONMENTAL & APPLIED SOLUTIONS
The Company’s Environmental & Applied Solutions segment offers products and services that help protect important resources
and keep global food and water supplies safe. The Company’s water quality business provides instrumentation, consumables,
software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial,
waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. The
Company’s product identification business provides instruments, software, services and consumables for various color and
appearance management, packaging design and quality management, packaging converting, printing, marking, coding and
traceability applications for consumer, pharmaceutical and industrial products.
43

-- 65 of 162 --

=E8A>=<4=C0;??;843(>;DC8>=B(4;42C438=0=280;0C0
 	.40A=343424<14A
>CB>AA>DCH 	 	
,6A:H 	 	  	 	  	 	 
(E:G6I>C<EGD;>I 	 	 	 	  	 	
:EG:8>6I>DC 	 	 	 	 	 	
BDGI>O6I>DCD;>CI6C<>7A:6HH:IH 	 	 	 	 	 	
(E:G6I>C<EGD;>I6H6D;H6A:H 	  	  	 
:EG:8>6I>DC6H6D;H6A:H 	  	  	 
BDGI>O6I>DC6H6D;H6A:H 	  	  	 
>A4(0;4B42;8=4A>FC7
EB  	 	EB  	
-DI6AH6A:H9:8A>C:<GDLI= ) 	  	 
"BE68ID;
8FJ>H>I>DCH 9>K:HI>IJG:H 	T 	 
JGG:C8N:M8=6C<:G6I:H 	  	 
DG:H6A:H9:8A>C:<GDLI=CDC 	) 	  	 
><?0A43C> 	
)G>8:>C8G:6H:H>CI=:H:<B:CI8DCIG>7JI:9 IDH6A:H<GDLI=DC6N:6G DK:G N:6G76H>H9JG>C<6H8DBE6G:9L>I=
6C96G:G:;A:8I:96H68DBEDC:CID;I=:8=6C<:>C8DG:G:K:CJ:<GDLI=
JG>C< IDI6AH6A:H>CI=:H:<B:CI9:8G:6H:9 EG>B6G>AN6H6G:HJAID;I=:;68IDGH9>H8JHH:97:ADLG:A6I:9ID8DG:H6A:H
9:8A>C:H 6HL:AA6H;GDBI=:C:<6I>K:>BE68ID;8JGG:C8N:M8=6C<:G6I:H DG:H6A:H>CI=:H:<B:CIWHL6I:GFJ6A>IN7JH>C:HH:H
>C8G:6H:9HA><=IAN9JG>C<6H8DBE6G:9L>I=6H>C8G:6H:99:B6C9;DG8DCHJB67A:HL6HBDHIAND;;H:I7NADL:GDK:G
N:6G9:B6C9;DG:FJ>EB:CI6H6G:HJAID;I=:(/" E6C9:B>8 0=>A:9:B6C9;DG:FJ>EB:CI9:8G:6H:9DC6N:6G DK:G
N:6G76H>H>C I=:DBE6CNH6LH:FJ:CI>6A>BEGDK:B:CI>CI=:9:B6C9;DG:FJ>EB:CI;GDBI=:H:8DC9FJ6GI:GD;
I=GDJ<=I=::C9D;I=:N:6G 2:6G DK:G N:6G8DG:H6A:H>CI=:6C6ANI>86A>CHIGJB:CI6I>DCEGD9J8IA>C:>C8G:6H:9>C 6H
>C8G:6H:H>C0:HI:GCJGDE:6C9=>C6BDG:I=6CD;;H:I9:8G:6H:H>C'DGI=B:G>866C9I=:&>99A:6HI "CI=:7JH>C:HHW
8=:B>86AIG:6IB:CIHDAJI>DCHEGD9J8IA>C: >C8G:6H:99:B6C9>CI=:;DD96C97:K:G6<: 8DBB:G8>6A6C9>C9JHIG>6A 6C9EDL:G
:C9 B6G@:IHL6HD;;H:I7NADL:G9:B6C9>CI=:D>A6C9<6H EG>B6GNB:I6AH IG6CHEDGI6I>DC6C98=:B>86A:C9 B6G@:IH 
:D<G6E=>86AAN N:6G DK:G N:6G8DG:H6A:H>CI=:8=:B>86AIG:6IB:CIHDAJI>DCHEGD9J8IA>C:>C8G:6H:9>C'DGI=B:G>866C9
9:8G:6H:9>C%6I>CB:G>86 DG:H6A:H>CI=:7JH>C:HHWJAIG6K>DA:IL6I:G9>H>C;:8I>DCEGD9J8IA>C:>C8G:6H:9>C 6H
>C8G:6H:99:B6C9>C'DGI=B:G>866C90:HI:GCJGDE:BDG:I=6CD;;H:IL:6@:G9:B6C9>CI=:=><= <GDLI=B6G@:IH 
DG:H6A:H>CI=:H:<B:CIWHEGD9J8I>9:CI>;>86I>DC7JH>C:HH:H9:8G:6H:96I6B>9 H>C<A:9><>IG6I:9JG>C<6H8DBE6G:9L>I=
9G>K:C7NADL:G9:B6C9;DG:FJ>EB:CI6H6G:HJAID;I=:(/" E6C9:B>8 0=>A:9:B6C9;DG:FJ>EB:CI9:8G:6H:9
DC6N:6G DK:G N:6G76H>H>C I=:DBE6CNH6LH:FJ:CI>6A>BEGDK:B:CI>CI=:9:B6C9;DG:FJ>EB:CI;GDBI=:H:8DC9
FJ6GI:GD;I=GDJ<=I=::C9D;I=:N:6G DG:H6A:H>CI=:B6G@>C<6C98D9>C<7JH>C:HH9:8G:6H:9N:6G DK:G N:6G 6H
>C8G:6H:99:B6C9>C'DGI=B:G>86L6HBDG:I=6CD;;H:I7NL:6@:G9:B6C9>C0:HI:GCJGDE:6C9I=:=><= <GDLI=B6G@:IH 
:B6C9;DGB6G@>C<6C98D9>C<:FJ>EB:CI9:8G:6H:9>C D;;H:II>C<>C8G:6H:99:B6C9;DG8DCHJB67A:H>CI=:;DD96C9
7:K:G6<: 8DCHJB:G E68@6<:9<DD9H6C9E=6GB68:JI>86A:C9 B6G@:IH DGE68@6<>C<6C98DADGHDAJI>DCHEGD9J8IH6C9
H:GK>8:H 8DG:H6A:H9:8G:6H:9N:6G DK:G N:6G 9G>K:C7NADL:G9:B6C9;DG:FJ>EB:CI>C'DGI=B:G>86 0:HI:GCJGDE:6C9
I=:=><= <GDLI=B6G@:IH -=:DBE6CNH6L8DCI>CJ:9>BEGDK:B:CI>C9:B6C9;DGE68@6<>C<6C98DADGB6C6<:B:CIHDAJI>DCH
>CI=:H:8DC9=6A;D;8DBE6G:9IDI=:;>GHI=6A;D;I=:N:6G 
$?4A0C8=6%A>58C%4A5>A<0=24
(E:G6I>C<EGD;>IB6G<>CH9:8A>C:976H>HED>CIH9JG>C<6H8DBE6G:9ID 2:6G DK:G N:6GDE:G6I>C<EGD;>IB6G<>C
8DBE6G>HDCHL:G:JC;6KDG67AN>BE68I:97N
J 	%DL:G8DG:H6A:HKDAJB:H6C9>C8G:B:CI6AN:6G DK:G N:6G8DHIH6HHD8>6I:9L>I=H6A:H H:GK>8:6C9B6G@:I>C<
<GDLI=>CK:HIB:CIH C:ID;ADL:GDK:G6AAHE:C9>C<A:K:AH;DG7JH>C:HHIG6K:A6C9DI=:G7JH>C:HH68I>K>I>:H6H6G:HJAID;
I=:E6C9:B>8 >C8G:B:CI6AN:6G DK:G N:6G8DHIH6K>C<H6HHD8>6I:9L>I=I=:8DCI>CJ:9EGD9J8I>K>IN>BEGDK:B:CI
>C>I>6I>K:HI6@:C>C6C96C9I=:>BE68ID;;DG:><C8JGG:C8N:M8=6C<:G6I:H>C 76H>HED>CIH


-- 66 of 162 --

Q 	"BE6>GB:CI8=6G<:HG:A6I:9IDIG69:C6B:H>C8JGG:9>CI=:I=>G9FJ6GI:GD; 76H>HED>CIH
Q 	"BE6>GB:CI8=6G<:HG:A6I:9ID6IG69:C6B:6C9DI=:G>CI6C<>7A:6HH:IH>C8JGG:9>CI=:;>GHIFJ6GI:GD; 76H>H
ED>CIH
Q 	-=:>C8G:B:CI6AC:I9>AJI>K::;;:8I>CD;68FJ>G:97JH>C:HH:H 76H>HED>CIH
$()$(!(#'$((%'$)
 	.40A=343424<14A
>CB>AA>DCH 	 	
,6A:H 	 	  	 	  	 	 
DHID;H6A:H 	 	  	 	  	 	 
GDHHEGD;>I 	 	  	 	  	 	 
GDHHEGD;>IB6G<>C 	  	  	 
-=:N:6G DK:G N:6G>C8G:6H:>C8DHID;H6A:H9JG>C<6H8DBE6G:9L>I=L6H9J:EG>B6G>ANIDI=:>BE68ID;=><=:GN:6G
DK:G N:6GH6A:HKDAJB:H >C8AJ9>C<H6A:HKDAJB:H;GDBG:8:CIAN68FJ>G:97JH>C:HH:H 6C968FJ>H>I>DC G:A6I:98=6G<:H
6HHD8>6I:9L>I=;6>GK6AJ:69?JHIB:CIHID>CK:CIDGN>C8DCC:8I>DCL>I=I=:NI>K68FJ>H>I>DC L=>8=>C8G:6H:98DHID;H6A:H7N
B>AA>DC>C
-=:N:6G DK:G N:6G>C8G:6H:>C<GDHHEGD;>IB6G<>C9JG>C<6H8DBE6G:9L>I=L6H9J:EG>B6G>ANID=><=:GN:6G DK:G
N:6GH6A:HKDAJB:H >C8AJ9>C<H6A:HKDAJB:H;GDBG:8:CIAN68FJ>G:97JH>C:HH:H 6C9=><=:G<GDHHEGD;>IB6G<>CHD;G:8:CIAN
68FJ>G:97JH>C:HH:H E6GI>6AAND;;H:I7NI=:>BE68ID;68FJ>H>I>DC G:A6I:98=6G<:H6HHD8>6I:9L>I=;6>GK6AJ:69?JHIB:CIHID
>CK:CIDGN6C99:;:GG:9G:K:CJ:>C8DCC:8I>DCL>I=I=:NI>K68FJ>H>I>DC L=>8=69K:GH:AN>BE68I:9<GDHHEGD;>IB6G<>C
8DBE6G>HDCH7N6EEGDM>B6I:AN76H>HED>CIH>C8DBE6G:9ID
$%')#-%#((
 	.40A=343424<14A
>CB>AA>DCH 	 	
,6A:H 	 	  	 	  	 	 
,:AA>C< <:C:G6A6C969B>C>HIG6I>K:U, V:ME:CH:H 	 	  	 	  	 	 
+:H:6G8=6C99:K:ADEB:CIU+V:ME:CH:H 	 	  	 	  	 	 
, 6H6D;H6A:H 	  	  	 
+6H6D;H6A:H 	  	  	 
, :ME:CH:H6H6E:G8:CI6<:D;H6A:H9:8A>C:976H>HED>CIHDC6N:6G DK:G N:6G76H>H;DG8DBE6G:9L>I= -=:
9:8A>C:L6H9G>K:C7NI=:7:C:;>ID;>C8G:6H:9A:K:G6<:D;I=:DBE6CNWH<:C:G6A6C969B>C>HIG6I>K:8DHI76H:G:HJAI>C<;GDB
=><=:GH6A:HKDAJB:H >C8AJ9>C<H6A:HKDAJB:H;GDBG:8:CIAN68FJ>G:98DBE6C>:H >C8G:B:CI6AN:6G DK:G N:6G8DHIH6K>C<H
6HHD8>6I:9L>I=I=:8DCI>CJ>C<EGD9J8I>K>IN>BEGDK:B:CI>C>I>6I>K:HI6@:C>C6C9 ADL:GIG6K:A:ME:CH:H>C6C9
ADL:GN:6G DK:G N:6GIG6CH68I>DC8DHIHG:A6I:9IDI=:NI>K68FJ>H>I>DC -=:H:9:8G:6H:HL:G:E6GI>6AAND;;H:I7N>C8G:B:CI6A
N:6G DK:G N:6G6BDGI>O6I>DC8=6G<:HL=>8=69K:GH:AN>BE68I:9, 6H6E:G8:CI6<:D;H6A:H7N6EEGDM>B6I:AN76H>H
ED>CIH EG>B6G>ANG:A6I:9IDI=:NI>K68FJ>H>I>DC>C 6HL:AA6H>BE6>GB:CI8=6G<:HG:A6I:9ID6;68>A>IN>CI=:>6<CDHI>8H
H:<B:CI6C9IG69:C6B:6C9DI=:G>CI6C<>7A:6HH:IH>CI=:CK>GDCB:CI6AEEA>:9HDAJI>DCHH:<B:CI>C8JGG:9>CI=:;>GHI6C9
I=>G9FJ6GI:GHD;6C98DCI>CJ:9>CK:HIB:CIH>CH6A:H6C9B6G@:I>C<<GDLI=>C>I>6I>K:H 
+:ME:CH:H8DCH>HI>C<EG>C8>E6AAND;>CI:GC6A6C98DCIG68I:C<>C::G>C<E:GHDCC:A8DHIH6H6E:G8:CI6<:D;H6A:H9:8A>C:9>C
6H8DBE6G:9L>I= EG>B6G>AN9J:IDADL:G+:ME:CH:H6H6E:G8:CI6<:D;H6A:H>C7JH>C:HH:HG:8:CIAN68FJ>G:96H
L:AA6HI=:>BE68ID;H6A:H<GDLI=G6I:H>C:M8::9>C<I=:HE:C9>C<<GDLI=G:A6I:9IDI=:DBE6CNHC:LEGD9J8I
9:K:ADEB:CI>C>I>6I>K:H 


-- 67 of 162 --

NONOPERATING INCOME (EXPENSE)
The Company disaggregates the service cost component of net periodic benefit costs of noncontributory defined benefit pension
plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in other
(expense) income, net. These other components include the assumed rate of return on plan assets, partially offset by
amortization of actuarial losses and interest and aggregated to a gain of $16 million, $12 million and $35 million as of
December 31, 2020, 2019 and 2018, respectively. The Company’s net periodic pension cost for the year ended December 31,
2019 includes a settlement loss of $7 million ($6 million after tax or $0.01 per diluted common share) as a result of the transfer
of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third party.
The Company estimates the fair value of investments in equity securities using the Fair Value Alternative and records
adjustments to fair value within net earnings. Additionally, the Company is a limited partner in a partnership that invests in
early stage companies. While the partnership records these investments at fair value, the Company’s investment in the
partnership is accounted for under the equity method of accounting. During the year ended December 31, 2020, the Company
recorded net realized and unrealized gains of $18 million related to changes in the fair value of these investments. In addition,
the Company recorded other income of $5 million related to certain other transactions during 2020. These items are reflected in
other income (expense), net in the Company’s Consolidated Statement of Earnings. No significant realized or unrealized gains
or losses were recorded in either 2019 or 2018 with respect to these investments.
GAIN ON SALE OF PRODUCT LINES
As a condition to obtaining certain regulatory approvals for the closing of the Cytiva Acquisition, the Company was required to
divest certain of its existing product lines in the Life Sciences segment that in the aggregate generated revenues of
approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of these product lines for a cash
purchase price, net of cash transferred and transaction costs, of $826 million and recognized a pretax gain on sale of $455
million ($305 million after-tax or $0.42 per diluted common share) in the second quarter of 2020. The divestiture of these
product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and
therefore is not reported as a discontinued operation.
LOSS ON EARLY EXTINGUISHMENT OF BORROWINGS
In the fourth quarter of 2020, the Company redeemed the €800 million aggregate principal amount of 1.7% senior unsecured
notes due 2022 at a redemption price equal to the outstanding principal amount and a make-whole premium as specified in the
applicable indenture, plus accrued and unpaid interest. The Company recorded a loss on early extinguishment of these
borrowings of $26 million ($20 million after-tax or $0.03 per diluted common share) related to the payment of make-whole
premiums in connection with the redemption. The Company funded the redemption using available cash balances, including
proceeds from the fourth quarter 2020 issuance of the 2.6% senior unsecured notes due 2050.
In the fourth quarter of 2019, the Company redeemed the $500 million aggregate principal amount of 2.4% senior unsecured
notes due 2020 and the $375 million aggregate principal amount of 5.0% senior unsecured notes due 2020 at a redemption price
equal to the outstanding principal amount and a make-whole premium as specified in the applicable indenture, plus accrued and
unpaid interest. The Company recorded a loss on extinguishment of these borrowings of $7 million ($5 million after-tax or
$0.01 per diluted common share) related to the payment of make-whole premiums in connection with the redemption. The
Company funded the redemption using a portion of the cash distribution it received in connection with the Envista Disposition.
INTEREST COSTS
Interest expense of $275 million for 2020 was $167 million higher than in 2019, due primarily to the impact of higher average
debt balances as a result of the issuances of debt in 2019 and 2020 (primarily to fund the Cytiva Acquisition) and 2020
borrowings under the Company’s $5.0 billion unsecured revolving credit facility with a syndicate of banks that expires on
August 27, 2024, subject to a one-year extension option at the request of the Company with the consent of the lenders (the
“Five-Year Facility”) and the Company’s $5.0 billion 364-day unsecured revolving credit facility with a syndicate of banks that
was scheduled to expire on August 26, 2020 (the “Superseded 364-Day Facility”), prior to the subsequent repayment of such
credit facility borrowings. Proceeds from these borrowings as well as available cash balances were used to fund the acquisition
of Cytiva and for general corporate purposes. Interest income of $71 million for 2020 was $68 million lower than in 2019, due
primarily to lower interest rates and lower average cash balances in 2020 due to the funding of the Cytiva Acquisition.
In January 2019, the Company entered into approximately $1.9 billion of cross-currency swap derivative contracts on its U.S.
dollar-denominated bonds to effectively convert the Company’s U.S. dollar-denominated bonds to obligations denominated in
Danish kroner, Japanese yen, euro and Swiss franc and reduce the interest rate from the stated interest rates on the U.S. dollar-
denominated debt to the interest rates of the swaps. In addition, in 2020, the Company entered into approximately $1.0 billion
of cross-currency swap derivative contracts on its U.S. dollar-denominated bonds to effectively convert the Company’s U.S.
46

-- 68 of 162 --

9DAA6G 9:CDB>C6I:97DC9HIDD7A><6I>DCH9:CDB>C6I:9>C:JGD6C9G:9J8:I=:>CI:G:HIG6I:;GDBI=:HI6I:9>CI:G:HIG6I:HDCI=:
. , 9DAA6G 9:CDB>C6I:99:7IIDI=:>CI:G:HIG6I:HD;I=:HL6EH HD;:8:B7:G  6EEGDM>B6I:AN 7>AA>DCD;I=:
8GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IHG:B6>C:9DJIHI6C9>C< DG6;JGI=:G9:H8G>EI>DCD;I=:DBE6CNWH9:7I6C98GDHH
8JGG:C8NHL6E9:G>K6I>K:8DCIG68IHG:A6I:9IDI=:9:7I6HD;:8:B7:G G:;:GID'DI:H6C9IDI=:DCHDA>96I:9
>C6C8>6A,I6I:B:CIH 
#$")-(
4=4A0;
"C8DB:I6M:ME:CH:6C99:;:GG:9I6M6HH:IH6C9A>67>A>I>:HG:;A:8IB6C6<:B:CIWH6HH:HHB:CID;;JIJG:I6M:H:ME:8I:9ID7:E6>9
DC>I:BHG:;A:8I:9>CI=:DBE6CNWHDCHDA>96I:9>C6C8>6A,I6I:B:CIH -=:DBE6CNG:8DG9HI=:I6M:;;:8ID;9>H8G:I:>I:BH
6C9>I:BHI=6I6G:G:EDGI:9C:ID;I=:>GI6M:;;:8IH>CI=:E:G>D9>CL=>8=I=:ND88JG
-=:DBE6CNWH:;;:8I>K:I6MG6I:86C7:6;;:8I:97N8=6C<:H>CI=:B>MD;:6GC>C<H>C8DJCIG>:HL>I=9>;;:G:CIHI6IJIDGNI6M
G6I:H>C8AJ9>C<6H6G:HJAID;7JH>C:HH68FJ>H>I>DCH6C99>HEDH>I>DCH 8=6C<:H>CI=:K6AJ6I>DCD;9:;:GG:9I6M6HH:IH6C9
A>67>A>I>:H 688GJ6AHG:A6I:9ID8DCI>C<:CII6MA>67>A>I>:H6C9E:G>D9 ID E:G>D98=6C<:H>CHJ8=688GJ6AH I=:G:HJAIHD;6J9>IH6C9
:M6B>C6I>DCHD;EG:K>DJHAN;>A:9I6MG:IJGCH6H;JGI=:G9>H8JHH:97:ADL I=::ME>G6I>DCD;HI6IJI:HD;A>B>I6I>DCH I=:
>BEA:B:CI6I>DCD;I6MEA6CC>C<HIG6I:<>:H I6MGJA>C<H 8DJGI9:8>H>DCH H:IIA:B:CIHL>I=I6M6JI=DG>I>:H6C98=6C<:H>CI6MA6LH
6C9G:<JA6I>DCH HJ8=6HI=:-#6C9A:<>HA6I>K:EDA>8N8=6C<:HI=6IB6NG:HJAI;GDBI=:(WH>C>I>6I>K:DC6H:GDH>DC
6C9)GD;>I,=>;I>C<DGI=:8=6C<:>CI=:. , 69B>C>HIG6I>DC DG69:H8G>EI>DCD;I=:I6MIG:6IB:CID;:6GC>C<HI=6I6G:EA6CC:9
ID7:G:>CK:HI:9>C9:;>C>I:ANDJIH>9:I=:.C>I:9,I6I:H G:;:GIDUT%>FJ>9>IN6C96E>I6A+:HDJG8:HT6H=6C96H=
+:FJ>G:B:CIHV7:ADL
-=:6BDJCID;>C8DB:I6M:HI=:DBE6CNE6NH>HHJ7?:8IIDDC<D>C<6J9>IH7N;:9:G6A HI6I:6C9;DG:><CI6M6JI=DG>I>:H L=>8=
D;I:CG:HJAI>CEGDEDH:96HH:HHB:CIH &6C6<:B:CIE:G;DGBH68DBEG:=:CH>K:G:K>:LD;>IH<AD76AI6MEDH>I>DCHDC6FJ6GI:GAN
76H>H 6H:9DCI=:H:G:K>:LH L=>8=I6@:>CID688DJCII=:G:HJAIHD;9>H8JHH>DCH6C9G:HDAJI>DCHD;B6II:GHL>I=8:GI6>CI6M
6JI=DG>I>:H6C9I=:DI=:G;68IDGHG:;:G:C8:9>CI=:EG>DGE6G6<G6E= G:H:GK:H;DG8DCI>C<:CII6MA>67>A>I>:H6G:688GJ:9DG69?JHI:9
6HC:8:HH6GN DG69>H8JHH>DCD;G>H@HG:A6I:9IDI=:H:6C9DI=:GI6MB6II:GH G:;:GIDU"I:B +>H@68IDGHV
2:6G (K:G 2:6G=6C<:H>CI=:-6M)GDK>H>DC6C9;;:8I>K:-6M+6I:
.40A=343424<14A
 	
;;:8I>K:I6MG6I:;GDB8DCI>CJ>C<DE:G6I>DCH 	  	  	 
-=:DBE6CNWH:;;:8I>K:I6MG6I:;DG6C99>;;:GH;GDBI=:. , ;:9:G6AHI6IJIDGNG6I:D;  9J:EG>C8>E6AANIDI=:
DBE6CNWH:6GC>C<HDJIH>9:I=:.C>I:9,I6I:HI=6I6G:>C9:;>C>I:ANG:>CK:HI:96C9I6M:96IG6I:H9>;;:G:CII=6CI=:. , ;:9:G6A
HI6IJIDGNG6I: +:;:GID'DI:IDI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH;DG69>H8JHH>DCD;I=:DBE6CNWH:;;:8I>K:I6MG6I: 
-=:DBE6CN8DC9J8IH7JH>C:HH<AD76AAN 6C9;>A:HCJB:GDJH8DCHDA>96I:96C9H:E6G6I:>C8DB:I6MG:IJGCH>CI=:. , ;:9:G6A 
HI6I:6C9;DG:><C?JG>H9>8I>DCH -=:CDC . , 8DJCIG>:H>CL=>8=I=:DBE6CN=6H6H><C>;>86CIEG:H:C8:>C8AJ9:=>C6 
:CB6G@  :GB6CN ,>C<6EDG: ,L:9:C ,L>IO:GA6C96C9I=:.C>I:9$>C<9DB M8AJ9>C<I=:H:?JG>H9>8I>DCH I=:DBE6CN
7:A>:K:HI=6I68=6C<:>CI=:HI6IJIDGNI6MG6I:D;6CN>C9>K>9J6A;DG:><C8DJCIGNLDJA9CDI=6K:6B6I:G>6A:;;:8IDCI=:
DBE6CNWHDCHDA>96I:9>C6C8>6A,I6I:B:CIH<>K:CI=:<:D<G6E=>89>HE:GH>DCD;I=:DBE6CNWHI6M67A:>C8DB: 
-=:DBE6CN6C9>IHHJ7H>9>6G>:H6G:GDJI>C:AN:M6B>C:97NK6G>DJH9DB:HI>86C9>CI:GC6I>DC6AI6M>C<6JI=DG>I>:H -=:"+,=6H
8DBEA:I:9HJ7HI6CI>6AAN6AAD;I=::M6B>C6I>DCHD;I=:DBE6CNWH;:9:G6A>C8DB:I6MG:IJGCHI=GDJ<=6C9>H8JGG:CIAN
:M6B>C>C<8:GI6>CD;I=:DBE6CNWH;:9:G6A>C8DB:I6MG:IJGCH;DGI=GDJ<= "C699>I>DC I=:DBE6CN=6H
HJ7H>9>6G>:H>CJHIG>6 :A<>JB 6C696 =>C6 :CB6G@ G6C8:  :GB6CN "C9>6 #6E6C $DG:6 ,L>IO:GA6C9 I=:.C>I:9
$>C<9DB6C9K6G>DJHDI=:G8DJCIG>:H HI6I:H6C9EGDK>C8:HI=6I6G:8JGG:CIANJC9:G6J9>I;DGN:6GHG6C<>C<;GDBI=GDJ<=
 
"CI=:;DJGI=FJ6GI:GD;6C9I=:;>GHIFJ6GI:GD; I=:"+,EGDEDH:9H><C>;>86CI69?JHIB:CIHIDI=:DBE6CNWHI6M67A:
>C8DB:;DGI=:N:6GHI=GDJ<=L>I=G:HE:8IIDI=:9:;:GG6AD;I6MDC8:GI6>CEG:B>JB>C8DB:G:A6I:9IDI=:DBE6CNWH
H:A; >CHJG6C8:EGD<G6BH DG>C8DB:I6MEJGEDH:H I=:G:8D<C>I>DCD;EG:B>JB>C8DB:=6H7::C9:;:GG:9>C688DG96C8:L>I=
. , I6MA6LHG:A6I:9ID>CHJG6C8: -=:"+,8=6AA:C<:9I=:9:;:GG6AD;EG:B>JBH;DG8:GI6>CINE:HD;I=:DBE6CNWHH:A;
>CHJG6C8:EDA>8>:H -=:H:EGDEDH:969?JHIB:CIHLDJA9=6K:>C8G:6H:9I=:DBE6CNWHI6M67A:>C8DB:DK:GI=:I=GDJ<=
E:G>D97N6EEGDM>B6I:AN 7>AA>DC "CI=:I=>G9FJ6GI:GD; I=:DBE6CNH:IIA:9I=:I=GDJ<=6J9>I
E:G>D9L>I=I=:"+, >C8AJ9>C<I=:G:HDAJI>DCD;I=:H:EGDEDH:969?JHIB:CIH -=:H:IIA:B:CIL6HCDIB6I:G>6AIDI=:DBE6CNWH
;>C6C8>6AHI6I:B:CIH >C8AJ9>C<>IH86H=;ADLH6C9:;;:8I>K:I6MG6I: HI=:H:IIA:B:CIL>I=I=:"+,L6HHE:8>;>8IDI=:6J9>I
E:G>D9 I=:H:IIA:B:CI9D:HCDIEG:8AJ9:I=:"+,;GDBEGDEDH>C<H>B>A6G69?JHIB:CIHIDI=:DBE6CNWHH:A; >CHJG6C8:EGD<G6BH


-- 69 of 162 --

in current or future audits. In connection with its examination of the Company’s federal income tax returns for 2016, 2017 and
2018, the IRS has requested additional information on the Company’s self-insurance programs. Due to the enactment of the
TCJA in 2017 and the resulting reduction in the U.S. corporate tax rate for years after 2017, the Company revalued its deferred
tax liabilities related to the temporary differences associated with this deferred premium income from 35.0% to 21.0%. If the
IRS proposes adjustments related to the Company’s self-insurance premiums with respect to years subsequent to 2015 and prior
to adoption of the TCJA and the Company is unsuccessful in defending its position, any taxes owed to the IRS may be
computed under the previous 35.0% statutory tax rate and the Company may be required to revalue the related deferred tax
liabilities from 21.0% to 35.0%, which in addition to any interest due on the amounts assessed, would require a charge to future
earnings. Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant
tax laws.
Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries.
On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) of approximately DKK
1.9 billion including interest through December 31, 2020 (approximately $309 million based on exchange rates as of
December 31, 2020) imposing withholding tax relating to interest accrued in Denmark on borrowings from certain of the
Company’s subsidiaries for the years 2004 through 2009. The Company appealed these assessments to the Danish National
Tax Tribunal in 2014. The appeal is pending, awaiting the final outcome of other, preceding withholding tax cases that were
appealed to the Danish courts and subsequently to the Court of Justice of the European Union (“CJEU”). In February 2019, the
CJEU decided several of these cases and ruled that the exemption of interest payments from withholding taxes provided in the
applicable EU directive should be denied where taxpayers use the directive for abusive or fraudulent purposes, and that it is up
to the national courts to make this determination. This decision of the CJEU now awaits application by the Danish High Court
in the other, preceding withholding tax cases. SKAT has maintained a similar position related to withholding tax on interest
accrued in Denmark on borrowings from certain of the Company’s subsidiaries with respect to tax years 2010 through 2015. In
2019, the Company received aggregate assessments for these matters of approximately DKK 1.8 billion including interest
through December 31, 2020 (approximately $302 million based on the exchange rate as of December 31, 2020). The Company
is appealing these assessments as well.
Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is
vigorously defending its positions. The Company intends on pursuing this matter through the Danish High Court should the
appeal to the Danish National Tax Tribunal be unsuccessful. The Company will continue to monitor decisions of both the
Danish courts and the CJEU and evaluate the impact of these court rulings on the Company’s tax positions in Denmark. The
ultimate resolution of this matter is uncertain, could take many years, and could result in a further material adverse impact to the
Company’s financial statements, including its cash flow and effective tax rate.
On June 24, 2020, SKAT issued a press release to announce that it has misapplied Denmark’s interest rules in some
assessments concerning withholding tax and overcharged interest. Subsequent to year end, the Company received a notice from
SKAT dated January 15, 2021 that includes a significant reduction in the interest amounts due related to the assessments
discussed above. The Company is reviewing the notice and the revised interest calculations received from SKAT.
The Company expects its 2021 effective tax rate to be approximately 20.5% which is higher than the 2020 rate due primarily to
the geographic mix of earnings anticipated for 2021. Any future legislative changes in the United States and/or potential tax
reform in other jurisdictions, could cause the Company’s effective tax rate to differ from this estimate. Refer to Note 15 to the
Consolidated Financial Statements for additional information related to income taxes.
DISCONTINUED OPERATIONS
As further discussed in Note 4 to the Consolidated Financial Statements, discontinued operations include the results of Envista
which was disposed of during the fourth quarter of 2019. In 2019, earnings from discontinued operations, net of income taxes,
were $576 million and reflect the operating results of Envista prior to the Envista Disposition and a gain on the disposition of
Envista of $451 million, net of certain costs associated with the Envista Disposition including costs related to establishing
Envista as a stand-alone entity and legal, accounting and investment banking fees.
COMPREHENSIVE INCOME
Comprehensive income increased by approximately $3.6 billion in 2020 as compared to 2019, primarily due to a gain on
foreign currency translation adjustments in 2020 compared to a loss in 2019, higher net earnings and a decrease in the loss from
cash flow hedge adjustments in 2020 compared to 2019, partially offset by an increase in losses from pension and
postretirement plan benefit adjustments in 2020 compared to 2019. The Company recorded a foreign currency translation gain
of approximately $2.9 billion for 2020 compared to a translation loss of $75 million for 2019. The Company recorded a
pension and postretirement plan benefit loss of $147 million for 2020 compared to a loss of $90 million for 2019. The
48

-- 70 of 162 --

Company recorded losses from cash flow hedge adjustments related to the Company’s cross-currency swap derivative contracts
in 2020 of $72 million compared to losses of $113 million in 2019.
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT
The Company is exposed to market risk from changes in interest rates, foreign currency exchange rates, equity prices and
commodity prices as well as credit risk, each of which could impact its Consolidated Financial Statements. The Company
generally addresses its exposure to these risks through its normal operating and financing activities. The Company also
periodically uses derivative financial instruments to manage foreign exchange risks and interest rate risks. In addition, the
Company’s broad-based business activities help to reduce the impact that volatility in any particular area or related areas may
have on its financial statements as a whole.
Interest Rate Risk
The Company manages interest cost using a mixture of fixed-rate and variable-rate debt. A change in interest rates on fixed
rate debt impacts the fair value of the debt but not the Company’s earnings or cash flow because the interest on such debt is
fixed. Generally, the fair market value of fixed-rate debt will increase as interest rates fall and decrease as interest rates rise.
As of December 31, 2020, an increase of 100 basis points in interest rates would have decreased the fair value of the
Company’s fixed-rate long-term debt (excluding the LYONs, which have not been included in this calculation as the value of
this convertible debt was primarily derived from the value of its underlying common stock) by approximately $2.0 billion.
As of December 31, 2020, the Company’s variable-rate debt obligations consisted primarily of euro-based commercial paper
borrowings (refer to Note 11 to the Consolidated Financial Statements for information regarding the Company’s outstanding
commercial paper balances as of December 31, 2020). As a result, the Company’s primary interest rate exposure results from
changes in short-term interest rates. As these shorter duration obligations mature, the Company may issue additional short-term
commercial paper obligations to refinance all or part of these borrowings, to the extent commercial paper markets are available.
In 2020, the average annual interest rate associated with the Company’s outstanding commercial paper borrowings was
approximately negative 6 basis points. A hypothetical increase of this average to positive 13 basis points would have increased
the Company’s annual interest expense by $5 million. The hypothetical increase used is the actual amount by which the
Company’s commercial paper interest rates fluctuated during 2020.
Refer to “Results of Operations—Interest Costs” for discussion of the Company’s cross-currency swap derivative contracts and
interest rate swap agreements.
Currency Exchange Rate Risk
The Company faces transactional exchange rate risk from transactions with customers in countries outside the United States and
from intercompany transactions between affiliates. Transactional exchange rate risk arises from the purchase and sale of goods
and services in currencies other than Danaher’s functional currency or the functional currency of its applicable subsidiary. The
Company also faces translational exchange rate risk related to the translation of financial statements of its foreign operations
into U.S. dollars, Danaher’s functional currency. Costs incurred and sales recorded by subsidiaries operating outside of the
United States are translated into U.S. dollars using exchange rates effective during the respective period. As a result, the
Company is exposed to movements in the exchange rates of various currencies against the U.S. dollar. In particular, the
Company has more sales in European currencies than it has expenses in those currencies. Therefore, when European currencies
strengthen or weaken against the U.S. dollar, operating profits are increased or decreased, respectively. The effect of a change
in currency exchange rates on the Company’s net investment in international subsidiaries is reflected in the accumulated other
comprehensive income (loss) component of stockholders’ equity.
Currency exchange rates did not have a significant impact on 2020 reported sales on a year-over-year basis. If the currency
exchange rates in effect as of December 31, 2020 were to prevail throughout 2021, currency exchange rates would increase
2021 estimated sales relative to 2020 sales by approximately 3.0%. Strengthening of the U.S. dollar against other major
currencies compared to the exchange rates in effect as of December 31, 2020 would adversely impact the Company’s sales and
results of operations on an overall basis. Any weakening of the U.S. dollar against other major currencies compared to the
exchange rates in effect as of December 31, 2020 would positively impact the Company’s sales and results of operations.
The Company has generally accepted the exposure to exchange rate movements without using derivative financial instruments
to manage this transactional exchange risk, although the Company has used foreign currency-denominated debt and cross-
currency swaps to hedge a portion of its net investments in foreign operations against adverse movements in exchange rates.
Both positive and negative movements in currency exchange rates against the U.S. dollar will continue to affect the reported
amount of sales and net earnings in the Company’s Consolidated Financial Statements. In addition, the Company has assets
and liabilities held in foreign currencies. A 10% depreciation in major currencies relative to the U.S. dollar as of December 31,
49

-- 71 of 162 --

2020 would have reduced foreign currency-denominated net assets and stockholders’ equity by approximately $1.5 billion. As
of December 31, 2020, the Company had $2.0 billion of cross-currency swap derivative contracts outstanding as hedges of its
net investment in foreign operations. These contracts effectively convert the Company’s U.S. dollar-denominated bonds to
obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of changes in
currency rates on foreign currency-denominated net assets during the term of the swap. The Company also uses cross-currency
swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in a foreign subsidiary whose functional
currency is the euro against adverse movements in exchange rates between the U.S. dollar and the euro. For a further
description of the Company’s cross-currency swap derivative contracts as of December 31, 2020 refer to Note 12 to the
Consolidated Financial Statements.
Equity Price Risk
The Company’s investment portfolio from time to time includes publicly-traded equity securities that are sensitive to
fluctuations in market price, though as of December 31, 2020, the Company held no available-for-sale marketable equity
securities. The Company holds non-marketable equity investments in privately held companies that may be impacted by equity
price risks. These non-marketable equity investments are accounted for under the Fair Value Alternative method with changes
in fair value recorded in earnings. Volatility in the equity markets or other fair value considerations could affect the value of
these investments and require charges or gains to be recognized in earnings.
Commodity Price Risk
For a discussion of risks relating to commodity prices, refer to “Item 1A. Risk Factors.”
Credit Risk
The Company is exposed to potential credit losses in the event of nonperformance by counterparties to its financial instruments.
Financial instruments that potentially subject the Company to credit risk consist of cash and temporary investments, receivables
from customers and derivatives. The Company places cash and temporary investments with various high-quality financial
institutions throughout the world and exposure is limited at any one institution. Although the Company typically does not
obtain collateral or other security to secure these obligations, it does regularly monitor the third-party depository institutions
that hold its cash and cash equivalents. The Company’s emphasis is primarily on safety and liquidity of principal and
secondarily on maximizing yield on those funds.
In addition, concentrations of credit risk arising from receivables from customers are limited due to the diversity of the
Company’s customers. The Company’s businesses perform credit evaluations of their customers’ financial conditions as
deemed appropriate and also obtain collateral or other security when deemed appropriate.
The Company enters into derivative transactions infrequently and typically with high-quality financial institutions, so that
exposure at any one institution is limited.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing and
financing activities. The Company continues to generate substantial cash from operating activities and believes that its
operating cash flow and other sources of liquidity will be sufficient to allow it to continue investing in existing businesses,
consummating strategic acquisitions and investments, paying interest and servicing debt, funding restructuring activities and
managing its capital structure on a short and long-term basis.
Notwithstanding the foregoing, the Company continues to monitor the impact of the COVID-19 pandemic on the Company’s
liquidity and capital resources and has taken actions intended to mitigate adverse impacts. Historically, the Company has
generally relied on borrowings under its commercial paper program to address liquidity requirements that exceed the capacity
provided by its operating cash flows and cash on hand, while also accessing the capital markets from time to time to secure
financing for more significant acquisitions. The COVID-19 pandemic adversely affected the availability of new borrowings in
the commercial paper markets at times during 2020. Therefore, in the first half of 2020, the Company engaged in the following
financing transactions:
• The Company borrowed $2.5 billion under the Five-Year Facility and $2.5 billion under the Superseded 364-Day
Facility for general corporate purposes (including payment of a portion of the purchase price for the Cytiva
Acquisition and repayment of certain commercial paper obligations as they matured). The Company replaced the
Superseded 364-Day Facility with a new $2.5 billion 364-Day Facility, which was terminated on December 31, 2020.
All amounts borrowed under the credit facilities referenced above were repaid in 2020. As of December 31, 2020,
50

-- 72 of 162 --

6;I:GI6@>C<>CID688DJCI6BDJCIH768@HIDEE>C<DJIHI6C9>C<8DBB:G8>6AE6E:G I=:DBE6CN=696K6>A67>A>INJC9:GI=:
>K: 2:6GG:9>I68>A>IND;6EEGDM>B6I:AN 7>AA>DC;DG9>G:8I7DGGDL>C<HDGID768@HIDEI=:>HHJ6C8:D;699>I>DC6A
8DBB:G8>6AE6E:GIDI=::MI:CI6K6>A67A: 
Q 	-=:DBE6CN>HHJ:96EEGDM>B6I:ANX 7>AA>DC6EEGDM>B6I:AN 7>AA>DC76H:9DC8JGG:C8N:M8=6C<:G6I:H6HD;
I=:G:HE:8I>K:96I:HD;I=:EG>8>C<D;I=:CDI:H6<<G:<6I:EG>C8>E6A6BDJCID;:JGD 9:CDB>C6I:9H:C>DGJCH:8JG:9
CDI:H I=:EGD8::9HD;L=>8==6K:7::C6C96G:7:>C<JH:9;DG<:C:G6A8DGEDG6I:EJGEDH:H>C8AJ9>C<G:E6NB:CID;I=:
7DGGDL>C<HJC9:GI=:,JE:GH:9:9 6N68>A>IN6C9I=:>K: 2:6G68>A>IN 6C9G:E6NB:CID;8:GI6>C8DBB:G8>6A
E6E:GD7A><6I>DCH6HI=:NB6IJG: 
Q 	-=:DBE6CN8DBEA:I:9I=:DBBDC,ID8@(;;:G>C<6C9&),(;;:G>C<6C9G:8:>K:9C:IEGD8::9HD;
6EEGDM>B6I:AN 7>AA>DC6C9 7>AA>DC G:HE:8I>K:AN L=>8==6K:7::C6C9L>AA7:JH:9;DG<:C:G6A8DGEDG6I:
EJGEDH:H 
Q 	"C(8ID7:G I=:DBE6CN>HHJ:9 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCID;. , 9DAA6G 9:CDB>C6I:9H:C>DG
JCH:8JG:9CDI:H I=:EGD8::9HD;L=>8==6K:7::C6C9L>AA7:JH:9;DG<:C:G6A8DGEDG6I:EJGEDH:H >C8AJ9>C<I=:
G:9:BEI>DCD;I=:JGDCDI:H>CI=:;DJGI=FJ6GI:GD;
DAADL>C<>H6CDK:GK>:LD;I=:DBE6CNWH86H=;ADLH6C9A>FJ>9>IN;DGI=:N:6GH:C9:9:8:B7:G
$E4AE84F>50B7;>FB0=3!8@D838CH
>CB>AA>DCH 	 	
-DI6ADE:G6I>C<86H=;ADLHEGDK>9:97N8DCI>CJ>C<DE:G6I>DCH 	 	  	 	  	 	 
6H=E6>9;DG68FJ>H>I>DCH 	 	   	  	 
)6NB:CIH;DG699>I>DCHIDEGDE:GIN EA6CI6C9:FJ>EB:CI 	 	  	  	
)GD8::9H;GDBH6A:HD;EGDE:GIN EA6CI6C9:FJ>EB:CI 	 	 	 	 	 	
)6NB:CIH;DGEJG8=6H:HD;>CK:HIB:CIH 	 	  	  	
)GD8::9H;GDBH6A:HD;>CK:HIB:CIH 	 	 	 	T 	 	
)GD8::9H;GDBH6A:D;EGD9J8IA>C:H 	 	 	 	T 	 	T
AADI=:G>CK:HI>C<68I>K>I>:H 	 	 	 	 	 	
-DI6A>CK:HI>C<86H=JH:9>C9>H8DCI>CJ:9DE:G6I>DCH 	 	T 	 	  	
':I86H=JH:9>C>CK:HI>C<68I>K>I>:H 	 	   	   	 
)GD8::9H;GDBI=:>HHJ6C8:D;8DBBDCHID8@>C8DCC:8I>DCL>I=HID8@
76H:98DBE:CH6I>DC 	 	 	 	 	 	
)GD8::9H;GDBI=:EJ7A>8D;;:G>C<D;8DBBDCHID8@ C:ID;>HHJ6C8:8DHIH 	 	  	 	  	 	T
)GD8::9H;GDBI=:EJ7A>8D;;:G>C<D;EG:;:GG:9HID8@ C:ID;>HHJ6C8:8DHIH 	 	  	 	  	 	T
':IEGD8::9H;GDBI=:H6A:D;CK>HI6!DA9>C<HDGEDG6I>DC8DBBDC
HID8@ C:ID;>HHJ6C8:8DHIH 	 	T 	 	 	 	T
)6NB:CID;9>K>9:C9H 	 	  	  	
':IG:E6NB:CIHD;EGD8::9H;GDB7DGGDL>C<HB6IJG>I>:HD;96NHDG
A:HH 	 	   	  	 	
)GD8::9H;GDB7DGGDL>C<HB6IJG>I>:HADC<:GI=6C96NH 	 	  	 	  	 	T
+:E6NB:CIHD;7DGGDL>C<HB6IJG>I>:HADC<:GI=6C96NH 	 	   	   	
&6@: L=DA:EG:B>JBHIDG:9::B7DGGDL>C<HEG>DGIDB6IJG>IN 	 	  	  	T
AADI=:G;>C6C8>C<68I>K>I>:H 	 	  	  	
6H=9>HIG>7JI>DCHIDCK>HI6!DA9>C<HDGEDG6I>DC C:I 	 	T 	 	  	T
':I86H=EGDK>9:97NJH:9>C;>C6C8>C<68I>K>I>:H 	 	  	 	  	 	
 	(E:G6I>C<86H=;ADLH;GDB8DCI>CJ>C<DE:G6I>DCH>C8G:6H:96EEGDM>B6I:AN 7>AA>DC DG6EEGDM>B6I:AN 9JG>C<
6H8DBE6G:9ID 9J:ID=><=:GC:I:6GC>C<H6C9:M8AJ9>C<CDC86H=>BE6>GB:CI8=6G<:H6C9;6>GK6AJ:
69?JHIB:CIHG:A6I:9ID8:GI6>CADC< A>K:96HH:IH>C CDC86H=8=6G<:H;DG9:EG:8>6I>DC 6BDGI>O6I>DC6C9HID8@
8DBE:CH6I>DC>C7DI=E:G>D9H 6C9CDC86H=9>H8G:I:I6M8=6G<:H>C =><=:G86H=EGDK>9:97NIG69:688DJCIH
E6N67A: EG:E6>9:ME:CH:H6C9DI=:G6HH:IH 6C9688GJ:9:ME:CH:H6C9DI=:GA>67>A>I>:H9JG>C<I=:E:G>D9


-- 73 of 162 --

compared to the prior year, partially offset by higher cash used for trade accounts receivable and inventories in 2020
compared to the prior year.
• Net cash used in investing activities increased approximately $20.0 billion during 2020 as compared to 2019 and
consisted primarily of cash paid for acquisitions, primarily the Cytiva Acquisition, and to a lesser extent investments.
Refer to Notes 3 and 9 to the Consolidated Financial Statements included in this Annual Report for a discussion of the
Company’s acquisitions and investments.
• Refer to the discussion at the beginning of the “Liquidity and Capital Resources” section for a summary of the
Company’s 2020 financing activities.
• As of December 31, 2020, the Company held approximately $6.0 billion of cash and cash equivalents.
Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the timing
of payments for income taxes, restructuring activities and productivity improvement initiatives, pension funding and other items
impact reported cash flows.
Operating cash flows from continuing operations were approximately $6.2 billion for 2020, an increase of approximately $2.6
billion, or approximately 70%, as compared to 2019. The year-over-year change in operating cash flows from 2019 to 2020
was primarily attributable to the following factors:
• 2020 operating cash flows benefited from higher net earnings in 2020 as compared to 2019. Partially offsetting the
impact of this increase is the fact that 2019 net earnings from continuing operations included $215 million of net
discrete noncash tax charges compared to a net discrete noncash tax benefit of $85 million in 2020. In addition, net
earnings from continuing operations in 2020 included $22 million of noncash impairment charges and $6 million of
fair value adjustment gains related to certain long-lived assets and investments. These noncash charges and gains
impacted earnings without a corresponding impact to operating cash flows.
• Net earnings for 2020 reflected an increase of approximately $1.1 billion of depreciation, amortization (intangible
assets and inventory step-up) and stock compensation expense as compared to 2019. Amortization expense primarily
relates to the amortization of intangible assets and inventory fair value adjustments. Depreciation expense relates to
both the Company’s manufacturing and operating facilities as well as instrumentation leased to customers under
operating-type lease arrangements. The increase in depreciation and amortization in 2020 compared to 2019 is
primarily due to the Cytiva Acquisition in 2020. Depreciation, amortization and stock compensation are noncash
expenses that decrease earnings without a corresponding impact to operating cash flows.
• The aggregate of trade accounts receivable, inventories and trade accounts payable used $160 million in operating cash
flows during 2020, compared to $161 million of operating cash flows used in 2019. The amount of cash flow
generated from or used by the aggregate of trade accounts receivable, inventories and trade accounts payable depends
upon how effectively the Company manages the cash conversion cycle, which effectively represents the number of
days that elapse from the day it pays for the purchase of raw materials and components to the collection of cash from
its customers and can be significantly impacted by the timing of collections and payments in a period.
• The aggregate of prepaid expenses and other assets, deferred income taxes and accrued expenses and other liabilities
provided $765 million in operating cash flows during 2020, compared to $38 million provided in 2019. The timing of
cash payments for taxes, various employee-related liabilities, customer funding and accrued expenses drove the
majority of this change.
Investing Activities
Cash flows relating to investing activities consist primarily of cash used for acquisitions and capital expenditures, including
instruments leased to customers, cash used for investments and cash proceeds from divestitures of businesses or assets.
Net cash used in investing activities was approximately $21.2 billion during 2020 compared to approximately $1.2 billion of net
cash used in 2019.
52

-- 74 of 162 --

Acquisitions, Divestitures and Sale of Investments
For a discussion of the Company’s 2020 acquisitions and divestitures refer to “—Overview” and Note 3 to the Consolidated
Financial Statements. In addition, in 2020 and 2019, the Company invested $342 million and $241 million, respectively, in
non-marketable equity securities and partnerships.
During 2019, the Company acquired five businesses for total consideration of $331 million in cash, net of cash acquired. The
businesses acquired complement existing units of each of the Company’s three segments. The aggregate annual sales of these
businesses at the time of their acquisition, in each case based on the companies’ revenues for its last completed fiscal year prior
to the acquisition, were $72 million.
Refer to Note 4 to the Consolidated Financial Statements for additional information regarding the Company’s transfer of its
former dental business to Envista Holdings Corporation.
Capital Expenditures
Capital expenditures are made primarily for increasing capacity, replacing equipment, supporting new product development,
improving information technology systems and the manufacture of instruments that are used in operating-type lease
arrangements that certain of the Company’s businesses enter into with customers. Capital expenditures totaled $791 million in
2020 and $636 million in 2019. The year-over-year increase in capital spending in 2020 was primarily due to capital
expenditures to support production of products supporting customers’ efforts related to testing, treatment and vaccine
production for COVID-19 and capital expenditures at Cytiva, partially offset by declines in expenditures for instruments used in
OTL arrangements. In 2021, the Company expects to incur higher capital spending than the prior year, to primarily support
production of products related to testing, treatment and vaccine production for COVID-19. The Company’s actual expenditures
will ultimately depend on business conditions, including demand for the Company’s products related to COVID-19, regulatory
requirements, and the capability of suppliers to support increased production. As a result, the Company estimates capital
expenditures in 2021 to be between approximately $1.0 billion and $1.2 billion.
Financing Activities
Cash flows from financing activities consist primarily of cash flows associated with the issuance and repayments of commercial
paper, issuance and repayment of long-term debt, issuance and repurchases of common stock, issuance of preferred stock and
payments of cash dividends to shareholders. Financing activities provided cash of approximately $1.0 billion during 2020
compared to approximately $16.4 billion of cash provided during 2019. The year-over-year decrease in cash provided by
financing activities was due primarily to the significant borrowings incurred in 2019 to finance the Cytiva Acquisition, partially
offset by borrowings incurred in 2020 to finance the remaining amounts needed to acquire Cytiva and for general corporate
purposes.
Total debt was approximately $21.2 billion and $21.7 billion as of December 31, 2020 and 2019, respectively, and notes
payable and current portion of long-term debt was $11 million and $212 million as of December 31, 2020 and 2019,
respectively. As of December 31, 2020 the Company had the ability to incur approximately $4.4 billion of additional
indebtedness in direct borrowings or under the outstanding commercial paper facilities based on the amounts available under
the Company’s $5.0 billion Five-Year Facility which were not being used to backstop outstanding commercial paper balances.
As of December 31, 2020, the Company has classified $611 million of its borrowings outstanding under the euro-denominated
commercial paper program and $290 million of borrowings outstanding under the 2021 Yen Notes as long-term debt in the
accompanying Consolidated Balance Sheet as the Company has the intent and ability, as supported by availability under the
Five-Year Facility, to refinance these borrowings for at least one year from the balance sheet date. As commercial paper
obligations mature, the Company may issue additional short-term commercial paper obligations to refinance all or part of these
borrowings, to the extent commercial paper markets are available.
Under the Company’s U.S. and euro-denominated commercial paper program, the notes are typically issued at a discount from
par, generally based on the ratings assigned to the Company by credit rating agencies at the time of the issuance and prevailing
market rates measured by reference to LIBOR or EURIBOR. Additionally, the Company’s floating rate senior unsecured notes
due 2022 pay interest based upon the three-month EURIBOR plus 0.3%. In July 2017, the head of the United Kingdom
Financial Conduct Authority announced the intent to phase out the use of LIBOR by the end of 2021. The U.S. Federal
Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S.
financial institutions, is considering replacing U.S. dollar LIBOR with the Secured Overnight Financing Rate, or SOFR, a new
index calculated by short-term repurchase agreements, backed by Treasury securities. The Company has evaluated the
anticipated impact of the transition from LIBOR and does not expect the transition to be material to the Company’s financial
position.
53

-- 75 of 162 --

Refer to Note 11 to the Consolidated Financial Statements for additional information regarding the Company’s financing
activities and indebtedness, including the Company’s outstanding debt as of December 31, 2020, and the Company’s
commercial paper program and Five-Year Facility.
Common Stock Offering and MCPS Offering
For a description of the 2019 Common Stock and MCPS Series A Offerings and the 2020 Common Stock and MCPS Series B
Offerings, refer to Note 19 to the Consolidated Financial Statements.
Shelf Registration Statement
The Company has filed a “well-known seasoned issuer” shelf registration statement on Form S-3 with the SEC that registers an
indeterminate amount of debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts and
units for future issuance. The Company expects to use net proceeds realized by the Company from future securities sales off
this shelf registration statement for general corporate purposes, including without limitation repayment or refinancing of debt or
other corporate obligations, acquisitions, capital expenditures, share repurchases and dividends and/or working capital.
Stock Repurchase Program
Please see Note 19 to the Consolidated Financial Statements for a description of the Company’s stock repurchase program.
Dividends
The Company declared a regular quarterly dividend of $0.18 per share of Company common stock that was paid on January 29,
2021 to holders of record on December 28, 2020. In addition, the Company declared quarterly cash dividends of $11.875 per
MCPS Series A and $12.50 per MCPS Series B that were paid on January 15, 2021 to holders of record as of December 31,
2020. Aggregate 2020 and 2019 cash payments for dividends on Company common stock were $500 million and $478 million,
respectively, and aggregate 2020 and 2019 cash payments for the dividends on the Company’s MCPS were $115 million and
$49 million, respectively. The year-over-year increase in dividend payments in 2020 primarily relates to dividends paid on the
MCPS Series A and MCPS Series B, which were issued in March 2019 and May 2020, respectively, and an increase in the
quarterly dividend rate on common stock effective with respect to the dividend paid in the second quarter of 2020.
Cash and Cash Requirements
As of December 31, 2020, the Company held approximately $6.0 billion of cash and cash equivalents that were on deposit with
financial institutions or invested in highly liquid investment-grade debt instruments with a maturity of 90 days or less with an
approximate weighted average annual interest rate of 0.2%. Of this amount, approximately $1.5 billion was held within the
United States and approximately $4.5 billion was held outside of the United States. The Company will continue to have cash
requirements to support working capital needs, capital expenditures, acquisitions and investments, pay interest and service debt,
pay taxes and any related interest or penalties, fund its restructuring activities and pension plans as required, pay dividends to
shareholders, repurchase shares of the Company’s common stock as applicable and support other business needs. The
Company generally intends to use available cash and internally generated funds to meet these cash requirements, but in the
event that additional liquidity is required, particularly in connection with acquisitions, the Company may also borrow under its
commercial paper programs or Five-Year Facility, enter into new credit facilities and either borrow directly thereunder or use
such credit facilities to backstop additional borrowing capacity under its commercial paper program and/or issue debt and/or
equity in the capital markets, in each case to the extent such sources of capital remain available. The Company also may from
time to time access the capital markets to take advantage of favorable interest rate environments or other market conditions.
While repatriation of some cash held outside the United States may be restricted by local laws, most of the Company’s foreign
cash could be repatriated to the United States. Following enactment of the TCJA and the associated Transition Tax, in general,
repatriation of cash to the United States can be completed with no incremental U.S. tax; however, repatriation of cash could
subject the Company to non-U.S. jurisdictional taxes on distributions. The cash that the Company’s non-U.S. subsidiaries hold
for indefinite reinvestment is generally used to finance foreign operations, investments and acquisitions. The income taxes
applicable to repatriating such earnings are not readily determinable. As of December 31, 2020, principally all of the
Company’s non-U.S. earnings are indefinitely reinvested and management believes that the Company has sufficient liquidity to
satisfy its cash needs, including its cash needs in the United States.
During 2020, the Company contributed $140 million to its U.S. defined benefit pension plans and $51 million to its non-U.S.
defined benefit pension plans. During 2021, the Company’s cash contribution requirements for its U.S. and its non-U.S.
defined benefit pension plans are expected to be approximately $10 million and $44 million, respectively. The ultimate
54

-- 76 of 162 --

amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan’s funded
status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates and other factors.
Contractual and Other Obligations
For a description of the Company’s debt and lease obligations, commitments, and litigation and contingencies, refer to Notes 5,
11, 17, and 18 to the Consolidated Financial Statements.
Legal Proceedings
Refer to “Item 3. Legal Proceedings” and Note 18 to the Consolidated Financial Statements for information regarding legal
proceedings and contingencies, and for a discussion of risks related to legal proceedings and contingencies, refer to “Item 1A.
Risk Factors.”
CRITICAL ACCOUNTING ESTIMATES
Management’s discussion and analysis of the Company’s financial condition and results of operations is based upon the
Company’s Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally
accepted in the United States. The preparation of these financial statements requires management to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent
assets and liabilities. The Company bases these estimates and judgments on historical experience, the current economic
environment and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may
differ materially from these estimates and judgments.
The Company believes the following accounting estimates are most critical to an understanding of its financial statements.
Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about
material matters that are uncertain at the time the estimate is made, and (2) material changes in the estimate are reasonably
likely from period-to-period. For a detailed discussion on the application of these and other accounting estimates, refer to Note
1 to the Consolidated Financial Statements.
Acquired Intangibles—The Company’s business acquisitions, including the Cytiva Acquisition, typically result in the
recognition of goodwill, developed technology and other intangible assets, which affect the amount of future period
amortization expense and possible impairment charges that the Company may incur. The fair values of acquired intangibles are
determined using information available near the acquisition date based on estimates and assumptions that are deemed
reasonable by the Company. Significant assumptions include the discount rates and certain assumptions that form the basis of
the forecasted results of the acquired business including revenue, earnings before interest, taxes, depreciation and amortization
(“EBITDA”), growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could
be affected by future economic and market conditions. The Company engages third-party valuation specialists who review the
Company’s critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant
acquisitions. In connection with acquisitions during the year ended December 31, 2020, the Company recognized aggregate
goodwill of approximately $10.4 billion and intangible assets of approximately $10.7 billion. Refer to Notes 1, 3 and 8 to the
Consolidated Financial Statements for a description of the Company’s policies relating to goodwill, acquired intangibles and
acquisitions.
In performing its goodwill impairment testing, the Company estimates the fair value of its reporting units primarily using a
market-based approach which relies on current trading multiples of forecasted EBITDA for companies operating in businesses
similar to each of the Company’s reporting units to calculate an estimated fair value of each reporting unit. In evaluating the
estimates derived by the market-based approach, management makes judgments about the relevance and reliability of the
multiples by considering factors unique to its reporting units, including operating results, business plans, economic projections,
anticipated future cash flows, and transactions and marketplace data as well as judgments about the comparability of the market
proxies selected. There are inherent uncertainties related to these assumptions and management’s judgment in applying them to
the analysis of goodwill impairment.
As of December 31, 2020, the Company had five reporting units for goodwill impairment testing. Reporting units resulting
from recent acquisitions generally present the highest risk of impairment. Management believes the impairment risk associated
with these reporting units generally decreases as these businesses are integrated into the Company and better positioned for
potential future earnings growth. The Company’s annual goodwill impairment analysis in 2020 indicated that in all instances,
the fair values of the Company’s reporting units exceeded their carrying values and consequently did not result in an
impairment charge. The excess of the estimated fair value over carrying value (expressed as a percentage of carrying value for
the respective reporting unit) for each of the Company’s reporting units as of the annual testing date ranged from approximately
80% to approximately 695%. In order to evaluate the sensitivity of the fair value calculations used in the goodwill impairment
55

-- 77 of 162 --

test, the Company applied a hypothetical 10% decrease to the fair values of each reporting unit and compared those
hypothetical values to the reporting unit carrying values. Based on this hypothetical 10% decrease, the excess of the estimated
fair value over carrying value (expressed as a percentage of carrying value for the respective reporting unit) for each of the
Company’s reporting units ranged from approximately 60% to approximately 615%.
The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the
related carrying amounts may not be recoverable. Determining whether an impairment loss occurred for finite-lived intangibles
requires a comparison of the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset.
These analyses require management to make judgments and estimates about future revenues, expenses, market conditions and
discount rates related to these assets. Indefinite-lived intangibles are subject to impairment testing at least annually or more
frequently if events or changes in circumstances indicate that potential impairment exists. Determining whether an impairment
loss occurred for indefinite-lived intangible assets involves calculating the fair value of the indefinite-lived intangible assets and
comparing the fair value to their carrying value. If the fair value is less than the carrying value, the difference is recorded as an
impairment loss. Refer to Note 8 to the Consolidated Financial Statements for a description of intangible assets impairment
charges recorded during 2020.
If actual results are not consistent with management’s estimates and assumptions, goodwill and other intangible assets may be
overstated and a charge would need to be taken against net earnings which would adversely affect the Company’s financial
statements. Historically, the Company’s estimates of goodwill and intangible assets have been materially correct.
Contingent Liabilities—As discussed in “Item 3. Legal Proceedings” and Note 18 to the Consolidated Financial Statements, the
Company is, from time to time, subject to a variety of litigation and similar contingent liabilities incidental to its business (or
the business operations of previously owned entities). The Company recognizes a liability for any legal contingency that is
known or probable of occurrence and reasonably estimable. These assessments require judgments concerning matters such as
litigation developments and outcomes, the anticipated outcome of negotiations, the number of future claims and the cost of both
pending and future claims. In addition, because most contingencies are resolved over long periods of time, liabilities may
change in the future due to various factors, including those discussed in Note 18 to the Consolidated Financial Statements. If
the reserves established by the Company with respect to these contingent liabilities are inadequate, the Company would be
required to incur an expense equal to the amount of the loss incurred in excess of the reserves, which would adversely affect the
Company’s financial statements.
Revenue Recognition—The Company derives revenues from the sale of products and services. Revenue is recognized when
control over the promised products or services is transferred to the customer in an amount that reflects the consideration that the
Company expects to receive in exchange for those goods or services. In determining if control has transferred, the Company
considers whether certain indicators of the transfer of control are present, such as the transfer of title, present right to payment,
significant risks and rewards of ownership and customer acceptance when acceptance is not a formality. To determine the
consideration that the customer owes the Company, the Company must make judgments regarding the amount of customer
allowances and rebates, as well as an estimate for product returns. The Company also enters into lease arrangements with
customers which requires the Company to determine whether the arrangements are operating or sales-type leases. Refer to
Notes 1 and 2 to the Consolidated Financial Statements for a description of the Company’s revenue recognition policies.
If the Company’s judgments regarding revenue recognition prove incorrect, the Company’s reported revenues in particular
periods may be incorrect. Historically, the Company’s estimates of revenue have been materially correct.
Pension and Other Postretirement Benefits—For a description of the Company’s pension and other postretirement benefit
accounting practices, refer to Notes 13 and 14 to the Consolidated Financial Statements. Calculations of the amount of pension
and other postretirement benefit costs and obligations depend on the assumptions used in the actuarial valuations, including
assumptions regarding discount rates, expected return on plan assets, rates of salary increases, health care cost trend rates,
mortality rates and other factors. If the assumptions used in calculating pension and other postretirement benefits costs and
obligations are incorrect or if the factors underlying the assumptions change (as a result of differences in actual experience,
changes in key economic indicators or other factors) the Company’s financial statements could be materially affected. A 50
basis point reduction in the discount rates used for the plans would have increased the U.S. net obligation by $144 million
($110 million on an after-tax basis) and the non-U.S. net obligation by $191 million ($147 million on an after-tax basis) from
the amounts recorded in the Consolidated Financial Statements as of December 31, 2020. A 50 basis point increase in the
discount rates used for the plans would have decreased the U.S. net obligation by $133 million ($101 million on an after-tax
basis) and the non-U.S. net obligation by $175 million ($135 million on an after-tax basis) from the amounts recorded in the
Consolidated Financial Statements as of December 31, 2020.
For 2020, the estimated long-term rate of return for the U.S. plans was 7.0%, and the Company intends to use an assumption of
6.75% for 2021. The estimated long-term rate of return for the non-U.S. plans was determined on a plan-by-plan basis based on
56

-- 78 of 162 --

the nature of the plan assets and ranged from 0.5% to 5.0%. If the expected long-term rate of return on plan assets for 2020 was
reduced by 50 basis points, pension expense for the U.S. and non-U.S. plans for 2020 would have increased $9 million ($7
million on an after-tax basis) and $6 million ($4 million on an after-tax basis), respectively.
For a discussion of the Company’s 2020 and anticipated 2021 defined benefit pension plan contributions, refer to “—Liquidity
and Capital Resources—Cash and Cash Requirements”.
Income Taxes—For a description of the Company’s income tax accounting policies, refer to Notes 1 and 15 to the Consolidated
Financial Statements. The Company establishes valuation allowances for its deferred tax assets if it is more likely than not that
some or all of the deferred tax asset will not be realized. This requires management to make judgments and estimates
regarding: (1) the timing and amount of the reversal of taxable temporary differences, (2) expected future taxable income, and
(3) the impact of tax planning strategies. Future changes to tax rates would also impact the amounts of deferred tax assets and
liabilities and could have an adverse impact on the Company’s financial statements.
The Company provides for unrecognized tax benefits when, based upon the technical merits, it is “more likely than not” that an
uncertain tax position will not be sustained upon examination. Judgment is required in evaluating tax positions and determining
income tax provisions. The Company re-evaluates the technical merits of its tax positions and may recognize an uncertain tax
benefit in certain circumstances, including when: (1) a tax audit is completed; (2) applicable tax laws change, including a tax
case ruling or legislative guidance; or (3) the applicable statute of limitations expires.
In addition, certain of the Company’s tax returns are currently under review by tax authorities including in Denmark and the
United States (refer to “—Results of Operations—Income Taxes” and Note 15 to the Consolidated Financial Statements).
Management believes the positions taken in these returns are in accordance with the relevant tax laws. However, the outcome
of these audits is uncertain and could result in the Company being required to record charges for prior year tax obligations
which could have a material adverse impact to the Company’s financial statements, including its effective tax rate.
An increase of 1.0% in the Company’s 2020 nominal tax rate would have resulted in an additional income tax provision for
continuing operations for the year ended December 31, 2020 of $45 million.
NEW ACCOUNTING STANDARDS
For a discussion of the new accounting standards impacting the Company, refer to Note 1 to the Consolidated Financial
Statements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The information required by this item is included under “Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations.”
57

-- 79 of 162 --

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Report of Management on Danaher Corporation’s Internal Control Over Financial Reporting
The management of the Company is responsible for establishing and maintaining adequate internal control over financial
reporting for the Company. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated
under the Securities Exchange Act of 1934.
The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of
December 31, 2020. In making this assessment, the Company’s management used the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission (“COSO”) in “Internal Control-Integrated Framework” (2013
framework). Based on this assessment, management concluded that, as of December 31, 2020, the Company’s internal control
over financial reporting is effective.
The Company completed the acquisition of Cytiva on March 31, 2020. Since the Company has not yet fully incorporated the
internal controls and procedures of Cytiva into the Company’s internal control over financial reporting, management excluded
Cytiva from its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31,
2020. Cytiva constituted 36% of the Company’s total assets as of December 31, 2020 and 15% of the Company’s total
revenues for the year then ended.
The Company’s independent registered public accounting firm has issued an audit report on the effectiveness of the Company’s
internal control over financial reporting. This report dated February 24, 2021 appears on pages 59-60 of this Form 10-K.
58

-- 80 of 162 --

Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Danaher Corporation
Opinion on Internal Control over Financial Reporting
We have audited Danaher Corporation and subsidiaries’ internal control over financial reporting as of December 31, 2020,
based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Danaher Corporation and subsidiaries
(the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020,
based on the COSO criteria.
As indicated in the accompanying Report of Management on Danaher Corporation’s Internal Control Over Financial Reporting,
management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the
internal controls of Cytiva, which is included in the 2020 consolidated financial statements of the Company and constituted
36% of total assets as of December 31, 2020 and 15% of the Company’s total revenue for the year then ended. Our audit of
internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial
reporting of Cytiva.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated
statements of earnings, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period
ended December 31, 2020, and the related notes and financial statement schedule listed in the Index at Item 15(a) and our report
dated February 24, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Report of
Management on Danaher Corporation’s Internal Control Over Financial Reporting. Our responsibility is to express an opinion
on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with
the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws
and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a
reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
59

-- 81 of 162 --

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Tysons, Virginia
February 24, 2021
60

-- 82 of 162 --

Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Danaher Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Danaher Corporation and subsidiaries (the Company) as of
December 31, 2020 and 2019, the related consolidated statements of earnings, comprehensive income, stockholders’ equity and
cash flows for each of the three years in the period ended December 31, 2020, and the related notes and financial statement
schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company at
December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended
December 31, 2020, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in
Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission
(2013 framework), and our report dated February 24, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due
to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that
were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that
are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as
a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit
matters or on the accounts or disclosures to which they relate.
61

-- 83 of 162 --

Uncertain Tax Positions
Description
of the
Matter
As discussed in Note 15 to the consolidated financial statements, the Company operates in the U.S. and multiple
international tax jurisdictions and as a result files numerous tax returns in those locations. Uncertainty in a tax
position may arise for multiple reasons, including because tax laws are subject to interpretation. For some
matters, the Company uses judgment to (1) determine whether, based on the technical merits, a tax position is
more likely than not to be sustained and (2) measure the amount of tax benefit that qualifies for recognition. As
of December 31, 2020, the Company’s gross unrecognized tax benefits related to uncertain tax positions were
approximately $1.2 billion. As further discussed in Note 15, if the Internal Revenue Service proposes
adjustments related to the Company's self-insurance programs and if the Company is unsuccessful in defending
its position the Company may be required to record a charge against future earnings. The Company believes its
positions related to the self-insurance programs are more likely than not sustainable and accordingly has no
unrecognized tax benefit related to these self-insurance programs.
Due to the inherent uncertainty in predicting the resolution of some of these tax matters, auditing the Company’s
uncertain tax positions and the related unrecognized tax benefits is complex and required the use of tax subject
matter resources to determine whether the more likely than not criteria was met.
How We
Addressed
the Matter
in Our Audit
We tested controls over management’s accounting for uncertain tax positions, including assessment of the
technical merits of tax positions.
To evaluate whether the technical merits of some uncertain tax positions are more likely than not sustainable,
our audit procedures included, among others, evaluation of applicable tax law, court cases, tax regulations and
other regulatory guidance by our tax subject matter resources. We also involved tax subject matter resources in
verifying our understanding of the relevant facts and analysis by reading relevant correspondence with the tax
authority and reading third-party advice obtained by management. We also evaluated the adequacy of the
Company’s disclosures included in Note 15 to the consolidated financial statements in relation to these matters.
Accounting for the Acquisition of Cytiva
Description
of the
Matter
As discussed in Note 3 to the consolidated financial statements, on March 31, 2020, the Company acquired the
Biopharma business now known as Cytiva, for a purchase price of $20.7 billion. The transaction was accounted
for as a business combination. As part of the allocation of the purchase price, the Company estimated the fair
value of finite-lived intangible assets to be $10.7 billion, comprised of product trade names, developed
technology and customer relationships.
Auditing the Company's accounting for its acquisition of Cytiva was complex due to the estimation uncertainty
in determining the fair value of finite-lived intangible assets. The estimation uncertainty was primarily due to
the sensitivity of the respective assets’ fair value to underlying assumptions about the future performance of
Cytiva and other related valuation assumptions. The significant assumptions used to estimate the value of these
assets included discount rates and certain assumptions that form the basis of the forecasted results including
revenue and EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) growth rates, royalty
rates and technology obsolescence rates. These assumptions are forward looking and could be affected by
future economic and market conditions.
How We
Addressed
the Matter
in Our Audit
We tested the Company's controls over its accounting for acquisitions, including controls over management’s
review of the significant assumptions described above.
To test the estimated fair value of these intangible assets, we performed audit procedures that included, among
others, evaluating the Company's use of the selected valuation model and testing the significant assumptions
used in the model and testing the completeness and accuracy of the underlying data. For example, we compared
certain assumptions to current market and economic trends, to historical results of the acquired business, to
assumptions used by guideline companies within the industry, and to internal communications and analysis.
Our valuation specialists assisted with the evaluation of the valuation model selected and certain assumptions,
including the discount rate, royalty rates and technological obsolescence rates.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2002.
Tysons, Virginia
February 24, 2021
62

-- 84 of 162 --

#'$'%$')$##(*('(
$#($!)!#()(
8=<8;;8>=B4G24?C?4AB70A40<>D=C
 	B>5424<14A
 	
(()(
JGG:CI6HH:IH
6H=6C9:FJ>K6A:CIH 	 	  	 	 
-G69:688DJCIHG:8:>K67A: A:HH6AADL6C8:;DG9DJ7I;JA688DJCIHD;6HD;:8:B7:G
 6C96HD;:8:B7:G  	 	  	 	 
"CK:CIDG>:H 	 	  	 	 
)G:E6>9:ME:CH:H6C9DI=:G8JGG:CI6HH:IH 	 	  	 	
-DI6A8JGG:CI6HH:IH 	 	  	 	 
)GDE:GIN EA6CI6C9:FJ>EB:CI C:I 	 	  	 	 
(I=:GADC< I:GB6HH:IH 	 	  	 	 
DD9L>AA 	 	  	 	 
(I=:G>CI6C<>7A:6HH:IH C:I 	 	  	 	 
-DI6A6HH:IH 	 	  	 	 
!!)(#()$ $!'(M&*).
JGG:CIA>67>A>I>:H
'DI:HE6N67A:6C98JGG:CIEDGI>DCD;ADC< I:GB9:7I 	 	 	 	
-G69:688DJCIHE6N67A: 	 	  	 	 
88GJ:9:ME:CH:H6C9DI=:GA>67>A>I>:H 	 	  	 	 
-DI6A8JGG:CIA>67>A>I>:H 	 	  	 	 
(I=:GADC< I:GBA>67>A>I>:H 	 	  	 	 
%DC< I:GB9:7I 	 	  	 	 
,ID8@=DA9:GHW:FJ>IN
)G:;:GG:9HID8@ CDE6GK6AJ:  B>AA>DCH=6G:H6JI=DG>O:9 B>AA>DCH=6G:HD;
 &6C96IDGNDCK:GI>7A:)G:;:GG:9,ID8@ ,:G>:H >HHJ:96C9DJIHI6C9>C<6HD;
:8:B7:G 6C9:8:B7:G  B>AA>DCH=6G:HD; &6C96IDGN
DCK:GI>7A:)G:;:GG:9,ID8@ ,:G>:H >HHJ:96C9DJIHI6C9>C<6HD;:8:B7:G 
6C9CDH=6G:H>HHJ:9DGDJIHI6C9>C<6HD;:8:B7:G  	 	  	 	 
DBBDCHID8@  E6GK6AJ:  7>AA>DCH=6G:H6JI=DG>O:9 B>AA>DC>HHJ:96C9
 B>AA>DCDJIHI6C9>C<6HD;:8:B7:G  B>AA>DC>HHJ:96C9 
B>AA>DCDJIHI6C9>C<6HD;:8:B7:G  	 	 	 	
99>I>DC6AE6>9 >C86E>I6A 	 	  	 	 
+:I6>C:9:6GC>C<H 	 	  	 	 
88JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH 	 	  	 
-DI6A6C6=:GHID8@=DA9:GHW:FJ>IN 	 	  	 	 
'DC8DCIGDAA>C<>CI:G:HIH 	 	 	 	
-DI6AHID8@=DA9:GHW:FJ>IN 	 	  	 	 
-DI6AA>67>A>I>:H6C9HID8@=DA9:GHW:FJ>IN 	 	  	 	 
,::I=:688DBE6CN>C<'DI:HIDI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH


-- 85 of 162 --

#'$'%$')$##(*('(
$#($!)())"#)($'##(
0=3B70A4B8=<8;;8>=B4G24?C?4AB70A40<>D=CB
 	.40A=343424<14A
 	 	
,6A:H 	 	  	 	  	 	 
DHID;H6A:H 	 	  	 	  	 	 
GDHHEGD;>I 	 	  	 	  	 	 
(E:G6I>C<8DHIH
,:AA>C< <:C:G6A6C969B>C>HIG6I>K::ME:CH:H 	 	  	 	  	 	 
+:H:6G8=6C99:K:ADEB:CI:ME:CH:H 	 	  	 	  	 	 
(E:G6I>C<EGD;>I 	 	  	 	  	 	 
'DCDE:G6I>C<>C8DB::ME:CH:
(I=:G>C8DB::ME:CH: C:I 	 	 	 	 	 	
6>CDCH6A:D;EGD9J8IA>C:H 	 	 	 	T 	 	T
%DHHDC:6GAN:MI>C<J>H=B:CID;7DGGDL>C<H 	 	 	 	 	 	T
"CI:G:HI:ME:CH: 	 	 	 	 	 	
"CI:G:HI>C8DB: 	 	 	 	 	 	
6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH7:;DG:>C8DB:I6M:H 	 	  	 	  	 	 
"C8DB:I6M:H 	 	 	 	 	 	
':I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH 	 	  	 	  	 	 
6GC>C<H;GDB9>H8DCI>CJ:9DE:G6I>DCH C:ID;>C8DB:I6M:H 	 	T 	 	 	 	
':I:6GC>C<H 	 	  	 	  	 	 
&6C96IDGN8DCK:GI>7A:EG:;:GG:9HID8@9>K>9:C9H 	 	 	 	 	 	T
':I:6GC>C<H6IIG>7JI67A:ID8DBBDCHID8@=DA9:GH 	 	  	 	  	 	 
':I:6GC>C<HE:G8DBBDCH=6G:;GDB8DCI>CJ>C<DE:G6I>DCH
6H>8 	 	  	 	  	 	 
>AJI:9 	 	  	 	  	 	 
':I:6GC>C<HE:G8DBBDCH=6G:;GDB9>H8DCI>CJ:9DE:G6I>DCH
6H>8 	 	T 	 	  	 	 
>AJI:9 	 	T 	 	  	 	 
':I:6GC>C<HE:G8DBBDCH=6G:
6H>8 	 	  	 	    	 
>AJI:9 	 	  	 	  	 	  
K:G6<:8DBBDCHID8@6C98DBBDC:FJ>K6A:CIH=6G:HDJIHI6C9>C<
6H>8 	 	  	 	  	 	 
>AJI:9 	 	  	 	  	 	 
 ':I:6GC>C<HE:G8DBBDCH=6G:6BDJCI9D:HCDI6999J:IDGDJC9>C<
,::I=:688DBE6CN>C<'DI:HIDI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH


-- 86 of 162 --

#'$'%$')$##(*('(
$#($!)())"#)($$"%'#(+#$"
8=<8;;8>=B
.40A=343424<14A
 	
':I:6GC>C<H 	 	  	 	  	 	 
(I=:G8DBEG:=:CH>K:>C8DB:ADHH C:ID;>C8DB:I6M:H
DG:><C8JGG:C8NIG6CHA6I>DC69?JHIB:CIH 	 	  	 	  	
):CH>DC6C9EDHIG:I>G:B:CIEA6C7:C:;>I69?JHIB:CIH 	 	  	  	
.CG:6A>O:9<6>CADHHDC6K6>A67A: ;DG H6A:H:8JG>I>:H 	 	 	 	 	 	
6H=;ADL=:9<:69?JHIB:CIH 	 	  	  	T
-DI6ADI=:G8DBEG:=:CH>K:>C8DB:ADHH C:ID;>C8DB:I6M:H 	 	  	 	  	
DBEG:=:CH>K:>C8DB: 	 	  	 	  	 	 
,::I=:688DBE6CN>C<'DI:HIDI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH


-- 87 of 162 --

#'$'%$')$##(*('(
$#($!)())"#)($()$ $!'(M&*).
8=<8;;8>=B
.40A=343424<14A
 	
)G:;:GG:9HID8@
6A6C8: 7:<>CC>C<D;E:G>D9 	 	  	 	T 	 	T
"HHJ6C8:D;&6C96IDGNDCK:GI>7A:)G:;:GG:9,ID8@ 	 	  	 	  	 	T
6A6C8: :C9D;E:G>D9 	 	  	 	  	 	T
DBBDCHID8@
6A6C8: 7:<>CC>C<D;E:G>D9 	 	 	 	 	 	
DBBDCHID8@ 76H:96L6G968I>K>IN 	 	 	 	T 	 	T
"HHJ6C8:D;8DBBDCHID8@ 	 	T 	 	T 	 	T
6A6C8: :C9D;E:G>D9 	 	 	 	 	 	
99>I>DC6AE6>9 >C86E>I6A
6A6C8: 7:<>CC>C<D;E:G>D9 	 	  	 	  	 	 
DBBDCHID8@ 76H:96L6G968I>K>IN 	 	 	 	 	 	
DBBDCHID8@>HHJ:9>C8DCC:8I>DCL>I=68FJ>H>I>DCH 	 	T 	 	T 	 	
DBBDCHID8@>HHJ:9>C8DCC:8I>DCL>I=%2('HW8DCK:GH>DCH 	 	 	 	 	 	
"HHJ6C8:D;8DBBDCHID8@ 	 	  	 	  	 	T
,6A:D;CK>HI6!DA9>C<HDGEDG6I>DC8DBBDCHID8@ 	 	T 	 	  	T
6A6C8: :C9D;E:G>D9 	 	  	 	  	 	 
+:I6>C:9:6GC>C<H
6A6C8: 7:<>CC>C<D;E:G>D9 	 	  	 	  	 	 
9DEI>DCD;688DJCI>C<HI6C96G9H 	 	  	T 	 	
':I:6GC>C<H 	 	  	 	  	 	 
DBBDCHID8@9>K>9:C9H9:8A6G:9 	 	  	  	
&6C96IDGNDCK:GI>7A:)G:;:GG:9,ID8@9>K>9:C9H9:8A6G:9 	 	  	  	T
-:C9:G:98DBBDCHID8@>C:M8=6C<:D;;:G;DGCK>HI6!DA9>C<H
DGEDG6I>DC8DBBDCHID8@ 	 	T 	 	   	T
6A6C8: :C9D;E:G>D9 	 	  	 	  	 	 
88JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH
6A6C8: 7:<>CC>C<D;E:G>D9 	 	   	   	 
9DEI>DCD;688DJCI>C<HI6C96G9H 	 	T 	 	T 	 	
(I=:G8DBEG:=:CH>K:>C8DB:ADHH 	 	  	 	  	
6A6C8: :C9D;E:G>D9 	 	  	   	 
'DC8DCIGDAA>C<>CI:G:HIH
6A6C8: 7:<>CC>C<D;E:G>D9 	 	 	 	 	 	
8I>K>ING:A6I:9IDCK>HI6!DA9>C<HDGEDG6I>DC 	 	T 	 	  	T
=6C<:>CCDC8DCIGDAA>C<>CI:G:HIH 	 	T 	 	 	 	
6A6C8: :C9D;E:G>D9 	 	 	 	 	 	
-DI6AHID8@=DA9:GHW:FJ>IN :C9D;E:G>D9 	 	  	 	  	 	 
,::I=:688DBE6CN>C<'DI:HIDI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH


-- 88 of 162 --

#'$'%$')$##(*('(
$#($!)())"#)($(!$,(
8=<8;;8>=B
.40A=343424<14A
 	 	
6H=;ADLH;GDBDE:G6I>C<68I>K>I>:H
':I:6GC>C<H 	 	   	   	 
%:HH:6GC>C<H;GDB9>H8DCI>CJ:9DE:G6I>DCH C:ID;>C8DB:I6M:H 	 	T  	  	
':I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH 	 	   	   	 
'DC86H=>I:BH
:EG:8>6I>DC 	 	  	  	
BDGI>O6I>DCD;>CI6C<>7A:6HH:IH 	 	   	  	
BDGI>O6I>DCD;68FJ>H>I>DC G:A6I:9>CK:CIDGN;6>GK6AJ:HI:E JE 	 	  	T  	T
,ID8@ 76H:98DBE:CH6I>DC:ME:CH: 	 	  	  	
)G:I6M<6>CDCH6A:D;EGD9J8IA>C:H 	 	  	T  	T
=6C<:>C9:;:GG:9>C8DB:I6M:H 	 	  	  	
=6C<:>CIG69:688DJCIHG:8:>K67A: C:I 	 	  	  	
=6C<:>C>CK:CIDG>:H 	 	  	  	
=6C<:>CIG69:688DJCIHE6N67A: 	 	  	  	
=6C<:>CEG:E6>9:ME:CH:H6C9DI=:G6HH:IH 	 	  	  	
=6C<:>C688GJ:9:ME:CH:H6C9DI=:GA>67>A>I>:H 	 	  	  	
-DI6ADE:G6I>C<86H=EGDK>9:97N8DCI>CJ>C<DE:G6I>DCH 	 	   	   	 
-DI6ADE:G6I>C<86H=JH:9>CEGDK>9:97N9>H8DCI>CJ:9DE:G6I>DCH 	 	  	  	
':I86H=EGDK>9:97NDE:G6I>C<68I>K>I>:H 	 	   	   	 
6H=;ADLH;GDB>CK:HI>C<68I>K>I>:H
6H=E6>9;DG68FJ>H>I>DCH 	 	   	  	 
)6NB:CIH;DG699>I>DCHIDEGDE:GIN EA6CI6C9:FJ>EB:CI 	 	  	  	
)GD8::9H;GDBH6A:HD;EGDE:GIN EA6CI6C9:FJ>EB:CI 	 	  	  	
)6NB:CIH;DGEJG8=6H:HD;>CK:HIB:CIH 	 	  	  	
)GD8::9H;GDBH6A:HD;>CK:HIB:CIH 	 	  	T  	
)GD8::9H;GDBH6A:D;EGD9J8IA>C:H 	 	  	T  	T
AADI=:G>CK:HI>C<68I>K>I>:H 	 	  	  	
-DI6A>CK:HI>C<86H=JH:9>C8DCI>CJ>C<DE:G6I>DCH 	 	   	   	 
-DI6A>CK:HI>C<86H=JH:9>C9>H8DCI>CJ:9DE:G6I>DCH 	 	T  	  	
':I86H=JH:9>C>CK:HI>C<68I>K>I>:H 	 	   	   	 
6H=;ADLH;GDB;>C6C8>C<68I>K>I>:H
)GD8::9H;GDBI=:>HHJ6C8:D;8DBBDCHID8@>C8DCC:8I>DCL>I=HID8@ 76H:9
8DBE:CH6I>DC 	 	  	  	
)GD8::9H;GDBI=:EJ7A>8D;;:G>C<D;8DBBDCHID8@ C:ID;>HHJ6C8:8DHIH 	 	   	   	T
)GD8::9H;GDBI=:EJ7A>8D;;:G>C<D;EG:;:GG:9HID8@ C:ID;>HHJ6C8:8DHIH 	 	   	   	T
':IEGD8::9H;GDBI=:H6A:D;CK>HI6!DA9>C<HDGEDG6I>DC8DBBDCHID8@ C:I
D;>HHJ6C8:8DHIH 	 	T  	  	T
)6NB:CID;9>K>9:C9H 	 	  	  	
':IG:E6NB:CIHD;EGD8::9H;GDB7DGGDL>C<HB6IJG>I>:HD;96NHDGA:HH 	 	   	   	
)GD8::9H;GDB7DGGDL>C<HB6IJG>I>:HADC<:GI=6C96NH 	 	   	   	T
+:E6NB:CIHD;7DGGDL>C<HB6IJG>I>:HADC<:GI=6C96NH 	 	   	   	
&6@: L=DA:EG:B>JBHIDG:9::B7DGGDL>C<HEG>DGIDB6IJG>IN 	 	  	  	T
AADI=:G;>C6C8>C<68I>K>I>:H 	 	  	  	
-DI6A;>C6C8>C<86H=EGDK>9:97NJH:9>C8DCI>CJ>C<DE:G6I>DCH 	 	   	   	
6H=9>HIG>7JI>DCHIDCK>HI6!DA9>C<HDGEDG6I>DC C:I 	 	T  	  	T
':I86H=EGDK>9:97NJH:9>C;>C6C8>C<68I>K>I>:H 	 	   	   	
;;:8ID;:M8=6C<:G6I:8=6C<:HDC86H=6C9:FJ>K6A:CIH 	 	  	  	
':I8=6C<:>C86H=6C9:FJ>K6A:CIH 	 	   	   	
:<>CC>C<76A6C8:D;86H=6C9:FJ>K6A:CIH 	 	   	  	
C9>C<76A6C8:D;86H=6C9:FJ>K6A:CIH 	 	   	   	
,JEEA:B:CI6A9>H8ADHJG:
,=6G:HG:9::B:9I=GDJ<=I=:HEA>I D;;D;CK>HI6!DA9>C<HDGEDG6I>DC
 B>AA>DCH=6G:H=:A96H-G:6HJGNH=6G:H 	 	T  	   	T
,::I=:688DBE6CN>C<'DI:HIDI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH


-- 89 of 162 --

DANAHER CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business—Danaher Corporation (“Danaher” or the “Company”) designs, manufactures and markets professional, medical,
industrial and commercial products and services, which are typically characterized by strong brand names, innovative
technology and major market positions. As of December 31, 2020, the Company operates in three business segments: Life
Sciences; Diagnostics; and Environmental & Applied Solutions.
The Company’s Life Sciences segment offers a broad range of instruments and consumables that are primarily used by
customers to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the
causes of disease, identify new therapies, and test and manufacture new drugs and vaccines.
The Company’s Diagnostics segment offers analytical instruments, reagents, consumables, software and services that hospitals,
physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
The Company’s Environmental & Applied Solutions segment offers products and services that help protect important resources
and keep global food and water supplies safe. The Company’s water quality business provides instrumentation, consumables,
software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial,
waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. The
Company’s product identification business provides instruments, software, services and consumables for various color and
appearance management, packaging design and quality management, packaging converting, printing, marking, coding and
traceability applications for consumer, pharmaceutical and industrial products.
Refer to Notes 3 and 4 for a discussion of significant acquisitions, discontinued operations and other dispositions.
Accounting Principles—The accompanying financial statements have been prepared in accordance with accounting principles
generally accepted in the United States (“GAAP”). The Consolidated Financial Statements include the accounts of the
Company and its subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. The
Consolidated Financial Statements also reflect the impact of noncontrolling interests. Noncontrolling interests do not have a
significant impact on the Company’s consolidated results of continuing operations, therefore earnings attributable to
noncontrolling interests for continuing operations are not presented separately in the Company’s Consolidated Statements of
Earnings. Earnings attributable to noncontrolling interests have been reflected in selling, general and administrative expenses
and were insignificant in all periods presented. Reclassifications of certain prior year amounts have been made to conform to
the current year presentation.
Use of Estimates—The preparation of these financial statements in conformity with accounting principles generally accepted in
the United States requires management to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. The Company bases these estimates on
historical experience, the current economic environment and on various other assumptions that are believed to be reasonable
under the circumstances. However, uncertainties associated with these estimates exist and actual results may differ materially
from these estimates.
Cash and Equivalents—The Company considers all highly liquid investments with a maturity of three months or less at the date
of purchase to be cash equivalents.
Accounts Receivable and Allowances for Doubtful Accounts—All trade accounts, contract and finance receivables are reported
on the accompanying Consolidated Balance Sheets adjusted for any write-offs and net of allowances for doubtful accounts.
The allowances for doubtful accounts represent management’s best estimate of the expected future credit losses from the
Company’s trade accounts, contract and finance receivable portfolios. Determination of the allowances requires management to
exercise judgment about the timing, frequency and severity of credit losses that could materially affect the provision for credit
losses and, therefore, net earnings. The Company regularly performs detailed reviews of its portfolios to determine if an
impairment has occurred and evaluates the collectability of receivables based on a combination of various financial and
qualitative factors that may affect customers’ ability to pay, including customers’ financial condition, collateral, debt-servicing
ability, past payment experience and credit bureau information. In circumstances where the Company is aware of a specific
customer’s inability to meet its financial obligations, a specific reserve is recorded against amounts due to reduce the
recognized receivable to the amount reasonably expected to be collected. Additions to the allowances for doubtful accounts are
charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while
amounts recovered on previously written-off accounts increase the allowances. If the financial condition of the Company’s
customers were to deteriorate, resulting in an impairment of their ability to make payments, additional reserves would be
68

-- 90 of 162 --

G:FJ>G:9 -=:DBE6CN9D:HCDI7:A>:K:I=6IIG69:688DJCIHG:8:>K67A:G:EG:H:CIH><C>;>86CI8DC8:CIG6I>DCHD;8G:9>IG>H@
7:86JH:D;I=:9>K:GH>;>:9EDGI;DA>DD;>C9>K>9J6A8JHIDB:GH6C9<:D<G6E=>86A6G:6H (C#6CJ6GN  I=:DBE6CN69DEI:9
88DJCI>C<,I6C96G9H.E96I:U,.V'D   ,1$1&,$/167580(176>5(',7266(6 23,& 	($685(0(172)
5(',7266(621,1$1&,$/167580(176 JH>C<I=:BD9>;>:9G:IGDHE:8I>K:IG6CH>I>DCB:I=D96C9G:8DG9:96C:I>C8G:6H:IDI=:
6AADL6C8:;DG9DJ7I;JA688DJCIHD;B>AA>DC9J:IDI=:8JBJA6I>K:>BE68ID;69DEI>DC H6G:HJAID;I=:69DEI>DCD;I=:
,. I=:DBE6CNWH6AADL6C8:;DG9DJ7I;JA688DJCIH6HD;:8:B7:G G:;A:8IHI=:DBE6CNWH7:HI:HI>B6I:D;I=:
:ME:8I:9;JIJG:ADHH:H;DG>IH688DJCIHG:8:>K67A:H76H:9DC:8DCDB>88DC9>I>DCH=DL:K:G 6H6G:HJAID;I=:JC8:GI6>CIN86JH:9
7NI=:8DGDC6K>GJH(/" E6C9:B>86C9DI=:G;68IDGH I=:H::HI>B6I:HB6N8=6C<:6C9;JIJG:68IJ6AADHH:HB6N9>;;:G
;GDBI=:DBE6CNWH:HI>B6I:H -=:DBE6CNL>AA8DCI>CJ:IDBDC>IDG:8DCDB>88DC9>I>DCH6C9L>AAG:K>H:I=::HI>B6I:HD;I=:
:ME:8I:9;JIJG:ADHH:H;DG688DJCIHG:8:>K67A:6HC:8:HH6GN -=:DBE6CNG:8DG9:9B>AA>DC B>AA>DC6C9B>AA>DC
D;:ME:CH:6HHD8>6I:9L>I=9DJ7I;JA688DJCIH;DGI=:N:6GH:C9:9:8:B7:G  6C9 G:HE:8I>K:AN 
"C8AJ9:9>CI=:DBE6CNWHIG69:688DJCIHG:8:>K67A:6C9DI=:GADC< I:GB6HH:IH6HD;:8:B7:G 6C96G:
B>AA>DC6C9B>AA>DCD;C:I6<<G:<6I:;>C6C8>C<G:8:>K67A:H G:HE:8I>K:AN AA;>C6C8>C<G:8:>K67A:H6G::K6AJ6I:9;DG
>BE6>GB:CI76H:9DC>C9>K>9J6A8JHIDB:G8G:9>IEGD;>A:H
"CK:CIDGN/6AJ6I>DCT"CK:CIDG>:H>C8AJ9:I=:8DHIHD;B6I:G>6A A67DG6C9DK:G=:69 DB:HI>8>CK:CIDG>:H6G:HI6I:96II=:
ADL:GD;8DHI6C9C:IG:6A>O67A:K6AJ:EG>B6G>ANJH>C<I=:;>GHI >C ;>GHI DJIU"(VB:I=D9L>I=8:GI6>C7JH>C:HH:H6EEAN>C<
I=:A6HI >C ;>GHI DJIB:I=D9U%"(VIDK6AJ:>CK:CIDGN "CK:CIDG>:H=:A9DJIH>9:I=:.C>I:9,I6I:H6G:HI6I:96II=:ADL:GD;
8DHIDGB6G@:IEG>B6G>ANJH>C<I=:"(B:I=D9
)GDE:GIN )A6CI6C9FJ>EB:CIT)GDE:GIN EA6CI6C9:FJ>EB:CI6G:86GG>:96I8DHI -=:EGDK>H>DC;DG9:EG:8>6I>DC=6H7::C
8DBEJI:9EG>C8>E6AAN7NI=:HIG6><=I A>C:B:I=D976H:9DCI=::HI>B6I:9JH:;JAA>K:HD;I=:9:EG:8>67A:6HH:IH6H;DAADLH
0C46>AH 	*B45D;!854
J>A9>C<H 	N:6GH
%:6H:96HH:IH6C9A:6H:=DA9>BEGDK:B:CIH 	BDGI>O:9DK:GI=:A:HH:GD;I=::8DCDB>8A>;:D;I=:6HH:IDG
I=:I:GBD;I=:A:6H:
&68=>C:GN6C9:FJ>EB:CI 	SN:6GH
JHIDB:G A:6H:9>CHIGJB:CIH 	SN:6GH
HI>B6I:9JH:;JAA>K:H6G:E:G>D9>86AANG:K>:L:96C9 L=:C6EEGDEG>6I: 8=6C<:HID:HI>B6I:H6G:B69:EGDHE:8I>K:AN
"CK:HIB:CIHT"CK:HIB:CIHDK:GL=>8=I=:DBE6CN=6H6H><C>;>86CI>C;AJ:C8:7JICDI68DCIGDAA>C<>CI:G:HI 6G:688DJCI:9;DG
JH>C<I=::FJ>INB:I=D9D;688DJCI>C<L=>8=G:FJ>G:HI=:DBE6CNIDG:8DG9>IH>C>I>6A>CK:HIB:CI6I8DHI6C969?JHII=:76A6C8:
:68=E:G>D9;DGI=:DBE6CNWHH=6G:D;I=:>CK:HI::WH>C8DB:DGADHH6C99>K>9:C9HE6>9 -=:DBE6CN6AHD>CK:HIH>CHI6GI JE
8DBE6C>:HL=:G:I=:DBE6CN=6HC:>I=:G8DCIGDAD;CDGH><C>;>86CI>C;AJ:C8:DK:GI=:>CK:HI:: -=:DBE6CNB:6HJG:HI=:H:
CDC B6G@:I67A::FJ>INH:8JG>I>:H6I;6>GK6AJ:6C9G:8D<C>O:H8=6C<:H>C;6>GK6AJ:>CC:I:6GC>C<H DGH:8JG>I>:HL>I=DJI
G:69>AN6K6>A67A:;6>GK6AJ:H I=:DBE6CN=6H:A:8I:9I=:B:6HJG:B:CI6AI:GC6I>K:IDG:8DG9I=:H:>CK:HIB:CIH6I8DHI6C9ID
69?JHI;DG>BE6>GB:CIH6C9D7H:GK67A:EG>8:8=6C<:HL>I=6H6B:DGH>B>A6GH:8JG>IN;GDBI=:H6B:>HHJ:GL>I=>CC:I:6GC>C<H
I=:U6>G/6AJ:AI:GC6I>K:V 99>I>DC6AAN I=:DBE6CN>H6A>B>I:9E6GIC:G>C6E6GIC:GH=>EI=6I>CK:HIH>CHI6GI JE
8DBE6C>:H 0=>A:I=:E6GIC:GH=>EG:8DG9HI=:H:>CK:HIB:CIH6I;6>GK6AJ: I=:DBE6CNWH>CK:HIB:CI>CI=:E6GIC:GH=>E>H
688DJCI:9;DGJC9:GI=::FJ>INB:I=D9D;688DJCI>C< -=:DBE6CNB69:B>CDG>IN>CK:HIB:CIH>CCDC B6G@:I67A::FJ>IN
H:8JG>I>:H6C9:FJ>INB:I=D9>CK:HIB:CIHIDI6A>C<B>AA>DC>C6C9B>AA>DC>C >C8AJ9>C<>CK:HIB:CIH>C6
E6GIC:GH=>ED;B>AA>DC>C6C9B>AA>DC>C JG>C< I=:DBE6CNG:8DG9:9C:IG:6A>O:96C9JCG:6A>O:9
<6>CHD;B>AA>DC G:A6I:9ID8=6C<:H>CI=:;6>GK6AJ:D;I=:H:>CK:HIB:CIHL=>8=>HG:;A:8I:9>CDI=:G>C8DB::ME:CH: C:I 
>CI=:DCHDA>96I:9,I6I:B:CID;6GC>C<H 'DH><C>;>86CIG:6A>O:9DGJCG:6A>O:9<6>CHDGADHH:HL:G:G:8DG9:9>CDG
L>I=G:HE:8IIDI=:H:>CK:HIB:CIH 
(I=:GHH:IHT(I=:G6HH:IHEG>C8>E6AAN>C8AJ9:CDC8JGG:CI;>C6C8>C<G:8:>K67A:H CDC8JGG:CI9:;:GG:9I6M6HH:IH6C9DI=:G
>CK:HIB:CIH
6>G/6AJ:D;>C6C8>6A"CHIGJB:CIHT-=:DBE6CNWH;>C6C8>6A>CHIGJB:CIH8DCH>HIEG>B6G>AND;86H=6C986H=:FJ>K6A:CIH 
IG69:688DJCIHG:8:>K67A: >CK:HIB:CIH>C:FJ>INH:8JG>I>:H 6K6>A67A: ;DG H6A:9:7IH:8JG>I>:H6C98GDHH 8JGG:C8NHL6EH 
CDCFJ6A>;>:99:;:GG:98DBE:CH6I>DCEA6CH D7A><6I>DCHJC9:GIG69:688DJCIHE6N67A:6C9H=DGI6C9ADC< I:GB9:7I J:IDI=:>G
H=DGI I:GBC6IJG: I=:86GGN>C<K6AJ:H;DG86H=6C986H=:FJ>K6A:CIH IG69:688DJCIHG:8:>K67A:6C9IG69:688DJCIHE6N67A:
6EEGDM>B6I:;6>GK6AJ: +:;:GID'DI:;DGI=:;6>GK6AJ:HD;I=:DBE6CNWH>CK:HIB:CIH>C:FJ>INH:8JG>I>:H 6K6>A67A: ;DG H6A:
9:7IH:8JG>I>:H6C98GDHH 8JGG:C8NHL6EH6C9DI=:GD7A><6I>DCH


-- 91 of 162 --

Goodwill and Other Intangible Assets—Goodwill and other intangible assets result from the Company’s acquisition of existing
businesses. In accordance with accounting standards related to business combinations, goodwill is not amortized; however,
certain finite-lived identifiable intangible assets, primarily customer relationships and acquired technology, are amortized over
their estimated useful lives. Intangible assets with indefinite lives are not amortized. In-process research and development
(“IPR&D”) is initially capitalized at fair value and when the IPR&D project is complete, the asset is considered a finite-lived
intangible asset and amortized over its estimated useful life. If an IPR&D project is abandoned, an impairment loss equal to the
value of the intangible asset is recorded in the period of abandonment. The Company reviews identified intangible assets and
goodwill for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be
recoverable. The Company also tests intangible assets with indefinite lives and goodwill for impairment at least annually.
Refer to Notes 3 and 8 for additional information about the Company’s goodwill and other intangible assets.
Revenue Recognition—The Company derives revenues primarily from the sale of Life Sciences, Diagnostics and
Environmental & Applied Solutions products and services. Revenue is recognized when control of the promised products or
services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be
entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a
contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standards
Codification (“ASC”) 606, Revenue from Contracts with Customers. For equipment, consumables and most software licenses
sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must
have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and
rewards of ownership, and where acceptance is not a formality, the customer must have accepted the product or service. The
Company’s principal terms of sale are FOB Shipping Point, or equivalent, and, as such, the Company primarily transfers
control and records revenue for product sales upon shipment. Sales arrangements with delivery terms that are not FOB
Shipping Point are not recognized upon shipment and the transfer of control for revenue recognition is evaluated based on the
associated shipping terms and customer obligations. If a performance obligation to the customer with respect to a sales
transaction remains to be fulfilled following shipment (typically installation or acceptance by the customer), revenue
recognition for that performance obligation is deferred until such commitments have been fulfilled. Returns for products sold
are estimated and recorded as a reduction of revenue at the time of sale. Customer allowances and rebates, consisting primarily
of volume discounts and other short-term incentive programs, are recorded as a reduction of revenue at the time of sale because
these allowances reflect a reduction in the transaction price. Product returns, customer allowances and rebates are estimated
based on historical experience and known trends. For extended warranty, service, post contract support (“PCS”), software-as-a-
service (“SaaS”) and other long-term contracts, control transfers to the customer over the term of the arrangement. Revenue for
extended warranty, service, PCS, SaaS and certain software licenses is recognized based upon the period of time elapsed under
the arrangement. Revenue for other long-term contracts is generally recognized based upon the cost-to-cost measure of
progress, provided that the Company meets the criteria associated with transferring control of the good or service over time.
Certain of the Company’s revenues relate to operating-type lease (“OTL”) arrangements. Leases are outside the scope of ASC
606 and are therefore accounted for in accordance with ASC 842, Leases (or ASC 840, Leases (“ASC 840”) prior to January 1,
2019). Equipment lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the
cost of customer-leased equipment is recorded within property, plant and equipment in the accompanying Consolidated Balance
Sheets and depreciated over the equipment’s estimated useful life. Depreciation expense associated with the leased equipment
under OTL arrangements is reflected in cost of sales in the accompanying Consolidated Statements of Earnings. The OTLs are
generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of
consumables or tests throughout the contract term. The Company also enters into sales-type lease (“STL”) arrangements with
customers which result in earlier recognition of equipment lease revenue as compared to an OTL.
For a contract with multiple performance obligations, the Company allocates the contract’s transaction price to each
performance obligation on a relative standalone selling price basis using the Company’s best estimate of the standalone selling
price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the
price observed in standalone sales to customers; however, when prices in standalone sales are not available the Company may
use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction
price is determined at the contracts’ inception.
Shipping and Handling—Shipping and handling costs are included as a component of cost of sales. Revenue derived from
shipping and handling costs billed to customers is included in sales.
Advertising—Advertising costs are expensed as incurred.
Research and Development—The Company conducts research and development activities for the purpose of developing new
products, enhancing the functionality, effectiveness, ease of use and reliability of the Company’s existing products and
70

-- 92 of 162 --

expanding the applications for which uses of the Company’s products are appropriate. Research and development costs are
expensed as incurred.
Income Taxes—The Company’s income tax expense represents the tax liability for the current year, the tax benefit or expense
for the net change in deferred tax liabilities and assets during the year, as well as reserves for unrecognized tax benefits and
return to provision adjustments. Deferred tax liabilities and assets are determined based on the difference between the financial
statement and tax basis of assets and liabilities using enacted rates expected to be in effect during the year in which the
differences reverse. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the Company’s
tax return in future years for which the tax benefit has already been reflected on the Company’s Consolidated Statements of
Earnings. The Company establishes valuation allowances for its deferred tax assets if it is more likely than not that some or all
of the deferred tax asset will not be realized. Deferred tax liabilities generally represent items that have already been taken as a
deduction on the Company’s tax return but have not yet been recognized as an expense in the Company’s Consolidated
Statements of Earnings. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in income tax
expense in the period that includes the enactment date. The Company provides for unrecognized tax benefits when, based upon
the technical merits, it is “more likely than not” that an uncertain tax position will not be sustained upon examination.
Judgment is required in evaluating tax positions and determining income tax provisions. The Company re-evaluates the
technical merits of its tax positions and may recognize an uncertain tax benefit in certain circumstances, including when: (1) a
tax audit is completed; (2) applicable tax laws change, including a tax case ruling or legislative guidance; or (3) the applicable
statute of limitations expires. The Company recognizes potential accrued interest and penalties associated with unrecognized
tax positions in income tax expense. Refer to Note 15 for additional information and discussion of the impact of the enactment
of the Tax Cuts and Jobs Act (“TCJA”) in the United States.
Productivity Improvement and Restructuring—The Company periodically initiates productivity improvement and restructuring
activities to appropriately position the Company’s cost base relative to prevailing economic conditions and associated customer
demand as well as in connection with certain acquisitions. Costs associated with productivity improvement and restructuring
actions can include one-time termination benefits and related charges in addition to facility closure, contract termination and
other related activities. The Company records the cost of the productivity improvement and restructuring activities when the
associated liability is incurred.
Foreign Currency Translation—Exchange rate adjustments resulting from foreign currency transactions are recognized in net
earnings, whereas effects resulting from the translation of financial statements are reflected as a component of accumulated
other comprehensive income (loss) within stockholders’ equity. Assets and liabilities of subsidiaries operating outside the
United States with a functional currency other than U.S. dollars are translated into U.S. dollars using year end exchange rates
and income statement accounts are translated at weighted average rates. Net foreign currency transaction gains or losses were
not material in any of the years presented. As discussed below, the Company uses its foreign currency-denominated debt and
cross-currency swap arrangements whereby existing U.S. dollar-denominated borrowings are effectively converted to foreign
currency borrowings to partially hedge its net investments in foreign operations against adverse movements in exchange rates.
Derivative Financial Instruments—The Company is neither a dealer nor a trader in derivative instruments. The Company has
generally accepted the exposure to transactional exchange rate movements without using derivative instruments to manage this
risk, although the Company from time to time partially hedges its net investments in foreign operations against adverse
movements in exchange rates through foreign currency-denominated debt and cross-currency swaps. The Company will
periodically enter into foreign currency forward contracts to mitigate a portion of its foreign currency exchange risk and
forward starting swaps to mitigate interest rate risk related to the Company’s debt. The Company also uses cross-currency
swap derivative contracts to hedge long-term debt issuances in a foreign currency other than the functional currency of the
borrower. When utilized, the derivative instruments are recorded on the Consolidated Balance Sheets as either an asset or
liability measured at fair value. To the extent the derivative instrument qualifies as an effective hedge, changes in fair value are
recognized in accumulated other comprehensive income (loss) in stockholders’ equity. Changes in the value of the foreign
currency denominated debt and cross-currency swaps designated as hedges of the Company’s net investment in foreign
operations based on spot rates are recognized in accumulated other comprehensive income (loss) in stockholders’ equity and
offset changes in the value of the Company’s foreign currency denominated operations. Refer to Note 12 for additional
information.
71

-- 93 of 162 --

88JBJA6I:9(I=:GDBEG:=:CH>K:"C8DB:%DHHT88JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHHG:;:GHID8:GI6>C<6>CH
6C9ADHH:HI=6IJC9:G. ,  )6G:>C8AJ9:9>C8DBEG:=:CH>K:>C8DB:ADHH7JI6G::M8AJ9:9;GDBC:I:6GC>C<H6HI=:H:
6BDJCIH6G:>C>I>6AANG:8DG9:96H6C69?JHIB:CIIDHID8@=DA9:GHW:FJ>IN DG:><C8JGG:C8NIG6CHA6I>DC69?JHIB:CIH6G:<:C:G6AAN
CDI69?JHI:9;DG>C8DB:I6M:H6HI=:NG:A6I:ID>C9:;>C>I:>CK:HIB:CIH>CCDC . , HJ7H>9>6G>:H -=:8=6C<:H>C688JBJA6I:9
DI=:G8DBEG:=:CH>K:>C8DB:ADHH7N8DBEDC:CI6G:HJBB6G>O:97:ADL>CB>AA>DCH DG:><C8JGG:C8NIG6CHA6I>DC
69?JHIB:CIH<:C:G6AANG:A6I:ID>C9:;>C>I:>CK:HIB:CIH>CCDC . , HJ7H>9>6G>:H 6HL:AA6HI=:>BE68I;GDBI=:DBE6CNWH
=:9<:HD;>IHC:I>CK:HIB:CI>C;DG:><CDE:G6I>DCH >C8AJ9>C<I=:DBE6CNWH8GDHH 8JGG:C8NHL6E9:G>K6I>K:H C:ID;6CNI6M
>BE68IH
>A486=DAA4=2H
)A0=B;0C8>=
39DBC<4=CB
%4=B8>=0=3
%>BCA4C8A4<4=C
%;0=4=458C
39DBC<4=CB
*=A40;8I4308=
!>BB>=
E08;01;4>A
(0;4(42DA8C84B 0B7;>F4364
39DBC<4=CB 	)>C0;
0;0=240=D0AH  	 	 	  	 	 	 	 	 	T 	 	 
(I=:G8DBEG:=:CH>K:>C8DB:ADHH7:;DG:
G:8A6HH>;>86I>DCH
:8G:6H: 	 	 	 	 	 	 	 	T 	 	
"C8DB:I6M>BE68I 	 	T 	 	 	 	T 	 	T 	 	
(I=:G8DBEG:=:CH>K:>C8DB:ADHH7:;DG:
G:8A6HH>;>86I>DCH C:ID;>C8DB:I6M:H 	 	 	 	 	 	 	 	T 	 	
BDJCIHG:8A6HH>;>:9;GDB688JBJA6I:9DI=:G
8DBEG:=:CH>K:>C8DB:ADHH
"C8G:6H: 	 	T 	 	 6  	T 	 	T 	 	
"C8DB:I6M>BE68I 	 	T 	 	 	 	T 	 	T 	 	
BDJCIHG:8A6HH>;>:9;GDB688JBJA6I:9DI=:G
8DBEG:=:CH>K:>C8DB:ADHH C:ID;>C8DB:
I6M:H 	 	T 	 	 	 	T 	 	T 	 	
':I8JGG:CIE:G>D9DI=:G8DBEG:=:CH>K:>C8DB:
ADHH C:ID;>C8DB:I6M:H 	 	 	 	 	 	 	 	T 	 	
0;0=24424<14A  	 	 	  	 	 	 	 	 	T 	 	 
(I=:G8DBEG:=:CH>K:>C8DB:ADHH7:;DG:
G:8A6HH>;>86I>DCH
:8G:6H:>C8G:6H: 	 	 	 	 	 	 	 	 	 	
"C8DB:I6M>BE68I 	 	 	 	 	 	 	 	 	 	
(I=:G8DBEG:=:CH>K:>C8DB:ADHH7:;DG:
G:8A6HH>;>86I>DCH C:ID;>C8DB:I6M:H 	 	 	 	 	 	 	 	 	 	
BDJCIHG:8A6HH>;>:9;GDB688JBJA6I:9DI=:G
8DBEG:=:CH>K:>C8DB:ADHH
"C8G:6H: 	 	 8  	 6  	T 	 	 7  	
"C8DB:I6M>BE68I 	 	T 	 	 	 	T 	 	T 	 	
BDJCIHG:8A6HH>;>:9;GDB688JBJA6I:9DI=:G
8DBEG:=:CH>K:>C8DB:ADHH C:ID;>C8DB:
I6M:H 	 	 	 	 	 	T 	 	 	 	
':I8JGG:CIE:G>D9DI=:G8DBEG:=:CH>K:>C8DB:
ADHH C:ID;>C8DB:I6M:H 	 	 	 	 	 	 	 	 	 	
0;0=24424<14A  	 	 	  	 	 	 	 	 	 	 	 
(I=:G8DBEG:=:CH>K:>C8DB:ADHH7:;DG:
G:8A6HH>;>86I>DCH
"C8G:6H:9:8G:6H: 	 	  	 	 	 	 	 	 	 	 
"C8DB:I6M>BE68I 	 	 	 	 	 	T 	 	T 	 	
(I=:G8DBEG:=:CH>K:>C8DB:ADHH7:;DG:
G:8A6HH>;>86I>DCH C:ID;>C8DB:I6M:H 	 	  	 	 	 	 	 	 	 	 
BDJCIHG:8A6HH>;>:9;GDB688JBJA6I:9DI=:G
8DBEG:=:CH>K:>C8DB:ADHH
"C8G:6H: 	 	T 	 	 6  	T 	 	 7  	
"C8DB:I6M>BE68I 	 	T 	 	 	 	T 	 	 	 	
BDJCIHG:8A6HH>;>:9;GDB688JBJA6I:9DI=:G
8DBEG:=:CH>K:>C8DB:ADHH C:ID;>C8DB:
I6M:H 	 	T 	 	 	 	T 	 	 	 	
':I8JGG:CIE:G>D9DI=:G8DBEG:=:CH>K:>C8DB:
ADHH C:ID;>C8DB:I6M:H 	 	  	 	 	 	 	 	 	 	 
0;0=24424<14A  	 	 	 	 	 	T 	 	 	 	
6 -=>H688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH8DBEDC:CI>H>C8AJ9:9>CI=:8DBEJI6I>DCD;C:IE:G>D9>8E:CH>DC6C9EDHIG:I>G:B:CI
8DHIG:;:GID'DI:H6C9;DG699>I>DC6A9:I6>AH
7 +:;A:8IHG:8A6HH>;>86I>DCID:6GC>C<HG:A6I:9IDG:B:6HJG:B:CID;8:GI6>CADC< I:GB9:7IG:;:GID'DI:;DG699>I>DC6A9:I6>AH
8 +:;A:8IHG:8A6HH>;>86I>DCID:6GC>C<HG:A6I:9IDI=:CK>HI6>HEDH>I>DCG:;:GID'DI:;DG699>I>DC6A9:I6>AH


-- 94 of 162 --

Accounting for Stock-Based Compensation—The Company accounts for stock-based compensation by measuring the cost of
employee services received in exchange for all equity awards granted, including stock options, restricted stock units (“RSUs”)
and performance stock units (“PSUs”), based on the fair value of the award as of the grant date. Equity-based compensation
expense is recognized net of an estimated forfeiture rate on a straight-line basis over the requisite service period of the award,
except that in the case of RSUs, compensation expense is recognized using an accelerated attribution method. Refer to Note 19
for additional information on the stock-based compensation plans in which certain employees of the Company participate.
Pension and Postretirement Benefit Plans—The Company measures its pension and postretirement plans’ assets and its
obligations that determine the respective plan’s funded status as of the end of the Company’s fiscal year, and recognizes an
asset for a plan’s overfunded status or a liability for a plan’s underfunded status in its balance sheet. Changes in the funded
status of the plans are recognized in the year in which the changes occur and reported in comprehensive income (loss). Refer to
Notes 13 and 14 for additional information on the Company’s pension and postretirement plans including a discussion of the
actuarial assumptions, the Company’s policy for recognizing the associated gains and losses and the method used to estimate
service and interest cost components.
Accounting Standards Recently Adopted—In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU
Update No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosures on fair value measurements by
removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value
hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value
measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income (loss).
The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. On
January 1, 2020, the Company adopted the ASU and the ASU did not have a significant impact on the Company’s Consolidated
Financial Statements. Refer to Note 9 for the Company’s fair value measurement disclosures.
In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for
Defined Benefit Plans, which amends ASC 715, Compensation—Retirement Benefits, to add, remove and clarify disclosure
requirements related to defined benefit pension and other postretirement plans. Adoption of the ASU resulted in elimination of
the following disclosures (a) the amounts expected to be amortized from accumulated other comprehensive income and
reported as a component of net periodic benefit cost during the following fiscal year, and (b) the effects of a one-percentage-
point change in the assumed health care cost trend rates on the aggregate projected service and interest cost and accumulated
postretirement benefit obligation; and additional disclosures explaining the reasons for significant gains and losses related to the
change in benefit obligations for the period. Refer to Notes 13 and 14 for the Company’s pension and other postretirement
employee benefit plan disclosures.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach
based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including
trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities
for fiscal years beginning after December 15, 2019, with early adoption permitted. In November 2018, the FASB issued ASU
No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which provided additional
implementation guidance on the previously issued ASU. On January 1, 2020, the Company adopted the ASU using the
modified retrospective transition method. The Company recorded a decrease to beginning retained earnings of $8 million, net
of tax, as of January 1, 2020 due to the cumulative impact of adopting Topic 326. The impact to retained earnings was
primarily the result of an increase in the Company’s allowance for doubtful accounts as a result of Topic 326’s requirement to
use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of
financial instruments, including trade receivables.
Accounting Standards Not Yet Adopted—In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity. The ASU includes amendments to the guidance on convertible
instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for
convertible instruments which include beneficial conversion features or cash conversion features by removing certain
separation models in Subtopic 470-20. Additionally, the ASU will require entities to use the “if-converted” method when
calculating diluted earnings per share for convertible instruments. The ASU is effective for fiscal years beginning after
December 15, 2021, including interim periods within those fiscal years. Management has not yet completed its assessment of
the impact of the new standard on the Company’s Consolidated Financial Statements.
73

-- 95 of 162 --

#$) '+#*
-=:;DAADL>C<I67A:EG:H:CIHI=:DBE6CNWHG:K:CJ:H9>H6<<G:<6I:97N<:D<G6E=>86AG:<>DC6C9G:K:CJ:INE:>CB>AA>DCH 
,6A:HI6M:H6C9DI=:GJH6<: 76H:9I6M:H8DAA:8I:9;GDB8JHIDB:GH6G::M8AJ9:9;GDBG:K:CJ:H -=:DBE6CN9:;>C:H=><=
<GDLI=B6G@:IH6H9:K:ADE>C<B6G@:IHD;I=:LDGA9:ME:G>:C8>C<:MI:C9:9E:G>D9HD;688:A:G6I:9<GDLI=>C<GDHH9DB:HI>8
EGD9J8I6C9>C;G6HIGJ8IJG:L=>8=>C8AJ9:6HI:GCJGDE: I=:&>99A:6HI ;G>86 %6I>CB:G>866C9H>6L>I=I=::M8:EI>DC
D;#6E6C JHIG6A>66C9':L3:6A6C9 -=:DBE6CN9:;>C:H9:K:ADE:9B6G@:IH6H6AAB6G@:IHD;I=:LDGA9I=6I6G:CDI=><=
<GDLI=B6G@:IH
!854(284=24B 	806=>BC82B
=E8A>=<4=C0;
??;843
(>;DC8>=B 	)>C0;
.40A4=343424<14A  	
:D<G6E=>86AG:<>DC
'DGI=B:G>86 	 	  	 	  	 	  	 	 
0:HI:GCJGDE: 	 	  	 	  	 	  	 	 
(I=:G9:K:ADE:9B6G@:IH 	 	 	 	 	 	 	 	 
!><= <GDLI=B6G@:IH 	 	  	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	  	 	 
+:K:CJ:INE:
+:8JGG>C< 	 	  	 	  	 	  	 	 
'DCG:8JGG>C< 	 	  	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	  	 	 
.40A4=343424<14A  	
:D<G6E=>86AG:<>DC
'DGI=B:G>86 	 	  	 	  	 	  	 	 
0:HI:GCJGDE: 	 	  	 	  	 	  	 	 
(I=:G9:K:ADE:9B6G@:IH 	 	 	 	 	 	 	 	 
!><= <GDLI=B6G@:IH 	 	  	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	  	 	 
+:K:CJ:INE:
+:8JGG>C< 	 	  	 	  	 	  	 	 
'DCG:8JGG>C< 	 	  	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	  	 	 
.40A4=343424<14A  	
:D<G6E=>86AG:<>DC
'DGI=B:G>86 	 	  	 	  	 	  	 	 
0:HI:GCJGDE: 	 	  	 	  	 	  	 	 
(I=:G9:K:ADE:9B6G@:IH 	 	 	 	 	 	 	 	 
!><= <GDLI=B6G@:IH 	 	  	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	  	 	 
+:K:CJ:INE:
+:8JGG>C< 	 	  	 	  	 	  	 	 
'DCG:8JGG>C< 	 	  	 	 	 	  	 	 
-DI6A 	 	  	 	  	 	  	 	 


-- 96 of 162 --

The Company sells equipment to customers as well as consumables, software licenses and services, some of which customers
purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the
use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s
operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation
and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s
consumables are used on a standalone basis, such as water treatment solutions. The Company separates its goods and services
between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis.
Recurring revenue includes revenue from consumables, services, software licenses recognized over time, SaaS licenses, sales-
and-usage based royalties and OTLs. Nonrecurring revenue includes sales from equipment, software licenses recognized at a
point in time and STLs. OTLs and STLs are included in the above revenue amounts. For the years ended December 31, 2020,
2019 and 2018, lease revenue was $444 million, $432 million and $401 million, respectively.
Remaining Performance Obligations
Remaining performance obligations represent the aggregate transaction price allocated to performance obligations with an
original contract term greater than one year which are fully or partially unsatisfied at the end of the period. Remaining
performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments
under long-term consumable supply arrangements, extended warranty, service and PCS contracts, SaaS and other long-term
contracts. These remaining performance obligations do not include revenue from contracts with customers with an original
term of one year or less, revenue from long-term consumable supply arrangements with no minimum purchase requirements or
revenue expected from purchases made in excess of the minimum purchase requirements or revenue from equipment leased to
customers. While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining
performance obligations excludes leases and contracts that provide the customer with the right to cancel or terminate for
convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is
remote. Additionally, the Company has elected to exclude contracts with customers with an original term of one year or less
from remaining performance obligations while these contracts are included within backlog.
As of December 31, 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was
approximately $3.0 billion. The Company expects to recognize revenue on approximately 50% of the remaining performance
obligations over the next 12 months, 23% over the subsequent 12 months, and the remainder recognized thereafter.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed trade accounts receivable, unbilled receivables
(“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”)
on the Consolidated Balance Sheets. In addition, the Company defers certain costs incurred to obtain a contract (“contract
costs”).
Contract Assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract
terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing
occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current
assets in the Consolidated Balance Sheets. The balance of contract assets as of December 31, 2020 and 2019 was $65 million
and $77 million, respectively.
Contract Liabilities—The Company often receives cash payments from customers in advance of the Company’s performance
resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Consolidated
Balance Sheets based on the timing of when the Company expects to recognize revenue. As of December 31, 2020 and 2019,
contract liabilities were approximately $1.4 billion and $806 million, respectively, and are included within accrued expenses
and other liabilities and other long-term liabilities in the accompanying Consolidated Balance Sheets. The increase in the
contract liability balance during the year ended December 31, 2020 was primarily a result of cash payments received in advance
of satisfying performance obligations and acquisitions, partially offset by revenue recognized during the year that was included
in the opening contract liability balance. The increase in the contract liability balance during the year ended December 31,
2019 was primarily a result of cash payments received in advance of satisfying performance obligations and acquisitions,
partially offset by revenue recognized during the year that was included in the opening contract liability balance. Revenue
recognized during the years ended December 31, 2020 and 2019 that was included in the opening contract liability balance was
$638 million and $603 million, respectively.
Contract Costs—The Company capitalizes certain direct incremental costs incurred to obtain a contract, typically sales-related
commissions, where the amortization period for the related asset is greater than one year. These costs are amortized over the
contract term or a longer period, generally the expected life of the customer relationship if renewals are expected and the
renewal commission is not commensurate with the initial commission. Contract costs are classified as current or long-term
75

-- 97 of 162 --

other assets in the Consolidated Balance Sheets based on the timing of when the Company expects to recognize the expense and
are generally amortized into earnings on a straight-line basis (which is consistent with the transfer of control for the related
goods or services). Management assesses these costs for impairment at least quarterly and as “triggering” events occur that
indicate it is more likely than not that an impairment exists. The balance of contract costs as of December 31, 2020 and 2019
were not significant. Amortization expense related to these costs for the years ended December 31, 2020 and 2019 was also not
significant. The costs to obtain a contract where the amortization period for the related asset is one year or less are expensed as
incurred and recorded within selling, general and administrative expenses in the accompanying Consolidated Statements of
Earnings.
Contract assets, liabilities and costs are reported on the accompanying Consolidated Balance Sheets on a contract-by-contract
basis.
NOTE 3. ACQUISITIONS
The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or
expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions
and the purchases of the acquired businesses have resulted in the recognition of goodwill in the Company’s Consolidated
Financial Statements. This goodwill arises because the purchase prices for these businesses reflect a number of factors
including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at
which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the
Company acquired the businesses, the avoidance of the time and costs which would be required (and the associated risks that
would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and
profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations.
The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair
value of the acquired assets and assumed liabilities. The Company obtains the information used for the purchase price
allocation during due diligence and through other sources. In the months after closing, as the Company obtains additional
information about the acquired assets and liabilities, including through tangible and intangible asset appraisals, and learns more
about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price.
The fair values of acquired intangibles are determined based on estimates and assumptions that are deemed reasonable by the
Company. Significant assumptions include the discount rates and certain assumptions that form the basis of the forecasted
results of the acquired business including revenue, earnings before interest, taxes, depreciation and amortization (“EBITDA”),
growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could be affected by
future economic and market conditions. The Company engages third-party valuation specialists who review the Company’s
critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant acquisitions.
Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment. The Company is
continuing to evaluate certain pre-acquisition contingencies associated with certain of its 2020 acquisitions (including the
acquisition of Cytiva, as described below) and is also in the process of obtaining valuations of certain acquisition-related assets
and liabilities in connection with these acquisitions. The Company will make appropriate adjustments to the purchase price
allocation prior to completion of the measurement period, as required.
The following briefly describes the Company’s acquisition activity for the three years ended December 31, 2020.
On March 31, 2020, the Company acquired the Biopharma business of General Electric Company’s (“GE”) Life Sciences
division, now known as Cytiva, for a cash purchase price of approximately $20.7 billion (net of approximately $0.1 billion of
acquired cash) and the assumption of approximately $0.4 billion of pension liabilities (the “Cytiva Acquisition”). Cytiva is a
leading provider of instruments, consumables and software that support the research, discovery, process development and
manufacturing workflows of biopharmaceutical drugs. Cytiva is included in the Company’s Life Sciences segment results
beginning in the second quarter of 2020. The acquisition has provided and is expected to provide additional sales and earnings
growth opportunities for the Company’s Life Sciences segment by expanding the business’ geographic and product line
diversity, including new product and service offerings that complement the Company’s current biologics workflow solutions.
To fulfill a condition to obtaining certain regulatory approvals for the closing of the transaction, on April 30, 2020 the Company
divested certain of its existing product lines in the Life Sciences segment for a cash purchase price, net of cash transferred and
transaction costs, of $826 million and recognized a pretax gain on sale of $455 million ($305 million after-tax or $0.42 per
diluted common share). The divested product lines in the aggregate generated revenues of approximately $170 million in 2019.
The divestiture of these product lines did not represent a strategic shift with a major effect on the Company’s operations and
financial results and therefore is not reported as a discontinued operation.
The Company financed the Cytiva Acquisition with approximately $3.0 billion of proceeds from the 2019 underwritten public
offerings of its Common Stock and Series A Mandatory Convertible Preferred Stock (“MCPS Series A”), approximately
76

-- 98 of 162 --

 7>AA>DCD;EGD8::9H;GDBI=:>HHJ6C8:D;:JGD 9:CDB>C6I:96C9. , 9DAA6G 9:CDB>C6I:9ADC< I:GB9:7I 6C9
6EEGDM>B6I:AN 7>AA>DC;GDBI=:6<<G:<6I:D;EGD8::9H;GDB8DBB:G8>6AE6E:G7DGGDL>C<H 7DGGDL>C<HJC9:GI=:
DBE6CNWH>K: 2:6G68>A>IN6H9:;>C:97:ADL6C986H=DC=6C9 -=:DBE6CNEG:A>B>C6G>ANG:8DG9:96EEGDM>B6I:AN 
7>AA>DCD;<DD9L>AAG:A6I:9IDI=:NI>K68FJ>H>I>DC 
JG>C< >C699>I>DCIDI=:NI>K68FJ>H>I>DC I=:DBE6CN68FJ>G:9;DJG7JH>C:HH:H;DGIDI6A8DCH>9:G6I>DCD;
B>AA>DC>C86H= C:ID;86H=68FJ>G:9 -=:7JH>C:HH:H68FJ>G:98DBEA:B:CI:M>HI>C<JC>IHD;I=:DBE6CNWH%>;:,8>:C8:H6C9
CK>GDCB:CI6AEEA>:9,DAJI>DCHH:<B:CIH -=:DBE6CNEG:A>B>C6G>ANG:8DG9:96C6<<G:<6I:D;B>AA>DCD;<DD9L>AA
G:A6I:9IDI=:H:68FJ>H>I>DCH -=:6<<G:<6I:6CCJ6AH6A:HD;I=:;>K:7JH>C:HH:H68FJ>G:9>C6II=:I>B:D;I=:>G68FJ>H>I>DC 
>C:68=86H:76H:9DCI=:8DBE6CNWHG:K:CJ:H;DG>IHA6HI8DBEA:I:9;>H86AN:6GEG>DGIDI=:68FJ>H>I>DC L:G:6EEGDM>B6I:AN
 7>AA>DC 
JG>C< I=:DBE6CN68FJ>G:9;>K:7JH>C:HH:H;DGIDI6A8DCH>9:G6I>DCD;B>AA>DC>C86H= C:ID;86H=68FJ>G:9 -=:
7JH>C:HH68FJ>G:98DBEA:B:CIH:M>HI>C<JC>IHD;:68=D;I=:DBE6CNWHI=G::H:<B:CIH -=:6<<G:<6I:6CCJ6AH6A:HD;I=:H:
7JH>C:HH:H6II=:I>B:D;I=:>G68FJ>H>I>DC >C:68=86H:76H:9DCI=:8DBE6CNWHG:K:CJ:H;DG>IHA6HI8DBEA:I:9;>H86AN:6GEG>DG
IDI=:68FJ>H>I>DC L:G:B>AA>DC -=:DBE6CNG:8DG9:96C6<<G:<6I:D;B>AA>DCD;<DD9L>AAG:A6I:9IDI=:H:
68FJ>H>I>DCH
(CEG>A  I=:DBE6CN68FJ>G:9"CI:<G6I:9'-:8=CDAD<>:H "C8 U"-V 6EG>K6I:AN =:A9B6CJ;68IJG:GD;
8JHIDB'6C9+'DA><DCJ8A:DI>9:HH:GK>C<8JHIDB:GH>CI=:6869:B>86C97>DE=6GB68:JI>86AG:H:6G8= 7>DI:8=CDAD<N 
6<G>8JAIJG: 8A>C>86A9>6<CDHI>8H6C9E=6GB68:JI>86A9:K:ADEB:CI:C9 B6G@:IH ;DG6EJG8=6H:EG>8:D;6EEGDM>B6I:AN 
7>AA>DC C:ID;86H=68FJ>G:9 "-=69G:K:CJ:HD;6EEGDM>B6I:ANB>AA>DC>C 6C9>HCDLE6GID;I=:DBE6CNWH%>;:
,8>:C8:HH:<B:CI 
-=:DBE6CN;>C6C8:9I=:68FJ>H>I>DCD;"-L>I=6K6>A67A:86H=6C9EGD8::9H;GDBI=:>HHJ6C8:D;8DBB:G8>6AE6E:G -=:
DBE6CNG:8DG9:96EEGDM>B6I:AN 7>AA>DCD;<DD9L>AAG:A6I:9IDI=:"-68FJ>H>I>DC -=:68FJ>H>I>DCD;"-=6HEGDK>9:9
699>I>DC6AH6A:H6C9:6GC>C<H<GDLI=DEEDGIJC>I>:H;DGI=:DBE6CNWH%>;:,8>:C8:HH:<B:CI7N:ME6C9>C<I=:H:<B:CIWH
EGD9J8IA>C:9>K:GH>IN >C8AJ9>C<C:LEGD9J8I6C9H:GK>8:D;;:G>C<H>CI=:6G:6D;<:CDB>8H8DCHJB67A:H 6C9I=GDJ<=I=:
EDI:CI>6A;JIJG:68FJ>H>I>DCD;8DBEA:B:CI6GN7JH>C:HH:H 
"C699>I>DCIDI=:"-68FJ>H>I>DC 9JG>C< I=:DBE6CN68FJ>G:9DC:DI=:G7JH>C:HH;DGIDI6A8DCH>9:G6I>DCD;B>AA>DC
>C86H= C:ID;86H=68FJ>G:9 -=:7JH>C:HH68FJ>G:98DBEA:B:CIH6C:M>HI>C<JC>ID;I=:CK>GDCB:CI6AEEA>:9,DAJI>DCH
H:<B:CI -=:6<<G:<6I:6CCJ6AH6A:HD;I=>H7JH>C:HH6II=:I>B:D;>IH68FJ>H>I>DC 76H:9DCI=:8DBE6CNWHG:K:CJ:H;DG>IHA6HI
8DBEA:I:9;>H86AN:6GEG>DGIDI=:68FJ>H>I>DC L:G:B>AA>DC -=:DBE6CNG:8DG9:96C6<<G:<6I:D;B>AA>DCD;
<DD9L>AAG:A6I:9IDI=>H68FJ>H>I>DC
-=:;DAADL>C<HJBB6G>O:HI=::HI>B6I:9;6>GK6AJ:HD;I=:6HH:IH68FJ>G:96C9A>67>A>I>:H6HHJB:96II=:96I:D;68FJ>H>I>DC>C
B>AA>DCH
 	
-G69:688DJCIHG:8:>K67A: 	 	 	 	 	 	
"CK:CIDG>:H 	 	 	 	 	 	
)GDE:GIN EA6CI6C9:FJ>EB:CI 	 	 	 	 	 	
DD9L>AA 	 	  	 	 	 	 
(I=:G>CI6C<>7A:6HH:IH EG>B6G>ANI:8=CDAD<N 8JHIDB:GG:A6I>DCH=>EH6C9
IG69:C6B:H 	 	  	 	 	 	
-G69:688DJCIHE6N67A: 	 	  	  	
):CH>DCA>67>A>I>:H 	 	  	T 	 	T
:;:GG:9I6MA>67>A>I>:H 	 	   	T 	 	
(I=:G6HH:IH6C9A>67>A>I>:H C:I 	 	  	  	
':I6HH:IH68FJ>G:9 	 	  	 	 	 	 
%:HHCDC86H=8DCH>9:G6I>DC 	 	T 	 	T 	 	
':I86H=8DCH>9:G6I>DC 	 	  	 	 	 	 


-- 99 of 162 --

-=:;DAADL>C<HJBB6G>O:HI=::HI>B6I:9;6>GK6AJ:HD;I=:6HH:IH68FJ>G:96C9A>67>A>I>:H6HHJB:96II=:96I:D;68FJ>H>I>DC;DG
I=:>C9>K>9J6AANH><C>;>86CI68FJ>H>I>DC>C9>H8JHH:967DK: 6C96AAD;I=:DI=:G68FJ>H>I>DCH6H6<GDJE>C
B>AA>DCH
HC8E0 	$C74AB 	)>C0;
-G69:688DJCIHG:8:>K67A: 	 	 	 	 	 	
"CK:CIDG>:H 	 	 	 	 	 	
)GDE:GIN EA6CI6C9:FJ>EB:CI 	 	 	 	 	 	
DD9L>AA 	 	  	 	 	 	 
(I=:G>CI6C<>7A:6HH:IH EG>B6G>ANI:8=CDAD<N 8JHIDB:GG:A6I>DCH=>EH6C9
IG69:C6B:H 	 	  	 	 	 	 
-G69:688DJCIHE6N67A: 	 	  	  	
):CH>DCA>67>A>I>:H 	 	  	T 	 	
:;:GG:9I6MA>67>A>I>:H 	 	   	  	 
(I=:G6HH:IH6C9A>67>A>I>:H C:I 	 	  	  	
':I86H=8DCH>9:G6I>DC 	 	  	 	 	 	 
-=:;DAADL>C<HJBB6G>O:HI=::HI>B6I:9;6>GK6AJ:HD;I=:6HH:IH68FJ>G:96C9A>67>A>I>:H6HHJB:96II=:96I:D;68FJ>H>I>DC;DG
I=:>C9>K>9J6AANH><C>;>86CI68FJ>H>I>DC>C9>H8JHH:967DK: 6C96AAD;I=:DI=:G68FJ>H>I>DCH6H6<GDJE>C
B>AA>DCH
) 	$C74AB 	)>C0;
-G69:688DJCIHG:8:>K67A: 	 	 	 	 	 	
"CK:CIDG>:H 	 	 	 	T 	 	
)GDE:GIN EA6CI6C9:FJ>EB:CI 	 	 	 	T 	 	
DD9L>AA 	 	  	 	 	 	 
(I=:G>CI6C<>7A:6HH:IH EG>B6G>ANI:8=CDAD<N 8JHIDB:GG:A6I>DCH=>EH6C9
IG69:C6B:H 	 	 	 	 	 	
-G69:688DJCIHE6N67A: 	 	  	  	
:;:GG:9I6MA>67>A>I>:H 	 	  	T 	 	
(I=:G6HH:IH6C9A>67>A>I>:H C:I 	 	  	  	
':I6HH:IH68FJ>G:9 	 	  	 	 	 	 
%:HHCDC86H=8DCH>9:G6I>DC 	 	  	T 	 	
':I86H=8DCH>9:G6I>DC 	 	  	 	 	 	 
-G6CH68I>DC G:A6I:98DHIH;DGI=:NI>K68FJ>H>I>DCL:G:B>AA>DC6C9B>AA>DC;DGI=:N:6GH:C9:9:8:B7:G 
6C9 G:HE:8I>K:AN JG>C< I=:DBE6CN>C8JGG:968FJ>H>I>DC G:A6I:9IG6CH68I>DC8DHIH6C98=6C<:>C8DCIGDA
E6NB:CIHD;B>AA>DC6HHD8>6I:9L>I=I=:"-68FJ>H>I>DC "C699>I>DC I=:DBE6CNWH:6GC>C<H;DGG:;A:8II=:EG:I6M
>BE68ID;B>AA>DCD;CDCG:8JGG>C<68FJ>H>I>DC96I:;6>GK6AJ:69?JHIB:CIHID>CK:CIDGNG:A6I:9IDI=:"-68FJ>H>I>DC 
-G6CH68I>DC G:A6I:98DHIH6C968FJ>H>I>DC G:A6I:9;6>GK6AJ:69?JHIB:CIH6IIG>7JI67A:IDDI=:G68FJ>H>I>DCHL:G:CDIB6I:G>6A;DG
I=:N:6GH:C9:9:8:B7:G  DG
%A>>A<08=0=280;=5>A<0C8>=*=0D38C43
-=:JC6J9>I:9EGD;DGB6>C;DGB6I>DC;DGI=:E:G>D9HH:I;DGI=7:ADL<>K:H:;;:8IIDI=:6C968FJ>H>I>DCH6H>;I=:N
=69D88JGG:96HD;#6CJ6GN  -=:EGD;DGB6>C;DGB6I>DC>HEG:H:CI:9;DG>C;DGB6I>DC6AEJGEDH:HDCAN6C9>HCDI
C:8:HH6G>AN>C9>86I>K:D;I=:G:HJAIHD;DE:G6I>DCHI=6I68IJ6AANLDJA9=6K:7::C68=>:K:9=69I=:68FJ>H>I>DCH7::C
8DCHJBB6I:96HD;I=6II>B:>CB>AA>DCH:M8:EIE:GH=6G:6BDJCIH

,6A:H 	 	  	 	 
':I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH 	 	  	 	 
>AJI:9C:I:6GC>C<HE:G8DBBDCH=6G:;GDB8DCI>CJ>C<DE:G6I>DCH 6 	 	  	 	 
6
>AJI:9C:I:6GC>C<HE:G8DBBDCH=6G:;GDB8DCI>CJ>C<DE:G6I>DCH>H86A8JA6I:97N699>C<I=:>CI:G:HIDCI=:DBE6CNWH%2('HIDC:I
:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH6C99:9J8I>C<I=:&),9>K>9:C9H;GDBC:I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH


-- 100 of 162 --

The 2020 unaudited pro forma sales and net earnings set forth above were adjusted to exclude the pretax impact of $509 million
of nonrecurring acquisition date fair value adjustments to inventory and deferred revenue related to the Cytiva Acquisition. The
2019 unaudited pro forma sales and net earnings from continuing operations were adjusted to include the impact of these items.
In addition, acquisition-related transaction costs of $59 million and $93 million for the years ended December 31, 2020 and
2019, respectively, associated with the Cytiva Acquisition were excluded from pro forma net earnings from continuing
operations. The pretax gain of $455 million ($305 million after-tax or $0.42 per diluted common share) related to the
divestiture of certain product lines that was required as a condition to obtaining certain regulatory approvals for the closing of
the Cytiva Acquisition was also excluded from the 2020 pro forma net earnings from continuing operations.
NOTE 4. DISCONTINUED OPERATIONS
On September 20, 2019, Envista Holdings Corporation (“Envista”), completed an initial public offering (“IPO”) of 30.8 million
shares of its common stock, which represented 19.4% of Envista’s outstanding shares at the time of the offering, at a public
offering price of $22.00 per share. Envista realized net proceeds of $643 million from the IPO, after deducting underwriting
discounts and deal expenses.
In connection with the completion of the IPO, through a series of equity and other transactions, the Company transferred its
dental businesses to Envista (the “Separation”). In exchange, Envista transferred consideration of approximately $2.0 billion to
the Company, which consists primarily of the net proceeds from the IPO and approximately $1.3 billion of proceeds from
Envista’s term debt financing. The excess of the net book value of the business transferred to Envista over the net proceeds
from the IPO was $60 million and was recorded as a reduction to additional paid-in capital in the accompanying Consolidated
Balance Sheet.
On December 18, 2019, Danaher completed the disposition of the remaining 80.6% ownership of Envista common stock
through a split-off exchange offer, which resulted in Danaher’s repurchase of 22.9 million shares of the Company’s common
stock in exchange for the remaining shares of Envista held by Danaher (the “Split-Off”). The IPO, Separation and Split-Off are
collectively referred to as the “Envista Disposition”. As a result, the Company recognized a gain on the disposition of $451
million in the fourth quarter of 2019. At the time of the disposition, the Company reclassified $109 million of foreign currency
translation adjustment losses related to Envista from accumulated other comprehensive income (loss) to the Company’s results
of discontinued operations as a component of the net gain on the Envista Disposition. As a result of the IPO, Danaher recorded
an increase to noncontrolling interest of $689 million in 2019 for the sale of the Envista common stock and subsequent earnings
and other comprehensive income (loss) attributable to the noncontrolling interest. At the time of the Envista Disposition,
Danaher decreased noncontrolling interests by $692 million to record the deconsolidation of Envista and the elimination of the
noncontrolling interest.
The accounting requirements for reporting Envista as a discontinued operation were met when the Split-Off was completed.
Accordingly, the Consolidated Financial Statements for all periods presented reflect this business as a discontinued operation.
The Company allocated a portion of the consolidated interest expense to discontinued operations based on the ratio of the
discontinued business’ net assets to the Company’s consolidated net assets. Envista had revenues of approximately $2.6 billion
in 2019 prior to the exchange offer and approximately $2.8 billion in 2018.
As a result of the Envista Disposition, the Company incurred $69 million and $15 million in IPO and Separation-related costs
during the years ended December 31, 2019 and 2018, respectively, which are reflected in earnings from discontinued
operations, net of income taxes in the accompanying Consolidated Statements of Earnings. These costs primarily relate to
professional fees associated with preparation of regulatory filings and activities within finance, tax, legal and information
technology functions as well as certain investment banking fees and tax costs.
Danaher used a portion of the consideration received from Envista to redeem $882 million in aggregate principal amount of
outstanding indebtedness in the fourth quarter of 2019 (consisting of the Company’s 2.4% senior unsecured notes due 2020 and
5.0% senior unsecured notes due 2020). The Company incurred make-whole premiums in connection with the redemption of
$7 million ($5 million after-tax or $0.01 per diluted common share). The Company used the balance of the consideration it
received from Envista to redeem commercial paper borrowings as they matured.
In connection with the Envista IPO and Separation, Danaher and Envista entered into various agreements to effect the
disposition and provide a framework for their relationship after the Envista Separation, including a separation agreement,
transition services agreement, employee matters agreement, tax matters agreement, intellectual property matters agreement and
DANAHER BUSINESS SYSTEM (“DBS”) license agreement. These agreements provide for the allocation between Danaher
and Envista of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-
related assets and liabilities) attributable to periods prior to, at and after Envista’s separation from Danaher and govern certain
relationships between Danaher and Envista after the Envista Separation. In addition, Danaher is also party to various
79

-- 101 of 162 --

8DBB:G8>6A6<G::B:CIHL>I=CK>HI6:CI>I>:H -=:6BDJCIHE6>96C9G:8:>K:97N6C6=:G;DGIG6CH>I>DCH:GK>8:HEGDK>9:9JC9:G
I=:67DK:6<G::B:CIH6HL:AA6HH6A:H6C9EJG8=6H:HID6C9;GDBCK>HI6L:G:CDIB6I:G>6AIDI=:DBE6CNWHG:HJAIHD;
DE:G6I>DCH;DGI=:N:6GH:C9:9:8:B7:G 6C9
-=:@:N8DBEDC:CIHD;>C8DB:;GDBCK>HI6;GDB9>H8DCI>CJ:9DE:G6I>DCH;DGI=:N:6GH:C9:9:8:B7:GL:G:6H;DAADLH
>CB>AA>DCH
 	
,6A:H 	 	  	 	 
DHID;H6A:H 	 	   	 
,:AA>C< <:C:G6A6C969B>C>HIG6I>K::ME:CH:H 	 	   	 
+:H:6G8=6C99:K:ADEB:CI:ME:CH:H 	 	  	
(I=:G>C8DB::ME:CH: C:I 	 	 	 	
"CI:G:HI:ME:CH: 	 	  	
"C8DB:;GDB9>H8DCI>CJ:9DE:G6I>DCH7:;DG:>C8DB:I6M:H 	 	 	 	
6>CDC9>HEDH>I>DCD;CK>HI67:;DG:>C8DB:I6M:H 	 	 	 	T
6GC>C<H;GDB9>H8DCI>CJ:9DE:G6I>DCH7:;DG:>C8DB:I6M:H 	 	 	 	
"C8DB:I6M:H 	 	  	
6GC>C<H;GDB9>H8DCI>CJ:9DE:G6I>DCH C:ID;>C8DB:I6M:H 	 	 	 	
':I:6GC>C<H6IIG>7JI67A:IDCDC8DCIGDAA>C<>CI:G:HI 	 	  	T
':I:6GC>C<H;GDB9>H8DCI>CJ:9DE:G6I>DCH6IIG>7JI67A:ID8DBBDCHID8@=DA9:GH 	 	 	 	
#$) !((
-=:DBE6CN=6HDE:G6I>C<A:6H:H;DGD;;>8:HE68: L6G:=DJH:H 9>HIG>7JI>DC8:CI:GH G:H:6G8=6C99:K:ADEB:CI;68>A>I>:H 
B6CJ;68IJG>C<AD86I>DCH6C98:GI6>C:FJ>EB:CI EG>B6G>AN6JIDBD7>A:H &6CNA:6H:H>C8AJ9:DC:DGBDG:DEI>DCHIDG:C:L 
HDB:D;L=>8=>C8AJ9:DEI>DCHID:MI:C9I=:A:6H:H;DGJEIDN:6GH 6C9HDB:A:6H:H>C8AJ9:DEI>DCHIDI:GB>C6I:I=:A:6H:H
L>I=>C96NH "C8:GI6>CD;I=:DBE6CNWHA:6H:6<G::B:CIH I=:G:CI6AE6NB:CIH6G:69?JHI:9E:G>D9>86AANIDG:;A:8I68IJ6A
8=6G<:H>C8JGG:9;DG8DBBDC6G:6B6>CI:C6C8: JI>A>I>:H >C;A6I>DC6C9 DG8=6C<:H>CDI=:G>C9:M:H -=:DBE6CNWH;>C6C8:
A:6H:HL:G:CDIB6I:G>6A6HD;:8:B7:G 6C9 +><=I D; JH:U+(.V6HH:IH6G>H>C<;GDB;>C6C8:A:6H:H6G:
>C8AJ9:9>CEGDE:GIN EA6CI6C9:FJ>EB:CI C:I6C9I=:A>67>A>I>:H6G:>C8AJ9:9>CCDI:HE6N67A:6C98JGG:CIEDGI>DCD;ADC< I:GB
9:7I6C9ADC< I:GB9:7I>CI=:688DBE6CN>C<DCHDA>96I:96A6C8:,=::IH
-=:8DBEDC:CIHD;DE:G6I>C<A:6H::ME:CH:;DGI=:N:6GH:C9:9:8:B7:GL:G:6H;DAADLH>CB>AA>DCH

>M:9DE:G6I>C<A:6H::ME:CH:6 	 	 	 	
/6G>67A:DE:G6I>C<A:6H::ME:CH: 	 	 	 	
-DI6ADE:G6I>C<A:6H::ME:CH: 	 	 	 	
6
"C8AJ9:HH=DGI I:GBA:6H:H6C9HJ7A:6H:>C8DB: 7DI=D;L=>8=L:G:>BB6I:G>6A
,JEEA:B:CI6A86H=;ADL>C;DGB6I>DCG:A6I:9IDI=:DBE6CNWHDE:G6I>C<A:6H:H;DGI=:N:6GH:C9:9:8:B7:GL:G:6H
;DAADLH>CB>AA>DCH

6H=E6>9;DG6BDJCIH>C8AJ9:9>CI=:B:6HJG:B:CID;DE:G6I>C<A:6H:A>67>A>I>:H 	 	 	 	
+(.6HH:IHD7I6>C:9>C:M8=6C<:;DGDE:G6I>C<A:6H:D7A><6I>DCH 	 	 	 	


-- 102 of 162 --

-=:;DAADL>C<I67A:EG:H:CIHI=:A:6H:76A6C8:HL>I=>CI=:DCHDA>96I:96A6C8:,=::IH L:><=I:96K:G6<:G:B6>C>C<A:6H:
I:GB 6C9L:><=I:96K:G6<:9>H8DJCIG6I:HG:A6I:9IDI=:DBE6CNWHDE:G6I>C<A:6H:H6HD;:8:B7:G>CB>AA>DCH

!40B4BB4CB0=3!8018;8C84B 	;0BB85820C8>=
HH:IH
(E:G6I>C<A:6H:+(.6HH:IH 	(I=:GADC< I:GB6HH:IH 	 	 	 	
%>67>A>I>:H
JGG:CI
(E:G6I>C<A:6H:A>67>A>I>:H 	88GJ:9:ME:CH:H6C9DI=:GA>67>A>I>:H 	 	 	 	
%DC< I:GB
(E:G6I>C<A:6H:A>67>A>I>:H 	(I=:GADC< I:GBA>67>A>I>:H 	 	 	 	
-DI6ADE:G6I>C<A:6H:A>67>A>I>:H 	 	 	 	
0:><=I:96K:G6<:G:B6>C>C<A:6H:I:GB 	N:6GH 	N:6GH
0:><=I:96K:G6<:9>H8DJCIG6I: 	  	 
-=:;DAADL>C<I67A:EG:H:CIHI=:B6IJG>IND;I=:DBE6CNWHDE:G6I>C<A:6H:A>67>A>I>:H6HD;:8:B7:G >CB>AA>DCH
 	 	
 	 	
 	 	
 	 	
 	 	
-=:G:6;I:G 	 	
-DI6ADE:G6I>C<A:6H:E6NB:CIH 	 	 
%:HH>BEJI:9>CI:G:HI 	 	
-DI6ADE:G6I>C<A:6H:A>67>A>I>:H 	 	
HD;:8:B7:G  I=:DBE6CN=69CD699>I>DC6AH><C>;>86CIDE:G6I>C<DG;>C6C8:A:6H:HI=6I=69CDIN:I8DBB:C8:9
( ><?0A0C8E48B2;>BDA4B
-DI6AG:CI:ME:CH:JC9:G,;DG6AADE:G6I>C<A:6H:HL6HB>AA>DC;DGI=:N:6G:C9:9:8:B7:G 
#$) #+#)$'(
-=:8A6HH:HD;>CK:CIDGN6HD;:8:B7:G6G:HJBB6G>O:96H;DAADLH>CB>AA>DCH

>C>H=:9<DD9H 	 	  	 	
0DG@>CEGD8:HH 	 	 	 	
+6LB6I:G>6AH 	 	 	 	
-DI6A 	 	  	 	 
HD;:8:B7:G 6C9 I=:9>;;:G:C8:7:IL::C>CK:CIDG>:HK6AJ:96I%"(6C9I=:K6AJ:D;I=6IH6B:>CK:CIDGN>;
I=:"(B:I=D9=697::CJH:9L6HCDIH><C>;>86CI -=:A>FJ>96I>DCD;%"(>CK:CIDGN9>9CDI=6K:6H><C>;>86CI>BE68IDCI=:
DBE6CNWHG:HJAIHD;DE:G6I>DCH>C6CNE:G>D9EG:H:CI:9


-- 103 of 162 --

#$) %'$%').%!#)#&*%"#)
-=:8A6HH:HD;EGDE:GIN EA6CI6C9:FJ>EB:CI6HD;:8:B7:G6G:HJBB6G>O:96H;DAADLH>CB>AA>DCH

%6C96C9>BEGDK:B:CIH 	 	 	 	
J>A9>C<H 	 	  	 	
&68=>C:GN6C9:FJ>EB:CI 	 	  	 	 
JHIDB:G A:6H:9:FJ>EB:CI 	 	  	 	 
GDHHEGDE:GIN EA6CI6C9:FJ>EB:CI 	 	  	 	 
%:HH688JBJA6I:99:EG:8>6I>DC 	 	  	 	 
)GDE:GIN EA6CI6C9:FJ>EB:CI C:I 	 	  	 	 
#$) $$,!!#$)'#)#!(()(
H9>H8JHH:9>C'DI: <DD9L>AA6G>H:H;GDBI=:EJG8=6H:EG>8:;DG68FJ>G:97JH>C:HH:H:M8::9>C<I=:;6>GK6AJ:D;I6C<>7A:6C9
>CI6C<>7A:6HH:IH68FJ>G:9A:HH6HHJB:9A>67>A>I>:H6C9CDC8DCIGDAA>C<>CI:G:HIH &6C6<:B:CI6HH:HH:HI=:<DD9L>AAD;:68=D;>IH
G:EDGI>C<JC>IH;DG>BE6>GB:CI6IA:6HI6CCJ6AAN6II=:7:<>CC>C<D;I=:;DJGI=FJ6GI:G6C96HUIG><<:G>C<V:K:CIHD88JGI=6I
>C9>86I:I=6I>I>HBDG:A>@:ANI=6CCDII=6I6C>BE6>GB:CI:M>HIH -=:DBE6CN:A:8I:9ID7NE6HHI=:DEI>DC6AFJ6A>I6I>K:
<DD9L>AA6HH:HHB:CI6AADL:97N6EEA>867A:688DJCI>C<HI6C96G9H6C9E:G;DGB:96FJ6CI>I6I>K:>BE6>GB:CII:HI;DG6AAG:EDGI>C<
JC>IH6HI=>HL6H9:I:GB>C:9ID7:I=:BDHI:;;:8I>K:B:I=D9ID6HH:HH;DG>BE6>GB:CI68GDHHI=:G:EDGI>C<JC>IH 
-=:DBE6CN:HI>B6I:HI=:;6>GK6AJ:D;>IHG:EDGI>C<JC>IHEG>B6G>ANJH>C<6B6G@:I6EEGD68= 76H:9DC8JGG:CIIG69>C<
BJAI>EA:HD;"-;DG8DBE6C>:HDE:G6I>C<>C7JH>C:HH:HH>B>A6GID:68=D;I=:DBE6CNWHG:EDGI>C<JC>IH >C699>I>DCID
G:8:CI6K6>A67A:B6G@:IH6A:IG6CH68I>DCHD;8DBE6G67A:7JH>C:HH:H "C9:I:GB>C>C<I=::HI>B6I:9;6>GK6AJ:D;:68=G:EDGI>C<
JC>I I=:DBE6CN6AHD6EEA>:H68DCIGDAEG:B>JB ";I=::HI>B6I:9;6>GK6AJ:D;I=:G:EDGI>C<JC>I>HA:HHI=6C>IH86GGN>C<
K6AJ: I=:DBE6CNBJHIE:G;DGB699>I>DC6A6C6ANH>HID9:I:GB>C:>;I=:G:EDGI>C<JC>IWH<DD9L>AA=6H7::C>BE6>G:9
HD;:8:B7:G  I=:DBE6CN=69;>K:G:EDGI>C<JC>IH;DG<DD9L>AA>BE6>GB:CII:HI>C< HD;I=:96I:D;I=:
6CCJ6A>BE6>GB:CII:HI I=:86GGN>C<K6AJ:D;I=:<DD9L>AA>C8AJ9:9>C:68=>C9>K>9J6AG:EDGI>C<JC>IG6C<:9;GDBB>AA>DC
ID6EEGDM>B6I:AN 7>AA>DC 'D<DD9L>AA>BE6>GB:CI8=6G<:HL:G:G:8DG9:9;DGI=:N:6GH:C9:9:8:B7:G  
6C96C9CDUIG><<:G>C<V:K:CIH=6K:D88JGG:9HJ7H:FJ:CIIDI=:E:G;DGB6C8:D;I=:6CCJ6A>BE6>GB:CII:HI -=:
;68IDGHJH:97NB6C6<:B:CI>C>IH>BE6>GB:CI6C6ANH>H6G:>C=:G:CIANHJ7?:8IIDJC8:GI6>CIN ";68IJ6AG:HJAIH6G:CDI8DCH>HI:CI
L>I=B6C6<:B:CIWH:HI>B6I:H6C96HHJBEI>DCH <DD9L>AA6C9DI=:G>CI6C<>7A:6HH:IHB6N7:DK:GHI6I:96C968=6G<:LDJA9C::9
ID7:I6@:C6<6>CHIC:I:6GC>C<H


-- 104 of 162 --

-=:;DAADL>C<>H6GDAA;DGL6G9D;I=:DBE6CNWH<DD9L>AA7NH:<B:CI>CB>AA>DCH
!854
(284=24B 	806=>BC82B
=E8A>=<4=C0;
??;843
(>;DC8>=B 	)>C0;
0;0=240=D0AH  	 	 	  	 	  	 	  	 	 
IIG>7JI67A:ID68FJ>H>I>DCH 	 	 	 	 	 	 	 	
9?JHIB:CIH9J:ID;>C6A>O6I>DCD;EJG8=6H:EG>8:
6AAD86I>DCH 	 	  	T 	 	T 	 	
DG:><C8JGG:C8NIG6CHA6I>DC6C9DI=:G 	 	  	  	  	
0;0=24424<14A  	 	 	  	 	  	 	  	 	 
IIG>7JI67A:ID68FJ>H>I>DCH 	 	  	 	T 	 	 	 	 
IIG>7JI67A:ID9>K:HI>IJG:H 	 	  	T 	 	T 	 	
9?JHIB:CIH9J:ID;>C6A>O6I>DCD;EJG8=6H:EG>8:
6AAD86I>DCH 	 	  	T 	 	T 	 	
DG:><C8JGG:C8NIG6CHA6I>DC6C9DI=:G 	 	  	 	 	 	 	 	 
0;0=24424<14A  	 	  	 	  	 	  	 	 
-=:>C8G:6H:>CI=:<DD9L>AA76A6C8:D;I=:%>;:,8>:C8:HH:<B:CI>CI=:N:6G:C9:9:8:B7:G >HEG>B6G>AN6G:HJAID;
I=:NI>K68FJ>H>I>DC &:6HJG:B:CIE:G>D969?JHIB:CIH7:IL::CI=:68FJ>H>I>DC96I:6C9:8:B7:G 9:8G:6H:9I=:
<DD9L>AAG:8D<C>O:9;DGI=:NI>K68FJ>H>I>DC7N6EEGDM>B6I:AN 7>AA>DC 6HI=:>C>I>6A6AAD86I>DCD;I=:EJG8=6H:EG>8:L6H
69?JHI:9ID6AAD86I:699>I>DC6AEJG8=6H:EG>8:IDI:8=CDAD<N 8JHIDB:GG:A6I>DCH=>EH6C9IG69:C6B:HE6GI>6AAND;;H:I7NG:A6I:9
9:;:GG:9I6MA>67>A>I>:H +:;:GID'DI:;DGBDG:9:I6>A 
>C>I: A>K:9>CI6C<>7A:6HH:IH6G:6BDGI>O:9DK:GI=:>GA:<6ADG:HI>B6I:9JH:;JAA>;: -=:;DAADL>C<HJBB6G>O:HI=:<GDHH
86GGN>C<K6AJ:6C9688JBJA6I:96BDGI>O6I>DC;DG:68=B6?DG86I:<DGND;>CI6C<>7A:6HH:IH6HD;:8:B7:G>CB>AA>DCH
 	

A>BB
0AAH8=6
<>D=C 22D<D;0C43
<>AC8I0C8>=
A>BB
0AAH8=6
<>D=C 22D<D;0C43
<>AC8I0C8>=
>C>I: A>K:9>CI6C<>7A:H
)6I:CIH6C9I:8=CDAD<N 	 	  	 	   	  	 	
JHIDB:GG:A6I>DCH=>EH IG69:C6B:H6C9DI=:G
>CI6C<>7A:H 	 	  	 	   	  	 	 
-DI6A;>C>I: A>K:9>CI6C<>7A:H 	 	  	 	   	  	 	 
"C9:;>C>I: A>K:9>CI6C<>7A:H
-G69:B6G@H6C9IG69:C6B:H 	 	  	 	T 	 	  	 	T
-DI6A>CI6C<>7A:H 	 	  	 	   	  	 	 
JG>C< I=:DBE6CN68FJ>G:9;>C>I: A>K:9>CI6C<>7A:6HH:IH 8DCH>HI>C<EG>B6G>AND;9:K:ADE:9I:8=CDAD<N 8JHIDB:G
G:A6I>DCH=>EH6C9IG69:C6B:H L>I=6L:><=I:96K:G6<:A>;:D;N:6GHEG>B6G>AN6H6G:HJAID;I=:NI>K68FJ>H>I>DC JG>C<
 I=:DBE6CN68FJ>G:9;>C>I: A>K:9>CI6C<>7A:6HH:IH 8DCH>HI>C<EG>B6G>AND;8JHIDB:GG:A6I>DCH=>EH L>I=6L:><=I:9
6K:G6<:A>;:D;N:6GH +:;:GID'DI:;DG699>I>DC6A>C;DGB6I>DCDCI=:>CI6C<>7A:6HH:IH68FJ>G:9
-=:DBE6CNG:K>:LH>9:CI>;>:9>CI6C<>7A:6HH:IH;DG>BE6>GB:CIL=:C:K:G:K:CIHDG8=6C<:H>C8>G8JBHI6C8:H>C9>86I:I=6II=:
G:A6I:986GGN>C<6BDJCIHB6NCDI7:G:8DK:G67A: "C9:;>C>I: A>K:9>CI6C<>7A:H6G:HJ7?:8IID>BE6>GB:CII:HI>C<6IA:6HI6CCJ6AAN
DGBDG:;G:FJ:CIAN>;:K:CIHDG8=6C<:H>C8>G8JBHI6C8:H>C9>86I:I=6IEDI:CI>6A>BE6>GB:CI:M>HIH -=:DBE6CN>9:CI>;>:9
>BE6>GB:CIIG><<:GH9JG>C<I=:;>GHI6C9I=>G9FJ6GI:GHD;L=>8=G:HJAI:9>CI=:>BE6>GB:CID;8:GI6>CADC< A>K:96HH:IH 
>C8AJ9>C<IG69:C6B:H6C9DI=:G>CI6C<>7A:6HH:IH -=:DBE6CNG:8DG9:9>BE6>GB:CI8=6G<:HIDI6A>C<B>AA>DCG:A6I:9ID
I=:H:ADC< A>K:96HH:IH 
-DI6A>CI6C<>7A:6BDGI>O6I>DC:ME:CH:>C 6C9L6H B>AA>DC B>AA>DC6C9B>AA>DC G:HE:8I>K:AN 
-=:>C8G:6H:>C>CI6C<>7A:6BDGI>O6I>DC:ME:CH:>CL6HEG>B6G>AN6H6G:HJAID;I=:NI>K68FJ>H>I>DC6C9I=:6BDGI>O6I>DC
D;I=:6HHD8>6I:9;>C>I: A>K:9>CI6C<>7A:6HH:IH 6H:9DCI=:>CI6C<>7A:6HH:IHG:8DG9:96HD;:8:B7:G  6BDGI>O6I>DC
:ME:CH:>H:HI>B6I:9ID7: B>AA>DC9JG>C<  B>AA>DC9JG>C<  B>AA>DC9JG>C<  B>AA>DC
9JG>C<6C9 B>AA>DC9JG>C<


-- 105 of 162 --

#$) '+!*"(*'"#)(
88DJCI>C<HI6C96G9H9:;>C:;6>GK6AJ:76H:9DC6C:M>IEG>8:BD9:A :HI67A>H=6;G6B:LDG@;DGB:6HJG>C<;6>GK6AJ:L=:G:I=:
DBE6CNWH6HH:IH6C9A>67>A>I>:H6G:G:FJ>G:9ID7:86GG>:96I;6>GK6AJ:6C9EGDK>9:;DG8:GI6>C9>H8ADHJG:HG:A6I:9IDI=:
K6AJ6I>DCB:I=D9HJH:9L>I=>C6K6AJ6I>DC=>:G6G8=N6H:HI67A>H=:9L>I=>CI=:688DJCI>C<HI6C96G9H -=>H=>:G6G8=NEG>DG>I>O:H
I=:>CEJIH>CIDI=G::7GD69A:K:AH6H;DAADLH %:K:A>CEJIH6G:FJDI:9EG>8:HJC69?JHI:9>C68I>K:B6G@:IH;DG>9:CI>86A6HH:IH
DGA>67>A>I>:H %:K:A>CEJIH6G:FJDI:9EG>8:H;DGH>B>A6G6HH:IH6C9A>67>A>I>:H>C68I>K:B6G@:IH FJDI:9EG>8:H;DG>9:CI>86ADG
H>B>A6G6HH:IH>CB6G@:IHI=6I6G:CDI68I>K: DGDI=:GD7H:GK67A:8=6G68I:G>HI>8H;DGI=:6HH:IDGA>67>A>IN >C8AJ9>C<>CI:G:HIG6I:H 
N>:A98JGK:H6C98G:9>IG>H@H DG>CEJIHI=6I6G:9:G>K:9EG>C8>E6AAN;GDB DG8DGGD7DG6I:97N D7H:GK67A:B6G@:I96I6I=GDJ<=
8DGG:A6I>DC %:K:A>CEJIH6G:JCD7H:GK67A:>CEJIH76H:9DCI=:DBE6CNWH6HHJBEI>DCH ;>C6C8>6A6HH:IDGA>67>A>INWH
8A6HH>;>86I>DCL>I=>CI=:=>:G6G8=N>H9:I:GB>C:976H:9DCI=:ADL:HIA:K:A>CEJII=6I>HH><C>;>86CIIDI=:;6>GK6AJ:B:6HJG:B:CI
>C>IH:CI>G:IN
HJBB6GND;;>C6C8>6A6HH:IH6C9A>67>A>I>:HI=6I6G:B:6HJG:96I;6>GK6AJ:DC6G:8JGG>C<76H>HL:G:6H;DAADLH>CB>AA>DCH
.40A=343
424<14A
&D>C43%A824B8=
2C8E4"0A:4C
!4E4; 
(86=85820=C$C74A
$1B4AE01;4=?DCB
!4E4; 
(86=85820=C
*=>1B4AE01;4
=?DCB!4E4;

HH:IH
K6>A67A: ;DG H6A:9:7IH:8JG>I>:H 	 	 	 	T 	 	 	 	T
"CK:HIB:CI>C:FJ>INH:8JG>I>:H 	 	 	 	 	 	T 	 	T
%>67>A>I>:H
GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH 	 	 	 	T 	 	 	 	T
:;:GG:98DBE:CH6I>DCEA6CH 	 	 	 	T 	 	 	 	T

HH:IH
K6>A67A: ;DG H6A:9:7IH:8JG>I>:H 	 	 	 	T 	 	 	 	T
"CK:HIB:CI>C:FJ>INH:8JG>I>:H 	 	 	 	T 	 	T 	 	T
GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH 	 	 	 	T 	 	 	 	T
%>67>A>I>:H
GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH 	 	 	 	T 	 	 	 	T
:;:GG:98DBE:CH6I>DCEA6CH 	 	 	 	T 	 	 	 	T
K6>A67A: ;DG H6A:9:7IH:8JG>I>:H L=>8=6G:>C8AJ9:9>CDI=:GADC< I:GB6HH:IH>CI=:688DBE6CN>C<DCHDA>96I:96A6C8:
,=::IH 6G:B:6HJG:96I;6>GK6AJ:JH>C<FJDI:9EG>8:HG:EDGI:97N>CK:HIB:CI7GD@:GH6C99:6A:GH76H:9DCI=:JC9:GAN>C<I:GBH
D;I=:H:8JG>IN6C98DBE6G>HDCIDH>B>A6GH:8JG>I>:HIG69:9DC6C68I>K:B6G@:I HD;:8:B7:G 6C9 6K6>A67A:
;DG H6A:9:7IH:8JG>I>:HEG>B6G>AN>C8AJ9:. , -G:6HJGN'DI:H6C98DGEDG6I:9:7IH:8JG>I>:H L=>8=6G:K6AJ:976H:9DCI=:
I:GBHD;I=:>CHIGJB:CIH>C8DBE6G>HDCL>I=H>B>A6GI:GBHDCI=:68I>K:B6G@:I
-=:DBE6CNWH>CK:HIB:CIH>C:FJ>INH:8JG>I>:H8DCH>HID;>CK:HIB:CIH>CEJ7A>8ANIG69:9:FJ>INH:8JG>I>:H6C9>CK:HIB:CIH>C
CDC B6G@:I67A::FJ>INH:8JG>I>:H -=:EJ7A>8ANIG69:9H:8JG>I>:H6G:8A6HH>;>:96H%:K:A>CI=:;6>GK6AJ:=>:G6G8=N6HI=:N6G:
B:6HJG:976H:9DCFJDI:H>C68I>K:B6G@:IH DGI=:CDC B6G@:I67A::FJ>INH:8JG>I>:H I=:DBE6CN:HI>B6I:HI=:;6>GK6AJ:D;
I=:>CK:HIB:CIH>C:FJ>INH:8JG>I>:H76H:9DCI=:B:6HJG:B:CI6AI:GC6I>K:6C969?JHIH;DG>BE6>GB:CIH6C9D7H:GK67A:EG>8:
8=6C<:HL>I=6H6B:DGH>B>A6GH:8JG>IN;GDBI=:H6B:>HHJ:GL>I=>CC:I:6GC>C<HI=:6>G/6AJ:AI:GC6I>K: -=:DBE6CNWH
>CK:HIB:CIH>CI=:H::FJ>INH:8JG>I>:H6G:CDI8A6HH>;>:9>CI=:;6>GK6AJ:=>:G6G8=N9J:IDI=:JH:D;I=:H:B:6HJG:B:CIB:I=D9H 
99>I>DC6AAN I=:DBE6CN>H6A>B>I:9E6GIC:G>C6E6GIC:GH=>EI=6I>CK:HIH>C:6GAN HI6<:8DBE6C>:H 0=>A:I=:E6GIC:GH=>E
G:8DG9HI=:H:>CK:HIB:CIH6I;6>GK6AJ: I=:DBE6CNWH>CK:HIB:CI>CI=:E6GIC:GH=>E>H688DJCI:9;DGJC9:GI=::FJ>INB:I=D9
D;688DJCI>C<6C9>HCDIHJ7?:8IID;6>GK6AJ:B:6HJG:B:CI9>H8ADHJG:H JG>C<I=:N:6G:C9:9:8:B7:G  I=:
DBE6CNG:8DG9:9C:IG:6A>O:96C9JCG:6A>O:9<6>CHD;B>AA>DCG:A6I:9ID8=6C<:H>CI=:;6>GK6AJ:D;I=:H:>CK:HIB:CIH
L=>8=>HG:;A:8I:9>CDI=:G>C8DB::ME:CH: C:I>CI=:DCHDA>96I:9,I6I:B:CID;6GC>C<H 'DH><C>;>86CIG:6A>O:9DG
JCG:6A>O:9<6>CHDGADHH:HL:G:G:8DG9:9>C:>I=:GDGL>I=G:HE:8IIDI=:H:>CK:HIB:CIH 
-=:8GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH6G:JH:9IDE6GI>6AAN=:9<:I=:DBE6CNWHC:I>CK:HIB:CIH>C;DG:><CDE:G6I>DCH
6<6>CHI69K:GH:BDK:B:CIH>C:M8=6C<:G6I:H7:IL::CI=:. , 9DAA6G6C9I=:6C>H=@GDC:G #6E6C:H:N:C :JGD6C9,L>HH
;G6C8 -=:DBE6CN6AHDJH:H8GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IHID=:9<:I=::M8=6C<:G6I::MEDHJG:;GDBADC< I:GB
9:7I>HHJ6C8:H>C6;DG:><C8JGG:C8NDI=:GI=6CI=:;JC8I>DC6A8JGG:C8ND;I=:7DGGDL:G -=:8GDHH 8JGG:C8NHL6E9:G>K6I>K:
8DCIG68IH6G:8A6HH>;>:96H%:K:A>CI=:;6>GK6AJ:=>:G6G8=N6HI=:N6G:B:6HJG:9JH>C<I=:>C8DB:6EEGD68=L>I=I=:G:A:K6CI


-- 106 of 162 --

>CI:G:HIG6I:H6C98JGG:CI;DG:><C8JGG:C8N:M8=6C<:G6I:H6C9;DGL6G98JGK:H6H>CEJIH +:;:GID'DI:;DG699>I>DC6A
>C;DGB6I>DC
-=:DBE6CN=6H:HI67A>H=:9CDCFJ6A>;>:98DCIG>7JI>DC6C99:;:GG:98DBE:CH6I>DCEGD<G6BHI=6IE:GB>II=:DBE6CNIDB6@:
I6M 9:;:GG:98DCIG>7JI>DCHIDD;;>8:GH6C98:GI6>CDI=:G:BEADN::H 6C96AHDE:GB>I9>G:8IDGH D;;>8:GH6C98:GI6>CDI=:G
:BEADN::HIDKDAJCI6G>AN9:;:GI6M6I>DCDC6EDGI>DCD;I=:>G8DBE:CH6I>DC AA6BDJCIH8DCIG>7JI:9DG9:;:GG:9JC9:GHJ8=
EA6CH6G:JC;JC9:9 JCH:8JG:9D7A><6I>DCHD;I=:DBE6CN6C96G:EG:H:CI:96H68DBEDC:CID;I=:DBE6CNWH8DBE:CH6I>DC
6C97:C:;>IH688GJ6A>C8AJ9:9>CDI=:GADC< I:GBA>67>A>I>:H>CI=:688DBE6CN>C<DCHDA>96I:96A6C8:,=::IHG:;:GID'DI: 
'DC 9>G:8IDGE6GI>8>E6CIHB6N8=DDH:6BDC<6AI:GC6I>K::6GC>C<G6I:H;DGI=:6BDJCIHI=:N9:;:G L=>8=6G:EG>B6G>AN76H:9DC
>CK:HIB:CIDEI>DCHL>I=>CI=:DBE6CNWH@EGD<G6B =6C<:H>CI=:9:;:GG:98DBE:CH6I>DCA>67>A>INJC9:GI=:H:
EGD<G6BH6G:G:8D<C>O:976H:9DC8=6C<:H>CI=:;6>GK6AJ:D;I=:E6GI>8>E6CIHW688DJCIH L=>8=6G:76H:9DCI=:6EEA>867A:
:6GC>C<HG6I:H BDJCIHKDAJCI6G>AN9:;:GG:97N9>G:8IDGH6C96BDJCIHJC>A6I:G6AAN8DCIG>7JI:9IDE6GI>8>E6CI688DJCIH7NI=:
DBE6CN6G:9::B:9>CK:HI:9>CI=:DBE6CNWH8DBBDCHID8@6C9;JIJG:9>HIG>7JI>DCHD;HJ8=8DCIG>7JI>DCH6HL:AA6H;JIJG:
9>HIG>7JI>DCHD;6CNKDAJCI6GN9:;:GG6AH6AAD86I:96I6CNI>B:IDI=:6C6=:G8DBBDCHID8@>CK:HIB:CIDEI>DCL>AA7:B69:
HDA:AN>CH=6G:HD;DBE6CN8DBBDCHID8@ 6C9I=:G:;DG:6G:CDIG:;A:8I:9>CI=:67DK:6BDJCIH
08A+0;D4>58=0=280;=BCAD<4=CB
-=:86GGN>C<6BDJCIH6C9;6>GK6AJ:HD;I=:DBE6CNWH;>C6C8>6A>CHIGJB:CIH6HD;:8:B7:GL:G:6H;DAADLH>C
B>AA>DCH

0AAH8=6
<>D=C 	08A+0;D4 0AAH8=6
<>D=C 	08A+0;D4
HH:IH
K6>A67A: ;DG H6A:9:7IH:8JG>I>:H 	 	 	 	 	 	 	 	
"CK:HIB:CI>C:FJ>INH:8JG>I>:H 	 	 	 	 	 	 	 	
GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH 	 	T 	 	T 	 	 	 	
%>67>A>I>:H
GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH 	 	 	 	 	 	 	 	
'DI:HE6N67A:6C98JGG:CIEDGI>DCD;ADC< I:GB9:7I 	 	 	 	 	 	 	 	
%DC< I:GB9:7I 	 	  	 	  	 	  	 	 
HD;:8:B7:G 6C96K6>A67A: ;DG H6A:9:7IH:8JG>I>:H6C98GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IHL:G:
86I:<DG>O:96H%:K:A6C9H=DGI6C9ADC< I:GB7DGGDL>C<HL:G:86I:<DG>O:96H%:K:A 
-=:;6>GK6AJ:D;ADC< I:GB7DGGDL>C<HL6H76H:9DCFJDI:9B6G@:IEG>8:H -=:9>;;:G:C8:7:IL::CI=:;6>GK6AJ:6C9I=:
86GGN>C<6BDJCIHD;ADC< I:GB7DGGDL>C<HDI=:GI=6CI=:DBE6CNWH%>FJ>92>:A9(EI>DC'DI:H9J:I=:U%2('HV>H
6IIG>7JI67A:ID8=6C<:H>CB6G@:I>CI:G:HIG6I:H6C9 DGI=:DBE6CNWH8G:9>IG6I>C<HHJ7H:FJ:CIIDI=:>C8JGG:C8:D;I=:
7DGGDL>C< "CI=:86H:D;I=:%2('H 9>;;:G:C8:H>CI=:;6>GK6AJ:;GDBI=:86GGN>C<K6AJ:6G:6IIG>7JI67A:ID8=6C<:H>CI=:
EG>8:D;I=:DBE6CNWH8DBBDCHID8@9J:IDI=:%2('HW8DCK:GH>DC;:6IJG:H -=:;6>GK6AJ:HD;7DGGDL>C<HL>I=DG><>C6A
B6IJG>I>:HD;DC:N:6GDGA:HH 6HL:AA6H86H=6C986H=:FJ>K6A:CIH IG69:688DJCIHG:8:>K67A: C:I6C9IG69:688DJCIHE6N67A:
6EEGDM>B6I:I=:>G86GGN>C<6BDJCIH9J:IDI=:H=DGI I:GBB6IJG>I>:HD;I=:H:>CHIGJB:CIH
+:;:GID'DI:;DG>C;DGB6I>DCG:A6I:9IDI=:;6>GK6AJ:D;I=:DBE6CNHEDCHDG:99:;>C:97:C:;>IE:CH>DCEA6C6HH:IH


-- 107 of 162 --

#$) 	'*-%#((#$)'!!)(
88GJ:9:ME:CH:H6C9DI=:GA>67>A>I>:H6HD;:8:B7:GL:G:6H;DAADLH>CB>AA>DCH
 	
 	DAA4=C 	#>=2DAA4=C 	DAA4=C 	#>=2DAA4=C
DBE:CH6I>DC6C97:C:;>IH 	 	  	 	 	 	 	 	
):CH>DC6C9EDHIG:I>G:B:CI7:C:;>IH 	 	 	 	  	 	 	 	
-6M:H >C8DB:6C9DI=:G 	 	 	 	  	 	 	 	 
:;:GG:9G:K:CJ: 	 	  	 	 	 	 	 	
,6A:H6C9EGD9J8I6AADL6C8:H 	 	 	 	 	 	 	 	
(E:G6I>C<A:6H:A>67>A>I>:H 	 	 	 	 	 	 	 	
GDHH 8JGG:C8NHL6E9:G>K6I>K:A>67>A>I>:H 	 	 	 	T 	 	 	 	T
(I=:G 	 	  	 	 	 	 	 	
-DI6A 	 	  	 	  	 	  	 	 


-- 108 of 162 --

#$) 	###
-=:8DBEDC:CIHD;I=:DBE6CNWH9:7I6HD;:8:B7:GL:G:6H;DAADLH>CB>AA>DCH

JGD 9:CDB>C6I:98DBB:G8>6AE6E:GXB>AA>DC6C9X 7>AA>DC G:HE:8I>K:AN 	 	 	 	 
3:GD 8DJEDC%2('H9J: 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:R 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:
U2:C'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
JGDCDI:HV 	 	T 	 	
AD6I>C<G6I:H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCI
I=:UAD6I>C<+6I:JGDCDI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:I=:U>DE=6GB6'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:97DC9H9J:!B>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:
U!DC9HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
JGDCDI:HV 	 	  	 	T
 H:C>DGJCH:8JG:9CDI:H9J:I=:U>DE=6GB6'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
JGDCDI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:I=:U. , 'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:X 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
>DE=6GB6JGDCDI:HV 	 	  	 	 
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
JGDCDI:HV 	 	 	 	T
 H:C>DGJCH:8JG:9CDI:H9J:R 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
2:C'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
JGDCDI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:X 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
>DE=6GB6JGDCDI:HV 	 	  	 	 
 H:C>DGJCH:8JG:97DC9H9J:!B>AA>DC6<<G:<6I:EG>C8>E6A6BDJCI
I=:U!DC9HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:I=:U>DE=6GB6'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
JGDCDI:HV 	 	 	 	T
 H:C>DGJCH:8JG:9CDI:H9J:X 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
>DE=6GB6JGDCDI:HV 	 	  	 	 
 H:C>DGJCH:8JG:9CDI:H9J:R 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:
U2:C'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:X 7>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
>DE=6GB6JGDCDI:HV 	 	  	 	 
 H:C>DGJCH:8JG:9CDI:H9J:I=:U>DE=6GB6'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:I=:U. , 'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCII=:U
>DE=6GB6JGDCDI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:I=:U>DE=6GB6'DI:HV 	 	 	 	
 H:C>DGJCH:8JG:9CDI:H9J:I=:U. , 'DI:HV 	 	 	 	T
(I=:G 	 	 	 	
-DI6A9:7I 	 	  	 	 
%:HH8JGG:CIANE6N67A: 	 	 	 	
%DC< I:GB9:7I 	 	  	 	 
:7I9>H8DJCIH EG:B>JBH6C99:7I>HHJ6C8:6C9DI=:GG:A6I:98DHIHIDI6A:9B>AA>DC6C9B>AA>DC6HD;:8:B7:G 
6C9 G:HE:8I>K:AN 6C9=6K:7::CC:II:96<6>CHII=:6<<G:<6I:EG>C8>E6A6BDJCIHD;I=:G:A6I:99:7I>CI=:
8DBEDC:CIHD;9:7II67A:67DK:


-- 109 of 162 --

Commercial Paper Programs and Credit Facilities
In 2015, the Company entered into a $4.0 billion unsecured multi-year revolving credit facility with a syndicate of banks that
was scheduled to expire on July 10, 2020 (the “Superseded Credit Facility”). In 2019, the Company replaced the Superseded
Credit Facility with a $5.0 billion unsecured revolving credit facility with a syndicate of banks that expires on August 27, 2024,
subject to a one-year extension option at the request of the Company with the consent of the lenders (the “Five-Year Facility”).
The Five-Year Facility also contains an expansion option permitting Danaher to request up to five increases of up to an
aggregate additional $2.5 billion from lenders that elect to make such increase available, upon the satisfaction of certain
conditions. At the same time, the Company entered into a $5.0 billion 364-day unsecured revolving credit facility with a
syndicate of banks that was scheduled to expire on August 26, 2020 (the “Superseded 364-Day Facility”). In 2020, the
Company replaced the Superseded 364-Day Facility with a $2.5 billion 364-day unsecured revolving credit facility with a
syndicate of banks that was scheduled to expire on June 4, 2021 and then terminated such credit facility on December 31, 2020
(the “Terminated 364-Day Credit Facility”).
The Company expects to limit borrowings under the Five-Year Facility to amounts that would leave sufficient borrowing
capacity under the facilities so that it could borrow, if needed, to repay all of the outstanding commercial paper as it matures.
Borrowings under the Five-Year Facility bear interest as follows: (1) Eurocurrency Rate Committed Loans (as defined in the
Five-Year Facility) bear interest at a variable rate equal to the London inter-bank offered rate plus a margin of between 58.5 and
100 basis points, depending on Danaher’s long-term debt credit rating; (2) Base Rate Committed Loans and Swing Line Loans
(each as defined in the Five-Year Facility) bear interest at a variable rate equal to the highest of (a) the Federal funds rate (as
published by the Federal Reserve Bank of New York from time to time) plus 50 basis points; (b) Bank of America’s “prime
rate” as publicly announced from time to time and (c) the Eurocurrency Rate (as defined in the Five-Year Facility) plus 100
basis points; and (3) Bid Loans (as defined in the Five-Year Facility) bear interest at the rate bid by the particular lender
providing such loan. In addition, Danaher is required to pay a per annum facility fee of between 4 and 12.5 basis points
(depending on Danaher’s long-term debt credit rating) based on the aggregate commitments under the Five-Year Facility,
regardless of usage.
Borrowings under the Superseded and Terminated 364-Day Facility bore interest as follows: (1) Eurodollar Rate Loans (as
defined in the 364-Day Facility) bore interest at a variable rate per annum equal to the London inter-bank offered rate plus a
margin of between 59.5 and 100.5 basis points for the Superseded 364-Day Facility and 90 and 127.5 basis points for the
Terminated 364-Day Facility, depending on Danaher’s long-term debt credit rating; and (2) Base Rate Loans (as defined in the
364-Day Facility) bore interest at a variable rate per annum equal to the highest of (a) the Federal funds rate (as published by
the Federal Reserve Bank of New York from time to time) plus 50 basis points, (b) Bank of America’s “prime rate” as publicly
announced from time to time and (c) the Eurodollar Rate (as defined in the 364-Day Facility) plus 100 basis points, plus in each
case a margin of up to 0.5 basis points for the Superseded 364-Day Facility and between 0 and 27.5 basis points for the
Terminated 364-Day Facility, depending on Danaher’s long-term debt credit rating. In addition, Danaher was required to pay a
per annum facility fee of between 3 and 5 basis points for the Superseded 364-Day Facility and 10 and 22.5 basis points for the
Terminated 364-Day Facility (depending on Danaher’s long-term debt credit rating), based on the aggregate commitments
under the Superseded and Terminated 364-Day Facility, regardless of usage.
The Five-Year Facility requires the Company to maintain a consolidated leverage ratio (as defined in the facility) of 0.65 to
1.00 or less. Borrowings under the Five-Year Facility are prepayable at the Company’s option at any time in whole or in part
without premium or penalty. As of December 31, 2020, no borrowings were outstanding under the Five-Year Facility and the
Company was in compliance with all covenants under the facilities. The nonperformance by any member of the Five-Year
Facility syndicates would reduce the maximum capacity of the Five-Year Facility by such member’s commitment amount.
The Company’s obligations under the Five-Year Facility are unsecured. The Company has unconditionally and irrevocably
guaranteed the obligations of each of its subsidiaries in the event a subsidiary is named a borrower under the Five-Year Facility.
The Five-Year Facility contains customary representations, warranties, conditions precedent, events of default, indemnities and
affirmative and negative covenants. The Five-Year Facility is available for liquidity support for Danaher’s expanded U.S.
dollar and euro commercial paper programs, as discussed below, and for general corporate purposes.
Under the Company’s U.S. and euro-denominated commercial paper programs, the Company or a subsidiary of the Company,
as applicable, may issue and sell unsecured, short-term promissory notes. The notes are typically issued at a discount from par,
generally based on the ratings assigned to the Company by credit rating agencies at the time of the issuance and prevailing
market rates measured by reference to LIBOR or EURIBOR. The Five-Year Facility provides liquidity support for issuances
under the Company’s commercial paper programs, and can also be used for working capital and other general corporate
purposes. The availability of the Five-Year Facility as a standby liquidity facility to repay maturing commercial paper is an
important factor in maintaining the existing credit ratings of the Company’s commercial paper programs. As commercial paper
88

-- 110 of 162 --

obligations mature, the Company may issue additional short-term commercial paper obligations to refinance all or part of these
borrowings. As of December 31, 2020, borrowings outstanding under the Company’s euro commercial paper programs had a
weighted average annual interest rate of negative 0.05% and a weighted average remaining maturity of approximately 25 days.
As of December 31, 2020, the Company has classified approximately $611 million of its borrowings outstanding under the
euro-denominated commercial paper programs and $290 million of borrowings outstanding under the 2021 Yen Notes as long-
term debt in the accompanying Consolidated Balance Sheet as the Company had the intent and ability, as supported by
availability under the Five-Year Facility, to refinance these borrowings for at least one year from the balance sheet date.
The Company’s ability to access the commercial paper market, and the related costs of these borrowings, is affected by the
strength of the Company’s credit rating and market conditions. Any downgrade in the Company’s credit rating would increase
the cost of borrowings under the Company’s commercial paper program and the Five-Year Facility, and could limit or preclude
the Company’s ability to issue commercial paper. If the Company’s access to the commercial paper market is adversely
affected due to a credit downgrade, change in market conditions or otherwise, the Company expects it would rely on a
combination of available cash, operating cash flow and the Five-Year Facility to provide short-term funding. In such event, the
cost of borrowings under the Five-Year Facility could be higher than the cost of commercial paper borrowings.
2020 Financing Activity
The Company continues to monitor the impact of the COVID-19 pandemic on the Company’s liquidity and capital resources
and take actions intended to mitigate adverse impacts. Historically, the Company has generally relied on borrowings under its
commercial paper program to address liquidity requirements that exceed the capacity provided by its operating cash flows and
cash on hand, while also accessing the capital markets from time to time to secure financing for more significant acquisitions.
The COVID-19 pandemic adversely affected the availability of new borrowings in the commercial paper markets at times
during 2020. Therefore, in the first half of 2020, the Company engaged in the following financing transactions:
• The Company borrowed $2.5 billion under the Five-Year Facility and $2.5 billion under the Superseded 364-Day
Facility for general corporate purposes (including payment of a portion of the purchase price for the Cytiva
Acquisition and repayment of certain commercial paper obligations as they matured). The Company replaced the
Superseded 364-Day Facility with a new $2.5 billion 364-Day Facility, which was terminated on December 31, 2020.
All amounts borrowed under the credit facilities referenced above were repaid in 2020.
• The Company issued approximately €2.5 billion (approximately $2.7 billion based on currency exchange rates as of
the respective dates of the pricing of the notes) aggregate principal amount of euro-denominated senior unsecured
notes, the proceeds of which have been and are being used for general corporate purposes (including repayment of the
borrowings under the Superseded 364-Day Facility and the Five-Year Facility, and repayment of certain commercial
paper obligations as they matured).
• The Company completed the 2020 Common Stock Offering and 2020 MCPS Offering and received net proceeds of
approximately $1.73 billion and $1.67 billion, respectively, which have been and will be used for general corporate
purposes.
In addition, during the fourth quarter of 2020, the Company issued $1.0 billion aggregate principal amount of senior unsecured
notes, the proceeds of which have been and will be used for general corporate purposes, including the redemption of the
€800 million aggregate principal amount of 1.7% senior unsecured notes due 2022. These borrowings were redeemed in the
fourth quarter of 2020 at a redemption price equal to the outstanding principal amount and a make-whole premium as specified
in the applicable indenture, plus accrued and unpaid interest. The Company recorded a loss on early extinguishment of these
borrowings, net of certain deferred gains, related to the payment of the make-whole premiums in connection with the
redemption of $26 million ($20 million after-tax or $0.03 per diluted common share).
89

-- 111 of 162 --

41CBBD0=24B
H9>H8JHH:967DK: >C 6C6=:GDGEDG6I>DC8DBEA:I:9JC9:GLG>II:CEJ7A>8D;;:G>C<HD;H:C>DGJCH:8JG:9JGDCDI:H9J:
 6C98DAA:8I>K:ANI=:UJGDCDI:HV6C9. , 9DAA6G 9:CDB>C6I:9H:C>DGJCH:8JG:9CDI:H9J: -=:
;DAADL>C<HJBB6G>O:HI=:@:NI:GBHD;I=:D;;:G>C<H>C6<<G:<6I:X6C9>CB>AA>DCH
BBD40C4
66A460C4
%A8=28?0;
<>D=C
(C0C43
==D0;
=C4A4BC'0C4
BBD4%A8240B
>5%A8=28?0;
<>D=C 	"0CDA8CH0C4
=C4A4BC%0H<4=C0C4B
8=0AA40AB
JGDCDI:H 	&6G8=  	X 	 	  	  	&6G8=  	&6G8=
JGDCDI:H 	EG>A  	X 	 	  	  	&6G8=  	&6G8=
JGDCDI:H 	&6G8=  	X 	 	  	  	,:EI:B7:G  	,:EI:B7:G
JGDCDI:H 	EG>A  	X 	 	  	  	,:EI:B7:G  	,:EI:B7:G
JGDCDI:H 	&6G8=  	X 	 	  	  	&6G8=  	&6G8=
JGDCDI:H 	EG>A  	X 	 	  	  	&6G8=  	&6G8=
. , 'DI:H 	(8ID7:G  	 	  	  	  	(8ID7:G  	EG>A6C9(8ID7:G
-=:DBE6CNG:8:>K:9C:IEGD8::9H;GDBI=:CDI:H>HHJ:9DC&6G8=  6;I:GJC9:GLG>I>C<9>H8DJCIH6C98DBB>HH>DCH
6C9D;;:G>C<:ME:CH:H D;6EEGDM>B6I:ANX 7>AA>DC6EEGDM>B6I:AN 7>AA>DC76H:9DC8JGG:C8N:M8=6C<:G6I:H6HD;I=:
96I:D;I=:EG>8>C<D;I=:CDI:H -=:DBE6CNG:8:>K:9C:IEGD8::9H;GDBI=:CDI:H>HHJ:9DCEG>A  6;I:GJC9:GLG>I>C<
9>H8DJCIH6C98DBB>HH>DCH6C9D;;:G>C<:ME:CH:H D;XB>AA>DCB>AA>DC76H:9DC8JGG:C8N:M8=6C<:G6I:H6HD;I=:
96I:D;I=:EG>8>C<D;I=:CDI:H -=:DBE6CNG:8:>K:9C:IEGD8::9H;GDBI=:CDI:H>HHJ:9DC(8ID7:G  6;I:G
JC9:GLG>I>C<9>H8DJCIH6C98DBB>HH>DCH6C9D;;:G>C<:ME:CH:H D;B>AA>DC 
>E4=0=CB0=3'434<?C8>=%A>E8B8>=B??;8201;4C>#>C4B
0>I=G:HE:8IIDI=:6C92:C'DI:HI=:   6C9JGDCDI:HI=: 6C9. , 
'DI:HI=:   6C9>DE=6GB6'DI:H6C9I=:   6C9>DE=6GB6
JGDCDI:H 6I6CNI>B:EG>DGIDI=:6EEA>867A:B6IJG>IN96I: I=:DBE6CNB6NG:9::BI=:6EEA>867A:H:G>:HD;CDI:H>CL=DA:DG
>CE6GI 7NE6N>C<I=:EG>C8>E6A6BDJCI688GJ:96C9JCE6>9>CI:G:HI6C9 JCI>AI=:E6G86AA96I:HE:8>;>:9>CI=:6EEA>867A:
>C9:CIJG:DG8DBE6G67A:<DK:GC>C<9D8JB:CI I=:UB6@: L=DA:VEG:B>JBHE:8>;>:9I=:G:>C6C9>CI=:86H:D;I=:2:C'DI:H 
C:ID;8:GI6>CHL6E G:A6I:9<6>CHDGADHH:H6H6EEA>867A: 0>I=G:HE:8IID:68=D;I=:6C9!DC9H 6I6CNI>B:
6;I:GDGBDG:D;I=:6EEA>867A:7DC9H=6K:7::CG:9::B:9DGEJG8=6H:96C986C8:A:9 I=:DBE6CNB6NG:9::BHDB:DG
6AAD;I=:G:B6>C>C<7DC9H;DGI=:>GEG>C8>E6A6BDJCIEAJH688GJ:96C9JCE6>9>CI:G:HI 0>I=G:HE:8IIDI=: 6C9
2:C'DI:HAD6I>C<+6I:    6C9JGDCDI:HI=:6C9!DC9H6C9I=: 
  6C9>DE=6GB6JGDCDI:H I=:DBE6CNB6NG:9::BHJ8=CDI:H6C97DC9HJEDCI=:D88JGG:C8:D;
HE:8>;>:9 69K:GH:8=6C<:H>CI6MA6LH DG>CI:GEG:I6I>DCHJC9:GHJ8=A6LH 6I6G:9:BEI>DCEG>8::FJ6AIDI=:EG>C8>E6A6BDJCID;
I=:7DC9HID7:G:9::B:9
";68=6C<:D;8DCIGDAIG><<:G>C<:K:CID88JGHL>I=G:HE:8IID6CND;I=: 6C92:C'DI:HI=: AD6I>C<
+6I:    6C9JGDCDI:HI=: 6C9. , 'DI:HI=:6C9!DC9H
I=:   6C9>DE=6GB6'DI:HDGI=:   6C9>DE=6GB6JGDCDI:H :68=
=DA9:GD;HJ8=CDI:HB6NG:FJ>G:I=:DBE6CNIDG:EJG8=6H:HDB:DG6AAD;HJ8=CDI:H6C97DC9H6I6EJG8=6H:EG>8::FJ6AID
>CI=:86H:D;I=:6C92:C'DI:HD;I=:EG>C8>E6A6BDJCID;I=:CDI:H6C97DC9H EAJH688GJ:96C9
JCE6>9>CI:G:HI6C9>CI=:86H:D;I=:2:C'DI:H 8:GI6>CHL6E G:A6I:9ADHH:H6H6EEA>867A: 8=6C<:D;8DCIGDAIG><<:G>C<
:K:CIB:6CHI=:D88JGG:C8:D;7DI=68=6C<:D;8DCIGDA6C96G6I>C<:K:CI :68=6H9:;>C:9>CI=:6EEA>867A:>C9:CIJG:DG
8DBE6G67A:<DK:GC>C<9D8JB:CI M8:EI>C8DCC:8I>DCL>I=68=6C<:D;8DCIGDAIG><<:G>C<:K:CI I=:DBE6CN9D:HCDI=6K:
6CN8G:9>IG6I>C<9DLC<G69:IG><<:GHI=6ILDJA9688:A:G6I:I=:B6IJG>IND;6B6I:G>6A6BDJCID;DJIHI6C9>C<9:7I 68==DA9:G
D;I=:6C92:C'DI:HB6N6AHDG:FJ>G:I=:DBE6CNIDG:EJG8=6H:HDB:DG6AAD;>IHCDI:H6I6EJG8=6H:EG>8::FJ6A
IDD;I=:EG>C8>E6A6BDJCID;I=:CDI:H EAJH688GJ:96C9JCE6>9>CI:G:HI6C98:GI6>CHL6E G:A6I:9ADHH:H6H6EEA>867A: >C
8:GI6>C8>G8JBHI6C8:HL=:G:7NHJ8==DA9:G8DB:H>CIDK>DA6I>DCD;:8DCDB>8H6C8I>DCHA6LH6H6G:HJAID;=DA9>C<HJ8=CDI:H
-=:G:HE:8I>K:>C9:CIJG:HDG8DBE6G67A:<DK:GC>C<9D8JB:CIHJC9:GL=>8=I=:67DK: 9:H8G>7:9CDI:H6C97DC9HL:G:>HHJ:9
8DCI6>C8JHIDB6GN8DK:C6CIH>C8AJ9>C< ;DG:M6BEA: A>B>IHDCI=:>C8JGG:C8:D;H:8JG:99:7I6C9H6A: A:6H:768@IG6CH68I>DCH 
'DC:D;I=:H:8DK:C6CIH6G:8DCH>9:G:9G:HIG>8I>K:IDI=:DBE6CNWHDE:G6I>DCH6C96HD;:8:B7:G  I=:DBE6CN
L6H>C8DBEA>6C8:L>I=6AAD;>IH9:7I8DK:C6CIH


-- 112 of 162 --

!>=6)4A<=341C43=4BB
-=:;DAADL>C<HJBB6G>O:HI=:@:NI:GBH;DGI=:DBE6CNWHADC< I:GB9:7I6HD;:8:B7:G 
$DCBC0=38=6
0;0=240B>5
424<14A  (C0C43
==D0;
=C4A4BC'0C4
BBD4%A824
0B>5
%A8=28?0;
<>D=C 	BBD40C4 	"0CDA8CH0C4 =C4A4BC%0H<4=C
0C4B8=0AA40AB
%2('H 	 	 	H::7:ADL 	'  	#6CJ6GN  	#6CJ6GN  	#6CJ6GN6C9#JAN
2:C'DI:H 	 	  	 	:7GJ6GN  	&6G8=  &6G8=6C9
,:EI:B7:G
AD6I>C<+6I:
JGDCDI:H 	
I=G:: BDCI=
.+"(+ 
  	  	#JC:  	#JC: 
&6G8= #JC: 
,:EI:B7:G6C9
:8:B7:G
>DE=6GB6'DI:H 	 	  	  	'DK:B7:G  	'DK:B7:G  &6N6C9'DK:B7:G

!DC9H 	 	  	  	:8:B7:G  	:8:B7:G  	:8:B7:G
JGDCDI:H 	 	  	  	&6G8=  	&6G8=  	&6G8=
JGDCDI:H 	 	  	  	EG>A  	&6G8=  	&6G8=
>DE=6GB6'DI:H 	 	  	  	'DK:B7:G  	'DK:B7:G  &6N6C9'DK:B7:G

JGDCDI:H 	 	  	  	#JAN  	#JAN  	#JAN
. , 'DI:H 	 	  	  	,:EI:B7:G  	,:EI:B7:G  &6G8=6C9
,:EI:B7:G
>DE=6GB6
JGDCDI:H 	  	  	  	,:EI:B7:G  	&6G8=  	&6G8=
JGDCDI:H 	 	  	  	&6G8=  	,:EI:B7:G  	,:EI:B7:G
JGDCDI:H 	 	  	  	EG>A  	,:EI:B7:G  	,:EI:B7:G
2:C'DI:H 	 	  	 	&6N  	&6N  &6N6C9'DK:B7:G

JGDCDI:H 	 	  	  	#JC:  	#JC:  	#JC:
>DE=6GB6
JGDCDI:H 	  	  	  	,:EI:B7:G  	&6G8=  	&6G8=
!DC9H 	 	  	  :8:B7:G 6C9
:8:B7:G  	:8:B7:G  	:8:B7:G
>DE=6GB6'DI:H 	 	  	  	'DK:B7:G  	'DK:B7:G  &6N6C9'DK:B7:G

JGDCDI:H 	 	  	  	&6G8=  	&6G8=  	&6G8=
JGDCDI:H 	 	  	  	EG>A  	&6G8=  	&6G8=
>DE=6GB6
JGDCDI:H 	  	  	  	,:EI:B7:G  	,:EI:B7:G  	,:EI:B7:G
2:C'DI:H 	 	  	 	&6N  	&6N  &6N6C9'DK:B7:G

>DE=6GB6
JGDCDI:H 	  	  	  	,:EI:B7:G  	,:EI:B7:G  	,:EI:B7:G
>DE=6GB6'DI:H 	 	  	  	'DK:B7:G  	'DK:B7:G  &6N6C9'DK:B7:G

. , 'DI:H 	 	  	  	,:EI:B7:G  	,:EI:B7:G  &6G8=6C9
,:EI:B7:G
>DE=6GB6
JGDCDI:H 	 	  	  	,:EI:B7:G  	,:EI:B7:G  	,:EI:B7:G
>DE=6GB6'DI:H 	 	  	  	'DK:B7:G  	'DK:B7:G  &6N6C9'DK:B7:G

. , 'DI:H 	 	  	  	(8ID7:G  	(8ID7:G  	EG>A6C9(8ID7:G
JGD 9:CDB>C6I:9
8DBB:G8>6AE6E:G 	 	K6G>DJH 	K6G>DJH 	K6G>DJH 	K6G>DJH 	K6G>DJH
(I=:G 	 	K6G>DJH 	K6G>DJH 	K6G>DJH 	K6G>DJH 	K6G>DJH
-DI6A9:7I 	 	 
 -=:C:IEGD8::9H 6;I:GJC9:GLG>I>C<9>H8DJCIH6C98DBB>HH>DCH6C9D;;:G>C<:ME:CH:H D;6EEGDM>B6I:ANX 7>AA>DC6EEGDM>B6I:AN 
7>AA>DC76H:9DC8JGG:C8N:M8=6C<:G6I:H6HD;I=:96I:D;>HHJ6C8:;GDBI=:H:CDI:H6C9I=:JGDCDI:HL:G:JH:9IDE6N6EDGI>DCD;
I=:EJG8=6H:EG>8:;DGI=:68FJ>H>I>DCD;)6AADGEDG6I>DC>CI=:U)6AA8FJ>H>I>DCV 
 -=:C:IEGD8::9H >C8AJ9>C<I=:G:A6I:9EG:B>JB 6C96;I:GJC9:GLG>I>C<9>H8DJCIH6C98DBB>HH>DCH6C9D;;:G>C<:ME:CH:H D;!
B>AA>DCB>AA>DC76H:9DC8JGG:C8N:M8=6C<:G6I:H6HD;96I:D;EG>8>C<;GDBI=:H:7DC9HL:G:JH:9IDG:E6N6EDGI>DCD;I=:
8DBB:G8>6AE6E:G>HHJ:9ID;>C6C8:I=:)6AA8FJ>H>I>DC6C9I=:!B>AA>DC6<<G:<6I:EG>C8>E6A6BDJCID;I=: H:C>DGJCH:8JG:9
7DC9HI=6IB6IJG:9>C:8:B7:G


-- 113 of 162 --

(3) The net proceeds, after underwriting discounts and commissions and offering expenses, of approximately $2.0 billion from these notes
were used to repay a portion of the commercial paper issued to finance the Pall Acquisition.
(4) The net proceeds, after offering expenses, of approximately ¥29.9 billion ($262 million based on currency exchange rates as of the date of
issuance) from these notes were used to repay a portion of the commercial paper borrowings issued to finance the Pall Acquisition.
(5) The net proceeds at issuance, after offering expenses, of €843 million ($940 million based on currency exchange rates as of the date of
pricing) from these notes were used to partially repay commercial paper borrowings.
(6) The net proceeds at issuance, after offering expenses, of approximately ¥83.6 billion ($744 million based on currency exchange rates as of
the date of pricing) from these notes were used to partially repay commercial paper borrowings.
(7) The net proceeds at issuance, after offering expenses, of approximately €6.2 billion ($6.8 billion based on currency exchange rates as of the
date of pricing) from these notes were used to finance the Cytiva Acquisition.
(8) The net proceeds at issuance, after offering expenses, of approximately $4.0 billion from these notes were used to finance the Cytiva
Acquisition.
LYONs
In 2001, the Company issued $830 million (value at maturity) in LYONs. The net proceeds to the Company were $505 million,
of which approximately $100 million was used to pay down debt and the balance was used for general corporate purposes,
including acquisitions. The LYONs originally carry a yield to maturity of 2.375% (with contingent interest payable as
described below). Pursuant to the terms of the indenture that governs the Company’s LYONs, each $1,000 of principal amount
at maturity could be converted into 38.1998 shares of Danaher common stock at any time on or before the maturity date of
January 22, 2021.
During the year ended December 31, 2020, holders of certain of the Company’s LYONs converted such LYONs into an
aggregate of approximately 367 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s
deferred tax liability of $43 million associated with the book and tax basis difference in the converted LYONs was transferred
to additional paid-in capital.
As of December 31, 2020, an aggregate of approximately 24 million shares of the Company’s common stock had been issued
upon conversion of LYONs. As of December 31, 2020, the accreted value of the outstanding LYONs was lower than the traded
market value of the underlying common stock issuable upon conversion.
Under the terms of the LYONs, the Company paid contingent interest to the holders of LYONs during any six-month period
from January 23 to July 22 and from July 23 to January 22 if the average market price of a LYON for a specified measurement
period equaled 120% or more of the sum of the issue price and accrued original issue discount for such LYON. The amount of
contingent interest to be paid with respect to any quarterly period equaled the higher of either 0.0315% of the bonds’ average
market price during the specified measurement period or the amount of the cash dividend paid on Danaher’s common stock
during such quarterly period multiplied by the number of shares issuable upon conversion of a LYON. The Company paid $1
million, $1 million and $2 million of contingent interest on the LYONs for each of the years ended December 31, 2020, 2019
and 2018, respectively. Except for the contingent interest described above, the Company did not pay interest on the LYONs
prior to maturity. In 2021, prior to the redemption of the outstanding LYONs on January 22, 2021, holders of $24 million of
outstanding LYONs converted such LYONs into approximately 912 thousand shares of the Company’s common stock. As a
result of the conversion in the first quarter of 2021, the Company will transfer to additional paid-in capital the deferred tax
liability of $10 million associated with the book and tax basis difference in the converted LYONs. The residual LYONS not
converted into shares of the Company’s common stock were redeemed at face value.
2019 Long-Term Debt Repayments
On October 24, 2019, the Company redeemed the $500 million aggregate principal amount of 2.4% Senior Notes due 2020 and
the $375 million aggregate principal amount of 5.0% 2020 Assumed Pall Notes, in each case at a redemption price equal to the
outstanding principal amount and a make-whole premium as specified in the applicable indenture, plus accrued and unpaid
interest. The aggregate make-whole premiums required in connection with the redemption were $7 million ($5 million after-tax
or $0.01 per diluted common share). The payment of the make-whole premiums is reflected as a loss on early extinguishment
of borrowings. The Company funded the redemption using a portion of the cash distribution it received in connection with the
Envista Disposition.
The €600 million aggregate principal amount of the 2019 Euronotes were repaid with accrued interest upon their maturity on
July 8, 2019 using proceeds from the issuance of euro-denominated commercial paper.
92

-- 114 of 162 --

Guarantors of Debt
The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The
Floating Rate 2022 Euronotes, 2025 Euronotes, 2027 Euronotes and euro-denominated commercial paper were issued by DH
Europe Finance S.A. (“Danaher International”). The 2022 Biopharma Notes, 2024 Biopharma Notes, 2026 Biopharma
Euronotes, 2028 Biopharma Euronotes, 2029 Biopharma Notes, 2031 Biopharma Euronotes, 2039 Biopharma Euronotes, 2039
Biopharma Notes, 2049 Biopharma Euronotes, 2049 Biopharma Notes and euro-denominated commercial paper were issued by
DH Europe Finance II S.a.r.l. (“Danaher International II”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH
Switzerland Finance S.A. (“Danaher Switzerland”). The 2021 Yen Notes, 2027 Yen Notes and 2032 Yen Notes were issued by
DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher International II, Danaher Switzerland and
Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the outstanding and future securities
issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these guarantees rank
on parity with the Company’s unsecured and unsubordinated indebtedness.
Other
The Company’s minimum principal payments for the next five years are as follows ($ in millions):
2021 $ 11
2022 1,014
2023 597
2024 2,688
2025 1,468
Thereafter 15,426
The Company made interest payments of $331 million, $129 million and $140 million in 2020, 2019 and 2018, respectively.
Interest payments increased in 2020 due primarily to the impact of higher average debt balances as a result of the issuances of
debt in 2019 and 2020 (primarily to fund the Cytiva Acquisition) and 2020 borrowings under the Five-Year Facility and the
Superseded 364-Day Facility, prior to the subsequent repayment of such credit facility borrowings. Proceeds from these
borrowings as well as available cash balances were used to fund the acquisition of Cytiva and for general corporate purposes.
NOTE 12. HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company uses cross-currency swap derivative contracts to partially hedge its net investments in foreign operations against
adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The
cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate
payments in another currency. As of December 31, 2020, the Company had $2.0 billion, including $1.0 billion entered into
during 2020, of cross-currency swap derivative contracts outstanding as hedges of its net investment in foreign operations.
These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in Danish kroner, Japanese
yen, euro and Swiss franc, and partially offset the impact of changes in currency rates on foreign currency denominated net
investments. These contracts also reduce the interest rate from the stated interest rates on the U.S. dollar-denominated debt to
the interest rates of the swaps. The changes in the spot rate of these instruments are recorded in accumulated other
comprehensive income (loss) in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the
Company’s related net investment that is also recorded in accumulated other comprehensive income (loss) in the accompanying
Consolidated Statements of Stockholders’ Equity. Any ineffective portions of net investment hedges are reclassified from
accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense
from these swaps are recorded in interest expense in the accompanying Consolidated Statements of Earnings consistent with the
classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from
September 2025 to October 2030.
The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in
a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates between the U.S. dollar
and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The
changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss) in stockholders’
equity, with a reclassification from accumulated other comprehensive income (loss) to net earnings to offset the remeasurement
of the hedged debt that is also recorded in net earnings. Any ineffective portions of net investment hedges are reclassified from
accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense
from these swaps are recorded in interest expense in the accompanying Consolidated Statements of Earnings consistent with the
classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from
November 2022 to November 2049.
93

-- 115 of 162 --

-=:DBE6CN=6H6AHD>HHJ:9;DG:><C8JGG:C8N9:CDB>C6I:9ADC< I:GB9:7I6HE6GI>6A=:9<:HD;>IHC:I>CK:HIB:CIH>C;DG:><C
DE:G6I>DCH6<6>CHI69K:GH:BDK:B:CIH>C:M8=6C<:G6I:H7:IL::CI=:. , 9DAA6G6C9I=::JGD #6E6C:H:N:C6C9,L>HH;G6C8 
-=:H:;DG:><C8JGG:C8N9:CDB>C6I:9ADC< I:GB9:7I>HHJ6C8:H6G:9:H><C6I:96C9FJ6A>;N6HCDC9:G>K6I>K:=:9<>C<>CHIGJB:CIH 
88DG9>C<AN I=:;DG:><C8JGG:C8NIG6CHA6I>DCD;I=:H:9:7I>CHIGJB:CIH>HG:8DG9:9>C688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:
ADHH>CHID8@=DA9:GHW:FJ>IN>CI=:688DBE6CN>C<DCHDA>96I:96A6C8:,=::IH D;;H:II>C<I=:;DG:><C8JGG:C8NIG6CHA6I>DC
69?JHIB:CID;I=:DBE6CNWHG:A6I:9C:I>CK:HIB:CII=6I>H6AHDG:8DG9:9>C688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH 
CN>C:;;:8I>K:EDGI>DCHD;C:I>CK:HIB:CI=:9<:H6G:G:8A6HH>;>:9;GDB688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH>CID
:6GC>C<H9JG>C<I=:E:G>D9D;8=6C<: -=:H:>CHIGJB:CIHB6IJG:DC96I:HG6C<>C<;GDB&6G8=ID&6N
-=:DBE6CNJH:9>CI:G:HIG6I:HL6E6<G::B:CIHID=:9<:I=:K6G>67>A>IN>C86H=;ADLH9J:ID8=6C<:H>C7:C8=B6G@>CI:G:HI
G6I:HG:A6I:9ID6EDGI>DCD;I=:. , 9:7II=:DBE6CN>HHJ:9ID;JC9I=:NI>K68FJ>H>I>DC -=:H:8DCIG68IH:;;:8I>K:AN;>M:9
I=:>CI:G:HIG6I:;DG6EDGI>DCD;I=:DBE6CNWH. , 9DAA6G 9:CDB>C6I:99:7I:FJ6AIDI=:CDI>DC6A6BDJCID;I=:HL6EHIDI=:
G6I:HE:8>;>:9>CI=:>CI:G:HIG6I:HL6E6<G::B:CIH6C9L:G:H:IIA:9>C'DK:B7:G -=:8=6C<:H>CI=:;6>GK6AJ:D;I=:H:
>CHIGJB:CIHL:G:G:8DG9:9>C688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH>CHID8@=DA9:GHW:FJ>INEG>DGIDI=:>HHJ6C8:D;
I=:9:7I6C96G:HJ7H:FJ:CIAN7:>C<G:8A6HH>;>:9ID>CI:G:HI:ME:CH:DK:GI=:A>;:D;I=:G:A6I:99:7I
-=:;DAADL>C<I67A:HJBB6G>O:HI=:CDI>DC6AK6AJ:H6HD;:8:B7:G 6C96C9EG:I6M>BE68ID;8=6C<:H>CI=:;6>G
K6AJ:HD;>CHIGJB:CIH9:H><C6I:96HC:I>CK:HIB:CI=:9<:H6C986H=;ADL=:9<:H>C688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:
U("V;DGI=:N:6GI=:C:C9:9>CB>AA>DCH
$A868=0;
#>C8>=0;<>D=C #>C8>=0;<>D=C
$DCBC0=38=6
08=!>BB
'42>6=8I438=
$
.40A4=343424<14A  	
':I>CK:HIB:CI=:9<:H
DG:><C8JGG:C8N8DCIG68IH 	 	  	 	  	 	
DG:><C8JGG:C8N9:CDB>C6I:99:7I 	 	  	 	  	 	
6H=;ADL=:9<:H
DG:><C8JGG:C8N8DCIG68IH 	 	  	 	  	 	
-DI6A 	 	  	 	  	 	
.40A4=343424<14A  	
':I>CK:HIB:CI=:9<:H
DG:><C8JGG:C8N8DCIG68IH 	 	  	 	  	 	
DG:><C8JGG:C8N9:CDB>C6I:99:7I 	 	  	 	  	 	
6H=;ADL=:9<:H
DG:><C8JGG:C8N8DCIG68IH 	 	  	 	  	 	
"CI:G:HIG6I:HL6EH 	 	 	 	T 	 	
-DI6A 	 	  	 	  	 	
6>CHDGADHH:HG:A6I:9IDI=:C:I>CK:HIB:CI=:9<:H6G:8A6HH>;>:96H;DG:><C8JGG:C8NIG6CHA6I>DC69?JHIB:CIH>CI=:H8=:9JA:D;
8=6C<:H>C(">C'DI: 6HI=:H:>I:BH6G:6IIG>7JI67A:IDI=:DBE6CNWH=:9<:HD;>IHC:I>CK:HIB:CI>C;DG:><CDE:G6I>DCH 
6>CHDGADHH:HG:A6I:9IDI=:86H=;ADL=:9<:H6G:8A6HH>;>:96H86H=;ADL=:9<:69?JHIB:CIH>CI=:H8=:9JA:D;8=6C<:H>C("
>C'DI: -=:6BDJCIG:8A6HH>;>:9ID:6GC>C<H;DGI=:>CI:G:HIG6I:HL6EHL6HB>AA>DC6C9A:HHI=6CB>AA>DC>C6C9
 G:HE:8I>K:AN "C6C9 I=:DBE6CNG:8A6HH>;>:9B>AA>DC6C9B>AA>DC G:HE:8I>K:AN D;9:;:GG:9ADHH:H
;GDB688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHHIDC:I:6GC>C<HG:A6I:9IDI=:8GDHH 8JGG:C8NHL6E9:G>K6I>K:8DCIG68IH
I=6I6G:86H=;ADL=:9<:HD;I=:DBE6CNWH. , 9DAA6G 9:CDB>C6I:99:7I -=>HG:8A6HH>;>86I>DCL6H:FJ6AIDI=:
G:B:6HJG:B:CI<6>CG:8DG9:9DCI=:=:9<:99:7I -=:DBE6CN9>9CDIG:8A6HH>;N6CNDI=:G9:;:GG:9<6>CHDGADHH:HG:A6I:9ID
C:I>CK:HIB:CI=:9<:HDG86H=;ADL=:9<:H;GDB688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHHID:6GC>C<H9JG>C<I=:N:6GH
:C9:9:8:B7:G 6C9 "C699>I>DC I=:DBE6CN9>9CDI=6K:6CN>C:;;:8I>K:C:HHG:A6I:9IDC:I>CK:HIB:CI
=:9<:HDG>CI:G:HIG6I:HL6EH9JG>C<I=:N:6GH:C9:9:8:B7:G 6C9 -=:86H=>C;ADLH6C9DJI;ADLH6HHD8>6I:9
L>I=I=:DBE6CNWH9:G>K6I>K:8DCIG68IH9:H><C6I:96HC:I>CK:HIB:CI=:9<:H6G:8A6HH>;>:9>C6AADI=:G>CK:HI>C<68I>K>I>:H>CI=:
688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;6H=ADLH -=:86H=>C;ADLH6C9DJI;ADLH6HHD8>6I:9L>I=I=:DBE6CNWH
9:G>K6I>K:8DCIG68IH9:H><C6I:96H86H=;ADL=:9<:H6G:8A6HH>;>:9>C86H=;ADLH;GDBDE:G6I>C<68I>K>I>:H>CI=:688DBE6CN>C<
DCHDA>96I:9,I6I:B:CIHD;6H=ADLH


-- 116 of 162 --

-=:DBE6CNWH9:G>K6I>K:>CHIGJB:CIH 6HL:AA6H>IHCDC9:G>K6I>K:9:7I>CHIGJB:CIH9:H><C6I:96C9FJ6A>;N>C<6HC:I
>CK:HIB:CI=:9<:H L:G:8A6HH>;>:96HD;:8:B7:G>CI=:DBE6CNWHDCHDA>96I:96A6C8:,=::IH6H;DAADLH>C
B>AA>DCH

:G>K6I>K:6HH:IH
)G:E6>9:ME:CH:H6C9DI=:G8JGG:CI6HH:IH 	 	T 	 	
:G>K6I>K:A>67>A>I>:H
88GJ:9:ME:CH:H6C9DI=:GA>67>A>I>:H 	 	 	 	
'DC9:G>K6I>K:=:9<>C<>CHIGJB:CIH
%DC< I:GB9:7I 	 	  	 	 
BDJCIHG:A6I:9IDI=:DBE6CNWH9:G>K6I>K:H:ME:8I:9ID7:G:8A6HH>;>:9;GDB688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH
IDC:I:6GC>C<H9JG>C<I=:C:MIBDCI=H>;>CI:G:HIG6I:H6C9;DG:><C:M8=6C<:G6I:HG:B6>CI=:H6B:6G:CDIH><C>;>86CI
#$)  %#($##)%!#(
-=:DBE6CN=6HCDC8DCIG>7JIDGN9:;>C:97:C:;>IE:CH>DCEA6CHL=>8=8DK:G8:GI6>CD;>IH. , :BEADN::H JG>C< 6AA
G:B6>C>C<7:C:;>I688GJ6AHJC9:GI=:. , EA6CH8:6H:9 :;>C:97:C:;>IEA6CH;GDB68FJ>H>I>DCHHJ7H:FJ:CIID6G:8:6H:9
6HHDDC6HEG68I>86A -=:DBE6CN6AHD=6HCDC8DCIG>7JIDGN9:;>C:97:C:;>IE:CH>DCEA6CHL=>8=8DK:G8:GI6>CD;>IHCDC . , 
:BEADN::H 6C9JC9:G8:GI6>CD;I=:H:EA6CH 7:C:;>I688GJ6AH8DCI>CJ: "C<:C:G6A I=:DBE6CNWHEDA>8N>HID;JC9I=:H:EA6CH
76H:9DC8DCH>9:G6I>DCHG:A6I>C<IDA:<6AG:FJ>G:B:CIH JC9:GAN>C<6HH:IG:IJGCH I=:EA6CWH;JC9:9HI6IJH I=:6CI>8>E6I:9I6M
9:9J8I>7>A>IND;I=:8DCIG>7JI>DC AD86AEG68I>8:H B6G@:I8DC9>I>DCH >CI:G:HIG6I:H6C9DI=:G;68IDGH 
-=:;DAADL>C<H:IH;DGI=I=:;JC9:9HI6IJHD;I=:. , 6C9CDC . , EA6CH6HD;I=:BDHIG:8:CI68IJ6G>6AK6AJ6I>DCHJH>C<
B:6HJG:B:CI96I:HD;:8:B7:G>CB>AA>DCH
 	* ( %4=B8>=4=458CB 	#>=* ( %4=B8>=4=458CB
 	 	
=6C<:>CE:CH>DC7:C:;>ID7A><6I>DC
:C:;>ID7A><6I>DC6I7:<>CC>C<D;N:6G 	 	   	   	   	 
,:GK>8:8DHI 	 	T 	 	  	  	
"CI:G:HI8DHI 	 	  	  	  	
BEADN::8DCIG>7JI>DCH 	 	T 	 	T 	 	  	
:C:;>IH6C9DI=:G:ME:CH:HE6>9 	 	 	 	 	 	 	 	
8FJ>H>I>DCH6C9DI=:G 	 	  	T 	 	  	T
8IJ6G>6AADHH 	 	  	  	  	
B:C9B:CIH H:IIA:B:CIH6C98JGI6>AB:CIH 	 	 	 	 	 	 	 	
DG:><C:M8=6C<:G6I:>BE68I 	 	T 	 	T 	 	  	
:C:;>ID7A><6I>DC6I:C9D;N:6G 	 	   	   	   	 
=6C<:>CEA6C6HH:IH
6>GK6AJ:D;EA6C6HH:IH6I7:<>CC>C<D;N:6G 	 	  	 	  	 	  	 	 
8IJ6AG:IJGCDCEA6C6HH:IH 	 	 	 	 	 	 	 	
BEADN:G8DCIG>7JI>DCH 	 	 	 	 	 	 	 	
BEADN::8DCIG>7JI>DCH 	 	T 	 	T 	 	 	 	
B:C9B:CIH6C9H:IIA:B:CIH 	 	  	  	  	
:C:;>IH6C9DI=:G:ME:CH:HE6>9 	 	  	  	  	
8FJ>H>I>DCH6C9DI=:G 	 	 	 	T 	 	 	 	T
DG:><C:M8=6C<:G6I:>BE68I 	 	T 	 	T 	 	 	 	
6>GK6AJ:D;EA6C6HH:IH6I:C9D;N:6G 	 	  	 	  	 	  	 	 
JC9:9HI6IJH 	 	  	  	  	


-- 117 of 162 --

-=:A6G<:HI8DCIG>7JIDGIDI=:C:I68IJ6G>6AADHH:H6;;:8I>C<I=:7:C:;>ID7A><6I>DC>C7DI=6C9;DGI=:. , EA6CH6C9
I=:CDC . , EA6CH>H9:8G:6H:H>CI=:9>H8DJCIG6I:H E6GI>6AAND;;H:I7NG:IJGCDCEA6C6HH:IH:M8::9>C<:ME:8I6I>DCH 
%A>942C4314=458C>1;860C8>=K%$L0=3508AE0;D4>5?;0=0BB4CB5>A?4=B8>=?;0=BF8C7%$MB8=4G24BB>5?;0=0BB4CB
8=<8;;8>=B
* ( %4=B8>=4=458CB 	#>=* ( %4=B8>=4=458CB
 	
)GD?:8I:97:C:;>ID7A><6I>DC 	 	  	 	  	 	  	 	
6>GK6AJ:D;EA6C6HH:IH 	 	  	 	  	 	 	 	
22D<D;0C4314=458C>1;860C8>=K$L0=3508AE0;D4>5?;0=0BB4CB5>A?4=B8>=?;0=BF8C7$MB8=4G24BB>5?;0=
0BB4CB8=<8;;8>=B
* ( %4=B8>=4=458CB 	#>=* ( %4=B8>=4=458CB
 	
88JBJA6I:97:C:;>ID7A><6I>DC 	 	  	 	  	 	  	 	
6>GK6AJ:D;EA6C6HH:IH 	 	  	 	  	 	 	 	
,4867C430E4A0640BBD<?C8>=BDB43C>34C4A<8=414=458C>1;860C8>=B0C30C4>5<40BDA4<4=C
 	* ( %;0=B 	#>=* ( %;0=B
 	 	
>H8DJCIG6I: 	  	  	  	 
+6I:D;8DBE:CH6I>DC>C8G:6H: 	'  	  	  	 
><?>=4=CB>5=4C?4A8>382?4=B8>=14=458C2>BC8=<8;;8>=B
 	* ( %4=B8>=4=458CB 	#>=* ( %4=B8>=4=458CB
 	
,:GK>8:8DHI 	 	T 	 	  	  	
"CI:G:HI8DHI 	 	  	  	  	
ME:8I:9G:IJGCDCEA6C6HH:IH 	 	 	 	 	 	 	 	
BDGI>O6I>DCD;EG>DGH:GK>8:8DHI8G:9>I 	 	  	  	 	 	T
BDGI>O6I>DCD;C:IADHH 	 	  	  	  	
JGI6>AB:CI6C9H:IIA:B:CI<6>CHADHH:HG:8D<C>O:9 	 	T 	 	T 	 	  	
':IE:G>D9>8E:CH>DC7:C:;>I8DHI 	 	 	 	 	 	  	
-=:C:IE:G>D9>87:C:;>I8DHID;I=:CDC8DCIG>7JIDGN9:;>C:97:C:;>IE:CH>DCEA6CH>C8JGG:99JG>C<I=:N:6GH:C9:9
:8:B7:G  6C96G:G:;A:8I:9>CI=:;DAADL>C<86EI>DCH>CI=:688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;
6GC>C<H>CB>AA>DCH
.40A=343424<14A
 	
,:GK>8:8DHI
DHID;H6A:H 	 	  	  	
,:AA>C< <:C:G6A6C969B>C>HIG6I>K::ME:CH:H 	 	  	  	
-DI6AH:GK>8:8DHI:ME:CH: 	 	  	  	
(I=:GC:IE:G>D9>8E:CH>DC8DHIH
(I=:G>C8DB::ME:CH: C:I 	 	 	 	 	 	
-DI6A:ME:CH:>C8DB: 	 	  	  	


-- 118 of 162 --

,4867C430E4A0640BBD<?C8>=BDB43C>34C4A<8=4=4C?4A8>382?4=B8>=14=458C2>BC0C30C4>5<40BDA4<4=C
 	* ( %;0=B 	#>=* ( %;0=B
 	 	
>H8DJCIG6I: 	  	  	  	 
ME:8I:9ADC< I:GBG:IJGCDCEA6C6HH:IH 	  	  	  	 
+6I:D;8DBE:CH6I>DC>C8G:6H: 	  	  	  	 
-=:9>H8DJCIG6I:G:;A:8IHI=:B6G@:IG6I:DC:8:B7:GD;I=:EG>DGN:6G;DG=><= FJ6A>IN;>M:9 >C8DB:>CK:HIB:CIHL>I=
B6IJG>I>:H8DGG:HEDC9>C<IDI=:DBE6CNWH7:C:;>ID7A><6I>DCH6C9>HHJ7?:8IID8=6C<::68=N:6G DGCDC . , EA6CH G6I:H
6EEGDEG>6I:;DG:68=EA6C6G:9:I:GB>C:976H:9DC>CK:HIB:CI <G69:>CHIGJB:CIHL>I=B6IJG>I>:H6EEGDM>B6I:AN:FJ6AIDI=:
6K:G6<::ME:8I:97:C:;>IE6NDJIJC9:GI=:EA6C JG>C< I=:DBE6CNJE96I:9I=:BDGI6A>IN6HHJBEI>DCHJH:9ID:HI>B6I:
I=:EGD?:8I:97:C:;>ID7A><6I>DCIDG:;A:8IJE96I:9BDGI6A>INI67A:H
"C8AJ9:9>C688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH6HD;:8:B7:G 6G:I=:;DAADL>C<6BDJCIHI=6I=6K:CDI
N:I7::CG:8D<C>O:9>CC:IE:G>D9>8E:CH>DC8DHIJCG:8D<C>O:9EG>DGH:GK>8:8G:9>ID;B>AA>DCB>AA>DC C:ID;I6M6C9
JCG:8D<C>O:968IJ6G>6AADHH:HD;6EEGDM>B6I:AN 7>AA>DCB>AA>DC C:ID;I6M -=:JCG:8D<C>O:9ADHH:H6C9EG>DG
H:GK>8:8DHI C:I >H86A8JA6I:96HI=:9>;;:G:C8:7:IL::CI=:68IJ6G>6AAN9:I:GB>C:9EGD?:8I:97:C:;>ID7A><6I>DC6C9I=:K6AJ:D;
I=:EA6C6HH:IHA:HH688GJ:9E:CH>DC8DHIH6HD;:8:B7:G  
(4;42C8>=>5G?42C43'0C4>5'4CDA=>=BB4CB
DGI=:N:6GH:C9:9:8:B7:G  6C9 I=:DBE6CNJH:96C:ME:8I:9ADC< I:GBG6I:D;G:IJGC6HHJBEI>DCD;
 ;DG>IH. , 9:;>C:97:C:;>IE:CH>DCEA6C -=:DBE6CN>CI:C9HIDJH:6C:ME:8I:9ADC< I:GBG6I:D;G:IJGC6HHJBEI>DCD;
 ;DG;DG>IH. , EA6C -=>H:ME:8I:9G6I:D;G:IJGCG:;A:8IHI=:6HH:I6AAD86I>DCD;I=:EA6C 6C9>H76H:9EG>B6G>ANDC
7GD69 EJ7A>8AN IG69:9:FJ>IN6C9;>M:9 >C8DB:>C9>8:H6C9;DGL6G9 ADD@>C<:HI>B6I:HD;68I>K:EDGI;DA>D6C9>CK:HIB:CI
B6C6<:B:CI %DC< I:GBG6I:D;G:IJGCDC6HH:I6HHJBEI>DCH;DGI=:CDC . , EA6CHL:G:9:I:GB>C:9DC6EA6C 7N EA6C76H>H
76H:9DCI=:8DBEDH>I>DCD;6HH:IH6C9G6C<:9;GDB ID >C6C9 ID >C L>I=6L:><=I:96K:G6<:
G6I:D;G:IJGC6HHJBEI>DCD; >C6C9 >C 
%;0=BB4CB
-=:. , EA6CWH<D6A>HIDB6>CI6>C7:IL::C6C9D;>IH6HH:IH>C:FJ>INEDGI;DA>DH L=>8=6G:>CK:HI:9>C>C9>K>9J6A
:FJ>INH:8JG>I>:HDG;JC9HI=6I6G::ME:8I:9IDB>GGDG7GD69B6G@:IG:IJGCH;DG:FJ>INH:8JG>I>:HDG>C6HH:IHL>I=8=6G68I:G>HI>8H
H>B>A6GID:FJ>IN>CK:HIB:CIH HJ8=6HK:CIJG:86E>I6A;JC9H6C9E6GIC:GH=>EH HH:I=DA9>C<H6G:E:G>D9>86AANG:76A6C8:9L=:C
:FJ>IN=DA9>C<H6G:DJIH>9:I=>HG6C<: -=:76A6C8:D;I=:. , EA6C6HH:IEDGI;DA>D>H>CK:HI:9>C7DC9;JC9H G:6A:HI6I:;JC9H 
K6G>DJH67HDAJI:6C9G:6AG:IJGC;JC9H6C9EG>K6I::FJ>IN;JC9H 'DC . , EA6C6HH:IH6G:>CK:HI:9>CK6G>DJH>CHJG6C8:
8DCIG68IH :FJ>IN6C99:7IH:8JG>I>:H6H9:I:GB>C:97NI=:69B>C>HIG6IDGD;:68=EA6C -=:K6AJ:D;I=:EA6C6HH:IH9>G:8IAN
6;;:8IHI=:;JC9:9HI6IJHD;I=:DBE6CNWHE:CH>DCEA6CHG:8DG9:9>CI=:DCHDA>96I:9>C6C8>6A,I6I:B:CIH
-=:DBE6CN=6HHDB:>CK:HIB:CIHI=6I6G:K6AJ:9JH>C<':IHH:I/6AJ:U'/V6HI=:EG68I>86A:ME:9>:CI "C699>I>DC 
HDB:D;I=:>CK:HIB:CIHK6AJ:9JH>C<'/6HI=:EG68I>86A:ME:9>:CI=6K:A>B>IHDCI=:>GG:9:BEI>DCIDBDCI=AN FJ6GI:GAN 
H:B>6CCJ6AANDG6CCJ6AAN6C9G:FJ>G:JEID96NHEG>DGLG>II:CCDI>8: -=:H:>CK:HIB:CIHK6AJ:9JH>C<'/8DCH>HID;
BJIJ6A;JC9H K:CIJG:86E>I6A;JC9H E6GIC:GH=>EH 6C9DI=:GEG>K6I:>CK:HIB:CIH L=>8=6AADLI=:DBE6CNID6AAD86I:
>CK:HIB:CIH68GDHH67GD696GG6ND;INE:HD;;JC9H6C99>K:GH>;NI=:EDGI;DA>D 


-- 119 of 162 --

-=:;6>GK6AJ:HD;I=:DBE6CNWHE:CH>DCEA6C6HH:IH;DG7DI=I=:. , 6C9CDC . , EA6CH6HD;:8:B7:G  7N6HH:I
86I:<DGNL:G:6H;DAADLH>CB>AA>DCH
&D>C43%A824B8=
2C8E4"0A:4C
!4E4; 
(86=85820=C$C74A
$1B4AE01;4=?DCB
!4E4; 
(86=85820=C
*=>1B4AE01;4
=?DCB!4E4; 	)>C0;
6H=6C9:FJ>K6A:CIH 	 	 	 	T 	 	T 	 	
FJ>INH:8JG>I>:H
DBBDCHID8@ 	 	 	 	T 	 	T 	 	
)G:;:GG:9HID8@ 	 	 	 	T 	 	T 	 	
>M:9>C8DB:H:8JG>I>:H
DGEDG6I:7DC9H 	 	T 	 	 	 	T 	 	
DK:GCB:CI>HHJ:9 	 	T 	 	 	 	T 	 	
&JIJ6A;JC9H 	 	 	 	 	 	T 	 	
"CHJG6C8:8DCIG68IH 	 	T 	 	 	 	T 	 	
-DI6A 	 	 	 	 	 	T 	 	 
"CK:HIB:CIHB:6HJG:96I'/6

DBBDC 8DAA:8I>K:IGJHIH 	 	 
/:CIJG:86E>I6A E6GIC:GH=>EH6C9DI=:GEG>K6I:
>CK:HIB:CIH 	 	
-DI6A6HH:IH6I;6>GK6AJ: 	 	 
6 -=:;6>GK6AJ:6BDJCIHEG:H:CI:9>CI=:I67A:67DK:6G:>CI:C9:9IDE:GB>IG:8DC8>A>6I>DCD;I=:;6>GK6AJ:=>:G6G8=NIDI=:IDI6AEA6C6HH:IH
-=:;6>GK6AJ:HD;I=:DBE6CNWHE:CH>DCEA6C6HH:IH;DG7DI=I=:. , 6C9CDC . , EA6CH6HD;:8:B7:G  7N6HH:I
86I:<DGNL:G:6H;DAADLH>CB>AA>DCH
&D>C43%A824B8=
2C8E4"0A:4C
!4E4; 
(86=85820=C$C74A
$1B4AE01;4=?DCB
!4E4; 
(86=85820=C
*=>1B4AE01;4
=?DCB!4E4; 	)>C0;
6H=6C9:FJ>K6A:CIH 	 	 	 	T 	 	T 	 	
FJ>INH:8JG>I>:H
DBBDCHID8@ 	 	 	 	T 	 	T 	 	
)G:;:GG:9HID8@ 	 	 	 	T 	 	T 	 	
>M:9>C8DB:H:8JG>I>:H
DGEDG6I:7DC9H 	 	T 	 	 	 	T 	 	
DK:GCB:CI>HHJ:9 	 	T 	 	 	 	T 	 	
&JIJ6A;JC9H 	 	 	 	 	 	T 	 	
"CHJG6C8:8DCIG68IH 	 	T 	 	 	 	T 	 	
-DI6A 	 	 	 	 	 	T 	 	 
"CK:HIB:CIHB:6HJG:96I'/6

DBBDC 8DAA:8I>K:IGJHIH 	 	 
/:CIJG:86E>I6A E6GIC:GH=>EH6C9DI=:GEG>K6I:
>CK:HIB:CIH 	 	
-DI6A6HH:IH6I;6>GK6AJ: 	 	 
6 -=:;6>GK6AJ:6BDJCIHEG:H:CI:9>CI=:I67A:67DK:6G:>CI:C9:9IDE:GB>IG:8DC8>A>6I>DCD;I=:;6>GK6AJ:=>:G6G8=NIDI=:IDI6AEA6C6HH:IH
)G:;:GG:9HID8@6C98DBBDCHID8@IG69:9DC6C68I>K:B6G@:I 6HL:AA6HBJIJ6A;JC9H6G:K6AJ:96II=:FJDI:98ADH>C<EG>8:
G:EDGI:9DCI=:68I>K:B6G@:IDCL=>8=I=:>C9>K>9J6AH:8JG>I>:H6G:IG69:9 )G:;:GG:9HID8@ 8DBBDCHID8@ 8DGEDG6I:7DC9H 
. , <DK:GCB:CIH:8JG>I>:H6C9BJIJ6A;JC9HI=6I6G:CDIIG69:9DC6C68I>K:B6G@:I6G:K6AJ:96IFJDI:9EG>8:HG:EDGI:97N
>CK:HIB:CI7GD@:GH6C99:6A:GH76H:9DCI=:JC9:GAN>C<I:GBHD;I=:H:8JG>IN6C98DBE6G>HDCIDH>B>A6GH:8JG>I>:HIG69:9DC6C
68I>K:B6G@:I "CHJG6C8:8DCIG68IH6G:K6AJ:976H:9JEDCI=:FJDI:9EG>8:HD;I=:JC9:GAN>C<>CK:HIB:CIHL>I=I=:>CHJG6C8:
8DBE6CN


-- 120 of 162 --

DBBDC 8DAA:8I>K:IGJHIH6G:K6AJ:976H:9DCI=:EA6CWH>CI:G:HI G:EG:H:CI:97N>CK:HIB:CIJC>IH >CI=:JC9:GAN>C<
>CK:HIB:CIH=:A9L>I=>CI=:IGJHII=6I6G:IG69:9>C6C68I>K:B6G@:I7NI=:IGJHI:: 
/:CIJG:86E>I6A E6GIC:GH=>EH6C9DI=:GEG>K6I:>CK:HIB:CIH6G:K6AJ:9JH>C<I=:'/76H:9DCI=:>C;DGB6I>DCEGDK>9:97NI=:
6HH:I;JC9B6C6<:GH L=>8=G:;A:8IHI=:EA6CWHH=6G:D;I=:;6>GK6AJ:D;I=:C:I6HH:IHD;I=:>CK:HIB:CI :E:C9>C<DCI=:
C6IJG:D;I=:6HH:IH I=:JC9:GAN>C<>CK:HIB:CIH6G:K6AJ:9JH>C<68DB7>C6I>DCD;:>I=:G9>H8DJCI:986H=;ADLH :6GC>C<H6C9
B6G@:IBJAI>EA:H I=>G9 E6GIN6EEG6>H6AHDGI=GDJ<=G:;:G:C8:IDI=:FJDI:9B6G@:IEG>8:HD;I=:JC9:GAN>C<>CK:HIB:CIH=:A97N
I=:K:CIJG: E6GIC:GH=>EDGEG>K6I::CI>INL=:G:6K6>A67A: /6AJ6I>DC69?JHIB:CIHG:;A:8I8=6C<:H>CDE:G6I>C<G:HJAIH ;>C6C8>6A
8DC9>I>DC DGEGDHE:8IHD;I=:6EEA>867A:EDGI;DA>D8DBE6CN
-=:B:I=D9H9:H8G>7:967DK:B6NEGD9J8:6;6>GK6AJ::HI>B6I:I=6IB6NCDI7:>C9>86I>K:D;C:IG:6A>O67A:K6AJ:DGG:;A:8I>K:
D;;JIJG:;6>GK6AJ:H JGI=:GBDG: L=>A:I=:DBE6CN7:A>:K:HI=:K6AJ6I>DCB:I=D9H6G:6EEGDEG>6I:6C98DCH>HI:CIL>I=I=:
B:I=D9HJH:97NDI=:GB6G@:IE6GI>8>E6CIH I=:JH:D;9>;;:G:CIB:I=D9DAD<>:HDG6HHJBEI>DCHID9:I:GB>C:I=:;6>GK6AJ:D;
8:GI6>C;>C6C8>6A>CHIGJB:CIH8DJA9G:HJAI>C69>;;:G:CI;6>GK6AJ:B:6HJG:B:CI6II=:G:EDGI>C<96I:
G?42C43>=CA81DC8>=B
JG>C< I=:DBE6CN8DCIG>7JI:9B>AA>DCID>IH. , 9:;>C:97:C:;>IE:CH>DCEA6C6C9B>AA>DCID>IHCDC . , 
9:;>C:97:C:;>IE:CH>DCEA6CH JG>C< I=:DBE6CNWH86H=8DCIG>7JI>DCG:FJ>G:B:CIH;DG>IH. , 6C9>IHCDC . , 
9:;>C:97:C:;>IE:CH>DCEA6CH6G::ME:8I:9ID7:6EEGDM>B6I:ANB>AA>DC6C9B>AA>DC G:HE:8I>K:AN
-=:;DAADL>C<H:IH;DGI=7:C:;>IE6NB:CIH L=>8=G:;A:8I:ME:8I:9;JIJG:H:GK>8: 6H6EEGDEG>6I: :ME:8I:9ID7:E6>97NI=:
EA6CH>CI=:E:G>D9H>C9>86I:9>CB>AA>DCH
* ( %4=B8>=
%;0=B #>=* ( 
%4=B8>=%;0=B 	;;%4=B8>=%;0=B
 	 	 	 	 	 	
 	 	 	 	 	 	
 	 	 	 	 	 	
 	 	 	 	 	 	
 	 	 	 	 	 	
  	 	 	 	 	 	 
$C74A"0CC4AB
,J7HI6CI>6AAN6AA:BEADN::HCDI8DK:G:97N9:;>C:97:C:;>IEA6CH6G:8DK:G:97N9:;>C:98DCIG>7JI>DCEA6CH L=>8=<:C:G6AAN
EGDK>9:;DGDBE6CN;JC9>C<76H:9DC6E:G8:CI6<:D;8DBE:CH6I>DC
A>B>I:9CJB7:GD;I=:DBE6CNWHHJ7H>9>6G>:HE6GI>8>E6I:>CBJAI>:BEADN:G9:;>C:97:C:;>I6C98DCIG>7JI>DCEA6CH EG>B6G>AN
DJIH>9:D;I=:.C>I:9,I6I:H I=6IG:FJ>G:I=:DBE6CNIDE:G>D9>86AAN8DCIG>7JI:;JC9HIDI=:EA6C -=:G>H@HD;E6GI>8>E6I>C<>C
6BJAI>:BEADN:GEA6C9>;;:G;GDBI=:G>H@HD;E6GI>8>E6I>C<>C6H>C<A: :BEADN:GEA6C>CI=:;DAADL>C<G:HE:8IH6HH:IH
8DCIG>7JI:9IDI=:BJAI>:BEADN:GEA6C7NDC::BEADN:GB6N7:JH:9IDEGDK>9:7:C:;>IHID:BEADN::HD;DI=:GE6GI>8>E6I>C<
:BEADN:GH >;6E6GI>8>E6I>C<:BEADN:G8:6H:H8DCIG>7JI>C<IDI=:EA6C I=:JC;JC9:9D7A><6I>DCHD;I=:EA6CB6N7:G:FJ>G:9
ID7:7DGC:7NI=:G:B6>C>C<E6GI>8>E6I>C<:BEADN:GH6C9>;I=:DBE6CN:A:8IHIDHIDEE6GI>8>E6I>C<>CI=:EA6C I=:
DBE6CNB6N7:G:FJ>G:9IDE6NI=:EA6C6C6BDJCI76H:9DCI=:JC;JC9:9HI6IJHD;I=:EA6C 'DC:D;I=:BJAI>:BEADN:G
EA6CH>CL=>8=I=:DBE6CNWHHJ7H>9>6G>:HE6GI>8>E6I:6G:8DCH>9:G:9ID7:FJ6CI>I6I>K:ANDGFJ6A>I6I>K:ANH><C>;>86CI :>I=:G
>C9>K>9J6AANDG>CI=:6<<G:<6I: "C699>I>DC 8DCIG>7JI>DCHB69:IDI=:H:EA6CH9JG>C< 6C9L:G:CDI
8DCH>9:G:9H><C>;>86CI :>I=:G>C9>K>9J6AANDG>CI=:6<<G:<6I:
-=:DBE6CNWHC:IE:G>D9>8E:CH>DC8DHI;DGI=:N:6G:C9:9:8:B7:G >C8AJ9:H6H:IIA:B:CIADHHD;B>AA>DC
B>AA>DC6;I:GI6MDG E:G9>AJI:98DBBDCH=6G:6H6G:HJAID;I=:IG6CH;:GD;6EDGI>DCD;>IHCDC . , E:CH>DCA>67>A>I>:H
G:A6I:9IDDC:9:;>C:97:C:;>IEA6CID6I=>G9E6GIN ME:CH:;DG6AA9:;>C:97:C:;>I6C99:;>C:98DCIG>7JI>DCE:CH>DCEA6CH
6BDJCI:9IDB>AA>DC B>AA>DC6C9B>AA>DC;DGI=:N:6GH:C9:9:8:B7:G  6C9 G:HE:8I>K:AN
#$)  $)'%$()')'"#)"%!$.#)%!#(
"C699>I>DCIDEGDK>9>C<E:CH>DC7:C:;>IH I=:DBE6CNEGDK>9:H8:GI6>C=:6AI=86G:6C9A>;:>CHJG6C8:7:C:;>IH;DGHDB:D;>IH
G:I>G:9:BEADN::H>CI=:.C>I:9,I6I:H :GI6>C:BEADN::HB6N7:8DB::A><>7A:;DGI=:H:7:C:;>IH6HI=:NG:68=CDGB6A
G:I>G:B:CI6<:L=>A:LDG@>C<;DGI=:DBE6CN


-- 121 of 162 --

-=:;DAADL>C<H:IH;DGI=I=:;JC9:9HI6IJHD;I=:9DB:HI>8EA6CH6HD;I=:BDHIG:8:CI68IJ6G>6AK6AJ6I>DCHJH>C<B:6HJG:B:CI
96I:H6HD;:8:B7:G>CB>AA>DCH
 	
=6C<:>C7:C:;>ID7A><6I>DC
:C:;>ID7A><6I>DC6I7:<>CC>C<D;N:6G 	 	  	
,:GK>8:8DHI 	 	T 	 	T
"CI:G:HI8DHI 	 	  	
8IJ6G>6A<6>CADHH 	 	  	
+:I>G::8DCIG>7JI>DCH 	 	  	
:C:;>IHE6>9 	 	 	 	
:C:;>ID7A><6I>DC6I:C9D;N:6G 	 	  	
=6C<:>CEA6C6HH:IH
6>GK6AJ:D;EA6C6HH:IH 	 	T 	 	T
JC9:9HI6IJH 	 	  	
HD;:8:B7:G 6C9 B>AA>DC6C9B>AA>DC G:HE:8I>K:AN D;I=:IDI6AJC9:G;JC9:9HI6IJHD;I=:EA6CL6H
G:8D<C>O:96HADC< I:GB688GJ:9EDHIG:I>G:B:CIA>67>A>INH>C8:>IL6HCDI:ME:8I:9ID7:;JC9:9L>I=>CDC:N:6G -=:A6G<:HI
8DCIG>7JIDGIDI=:C:I68IJ6G>6AADHH:H6;;:8I>C<I=:7:C:;>ID7A><6I>DC>C7DI=6C9;DGI=:EA6C>H9J:ID9:8G:6H:H>C
I=:9>H8DJCIG6I:H 
HD;:8:B7:G 6C9 I=:EGD?:8I:97:C:;>ID7A><6I>DCD;I=:EA6C:M8::9:9I=:;6>GK6AJ:D;I=:EA6C6HH:IH 6HI=:
EA6C=69CDEA6C6HH:IH 6C9I=:688JBJA6I:96C9EGD?:8I:97:C:;>ID7A><6I>DCL6HB>AA>DC6C9B>AA>DC G:HE:8I>K:AN
,4867C430E4A0640BBD<?C8>=BDB43C>34C4A<8=414=458C>1;860C8>=B0C30C4>5<40BDA4<4=C

>H8DJCIG6I: 	  	 
&:9>86AIG:C9G6I:S>C>I>6A 	  	 
&:9>86AIG:C9G6I:S<G69>C<E:G>D9 	N:6GH 	N:6GH
&:9>86AIG:C9G6I:SJAI>B6I: 	  	 
-=:B:9>86AIG:C9G6I:JH:9ID9:I:GB>C:I=:EDHIG:I>G:B:CI7:C:;>ID7A><6I>DCL6H ;DG -=:G6I:9:8G:6H:H<G69J6AAN
ID6CJAI>B6I:G6I:D; >C6C9G:B6>CH6II=6IA:K:AI=:G:6;I:G -=:IG:C9G6I:>H6H><C>;>86CI;68IDG>C9:I:GB>C>C<I=:
6BDJCIHG:EDGI:9
><?>=4=CB>5=4C?4A8>38214=458C2>BC8=<8;;8>=B

,:GK>8:8DHI 	 	T 	 	T
"CI:G:HI8DHI 	 	  	
BDGI>O6I>DCD;EG>DGH:GK>8:8G:9>I 	 	 	 	
BDGI>O6I>DCD;C:IADHH 	 	  	T
':IE:G>D9>87:C:;>I8DHI 	 	  	


-- 122 of 162 --

-=:C:IE:G>D9>88DHID;I=:DI=:GEDHIG:I>G:B:CI:BEADN::7:C:;>IEA6CH>C8JGG:99JG>C<I=:N:6GH:C9:9:8:B7:G  
6C96G:G:;A:8I:9>CI=:;DAADL>C<86EI>DCH>CI=:688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;6GC>C<H>CB>AA>DCH
.40A=343424<14A
 	
,:GK>8:8DHI
DHID;H6A:H 	 	T 	 	T 	 	T
,:AA>C< <:C:G6A6C969B>C>HIG6I>K::ME:CH:H 	 	T 	 	T 	 	
-DI6AH:GK>8:8DHI 	 	T 	 	T 	 	
(I=:GC:IE:G>D9>8E:CH>DC8DHIH
(I=:G>C8DB::ME:CH: C:I 	 	  	  	
-DI6A 	 	  	  	
"C8AJ9:9>C688JBJA6I:9DI=:G8DBEG:=:CH>K:>C8DB:ADHH6HD;:8:B7:G 6G:I=:;DAADL>C<6BDJCIHI=6I=6K:CDI
N:I7::CG:8D<C>O:9>CC:IE:G>D9>87:C:;>I8DHIJCG:8D<C>O:9EG>DGH:GK>8:8G:9>IHD;B>AA>DCB>AA>DC C:ID;I6M6C9
JCG:8D<C>O:968IJ6G>6AADHH:HD;B>AA>DCB>AA>DC C:ID;I6M -=:JCG:8D<C>O:9ADHH:H6C9EG>DGH:GK>8:8G:9>IH C:I >H
86A8JA6I:96HI=:9>;;:G:C8:7:IL::CI=:68IJ6G>6AAN9:I:GB>C:9EGD?:8I:97:C:;>ID7A><6I>DC6C9I=:K6AJ:D;I=:EA6C6HH:IHA:HH
688GJ:97:C:;>I8DHIH6HD;:8:B7:G  
-=:;DAADL>C<H:IH;DGI=7:C:;>IE6NB:CIH L=>8=G:;A:8I:ME:8I:9;JIJG:H:GK>8: 6H6EEGDEG>6I: :ME:8I:9ID7:E6>9>CI=:
E:G>D9H>C9>86I:9>CB>AA>DCH
 	 	
 	 	
 	 	
 	 	
 	 	
  	 	
#$)  #$")-(
6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH7:;DG:>C8DB:I6M:H;DGI=:N:6GH:C9:9:8:B7:GL:G:6H;DAADLH>CB>AA>DCH
 	
.C>I:9,I6I:H 	 	  	 	 	 	
"CI:GC6I>DC6A 	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	 
-=:EGDK>H>DC;DG>C8DB:I6M:H;GDB8DCI>CJ>C<DE:G6I>DCH;DGI=:N:6GH:C9:9:8:B7:GL:G:6H;DAADLH>CB>AA>DCH
 	
JGG:CI
:9:G6A. , 	 	  	 	 	
'DC . , 	 	 	 	 	 	
,I6I:6C9AD86A 	 	 	 	 	 	
:;:GG:9
:9:G6A. , 	 	 	 	  	
'DC . , 	 	  	  	
,I6I:6C9AD86A 	 	 	 	 	 	
"C8DB:I6MEGDK>H>DC 	 	 	 	 	 	


-- 123 of 162 --

'DC8JGG:CI9:;:GG:9I6M6HH:IH6C9CDC8JGG:CI9:;:GG:9I6MA>67>A>I>:H6G:>C8AJ9:9>CDI=:G6HH:IH6C9DI=:GADC< I:GBA>67>A>I>:H 
G:HE:8I>K:AN >CI=:688DBE6CN>C<DCHDA>96I:96A6C8:,=::IH :;:GG:9>C8DB:I6M6HH:IH6C9A>67>A>I>:H6HD;:8:B7:G
L:G:6H;DAADLH>CB>AA>DCH

:;:GG:9I6M6HH:IH
AADL6C8:;DG9DJ7I;JA688DJCIH 	 	 	 	
"CK:CIDG>:H 	 	 	 	
):CH>DC6C9EDHIG:I>G:B:CI7:C:;>IH 	 	 	 	
CK>GDCB:CI6A6C9G:<JA6IDGN8DBEA>6C8: 	 	 	 	
(I=:G688GJ6AH6C9EG:E6NB:CIH 	 	 	 	
,ID8@ 76H:98DBE:CH6I>DC:ME:CH: 	 	 	 	
(E:G6I>C<A:6H:A>67>A>I>:H 	 	 	 	
-6M8G:9>I6C9ADHH86GGN;DGL6G9H 	 	 	 	
/6AJ6I>DC6AADL6C8:H 	 	  	
-DI6A9:;:GG:9I6M6HH:I 	 	  	 	 
:;:GG:9I6MA>67>A>I>:H
)GDE:GIN EA6CI6C9:FJ>EB:CI 	 	  	
"CHJG6C8: >C8AJ9>C<H:A; >CHJG6C8: 	 	  	
6H>H9>;;:G:C8:>C%2('H 	 	  	
(E:G6I>C<A:6H:+(.6HH:IH 	 	  	
DD9L>AA6C9DI=:G>CI6C<>7A:H 	 	   	 
-DI6A9:;:GG:9I6MA>67>A>IN 	 	   	 
':I9:;:GG:9I6MA>67>A>IN 	 	   	 
-=:DBE6CN:K6AJ6I:HI=:;JIJG:G:6A>O67>A>IND;I6M8G:9>IH6C9ADHH86GGN;DGL6G9H8DCH>9:G>C<I=:6CI>8>E6I:9;JIJG::6GC>C<H
D;I=:DBE6CNWHHJ7H>9>6G>:H6HL:AA6HI6MEA6CC>C<HIG6I:<>:H>CI=:6HHD8>6I:9?JG>H9>8I>DCH :;:GG:9I6M:H6HHD8>6I:9L>I=
. , :CI>I>:H8DCH>HID;C:I9:;:GG:9I6MA>67>A>I>:HD;6EEGDM>B6I:AN 7>AA>DC6C9 7>AA>DC6HD;:8:B7:G 6C9
 G:HE:8I>K:AN :;:GG:9I6M:H6HHD8>6I:9L>I=CDC . , :CI>I>:H8DCH>HID;C:I9:;:GG:9I6MA>67>A>I>:HD; 7>AA>DC6C9
B>AA>DC6HD;:8:B7:G 6C9 G:HE:8I>K:AN -=:H><C>;>86CI>C8G:6H:IDC:I9:;:GG:9I6MA>67>A>I>:H>C>H
EG>B6G>AN9J:IDI=:NI>K68FJ>H>I>DC JG>C< I=:DBE6CNWHK6AJ6I>DC6AADL6C8:>C8G:6H:97NB>AA>DCEG>B6G>AN
9J:ID8:GI6>CI6M7:C:;>IHG:8D<C>O:9>CI=6I6G:CDI:ME:8I:9ID7:G:6A>O:9 E6GI>6AAND;;H:I7NG:A:6H:D;6K6AJ6I>DC
6AADL6C8:>C68:GI6>C;DG:><C?JG>H9>8I>DC HD;:8:B7:G  I=:IDI6A6BDJCID;I=:76H>H9>;;:G:C8:>C>CK:HIB:CIH
>C9:;>C>I:ANG:>CK:HI:9DJIH>9:I=:.C>I:9,I6I:H;DGL=>8=9:;:GG:9I6M:H=6K:CDI7::CEGDK>9:9>H6EEGDM>B6I:AN 
7>AA>DC -=:>C8DB:I6M:H6EEA>867A:IDG:E6IG>6I>C<HJ8=:6GC>C<H6G:CDIG:69>AN9:I:GB>C67A: HD;:8:B7:G  I=:
DBE6CN=69CDEA6CHL=>8=LDJA9HJ7?:8II=:H:76H>H9>;;:G:C8:HID>C8DB:I6M:H>CI=:.C>I:9,I6I:HDG:AH:L=:G:
(C:8:B7:G  I=:-#L6H:C68I:9 HJ7HI6CI>6AAN8=6C<>C<I=:. , I6MHNHI:B .C9:GI=:,,I6;;88DJCI>C<
JAA:I>C'D U,'D V<J>96C8: ;DGI=:N:6G:C9:9:8:B7:G  I=:DBE6CNG:8DG9:9EGDK>H>DC6A
6BDJCIH>C:6GC>C<H;DGI=::;;:8IHD;I=::C68IB:CID;I=:-#6C99JG>C< I=:DBE6CN8DBEA:I:9>IH688DJCI>C<;DG
I=:-#76H:9DCI=:DBE6CNWH>CI:GEG:I6I>DCD;I=:C:LI6MG:<JA6I>DCH6C9G:A6I:9<J>96C8:>HHJ:97NI=:. , :E6GIB:CI
D;I=:-G:6HJGN6C9I=:"CI:GC6A+:K:CJ:,:GK>8:U"+,V
-=:-#>BEDH:HI6MDC. , H=6G:=DA9:GH;DG<AD76A>CI6C<>7A:ADL I6M:9>C8DB:U "%-"V:6GC:97N8:GI6>C;DG:><C
HJ7H>9>6G>:H -=:DBE6CN=6H:A:8I:9I=:E:G>D98DHIB:I=D9;DG>IH688DJCI>C<;DG "%-"


-- 124 of 162 --

-=::;;:8I>K:>C8DB:I6MG6I:;GDB8DCI>CJ>C<DE:G6I>DCH;DGI=:N:6GH:C9:9:8:B7:GK6G>:H;GDBI=:. , HI6IJIDGN
;:9:G6A>C8DB:I6MG6I:6H;DAADLH
 	%4A24=C064>5%A4C0G0A=8=6B
 	 	
,I6IJIDGN;:9:G6A>C8DB:I6MG6I: 	  	  	 
"C8G:6H:9:8G:6H:>CI6MG6I:G:HJAI>C<;GDB
,I6I:>C8DB:I6M:HC:ID;;:9:G6A>C8DB:I6M7:C:;>I 	  	  	 
DG:><CG6I:9>;;:G:CI>6A 	  	  	 
+:HDAJI>DC6C9:ME>G6I>DCD;HI6IJI:HD;A>B>I6I>DCD;JC8:GI6>CI6MEDH>I>DCH 	  	  	 
+:H:6G8=8G:9>IH JC8:GI6>CI6MEDH>I>DCH6C9DI=:G 	  	  	 
M8:HHI6M7:C:;>IH;GDBHID8@ 76H:98DBE:CH6I>DC 	  	  	 
-# G:K6AJ6I>DCD;. , 9:;:GG:9>C8DB:I6M:H 	T 	T 	 
-# -G6CH>I>DC-6M 	T 	T 	 
;;:8I>K:>C8DB:I6MG6I: 	  	  	 
-=:DBE6CNWH:;;:8I>K:I6MG6I:;DG 6C99>;;:GH;GDBI=:. , ;:9:G6AHI6IJIDGNG6I:D;  9J:IDI=:
DBE6CNWH:6GC>C<HDJIH>9:I=:.C>I:9,I6I:HI=6I6G:>C9:;>C>I:ANG:>CK:HI:96C9I6M:96IG6I:H9>;;:G:CII=6CI=:. , ;:9:G6A
HI6IJIDGNG6I:6HL:AA6HI=:>BE68ID;I=:;DAADL>C<
Q 	-=::;;:8I>K:I6MG6I:D; >C>C8AJ9:HC:II6M7:C:;>IHEG>B6G>ANG:A6I:9IDI=:G:A:6H:D;G:H:GK:H;DG
JC8:GI6>CI6MEDH>I>DCH;GDB6J9>IH:IIA:B:CIH6C9:ME>G6I>DCD;HI6IJI:HD;A>B>I6I>DC6C9:M8:HHI6M7:C:;>IH;GDB
HID8@ 76H:98DBE:CH6I>DC E6GI>6AAND;;H:I7N6=><=:GI6MG6I:6HHD8>6I:9L>I=I=:<6>CDCI=:9>K:HI>IJG:D;8:GI6>C
EGD9J8IA>C:H>CI=:%>;:,8>:C8:HH:<B:CI6C98=6C<:H>C:HI>B6I:H6HHD8>6I:9L>I=EG>DGE:G>D9JC8:GI6>CI6M
EDH>I>DCH -=:H:>I:BH9:8G:6H:9I=:G:EDGI:9G6I:DC6C:I76H>H7N 
Q 	-=::;;:8I>K:I6MG6I:D; >C>C8AJ9:H76H>HED>CIHD;C:II6M8=6G<:HG:A6I:9EG>B6G>ANID8=6C<:H>C
:HI>B6I:H6HHD8>6I:9L>I=EG>DGE:G>D9JC8:GI6>CI6MEDH>I>DCH 6J9>IH:IIA:B:CIH 6C9CK>HI6>HEDH>I>DC8DHIH C:ID;
I=:G:A:6H:D;G:H:GK:H;DGJC8:GI6>CI6MEDH>I>DCH9J:IDI=::ME>G6I>DCD;HI6IJI:HD;A>B>I6I>DC G:A:6H:D;K6AJ6I>DC
6AADL6C8:H6HHD8>6I:9L>I=8:GI6>C;DG:><CI6M8G:9>IH I6M7:C:;>IHG:HJAI>C<;GDB8=6C<:H>CI6MA6L6C9:M8:HHI6M
7:C:;>IH;GDBHID8@ 76H:98DBE:CH6I>DC
Q 	-=::;;:8I>K:I6MG6I:D; >C>C8AJ9:H76H>HED>CIHD;I6M7:C:;>IHEG>B6G>ANG:A6I:9IDI=:G:A:6H:D;
G:H:GK:HJEDCI=::ME>G6I>DCD;HI6IJI:HD;A>B>I6I>DC 6J9>IH:IIA:B:CIH6C9G:A:6H:D;6K6AJ6I>DC6AADL6C8:>C68:GI6>C
;DG:><CI6M?JG>H9>8I>DC -=:H:I6M7:C:;>IHL:G:E6GI>6AAND;;H:I7N699>I>DC6AEGDK>H>DCHG:A6I:9ID8DBEA:I>C<I=:
688DJCI>C<;DGI=::C68IB:CID;I=:-#6C9I6M8DHIH9>G:8IANG:A6I:9IDG:DG<6C>O6I>DC68I>K>I>:H6HHD8>6I:9L>I=I=:
CK>HI6>HEDH>I>DC 
-=:DBE6CNB69:>C8DB:I6ME6NB:CIHG:A6I:9ID7DI=8DCI>CJ>C<6C99>H8DCI>CJ:9DE:G6I>DCHD;6EEGDM>B6I:AN 7>AA>DC 
B>AA>DC6C9B>AA>DC>C 6C9 G:HE:8I>K:AN JGG:CI>C8DB:I6M:HE6N67A:G:A6I:9ID7DI=8DCI>CJ>C<
6C99>H8DCI>CJ:9DE:G6I>DCH=6H7::CG:9J8:97NB>AA>DC B>AA>DC6C9B>AA>DC>C 6C9 
G:HE:8I>K:AN ;DGI6M9:9J8I>DCH6IIG>7JI67A:IDHID8@ 76H:98DBE:CH6I>DC D;L=>8= I=::M8:HHI6M7:C:;>IDK:GI=:6BDJCI
G:8DG9:9;DG;>C6C8>6AG:EDGI>C<EJGEDH:H;DG7DI=8DCI>CJ>C<6C99>H8DCI>CJ:9DE:G6I>DCHL6HB>AA>DC B>AA>DC6C9
B>AA>DC G:HE:8I>K:AN -=::M8:HHI6M7:C:;>IH=6K:7::CG:8DG9:96HG:9J8I>DCHIDI=:8JGG:CI>C8DB:I6MEGDK>H>DC6C96G:
G:;A:8I:96HDE:G6I>C<86H=>C;ADLH>CI=:688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;6H=ADLH -6M:HG:8:>K67A:;DG>C8DB:
6C9DI=:GI6M:H6G:8A6HH>;>:96HEG:E6>9:ME:CH:H6C9DI=:G8JGG:CI6HH:IH>CI=:DCHDA>96I:96A6C8:,=::IH HD;
:8:B7:G 6C9I=:H:76A6C8:HL:G:B>AA>DC6C9B>AA>DC G:HE:8I>K:AN
"C8AJ9:9>C9:;:GG:9>C8DB:I6M:H6HD;:8:B7:G 6G:I6M7:C:;>IH;DG. , 6C9CDC . , C:IDE:G6I>C<ADHH
86GGN;DGL6G9HIDI6A>C<B>AA>DCB>AA>DCD;L=>8=I=:DBE6CN9D:HCDI:ME:8IIDG:6A>O:6C9=6K:8DGG:HEDC9>C<
K6AJ6I>DC6AADL6C8:H :GI6>CD;I=:ADHH:H86C7:86GG>:9;DGL6G9>C9:;>C>I:AN6C9DI=:GH86C7:86GG>:9;DGL6G9IDK6G>DJH
96I:H;GDBI=GDJ<= "C699>I>DC I=:DBE6CN=69<:C:G6A7JH>C:HH6C9;DG:><CI6M8G:9>I86GGN;DGL6G9HD;
B>AA>DCB>AA>DCD;L=>8=I=:DBE6CN9D:HCDI:ME:8IIDG:6A>O:6C9=6K:8DGG:HEDC9>C<K6AJ6I>DC6AADL6C8:H6HD;
:8:B7:G  L=>8=86C7:86GG>:9;DGL6G9IDK6G>DJH96I:H;GDBID "C699>I>DC 6HD;:8:B7:G  
I=:DBE6CN=69B>AA>DCD;K6AJ6I>DC6AADL6C8:HG:A6I:9IDDI=:G9:;:GG:9I6M6HH:I76A6C8:HI=6I6G:CDIBDG:A>@:ANI=6C
CDID;7:>C<G:6A>O:9


-- 125 of 162 --

HD;:8:B7:G  <GDHHJCG:8D<C>O:9I6M7:C:;>IHIDI6A:96EEGDM>B6I:AN 7>AA>DC6EEGDM>B6I:AN 7>AA>DC C:ID;
I=:>BE68ID;B>AA>DCD;>C9>G:8II6M7:C:;>IHD;;H:I7NB>AA>DC6HHD8>6I:9L>I=EDI:CI>6A>CI:G:HI6C9E:C6AI>:H HD;
:8:B7:G  <GDHHJCG:8D<C>O:9I6M7:C:;>IHIDI6A:96EEGDM>B6I:AN 7>AA>DC6EEGDM>B6I:AN 7>AA>DC C:ID;I=:
>BE68ID;B>AA>DCD;>C9>G:8II6M7:C:;>IHD;;H:I7NB>AA>DC6HHD8>6I:9L>I=EDI:CI>6A>CI:G:HI6C9E:C6AI>:H -=:
DBE6CNG:8D<C>O:96EEGDM>B6I:ANB>AA>DC B>AA>DC6C9B>AA>DC>CEDI:CI>6A>CI:G:HI6C9E:C6AI>:HG:A6I:9ID7DI=
8DCI>CJ>C<6C99>H8DCI>CJ:9DE:G6I>DCH6HHD8>6I:9L>I=JC8:GI6>CI6MEDH>I>DCH9JG>C< 6C9 G:HE:8I>K:AN -D
I=::MI:CIJCG:8D<C>O:9I6M7:C:;>IH>C8AJ9>C<>CI:G:HI6C9E:C6AI>:H6G:G:8D<C>O:9L>I=G:HE:8IIDJC8:GI6>CI6MEDH>I>DCH 
6EEGDM>B6I:AN 7>AA>DC6C9 7>AA>DC6HD;:8:B7:G 6C9 G:HE:8I>K:AN LDJA9G:9J8:I=:I6M:ME:CH:6C9
:;;:8I>K:I6MG6I:>C;JIJG:E:G>D9H -=:DBE6CNG:8D<C>O:9>CI:G:HI6C9E:C6AI>:HG:A6I:9IDJCG:8D<C>O:9I6M7:C:;>IHL>I=>C
>C8DB:I6M:H>CI=:688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;6GC>C<H .CG:8D<C>O:9I6M7:C:;>IH6C96HHD8>6I:9688GJ:9
>CI:G:HI6C9E:C6AI>:H6G:>C8AJ9:9>CI6M:H >C8DB:6C9DI=:G688GJ:9:ME:CH:H6H9:I6>A:9>C'DI:
G:8DC8>A>6I>DCD;I=:7:<>CC>C<6C9:C9>C<6BDJCID;JCG:8D<C>O:9I6M7:C:;>IH :M8AJ9>C<6BDJCIH688GJ:9;DGEDI:CI>6A
>CI:G:HI6C9E:C6AI>:HG:A6I:9ID7DI=8DCI>CJ>C<6C99>H8DCI>CJ:9DE:G6I>DCH >H6H;DAADLH>CB>AA>DCH
 	
.CG:8D<C>O:9I6M7:C:;>IH 7:<>CC>C<D;N:6G 	 	  	 	 	 	
99>I>DCH76H:9DCI6MEDH>I>DCHG:A6I:9IDI=:8JGG:CIN:6G 	 	 	 	 	 	
99>I>DCH;DGI6MEDH>I>DCHD;EG>DGN:6GH 	 	 	 	 	 	
+:9J8I>DCH;DGI6MEDH>I>DCHD;EG>DGN:6GH 	 	  	  	
8FJ>H>I>DCH 9>K:HI>IJG:H6C9DI=:G 	 	  	 	 	
%6EH:D;HI6IJI:D;A>B>I6I>DCH 	 	  	  	
,:IIA:B:CIH 	 	  	  	
;;:8ID;;DG:><C8JGG:C8NIG6CHA6I>DC 	 	 	 	  	
.CG:8D<C>O:9I6M7:C:;>IH :C9D;N:6G 	 	  	 	  	 	
-=:DBE6CN8DC9J8IH7JH>C:HH<AD76AAN 6C9;>A:HCJB:GDJH8DCHDA>96I:96C9H:E6G6I:>C8DB:I6MG:IJGCH>CI=:. , ;:9:G6A 
HI6I:6C9;DG:><C?JG>H9>8I>DCH -=:CDC . , 8DJCIG>:H>CL=>8=I=:DBE6CN=6H6H><C>;>86CIEG:H:C8:>C8AJ9:=>C6 
:CB6G@  :GB6CN ,>C<6EDG: ,L:9:C ,L>IO:GA6C96C9I=:.C>I:9$>C<9DB M8AJ9>C<I=:H:?JG>H9>8I>DCH I=:DBE6CN
7:A>:K:HI=6I68=6C<:>CI=:HI6IJIDGNI6MG6I:D;6CN>C9>K>9J6A;DG:><C8DJCIGNLDJA9CDI=6K:6B6I:G>6A:;;:8IDCI=:
DBE6CNWHDCHDA>96I:9>C6C8>6A,I6I:B:CIH<>K:CI=:<:D<G6E=>89>HE:GH>DCD;I=:DBE6CNWHI6M67A:>C8DB:
-=:DBE6CN6C9>IHHJ7H>9>6G>:H6G:GDJI>C:AN:M6B>C:97NK6G>DJH9DB:HI>86C9>CI:GC6I>DC6AI6M>C<6JI=DG>I>:H -=:"+,=6H
8DBEA:I:9HJ7HI6CI>6AAN6AAD;I=::M6B>C6I>DCHD;I=:DBE6CNWH;:9:G6A>C8DB:I6MG:IJGCHI=GDJ<=6C9>H8JGG:CIAN
:M6B>C>C<8:GI6>CD;I=:DBE6CNWH;:9:G6A>C8DB:I6MG:IJGCH;DGI=GDJ<= "C699>I>DC I=:DBE6CN=6H
HJ7H>9>6G>:H>CJHIG>6 :A<>JB 6C696 =>C6 :CB6G@ G6C8:  :GB6CN "C9>6 #6E6C $DG:6 ,L>IO:GA6C9 I=:.C>I:9
$>C<9DB6C9K6G>DJHDI=:G8DJCIG>:H HI6I:H6C9EGDK>C8:HI=6I6G:8JGG:CIANJC9:G6J9>I;DGN:6GHG6C<>C<;GDBI=GDJ<=

"CI=:;DJGI=FJ6GI:GD;6C9I=:;>GHIFJ6GI:GD; I=:"+,EGDEDH:9H><C>;>86CI69?JHIB:CIHIDI=:DBE6CNWHI6M67A:
>C8DB:;DGI=:N:6GHI=GDJ<=L>I=G:HE:8IIDI=:9:;:GG6AD;I6MDC8:GI6>CEG:B>JB>C8DB:G:A6I:9IDI=:DBE6CNWH
H:A; >CHJG6C8:EGD<G6BH DG>C8DB:I6MEJGEDH:H I=:G:8D<C>I>DCD;EG:B>JB>C8DB:=6H7::C9:;:GG:9>C688DG96C8:L>I=
. , I6MA6LHG:A6I:9ID>CHJG6C8: -=:"+,8=6AA:C<:9I=:9:;:GG6AD;EG:B>JBH;DG8:GI6>CINE:HD;I=:DBE6CNWHH:A;
>CHJG6C8:EDA>8>:H -=:H:EGDEDH:969?JHIB:CIHLDJA9=6K:>C8G:6H:9I=:DBE6CNWHI6M67A:>C8DB:DK:GI=:I=GDJ<=
E:G>D97N6EEGDM>B6I:AN 7>AA>DC "CI=:I=>G9FJ6GI:GD; I=:DBE6CNH:IIA:9I=:I=GDJ<=6J9>I
E:G>D9L>I=I=:"+, >C8AJ9>C<I=:G:HDAJI>DCD;I=:H:EGDEDH:969?JHIB:CIH -=:H:IIA:B:CIL6HCDIB6I:G>6AIDI=:DBE6CNWH
;>C6C8>6AHI6I:B:CIH >C8AJ9>C<>IH86H=;ADLH6C9:;;:8I>K:I6MG6I: HI=:H:IIA:B:CIL>I=I=:"+,L6HHE:8>;>8IDI=:6J9>I
E:G>D9 I=:H:IIA:B:CI9D:HCDIEG:8AJ9:I=:"+,;GDBEGDEDH>C<H>B>A6G69?JHIB:CIHIDI=:DBE6CNWHH:A; >CHJG6C8:EGD<G6BH
>C8JGG:CIDG;JIJG:6J9>IH "C8DCC:8I>DCL>I=>IH:M6B>C6I>DCD;I=:DBE6CNWH;:9:G6A>C8DB:I6MG:IJGCH;DG 6C9
 I=:"+,=6HG:FJ:HI:9699>I>DC6A>C;DGB6I>DCDCI=:DBE6CNWHH:A; >CHJG6C8:EGD<G6BH J:IDI=::C68IB:CID;I=:
-#>C6C9I=:G:HJAI>C<G:9J8I>DC>CI=:. , 8DGEDG6I:I6MG6I:;DGN:6GH6;I:G I=:DBE6CNG:K6AJ:9>IH9:;:GG:9
I6MA>67>A>I>:HG:A6I:9IDI=:I:BEDG6GN9>;;:G:C8:H6HHD8>6I:9L>I=I=>H9:;:GG:9EG:B>JB>C8DB:;GDB ID  ";I=:
"+,EGDEDH:H69?JHIB:CIHG:A6I:9IDI=:DBE6CNWHH:A; >CHJG6C8:EG:B>JBHL>I=G:HE:8IIDN:6GHHJ7H:FJ:CIID6C9EG>DG
ID69DEI>DCD;I=:-#6C9I=:DBE6CN>HJCHJ88:HH;JA>C9:;:C9>C<>IHEDH>I>DC 6CNI6M:HDL:9IDI=:"+,B6N7:
8DBEJI:9JC9:GI=:EG:K>DJH HI6IJIDGNI6MG6I:6C9I=:DBE6CNB6N7:G:FJ>G:9IDG:K6AJ:I=:G:A6I:99:;:GG:9I6M
A>67>A>I>:H;GDB ID  L=>8=>C699>I>DCID6CN>CI:G:HI9J:DCI=:6BDJCIH6HH:HH:9 LDJA9G:FJ>G:68=6G<:ID;JIJG:
:6GC>C<H &6C6<:B:CI7:A>:K:HI=:EDH>I>DCHI=:DBE6CN=6HI6@:C>C>IH. , I6MG:IJGCH6G:>C688DG96C8:L>I=I=:G:A:K6CI
I6MA6LH 


-- 126 of 162 --

Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries.
On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) of approximately DKK
1.9 billion including interest through December 31, 2020 (approximately $309 million based on exchange rates as of
December 31, 2020) imposing withholding tax relating to interest accrued in Denmark on borrowings from certain of the
Company’s subsidiaries for the years 2004 through 2009. The Company appealed these assessments to the Danish National
Tax Tribunal in 2014. The appeal is pending, awaiting the final outcome of other, preceding withholding tax cases that were
appealed to the Danish courts and subsequently to the Court of Justice of the European Union (“CJEU”). In February 2019, the
CJEU decided several of these cases and ruled that the exemption of interest payments from withholding taxes provided in the
applicable European Union (“EU”) directive should be denied where taxpayers use the directive for abusive or fraudulent
purposes, and that it is up to the national courts to make this determination. This decision of the CJEU now awaits application
by the Danish High Court in the other, preceding withholding tax cases. SKAT has maintained a similar position related to
withholding tax on interest accrued in Denmark on borrowings from certain of the Company’s subsidiaries with respect to tax
years 2010 through 2015. In 2019, the Company received aggregate assessments for these matters of approximately DKK 1.8
billion including interest through December 31, 2020 (approximately $302 million based on the exchange rate as of December
31, 2020). The Company is appealing these assessments as well.
Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is
vigorously defending its positions. The Company intends on pursuing this matter through the Danish High Court should the
appeal to the Danish National Tax Tribunal be unsuccessful. The Company will continue to monitor decisions of both the
Danish courts and the CJEU and evaluate the impact of these court rulings on the Company’s tax positions in Denmark. The
ultimate resolution of this matter is uncertain, could take many years, and could result in a further material adverse impact to the
Company’s financial statements, including its cash flow and effective tax rate.
On June 24, 2020, SKAT issued a press release to announce that it has misapplied Denmark’s interest rules in some
assessments concerning withholding tax and overcharged interest. Subsequent to year end, the Company received a notice from
SKAT dated January 15, 2021 that includes a significant reduction in the interest amounts due related to the assessments
discussed above. The Company is reviewing the notice and the revised interest calculations received from SKAT.
Management estimates that it is reasonably possible that the amount of unrecognized tax benefits related to continuing
operations may be reduced by approximately $199 million within 12 months as a result of resolution of worldwide tax matters,
payments of tax audit settlements and/or statute of limitations expirations. Future resolution of uncertain tax positions related to
discontinued operations may result in additional charges or credits to earnings from discontinued operations in the Consolidated
Statements of Earnings (refer to Note 4).
The Company operates in various non-U.S. jurisdictions where income tax incentives and rulings have been granted for specific
periods of time. In Switzerland, the Company has various tax rulings and tax holiday arrangements which reduce the overall
effective tax rate of the Company. The tax holidays expire between 2021 and 2027. In Singapore, the Company operates under
various tax incentive agreements that provide for reduced tax rates. Subject to the Company satisfying certain requirements, the
agreements expire in 2022. As of December 31, 2020, the Company had satisfied the conditions enumerated in these
agreements. Included in the accompanying Consolidated Financial Statements are tax benefits of $43 million, $71 million and
$69 million (or $0.06, $0.10 and $0.10 per diluted common share) for 2020, 2019 and 2018, respectively, from these rulings
and tax holidays.
NOTE 16. NONOPERATING INCOME (EXPENSE)
The Company disaggregates the service cost component of net periodic benefit costs of noncontributory defined benefit pension
plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in other
income (expense), net. These other components include the assumed rate of return on plan assets, partially offset by
amortization of actuarial losses and interest and aggregated to a gain of $16 million, $12 million and $35 million as of
December 31, 2020, 2019 and 2018, respectively. The Company’s net periodic pension cost for the year ended December 31,
2019 includes a settlement loss of $7 million ($6 million after tax or $0.01 per diluted common share) as a result of the transfer
of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third party.
The Company estimates the fair value of investments in equity securities using the Fair Value Alternative and records
adjustments to fair value within net earnings. Additionally, the Company is a limited partner in a partnership that invests in
early stage companies. While the partnership records these investments at fair value, the Company’s investment in the
partnership is accounted for under the equity method of accounting. During the year ended December 31, 2020, the Company
recorded net realized and unrealized gains of $18 million related to changes in the fair value of these investments. In addition,
the Company recorded other income of $5 million related to certain other transactions during 2020. These items are reflected in
105

-- 127 of 162 --

DI=:G>C8DB::ME:CH: C:I>CI=:DBE6CNWHDCHDA>96I:9,I6I:B:CID;6GC>C<H 'DH><C>;>86CIG:6A>O:9DGJCG:6A>O:9<6>CH
DGADHH:HL:G:G:8DG9:9>C:>I=:GDGL>I=G:HE:8IIDI=:H:>CK:HIB:CIH 
H68DC9>I>DCIDD7I6>C>C<8:GI6>CG:<JA6IDGN6EEGDK6AH;DGI=:8ADH>C<D;I=:NI>K68FJ>H>I>DC I=:DBE6CNL6HG:FJ>G:9ID
9>K:HI8:GI6>CD;>IH:M>HI>C<EGD9J8IA>C:H>CI=:%>;:,8>:C8:HH:<B:CII=6I>CI=:6<<G:<6I:<:C:G6I:9G:K:CJ:HD;
6EEGDM>B6I:ANB>AA>DC>C (CEG>A  I=:DBE6CN8DBEA:I:9I=:H6A:D;I=:H:EGD9J8IA>C:H;DG686H=
EJG8=6H:EG>8: C:ID;86H=IG6CH;:GG:96C9IG6CH68I>DC8DHIH D;B>AA>DC6C9G:8D<C>O:96EG:I6M<6>CDCH6A:D;
B>AA>DCB>AA>DC6;I:G I6MDG E:G9>AJI:98DBBDCH=6G:>CI=:H:8DC9FJ6GI:GD; -=:9>K:HI>IJG:D;I=:H:
EGD9J8IA>C:H9>9CDIG:EG:H:CI6HIG6I:<>8H=>;IL>I=6B6?DG:;;:8IDCI=:DBE6CNWHDE:G6I>DCH6C9;>C6C8>6AG:HJAIH6C9
I=:G:;DG:>HCDIG:EDGI:96H69>H8DCI>CJ:9DE:G6I>DC 
"CI=:;DJGI=FJ6GI:GD; I=:DBE6CNG:9::B:9I=:XB>AA>DC6<<G:<6I:EG>C8>E6A6BDJCID; H:C>DGJCH:8JG:9
CDI:H9J:6I6G:9:BEI>DCEG>8::FJ6AIDI=:DJIHI6C9>C<EG>C8>E6A6BDJCI6C96B6@: L=DA:EG:B>JB6HHE:8>;>:9>CI=:
6EEA>867A:>C9:CIJG: EAJH688GJ:96C9JCE6>9>CI:G:HI -=:DBE6CNG:8DG9:96ADHHDC:6GAN:MI>C<J>H=B:CID;I=:H:
7DGGDL>C<H >C8AJ9>C<9:;:GG:98DHIH G:A6I:9IDI=:E6NB:CID;I=:B6@: L=DA:EG:B>JBH>C8DCC:8I>DCL>I=I=:G:9:BEI>DCD;
B>AA>DCB>AA>DC6;I:G I6MDG E:G9>AJI:98DBBDCH=6G:L=>8=>HG:;A:8I:96H6ADHHDC:6GAN:MI>C<J>H=B:CID;
7DGGDL>C<H>CI=:DCHDA>96I:9,I6I:B:CID;6GC>C<H 
"CI=:;DJGI=FJ6GI:GD; 6C6=:GJH:96EDGI>DCD;I=:8DCH>9:G6I>DCG:8:>K:9;GDBCK>HI6IDG:9::BB>AA>DC>C
6<<G:<6I:EG>C8>E6A6BDJCID;DJIHI6C9>C<>C9:7I:9C:HH8DCH>HI>C<D;I=:DBE6CNWH H:C>DGJCH:8JG:9CDI:H9J:
6C9 H:C>DGJCH:8JG:9CDI:H9J: -=:DBE6CN>C8JGG:9B6@: L=DA:EG:B>JBH>C8DCC:8I>DCL>I=I=:G:9:BEI>DC
D;B>AA>DCB>AA>DC6;I:G I6MDG E:G9>AJI:98DBBDCH=6G:L=>8=>HG:;A:8I:96H6ADHHDC:6GAN:MI>C<J>H=B:CID;
7DGGDL>C<H>CI=:DCHDA>96I:9,I6I:B:CID;6GC>C<H 
#$)  $"")"#)(
,0AA0=C84B
-=:DBE6CN<:C:G6AAN688GJ:H:HI>B6I:9L6GG6CIN8DHIH6II=:I>B:D;H6A: "C<:C:G6A B6CJ;68IJG:9EGD9J8IH6G:L6GG6CI:9
6<6>CHI9:;:8IH>CB6I:G>6A6C9LDG@B6CH=>EL=:CEGDE:GANJH:9;DGI=:>G>CI:C9:9EJGEDH: >CHI6AA:98DGG:8IAN6C9
6EEGDEG>6I:ANB6>CI6>C:9 06GG6CINE:G>D9H9:E:C9DCI=:C6IJG:D;I=:EGD9J8I6C9G6C<:;GDBI=:96I:D;HJ8=H6A:JEIDI:C
N:6GH -=:6BDJCID;I=:688GJ:9L6GG6CINA>67>A>IN>H9:I:GB>C:976H:9DC=>HIDG>86A>C;DGB6I>DCHJ8=6HE6HI:ME:G>:C8: 
EGD9J8I;6>AJG:G6I:HDGCJB7:GD;JC>IHG:E6>G:9 :HI>B6I:98DHID;B6I:G>6A6C9A67DG6C9>C8:GI6>C>CHI6C8:H:HI>B6I:9
EGDE:GIN96B6<: -=:688GJ:9L6GG6CINA>67>A>IN>HG:K>:L:9DC6FJ6GI:GAN76H>H6C9B6N7:69?JHI:96H699>I>DC6A>C;DGB6I>DC
G:<6G9>C<:ME:8I:9L6GG6CIN8DHIH7:8DB:H@CDLC
-=:;DAADL>C<>H6GDAA;DGL6G9D;I=:DBE6CNWH688GJ:9L6GG6CINA>67>A>IN>CB>AA>DCH

0;0=240=D0AH 	 	 	 	
88GJ6AH;DGL6GG6CI>:H>HHJ:99JG>C<I=:N:6G 	 	 	 	
,:IIA:B:CIHB69: 	 	  	
9?JHIB:CIH9J:ID68FJ>H>I>DCH 9>K:HI>IJG:H 	 	 	 	T
;;:8ID;;DG:><C8JGG:C8NIG6CHA6I>DC 	 	 	 	T
0;0=24424<14A 	 	 	 	
%DA270B4$1;860C8>=B
-=:DBE6CN=6H:CI:G:9>CID6<G::B:CIHIDEJG8=6H:<DD9HDGH:GK>8:HI=6I6G::C;DG8:67A:6C9A:<6AAN7>C9>C<DCI=:
DBE6CN6C9I=6IHE:8>;N6AAH><C>;>86CII:GBH >C8AJ9>C<;>M:9DGB>C>BJBFJ6CI>I>:HID7:EJG8=6H:9 ;>M:9 B>C>BJBDG
K6G>67A:EG>8:EGDK>H>DCH6C9I=:6EEGDM>B6I:I>B>C<D;I=:IG6CH68I>DC )JG8=6H:D7A><6I>DCH:M8AJ9:6<G::B:CIHI=6I6G:
86C8:AA67A:6I6CNI>B:L>I=DJIE:C6AIN HD;:8:B7:G  I=:6<<G:<6I:6BDJCID;I=:DBE6CNWHEJG8=6H:
D7A><6I>DCHIDI6A:96EEGDM>B6I:AN 7>AA>DC6C9I=:B6?DG>IND;I=:H:D7A><6I>DCH6G::ME:8I:9ID7:H:IIA:99JG>C<
#$)  !))$##$#)##(
-=:DBE6CN>HHJ7?:8IIDDGDI=:GL>H:G:HEDCH>7A:;DG6K6G>:IND;A>I><6I>DC6C9DI=:GA:<6A6C9G:<JA6IDGNEGD8::9>C<H>CI=:
8DJGH:D;>IH7JH>C:HHDGG:A6I:9IDI=:7JH>C:HHDE:G6I>DCHD;EG:K>DJHANDLC:9:CI>I>:H >C8AJ9>C<8A6>BHDG8DJCI:G8A6>BH;DG
96B6<:H6G>H>C<DJID;I=:JH:D;EGD9J8IHDGH:GK>8:H6C98A6>BHG:A6I>C<ID>CI:AA:8IJ6AEGDE:GINB6II:GH :BEADNB:CIB6II:GH 
I6MB6II:GH 8DBB:G8>6A9>HEJI:H 7G:68=D;8DCIG68I8A6>BH 8DBE:I>I>DC6C9H6A:H6C9IG69>C<EG68I>8:H :CK>GDCB:CI6AB6II:GH 


-- 128 of 162 --

personal injury, insurance coverage, securities matters, fiduciary duties and acquisition or divestiture-related matters, as well as
regulatory subpoenas, requests for information, investigations and enforcement. The Company also from time to time becomes
subject to lawsuits as a result of acquisitions or as a result of liabilities retained from, or representations, warranties or
indemnities provided in connection with, businesses divested by the Company or its predecessors. The types of claims made in
lawsuits include claims for compensatory damages, punitive and consequential damages (and in some cases, treble damages)
and/or injunctive relief.
While the Company maintains general, products, property, workers’ compensation, automobile, cargo, aviation, crime,
fiduciary and directors’ and officers’ liability insurance (and has acquired rights under similar policies in connection with
certain acquisitions) up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to
cover such losses. For general, products and property liability and most other insured risks, the Company purchases outside
insurance coverage only for severe losses and must establish and maintain reserves with respect to amounts within the self-
insured retention. In addition, while the Company believes it is entitled to indemnification from third-parties for some of these
claims, these rights may also be insufficient or unavailable to cover such losses.
The Company records a liability in the Consolidated Financial Statements for loss contingencies when a loss is known or
considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a
range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a
loss does not meet the known or probable level but is reasonably possible it is disclosed and if the loss or range of loss can be
reasonably estimated, the estimated loss or range of loss is disclosed. The Company’s reserves consist of specific reserves for
individual claims and additional amounts for anticipated developments of these claims as well as for incurred but not yet
reported claims. The specific reserves for individual known claims are quantified with the assistance of legal counsel and
outside risk professionals where appropriate. In addition, outside risk professionals assist in the determination of reserves for
incurred but not yet reported claims through evaluation of the Company’s specific loss history, actual claims reported and
industry trends together with statistical and other factors. Reserve estimates may be adjusted as additional information
regarding a claim becomes known. Because most contingencies are resolved over long periods of time, new developments
(including litigation developments, the discovery of new facts, changes in legislation and outcomes of similar cases), changes in
assumptions or changes in the Company’s strategy in any given period can require the Company to adjust the loss contingency
estimates that have been recorded in the financial statements, record estimates for liabilities or assets previously not susceptible
of reasonable estimates or pay cash settlements or judgments. While the Company actively pursues financial recoveries from
insurance providers and indemnifying parties, it does not recognize any recoveries until realized or until such time as a
sustained pattern of collections is established related to historical matters of a similar nature and magnitude. If the Company’s
self-insurance and litigation reserves prove inadequate, it would be required to incur an expense equal to the amount of the loss
incurred in excess of the reserves, which would adversely affect the Company’s Consolidated Financial Statements.
In addition, the Company’s operations, products and services are subject to numerous U.S. federal, state, local and non-U.S.
environmental, health and safety laws and regulations concerning, among other things, the health and safety of our employees,
the generation, storage, use and transportation of hazardous materials, emissions or discharges of substances into the
environment, investigation and remediation of hazardous substances or materials at various sites, chemical constituents in
products and end-of-life disposal and take-back programs for products sold. A number of the Company’s operations involve
the handling, manufacturing, use or sale of substances that are or could be classified as hazardous materials within the meaning
of applicable laws. Compliance with these laws and regulations has not had and, based on current information and the
applicable laws and regulations currently in effect, is not expected to have a material effect on the Company’s capital
expenditures, earnings or competitive position, and the Company does not anticipate material capital expenditures for
environmental control facilities.
In addition to environmental compliance costs, the Company from time to time incurs costs related to remedial efforts or
alleged environmental damage associated with past or current waste disposal practices or other hazardous materials handling
practices. For example, generators of hazardous substances found in disposal sites at which environmental problems are
alleged to exist, as well as the current and former owners of those sites and certain other classes of persons, are subject to claims
brought by state and federal regulatory agencies pursuant to statutory authority. The Company has received notification from
the U.S. Environmental Protection Agency, and from state and non-U.S. environmental agencies, that conditions at certain sites
where the Company and others previously disposed of hazardous wastes and/or are or were property owners require clean-up
and other possible remedial action, including sites where the Company has been identified as a potentially responsible party
under U.S. federal and state environmental laws. The Company has projects underway at a number of current and former
facilities, in both the United States and abroad, to investigate and remediate environmental contamination resulting from past
operations. Remediation activities generally relate to soil and/or groundwater contamination and may include pre-remedial
activities such as fact-finding and investigation, risk assessment, feasibility study and/or design, as well as remediation actions
such as contaminant removal, monitoring and/or installation, operation and maintenance of longer-term remediation systems.
The Company is also from time to time party to personal injury, property damage or other claims brought by private parties
107

-- 129 of 162 --

alleging injury or damage due to the presence of, or exposure to, hazardous substances. The Company can also become subject
to additional remedial, compliance or personal injury costs due to future events such as changes in existing laws or regulations,
changes in agency direction or enforcement policies, developments in remediation technologies, changes in the conduct of the
Company’s operations and changes in accounting rules.
The Company has recorded a provision for environmental investigation and remediation and environmental-related claims with
respect to sites owned or formerly owned by the Company and its subsidiaries and third-party sites where the Company has
been determined to be a potentially responsible party. The Company generally makes an assessment of the costs involved for
its remediation efforts based on environmental studies, as well as its prior experience with similar sites. The ultimate cost of
site cleanup is difficult to predict given the uncertainties of the Company’s involvement in certain sites, uncertainties regarding
the extent of the required cleanup, the availability of alternative cleanup methods, variations in the interpretation of applicable
laws and regulations, the possibility of insurance recoveries with respect to certain sites and the fact that imposition of joint and
several liability with right of contribution is possible under the Comprehensive Environmental Response, Compensation and
Liability Act of 1980 and other environmental laws and regulations. If the Company determines that potential liability for a
particular site or with respect to a personal injury claim is known or considered probable and reasonably estimable, the
Company accrues the total estimated loss, including investigation and remediation costs, associated with the site or claim. As
of December 31, 2020, the Company had a reserve of $194 million for environmental matters which are known or considered
probable and reasonably estimable (of which $124 million are noncurrent), which reflects the Company’s best estimate of the
costs to be incurred with respect to such matters.
While the Company actively pursues insurance recoveries, as well as recoveries from other potentially responsible parties, it
does not recognize any insurance recoveries for environmental liability claims until realized or until such time as a sustained
pattern of collections is established related to historical matters of a similar nature and magnitude.
The Company’s Restated Certificate of Incorporation requires it to indemnify to the full extent authorized or permitted by law
any person made, or threatened to be made a party to any action or proceeding by reason of his or her service as a director or
officer of the Company, or by reason of serving at the request of the Company as a director or officer of any other entity,
subject to limited exceptions. Danaher’s Amended and Restated By-laws provide for similar indemnification rights. In
addition, Danaher has executed with each director and executive officer of Danaher Corporation an indemnification agreement
which provides for substantially similar indemnification rights and under which Danaher has agreed to pay expenses in advance
of the final disposition of any such indemnifiable proceeding. While the Company maintains insurance for this type of liability,
a significant deductible applies to this coverage and any such liability could exceed the amount of the insurance coverage.
As of December 31, 2020, the Company had approximately $724 million of guarantees consisting primarily of outstanding
standby letters of credit, bank guarantees and performance and bid bonds. These guarantees have been provided in connection
with certain arrangements with vendors, customers, insurance providers, financing counterparties and governmental entities to
secure the Company’s obligations and/or performance requirements related to specific transactions. The Company believes that
if the obligations under these instruments were triggered, it would not have a material effect on its Consolidated Financial
Statements.
NOTE 19. STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION
On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing
the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately
negotiated transactions. There is no expiration date for the Repurchase Program, and the timing and amount of any shares
repurchased under the program will be determined by the Company’s management based on its evaluation of market conditions
and other factors. The Repurchase Program may be suspended or discontinued at any time. Any repurchased shares will be
available for use in connection with the Company’s equity compensation plans (or any successor plan) and for other corporate
purposes. As of December 31, 2020, 20 million shares remained available for repurchase pursuant to the Repurchase Program.
The Company expects to fund any future stock repurchases using the Company’s available cash balances or proceeds from the
issuance of debt.
Except in connection with the Envista Split-Off in 2019, neither the Company nor any “affiliated purchaser” repurchased any
shares of Company common stock during 2020, 2019 or 2018. Refer to Note 4 for discussion of the 22.9 million shares of
Danaher common stock tendered to and repurchased by the Company in connection with the Envista Split-Off.
108

-- 130 of 162 --

-=:;DAADL>C<I67A:HJBB6G>O:HI=:DBE6CNWHH=6G:68I>K>IN;DGI=:N:6GH:C9:9:8:B7:GH=6G:H>CB>AA>DCH
 	
)G:;:GG:9HID8@ H=6G:H>HHJ:9
6A6C8: 7:<>CC>C<D;E:G>D9 	  	 	T 	 	T
"HHJ6C8:D;&), 	 	  	 	  	 	T
6A6C8: :C9D;E:G>D9 	 	  	 	  	 	T
DBBDCHID8@ H=6G:H>HHJ:9
6A6C8: 7:<>CC>C<D;E:G>D9 	 	  	 	  	 	 
DBBDCHID8@ 76H:96L6G968I>K>IN 	 	  	 	  	 	 
DBBDCHID8@>HHJ:9>C8DCC:8I>DCL>I=68FJ>H>I>DCH 	 	T 	 	T 	 	 
DBBDCHID8@>HHJ:9>C8DCC:8I>DCL>I=%2('HW8DCK:GH>DCH 	 	  	 	  	 	 
"HHJ6C8:D;8DBBDCHID8@ 	 	  	 	  	 	T
6A6C8: :C9D;E:G>D9 	 	  	 	  	 	 
"C&6N I=:DBE6CN8DBEA:I:9I=:JC9:GLG>II:CEJ7A>8D;;:G>C<D; B>AA>DCH=6G:HD;6C6=:G8DBBDCHID8@6I6
EG>8:IDI=:EJ7A>8D; E:GH=6G:I=:UDBBDC,ID8@(;;:G>C<V G:HJAI>C<>CC:IEGD8::9HD;6EEGDM>B6I:AN
 7>AA>DC 6;I:G9:9J8I>C<:ME:CH:H6C9I=:JC9:GLG>I:GHW9>H8DJCID;B>AA>DC ,>BJAI6C:DJHAN I=:DBE6CN8DBEA:I:9
I=:JC9:GLG>II:CEJ7A>8D;;:G>C<D; B>AA>DCH=6G:HD;>IH ,:G>:H&6C96IDGNDCK:GI>7A:)G:;:GG:9,ID8@U&),
,:G>:HV L>I=DJIE6GK6AJ:6C9L>I=6A>FJ>96I>DCEG:;:G:C8:D; E:GH=6G:I=:U&),(;;:G>C<V G:HJAI>C<>C
C:IEGD8::9HD;6EEGDM>B6I:AN 7>AA>DC 6;I:G9:9J8I>C<:ME:CH:H6C9I=:JC9:GLG>I:GHW9>H8DJCID;B>AA>DC -=:
DBE6CN=6HJH:96C9>CI:C9HIDJH:I=:C:IEGD8::9H;GDBI=:DBBDC,ID8@(;;:G>C<6C9I=:&),(;;:G>C<;DG
<:C:G6A8DGEDG6I:EJGEDH:H6C9E:C9>C<HJ8=JH:=6H>CK:HI:9I=:C:IEGD8::9H>CH=DGI I:GB76C@9:EDH>IH6C9 DG>CI:G:HI
7:6G>C< >CK:HIB:CI <G69:H:8JG>I>:H 
(C&6G8=  I=:DBE6CN8DBEA:I:9I=:JC9:GLG>II:CEJ7A>8D;;:G>C<D; B>AA>DCH=6G:HD;6C6=:G8DBBDCHID8@
6I6EG>8:IDI=:EJ7A>8D; E:GH=6G:I=:UDBBDC,ID8@(;;:G>C<V G:HJAI>C<>CC:IEGD8::9HD;6EEGDM>B6I:AN
 7>AA>DC 6;I:G9:9J8I>C<:ME:CH:H6C9I=:JC9:GLG>I:GHW9>H8DJCID;B>AA>DC ,>BJAI6C:DJHAN I=:DBE6CN8DBEA:I:9
I=:JC9:GLG>II:CEJ7A>8D;;:G>C<D; B>AA>DCH=6G:HD;>IH &),,:G>:H L>I=DJIE6GK6AJ:6C9L>I=6A>FJ>96I>DC
EG:;:G:C8:D; E:GH=6G:I=:U&),(;;:G>C<V G:HJAI>C<>CC:IEGD8::9HD;6EEGDM>B6I:AN 7>AA>DC 6;I:G
9:9J8I>C<:ME:CH:H6C9I=:JC9:GLG>I:GHW9>H8DJCID;B>AA>DC -=:DBE6CNJH:9I=:C:IEGD8::9H;GDBI=:
DBBDC,ID8@(;;:G>C<6C9I=:&),(;;:G>C<ID;JC96EDGI>DCD;I=:86H=8DCH>9:G6I>DCE6N67A:;DG 6C98:GI6>C8DHIH
6HHD8>6I:9L>I= I=:NI>K68FJ>H>I>DC )G>DGIDI=:8DBEA:I>DCD;I=:NI>K68FJ>H>I>DC I=:DBE6CN>CK:HI:9I=:C:I
EGD8::9H>CH=DGI I:GB76C@9:EDH>IH6C9 DG>CI:G:HI 7:6G>C< >CK:HIB:CI <G69:H:8JG>I>:H
.CA:HH8DCK:GI:9:6GA>:G>C688DG96C8:L>I=I=:I:GBHD;I=:6EEA>867A:8:GI>;>86I:D;9:H><C6I>DCH :68=H=6G:D;&),,:G>:H
6C9&),,:G>:HID<:I=:G I=:U&),,=6G:HVL>AAB6C96IDG>AN8DCK:GIDCI=:>GG:HE:8I>K:&6C96IDGNDCK:GH>DC6I: 
H:I;DGI=7:ADL >CID6CJB7:GD;H=6G:HD;I=:DBE6CNWH8DBBDCHID8@7:IL::CI=:6EEA>867A:&>C>BJBDCK:GH>DC+6I:
6C9I=:6EEA>867A:&6M>BJBDCK:GH>DC+6I: H:I;DGI=7:ADL HJ7?:8IID;JGI=:G6CI> 9>AJI>DC69?JHIB:CIH -=:CJB7:GD;
H=6G:HD;I=:DBE6CNWH8DBBDCHID8@>HHJ67A:JEDC8DCK:GH>DCL>AA7:9:I:GB>C:976H:9DCI=:6K:G6<:KDAJB: L:><=I:9
6K:G6<:EG>8:E:GH=6G:D;I=:DBE6CNWH8DBBDCHID8@DK:GI=:8DCH:8JI>K:IG69>C<96NE:G>D97:<>CC>C<DC 6C9
>C8AJ9>C< I=:HIH8=:9JA:9IG69>C<96N>BB:9>6I:AN7:;DG:I=:6EEA>867A:&6C96IDGNDCK:GH>DC6I: ,J7?:8IID8:GI6>C
:M8:EI>DCH 6I6CNI>B:EG>DGIDI=:&6C96IDGNDCK:GH>DC6I: =DA9:GHB6N:A:8IID8DCK:GII=:&),,=6G:H>CID8DBBDC
HID8@76H:9DCI=:6EEA>867A:&>C>BJBDCK:GH>DC+6I: HJ7?:8IID;JGI=:G6CI> 9>AJI>DC69?JHIB:CIH "CI=::K:CID;6
;JC96B:CI6A8=6C<: I=:&),,=6G:HL>AA8DCK:GI6II=:;JC96B:CI6A8=6C<:G6I:HHE:8>;>:9>CI=:6EEA>867A:8:GI>;>86I:D;
9:H><C6I>DCH 6C9I=:=DA9:GHD;&),,=6G:HLDJA97::CI>IA:9ID6;JC96B:CI6A8=6C<:B6@: L=DA:9>K>9:C9 "C 
=DA9:GH8DCK:GI:9H=6G:HD;&),,:G>:H>CIDH=6G:HD;6C6=:G8DBBDCHID8@
!DA9:GHD;&),,=6G:HL>AA7::CI>IA:9IDG:8:>K: L=:C6C9>;9:8A6G:97NI=:DBE6CNWHD6G9D;>G:8IDGH 8JBJA6I>K:
9>K>9:C9H6II=:6EEA>867A:CCJ6AJBJA6I>K:>K>9:C9+6I:D;I=:%>FJ>96I>DC)G:;:G:C8:E:GH=6G: E6N67A:>C86H=DG 
HJ7?:8IID8:GI6>CA>B>I6I>DCH 7N9:A>K:GND;H=6G:HD;I=:DBE6CNWH8DBBDCHID8@DG6CN8DB7>C6I>DCD;86H=6C9H=6G:HD;
I=:DBE6CNWH8DBBDCHID8@ 6II=:DBE6CNWH:A:8I>DC ";9:8A6G:9 9>K>9:C9HDCI=:&),,=6G:H6G:E6N67A:FJ6GI:GANDC
#6CJ6GN EG>A #JAN6C9(8ID7:GD;:68=N:6GID 6C9>C8AJ9>C< I=:&6C96IDGNDCK:GH>DC6I: IDI=:=DA9:GHD;
G:8DG9D;I=:&),,=6G:H6HI=:N6EE:6GDCI=:DBE6CNWHHID8@G:<>HI:G6II=:8ADH:D;7JH>C:HHDCI=:>BB:9>6I:AN
EG:8:9>C<:8:B7:G &6G8= #JC:6C9,:EI:B7:G G:HE:8I>K:AN 


-- 131 of 162 --

-=:;DAADL>C<HJBB6G>O:HI=:@:NI:GBHD;I=:&),,=6G:H6HD;:8:B7:G 
==D0;D<D;0C8E4
8E834=3'0C4
!8@D830C8>=
%A454A4=24?4A(70A4
"8=8<D<>=E4AB8>=
'0C4
"0G8<D<>=E4AB8>=
'0C4
"0=30C>AH
>=E4AB8>=0C4
,:G>:H 	   	  	 H=6G:H 	 H=6G:H 	EG>A 
,:G>:H 	   	  	 H=6G:H 	 H=6G:H 	EG>A 
,ID8@DEI>DCH +,.H6C9),.H=6K:7::C>HHJ:9ID9>G:8IDGH D;;>8:GH6C9DI=:G:BEADN::HJC9:GI=:DBE6CNWH
(BC>7JH"C8:CI>K:)A6C "C699>I>DC >C8DCC:8I>DCL>I=I=:68FJ>H>I>DCD;)6AADGEDG6I>DC6C9I=:68FJ>H>I>DCD;
:E=:>9 I=:DBE6CN6HHJB:98:GI6>CDJIHI6C9>C<HID8@DEI>DCH6C9+,.H 6H6EEA>867A: I=6I=697::C6L6G9:9JC9:GI=:
HID8@8DBE:CH6I>DCEA6CHD;I=:G:HE:8I>K:68FJ>G::I=:UHHJB:9)A6CHV -=:HHJB:9)A6CHDE:G6I:>C6H>B>A6GB6CC:GID
I=:DBE6CNWH(BC>7JH"C8:CI>K:)A6C 6C9CD;JGI=:G:FJ>IN6L6G9HL>AA7:>HHJ:9JC9:GI=:HHJB:9)A6CH -=:
(BC>7JH"C8:CI>K:)A6CEGDK>9:H;DGI=:<G6CID;HID8@DEI>DCH HID8@6EEG:8>6I>DCG><=IH +,.H G:HIG>8I:9HID8@ ),.HDG6CN
DI=:GHID8@ 76H:96L6G96C986H= 76H:96L6G9H IDI6AD;6EEGDM>B6I:ANB>AA>DCH=6G:HD;6C6=:G8DBBDCHID8@=6K:
7::C6JI=DG>O:9;DG>HHJ6C8:JC9:GI=:(BC>7JH"C8:CI>K:)A6C HD;:8:B7:G  6EEGDM>B6I:ANB>AA>DC
H=6G:HD;I=:DBE6CNWH8DBBDCHID8@G:B6>C6K6>A67A:;DG>HHJ6C8:JC9:GI=:(BC>7JH"C8:CI>K:)A6C
,ID8@DEI>DCH<G6CI:9JC9:GI=:(BC>7JH"C8:CI>K:)A6C<:C:G6AANK:HIEGDG6I6DK:G6;>K: N:6GE:G>D96C9I:GB>C6I:I:C
N:6GH;GDBI=:<G6CI96I: I=DJ<=I=:HE:8>;>8I:GBHD;:68=<G6CI6G:9:I:GB>C:97NI=:DBE:CH6I>DCDBB>II::D;I=:
DBE6CNWHD6G9I=:UDBE:CH6I>DCDBB>II::V -=:DBE6CNWH:M:8JI>K:D;;>8:GH6C98:GI6>CDI=:G:BEADN::H=6K:
7::C6L6G9:9DEI>DCHL>I=9>;;:G:CIK:HI>C<8G>I:G>6 6C9DEI>DCH<G6CI:9IDDJIH>9:9>G:8IDGH6G:;JAANK:HI:96HD;I=:<G6CI
96I: (EI>DC:M:G8>H:EG>8:H;DGDEI>DCH<G6CI:97NI=:DBE6CN:FJ6AI=:8ADH>C<EG>8:D;I=:DBE6CNWH8DBBDCHID8@DC
I=:'2,DCI=:96I:D;<G6CI "C8DCC:8I>DCL>I=I=:DBE6CNWH6HHJBEI>DCD;DEI>DCH>HHJ:9EJGHJ6CIIDI=:HHJB:9
)A6CH I=:CJB7:GD;H=6G:HJC9:GAN>C<:68=DEI>DC6C9:M:G8>H:EG>8:D;:68=DEI>DCL:G:69?JHI:9IDG:;A:8II=:HJ7HI>IJI>DCD;
I=:DBE6CNWHHID8@;DGI=:HID8@D;I=:6EEA>867A:68FJ>G:98DBE6CN
+,.H>HHJ:9JC9:GI=:(BC>7JH"C8:CI>K:)A6CEGDK>9:;DGI=:>HHJ6C8:D;6H=6G:D;I=:DBE6CNWH8DBBDCHID8@6ICD
8DHIIDI=:=DA9:G -=:+,.HI=6I=6K:7::C<G6CI:9ID:BEADN::HJC9:GI=:(BC>7JH"C8:CI>K:)A6C<:C:G6AANEGDK>9:
;DGI>B: 76H:9K:HI>C<DK:G6;>K: N:6GE:G>D9 6AI=DJ<=:M:8JI>K:D;;>8:GH6C98:GI6>CDI=:G:BEADN::H=6K:7::C6L6G9:9
+,.HL>I=9>;;:G:CII>B: 76H:9K:HI>C<8G>I:G>6 6C9+,.HEG:K>DJHAN<G6CI:9IDB:B7:GHD;I=:DBE6CNWHH:C>DG
B6C6<:B:CI=6K:6AHD7::CHJ7?:8IIDE:G;DGB6C8: 76H:9K:HI>C<8G>I:G>6 -=:+,.HI=6I=6K:7::C<G6CI:9ID9>G:8IDGHJC9:G
I=:(BC>7JH"C8:CI>K:)A6CK:HIDCI=::6GA>:GD;I=:;>GHI6CC>K:GH6GND;I=:<G6CI96I:DGI=:96I:D; 6C9>BB:9>6I:AN
EG>DGID I=:C:MI6CCJ6AB::I>C<D;I=:DBE6CNWHH=6G:=DA9:GH;DAADL>C<I=:<G6CI96I: 7JII=:JC9:GAN>C<H=6G:H6G:CDI
>HHJ:9JCI>AI=::6GA>:GD;I=:9>G:8IDGWH9:6I=DGI=:;>GHI96ND;I=:H:K:CI=BDCI=;DAADL>C<I=:9>G:8IDGWHG:I>G:B:CI;GDBI=:
D6G9 )G>DGIDK:HI>C< +,.H<G6CI:9JC9:GI=:(BC>7JH"C8:CI>K:)A6C9DCDI=6K:9>K>9:C9:FJ>K6A:CIG><=IH 9DCDI
=6K:KDI>C<G><=IH6C9I=:H=6G:HJC9:GAN>C<I=:+,.H6G:CDI8DCH>9:G:9>HHJ:96C9DJIHI6C9>C< 0>I=G:HE:8IID+,.H
<G6CI:9JC9:GI=:HHJB:9)A6C >C8DCC:8I>DCL>I=I=:DBE6CNWH6HHJBEI>DCD;I=:H:+,.HI=:CJB7:GD;H=6G:HJC9:GAN>C<
:68=+,.L:G:69?JHI:9IDG:;A:8II=:HJ7HI>IJI>DCD;I=:DBE6CNWHHID8@;DGI=:HID8@D;I=:6EEA>867A:68FJ>G:98DBE6CN 
6C98:GI6>CD;I=:H:+,.H=6K:9>K>9:C9:FJ>K6A:CIG><=IH
),.H>HHJ:9JC9:GI=:(BC>7JH"C8:CI>K:)A6CEGDK>9:;DGI=:>HHJ6C8:D;6H=6G:D;I=:DBE6CNWH8DBBDCHID8@6ICD
8DHIIDI=:=DA9:G K:HI76H:9DCHE:8>;>:9E:G;DGB6C8:8G>I:G>6 6G:HJ7?:8IID6C699>I>DC6A=DA9>C<E:G>D96C96G::CI>IA:9ID
9>K>9:C9:FJ>K6A:CIG><=IH -=:),.9>K>9:C9:FJ>K6A:CIG><=IH6G:HJ7?:8IIDI=:H6B:K:HI>C<6C9E6NB:CIG:HIG>8I>DCH6HI=:
G:A6I:9H=6G:H 6C9I=:H=6G:HJC9:GAN>C<I=:),.WH6G:CDI8DCH>9:G:9>HHJ:96C9DJIHI6C9>C< 
"C8DCC:8I>DCL>I=I=:CK>HI6>HEDH>I>DC CK>HI669DEI:96HID8@ 76H:98DBE:CH6I>DCEA6C L=>8=EGDK>9:9;DGHID8@ 76H:9
6L6G9H9:CDB>C6I:9>CH=6G:HD;CK>HI68DBBDCHID8@ CK>HI6:BEADN::HL=DE6GI>8>E6I:9>CI=:6C6=:GHID8@
8DBE:CH6I>DCEGD<G6BEG>DGIDI=:,:E6G6I>DC8DCI>CJ:9IDE6GI>8>E6I:>CHJ8=EGD<G6BHDA:ANL>I=G:HE:8IIDDJIHI6C9>C<
8DBE:CH6I>DC6L6G9HG:8:>K:9EG>DGIDI=:,:E6G6I>DC JCI>AI=:,EA>I (;;6IL=>8=I>B:HJ8=6L6G9HL:G:I:GB>C6I:96C9
G:EA68:9L>I=6L6G9H9:CDB>C6I:9>CCK>HI68DBBDCHID8@JC9:GI=:CK>HI6HID8@8DBE:CH6I>DCEA6C ,ID8@ 76H:9
8DBE:CH6I>DC:ME:CH:;DGCK>HI6>H>C8AJ9:9>CG:HJAIH;GDB9>H8DCI>CJ:9DE:G6I>DCH
-=::FJ>IN8DBE:CH6I>DC6L6G9H<G6CI:97NI=:DBE6CN<:C:G6AANK:HIDCAN>;I=::BEADN::>H:BEADN:97NI=:DBE6CNDG
>CI=:86H:D;9>G:8IDGH I=:9>G:8IDG8DCI>CJ:HIDH:GK:DCI=:DBE6CND6G9DCI=:K:HI>C<96I:DG>CDI=:GA>B>I:9
8>G8JBHI6C8:H -D8DK:GI=::M:G8>H:D;DEI>DCH6C9K:HI>C<D;+,.H6C9),.H I=:DBE6CN<:C:G6AAN>HHJ:HC:LH=6G:H;GDB
>IH6JI=DG>O:97JIJC>HHJ:9H=6G:EDDA 6AI=DJ<=>IB6N>CHI:69>HHJ:IG:6HJGNH=6G:H>C8:GI6>C8>G8JBHI6C8:H
-=:DBE6CN688DJCIH;DGHID8@ 76H:98DBE:CH6I>DC7NB:6HJG>C<I=:8DHID;:BEADN::H:GK>8:HG:8:>K:9>C:M8=6C<:;DG6AA
:FJ>IN6L6G9H<G6CI:976H:9DCI=:;6>GK6AJ:D;I=:6L6G96HD;I=:<G6CI96I: -=:DBE6CNG:8D<C>O:HI=:8DBE:CH6I>DC
:ME:CH:DK:GI=:G:FJ>H>I:H:GK>8:E:G>D9L=>8=>H<:C:G6AANI=:K:HI>C<E:G>D97JIB6N7:H=DGI:GI=6CI=:K:HI>C<E:G>D9>;I=:


-- 132 of 162 --

:BEADN::7:8DB:HG:I>G:B:CI:A><>7A:7:;DG:I=::C9D;I=:K:HI>C<E:G>D9 -=:;6>GK6AJ:;DG+,.6L6G9HL6H86A8JA6I:9
JH>C<I=:8ADH>C<EG>8:D;I=:DBE6CNWH8DBBDCHID8@DCI=:96I:D;<G6CI 69?JHI:9;DGI=:;68II=6I+,.HDI=:GI=6C8:GI6>C
+,.H<G6CI:9JC9:GI=:HHJB:9)A6CH9DCDI688GJ:9>K>9:C9H -=:;6>GK6AJ:D;I=:),.6L6G9HL6H86A8JA6I:9JH>C<6
&DCI:6GADEG>8>C<BD9:A -=:;6>GK6AJ:D;I=:DEI>DCH<G6CI:9L6H86A8JA6I:9JH>C<6A68@ ,8=DA:H&:GIDCDEI>DCEG>8>C<
BD9:AUA68@ ,8=DA:HV
-=:;DAADL>C<HJBB6G>O:HI=:6HHJBEI>DCHJH:9>CI=:A68@ ,8=DA:HBD9:AIDK6AJ:DEI>DCH<G6CI:99JG>C<I=:N:6GH:C9:9
:8:B7:G
 	 	
+>H@ ;G::>CI:G:HIG6I: 	 S  	 S  	 S 
0:><=I:96K:G6<:KDA6I>A>IN 	  	  	 
>K>9:C9N>:A9 	  	  	 
ME:8I:9N:6GHJCI>A:M:G8>H: 	 S  	 S  	 S 
-=:A68@ ,8=DA:HBD9:A>C8DGEDG6I:H6HHJBEI>DCHIDK6AJ:HID8@ 76H:96L6G9H -=:G>H@ ;G::G6I:D;>CI:G:HI;DGE:G>D9H
L>I=>CI=:8DCIG68IJ6AA>;:D;I=:DEI>DC>H76H:9DC6O:GD 8DJEDC. , <DK:GCB:CI>CHIGJB:CIL=DH:B6IJG>INE:G>D9:FJ6AHDG
6EEGDM>B6I:HI=:DEI>DCWH:ME:8I:9I:GB ME:8I:9KDA6I>A>IN>H76H:9DC>BEA>:9KDA6I>A>IN;GDBIG69:9DEI>DCHDCI=:
DBE6CNWHHID8@6C9=>HIDG>86AKDA6I>A>IND;I=:DBE6CNWHHID8@ -=:9>K>9:C9N>:A9>H86A8JA6I:97N9>K>9>C<I=:DBE6CNWH
6CCJ6A8DBBDCHID8@9>K>9:C9 76H:9DCI=:BDHIG:8:CIFJ6GI:GAN9>K>9:C9G6I: 7NI=:8ADH>C<HID8@EG>8:DCI=:<G6CI96I: 
-D:HI>B6I:I=:DEI>DC:M:G8>H:I>B>C<JH:9>CI=:K6AJ6I>DCBD9:AL=>8=>BE68IHI=:G>H@ ;G::>CI:G:HIG6I:6C9I=::ME:8I:9
N:6GHJCI>A:M:G8>H: >C699>I>DCID8DCH>9:G>C<I=:K:HI>C<E:G>D96C98DCIG68IJ6AI:GBD;I=:DEI>DC I=:DBE6CN6C6ANO:H6C9
8DCH>9:GH68IJ6A=>HIDG>86A:M:G8>H::ME:G>:C8:;DGEG:K>DJHAN<G6CI:9DEI>DCH -=:DBE6CNHIG6I>;>:H>IH:BEADN::EDEJA6I>DC
>CIDBJAI>EA:<GDJEH;DGDEI>DCK6AJ6I>DC6C96IIG>7JI>DCEJGEDH:H76H:9JEDC9>HI>C8I>K:E6II:GCHD;;DG;:>IJG:G6I:H6C9DEI>DC
=DA9>C<E:G>D9H 6H>C9>86I:97NI=:G6C<:HH:I;DGI=>CI=:I67A:67DK:;DGI=:G>H@ ;G::>CI:G:HIG6I:6C9I=::ME:8I:9N:6GHJCI>A
:M:G8>H:
-=:6BDJCID;HID8@ 76H:98DBE:CH6I>DC:ME:CH:G:8D<C>O:99JG>C<6E:G>D9>H6AHD76H:9DCI=:EDGI>DCD;I=:6L6G9HI=6I6G:
JAI>B6I:AN:ME:8I:9IDK:HI -=:DBE6CN:HI>B6I:HEG: K:HI>C<;DG;:>IJG:H6II=:I>B:D;<G6CI7N6C6ANO>C<=>HIDG>86A96I66C9
G:K>H:HI=DH::HI>B6I:H>CHJ7H:FJ:CIE:G>D9H>;68IJ6A;DG;:>IJG:H9>;;:G;GDBI=DH::HI>B6I:H .AI>B6I:AN I=:IDI6A:ME:CH:
G:8D<C>O:9DK:GI=:K:HI>C<E:G>D9L>AA:FJ6AI=:;6>GK6AJ:D;6L6G9HI=6I68IJ6AANK:HI
-=:;DAADL>C<HJBB6G>O:HI=:8DBEDC:CIHD;I=:DBE6CNWH8DCI>CJ>C<DE:G6I>DCHHID8@ 76H:98DBE:CH6I>DC:ME:CH:;DGI=:
N:6GH:C9:9:8:B7:G>CB>AA>DCH
 	 	
+,.H ),.H
)G:I6M8DBE:CH6I>DC:ME:CH: 	 	 	 	 	 	
"C8DB:I6M7:C:;>I 	 	  	  	
+,. ),.:ME:CH: C:ID;>C8DB:I6M:H 	 	 	 	 	 	
,ID8@DEI>DCH
)G:I6M8DBE:CH6I>DC:ME:CH: 	 	 	 	 	 	
"C8DB:I6M7:C:;>I 	 	  	  	
,ID8@DEI>DC:ME:CH: C:ID;>C8DB:I6M:H 	 	 	 	 	 	
-DI6AHID8@ 76H:98DBE:CH6I>DC
)G:I6M8DBE:CH6I>DC:ME:CH: 	 	 	 	 	 	
"C8DB:I6M7:C:;>I 	 	  	  	
-DI6AHID8@ 76H:98DBE:CH6I>DC:ME:CH: C:ID;>C8DB:I6M:H 	 	 	 	 	 	
,ID8@ 76H:98DBE:CH6I>DC=6H7::CG:8D<C>O:96H68DBEDC:CID;H:AA>C< <:C:G6A6C969B>C>HIG6I>K::ME:CH:H>CI=:
688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;6GC>C<H HD;:8:B7:G  B>AA>DCD;IDI6AJCG:8D<C>O:9
8DBE:CH6I>DC8DHIG:A6I:9ID+,.H ),.H>H:ME:8I:9ID7:G:8D<C>O:9DK:G6L:><=I:96K:G6<:E:G>D9D;6EEGDM>B6I:ANILD
N:6GH HD;:8:B7:G  B>AA>DCD;IDI6AJCG:8D<C>O:98DBE:CH6I>DC8DHIG:A6I:9IDHID8@DEI>DCH>H:ME:8I:9ID
7:G:8D<C>O:9DK:G6L:><=I:96K:G6<:E:G>D9D;6EEGDM>B6I:ANI=G::N:6GH JIJG:8DBE:CH6I>DC6BDJCIHL>AA7:69?JHI:9;DG
6CN8=6C<:H>C:HI>B6I:9;DG;:>IJG:H


-- 133 of 162 --

-=:;DAADL>C<HJBB6G>O:HDEI>DC68I>K>INJC9:GI=:DBE6CNWHHID8@EA6CH>CB>AA>DCH :M8:EIL:><=I:9:M:G8>H:EG>8:6C9
CJB7:GD;N:6GH
$?C8>=B ,4867C43E4A064
G4A28B4%A824
,4867C43E4A064
'4<08=8=6
>=CA02CD0;)4A<
8=H40AB 66A460C4=CA8=B82
+0;D4
$DCBC0=38=60B>50=D0AH  	 	 	  	 	 
G6CI:9 	 	  	 	 
M:G8>H:9 	 	   	 
6C8:AA:9 ;DG;:>I:9 	 	   	 
$DCBC0=38=60B>5424<14A  	 	 	  	 	 
G6CI:9 	 	  	 	 
M:G8>H:9 	 	   	 
6C8:AA:9 ;DG;:>I:9 	 	   	 
9?JHIB:CI9J:IDCK>HI6,EA>I (;;6 	 	   	 
$DCBC0=38=60B>5424<14A  	 	 	  	 	 
G6CI:9 	 	  	 	 
M:G8>H:9 	 	   	 
6C8:AA:9 ;DG;:>I:9 	 	   	 
$DCBC0=38=60B>5424<14A  	 	  	 	  	 	 	 
+4BC430=34G?42C43C>E4BC0B>5424<14A 
1 	 	  	 	  	 	 	 
+4BC430B>5424<14A  	 	  	 	  	 	 	
6
-=:U9?JHIB:CI9J:IDCK>HI6,EA>I (;;VG:;A:8IHI=:86C8:AA6I>DCD;DEI>DCHL=>8=L:G:DJIHI6C9>C<6HD;:8:B7:G 6C9=:A9
7NCK>HI6:BEADN::H L=>8==6K:7::CI:GB>C6I:96C9G:EA68:97NCK>HI6:FJ>IN6L6G9H6HE6GID;I=:CK>HI6,EA>I (;;
7 -=:U:ME:8I:9IDK:HIVDEI>DCH6G:I=:C:IJCK:HI:9DEI>DCHI=6IG:B6>C6;I:G6EEAN>C<I=:;DG;:>IJG:G6I:6HHJBEI>DCIDIDI6AJCK:HI:9
DEI>DCH
-=:6<<G:<6I:>CIG>CH>8K6AJ:>CI=:I67A:67DK:G:EG:H:CIHI=:IDI6AEG:I6M>CIG>CH>8K6AJ:I=:9>;;:G:C8:7:IL::CI=:
DBE6CNWH8ADH>C<HID8@EG>8:DCI=:A6HIIG69>C<96ND;6C9I=::M:G8>H:EG>8: BJAI>EA>:97NI=:CJB7:GD;>C I=: BDC:N
DEI>DCHI=6ILDJA9=6K:7::CG:8:>K:97NI=:DEI>DC=DA9:GH=696AADEI>DC=DA9:GH:M:G8>H:9I=:>GDEI>DCHDC:8:B7:G 
 -=:6BDJCID;6<<G:<6I:>CIG>CH>8K6AJ:L>AA8=6C<:76H:9DCI=:EG>8:D;I=:DBE6CNWH8DBBDCHID8@ 
(EI>DCHDJIHI6C9>C<6HD;:8:B7:G 6G:HJBB6G>O:97:ADL>CB>AA>DCH :M8:EIEG>8:E:GH=6G:6C9CJB7:GD;N:6GH
 	$DCBC0=38=6 	G4A28B01;4
G4A28B4%A824 	(70A4B E4A064
G4A28B4%A824
E4A064
'4<08=8=6!854
8=H40AB 	(70A4B E4A064
G4A28B4%A824
 ID  	 	  	 	  	 	 	  	 	 
 ID  	 	  	 	  	 	 	  	 	 
 ID  	 	  	 	  	 	 	  	 	 
 ID  	 	  	 	  	 	 	  	 	 
 ID  	 	  	 	  	 	 	  	 	 
-=:6<<G:<6I:>CIG>CH>8K6AJ:D;DEI>DCH:M:G8>H:99JG>C<I=:N:6GH:C9:9:8:B7:G  6C9L6HB>AA>DC 
B>AA>DC6C9B>AA>DC G:HE:8I>K:AN M:G8>H:D;DEI>DCH9JG>C<I=:N:6GH:C9:9:8:B7:G  6C9
G:HJAI:9>C86H=G:8:>EIHD;B>AA>DC B>AA>DC6C9B>AA>DC G:HE:8I>K:AN .EDC:M:G8>H:D;I=:6L6G97NI=:
:BEADN:: I=:DBE6CN9:G>K:H6I6M9:9J8I>DCB:6HJG:97NI=::M8:HHD;I=:B6G@:IK6AJ:DK:GI=:<G6CIEG>8:6II=:96I:D;
:M:G8>H: -=:DBE6CNG:6A>O:96I6M7:C:;>ID;B>AA>DC B>AA>DC6C9B>AA>DC>C 6C9 G:HE:8I>K:AN 
G:A6I:9IDI=::M:G8>H:D;:BEADN::HID8@DEI>DCH 


-- 134 of 162 --

-=:;DAADL>C<HJBB6G>O:H>C;DGB6I>DCDCJCK:HI:9+,.6C9),.68I>K>IN>CB>AA>DCH :M8:EIL:><=I:96K:G6<:<G6CI 96I:;6>G
K6AJ:
#D<14A>5'(*B
%(*B
,4867C43
E4A064
A0=C0C4
08A+0;D4
*=E4BC430B>50=D0AH  	 	 	  	 	 
G6CI:9 	 	  	 	 
/:HI:9 	 	   	 
DG;:>I:9 	 	   	 
*=E4BC430B>5424<14A  	 	 	  	 	 
G6CI:9 	 	  	 	 
/:HI:9 	 	   	 
DG;:>I:9 	 	   	 
9?JHIB:CI9J:IDCK>HI6,EA>I (;; 6 	 	   	 
*=E4BC430B>5424<14A  	 	 	  	 	 
G6CI:9 	 	  	 	 
/:HI:9 	 	   	 
DG;:>I:9 	 	   	 
*=E4BC430B>5424<14A  	 	  	 	 
6 -=:U9?JHIB:CI9J:IDCK>HI6,EA>I (;;VG:;A:8IHI=:86C8:AA6I>DCD;+,.H6C9),.HL=>8=L:G:DJIHI6C9>C<6HD;:8:B7:G 
6C9=:A97NCK>HI6:BEADN::HL=>8==6K:7::CI:GB>C6I:96C9G:EA68:97NCK>HI6:FJ>IN6L6G9H6HE6GID;I=:CK>HI6,EA>I (;;
-=:DBE6CNG:6A>O:96I6M7:C:;>ID;B>AA>DC B>AA>DC6C9B>AA>DC>CI=:N:6GH:C9:9:8:B7:G  
6C9 G:HE:8I>K:AN G:A6I:9IDI=:K:HI>C<D;+,.H 
-=::M8:HHI6M7:C:;>ID;B>AA>DC B>AA>DC6C9B>AA>DCG:A6I:9IDI=::M:G8>H:D;:BEADN::HID8@DEI>DCH6C9K:HI>C<
D;+,.H;DGI=:N:6GH:C9:9:8:B7:G  6C9 G:HE:8I>K:AN =6H7::CG:8DG9:96H6G:9J8I>DCIDI=:8JGG:CI
>C8DB:I6MEGDK>H>DC6C9>HG:;A:8I:96H6CDE:G6I>C<86H=>C;ADL>CI=:688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;6H=ADLH 
"C8DCC:8I>DCL>I=I=::M:G8>H:D;8:GI6>CHID8@DEI>DCH6C9I=:K:HI>C<D;+,.HEG:K>DJHAN>HHJ:97NI=:DBE6CN 6CJB7:G
D;H=6G:HHJ;;>8>:CIID;JC9HI6IJIDGNB>C>BJBI6ML>I==DA9>C<G:FJ>G:B:CIH=6H7::CL>I==:A9;GDBI=:IDI6AH=6G:H>HHJ:9DG
G:A:6H:9IDI=:6L6G9=DA9:GI=DJ<=JC9:GI=:I:GBHD;I=:6EEA>867A:EA6C I=:H=6G:H6G:8DCH>9:G:9ID=6K:7::C>HHJ:96C9
6G:CDI699:9768@IDI=:EDDAD;H=6G:H6K6>A67A:;DG<G6CI JG>C<I=:N:6G:C9:9:8:B7:G  I=DJH6C9H=6G:H
L>I=6C6<<G:<6I:K6AJ:D;B>AA>DCL:G:L>I==:A9IDH6I>H;NI=:G:FJ>G:B:CI JG>C<I=:N:6G:C9:9:8:B7:G  
I=DJH6C9H=6G:HL>I=6C6<<G:<6I:K6AJ:D;B>AA>DCL:G:L>I==:A9IDH6I>H;NI=:G:FJ>G:B:CI -=:L>I==DA9>C<>H
IG:6I:96H6G:9J8I>DC>C699>I>DC6AE6>9 >C86E>I6A>CI=:688DBE6CN>C<DCHDA>96I:9,I6I:B:CIHD;,ID8@=DA9:GHWFJ>IN6C96
G:9J8I>DC>CEGD8::9H;GDBI=:>HHJ6C8:D;8DBBDCHID8@>C8DCC:8I>DCL>I=HID8@ 76H:98DBE:CH6I>DC>CI=:DCHDA>96I:9
,I6I:B:CIHD;6H=ADLH
#$) 	#)'##(%'$""$#(''$"$#)#*#$%')$#(
6H>8C:I:6GC>C<HE:GH=6G:U),V;GDB8DCI>CJ>C<DE:G6I>DCH>H86A8JA6I:97NI6@>C<C:I:6GC>C<H;GDB8DCI>CJ>C<
DE:G6I>DCHA:HHI=:&),9>K>9:C9H9>K>9:97NI=:L:><=I:96K:G6<:CJB7:GD;8DBBDCH=6G:HDJIHI6C9>C<;DGI=:6EEA>867A:
E:G>D9 >AJI:9C:I),;GDB8DCI>CJ>C<DE:G6I>DCH>H8DBEJI:97NI6@>C<C:I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCHEAJHI=:
>CI:G:HIDCI=:DBE6CNWH%2('HA:HHI=:&),9>K>9:C9H9>K>9:97NI=:L:><=I:96K:G6<:CJB7:GD;8DBBDCH=6G:H
DJIHI6C9>C<>C8G:6H:97NI=:CJB7:GD;699>I>DC6AH=6G:HI=6ILDJA9=6K:7::CDJIHI6C9>C<=69I=:EDI:CI>6AAN9>AJI>K:8DBBDC
H=6G:H7::C>HHJ:96C9G:9J8:97NI=:CJB7:GD;H=6G:HI=:DBE6CN8DJA9=6K:G:EJG8=6H:9L>I=I=:EGD8::9H;GDBI=:
>HHJ6C8:D;I=:EDI:CI>6AAN9>AJI>K:H=6G:H DGI=:N:6GH:C9:9:8:B7:G 6C9 B>AA>DCDEI>DCHIDEJG8=6H:
H=6G:HL:G:CDI>C8AJ9:9>CI=:9>AJI:9:6GC>C<HE:GH=6G:86A8JA6I>DC6HI=:>BE68ID;I=:>G>C8AJH>DCLDJA9=6K:7::C6CI>
9>AJI>K: DGI=:N:6G:C9:9:8:B7:G  CDDEI>DCHIDEJG8=6H:H=6G:HL:G::M8AJ9:9;GDBI=:9>AJI:9:6GC>C<HE:G
H=6G:86A8JA6I>DC 6H>86C99>AJI:9),6G:8DBEJI:9>C9:E:C9:CIAN;DG:68=FJ6GI:G6C96CCJ6AE:G>D9 L=>8=>CKDAK:HI=:
JH:D;9>;;:G:CIL:><=I:9 6K:G6<:H=6G:8DJCI;><JG:HG:A6I>C<IDFJ6GI:GAN6C96CCJ6AE:G>D9H H6G:HJAI 6C96;I:G;68IDG>C<
I=::;;:8ID;GDJC9>C<IDI=:C:6G:HI8:CIE:GH=6G: I=:HJBD;EG>DGFJ6GI:G ID 96I:),;><JG:HB6NCDI:FJ6A6CCJ6A),


-- 135 of 162 --

-=:>BE68ID;I=:&),86A8JA6I:9JC9:GI=:>; 8DCK:GI:9B:I=D9L6H6CI> 9>AJI>K: 6C96HHJ8=B>AA>DC6C9B>AA>DC
H=6G:HJC9:GAN>C<I=:&),6HHJB>C<68DCK:GH>DCG6I>D76H:9DCI=::8:B7:G 6C9H=6G:EG>8:H G:HE:8I>K:AN
L:G::M8AJ9:9;GDBI=:9>AJI:9),86A8JA6I>DC;DGI=:N:6GH:C9:9:8:B7:G 6C9 G:HE:8I>K:AN
"C;DGB6I>DCG:A6I:9IDI=:86A8JA6I>DCD;C:I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCHE:GH=6G:D;8DBBDCHID8@;DGI=:N:6GH:C9:9
:8:B7:G>HHJBB6G>O:96H;DAADLH6C9H=6G:H>CB>AA>DCH :M8:EIE:GH=6G:6BDJCIH
 	
'JB:G6IDG
':I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH 	 	  	 	  	 	 
&),9>K>9:C9H 	  	  	T
':I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH6IIG>7JI67A:ID8DBBDC
HID8@=DA9:GH;DG6H>8), 	 	  	 	  	 	 
9?JHIB:CI;DG>CI:G:HIDC8DCK:GI>7A:9:7:CIJG:H 	 	 	 	 	 	
':I:6GC>C<H;GDB8DCI>CJ>C<DE:G6I>DCH6IIG>7JI67A:ID8DBBDC
HID8@=DA9:GH6;I:G6HHJB:98DCK:GH>DCH;DG>AJI:9), 	 	  	 	  	 	 
:CDB>C6IDG
0:><=I:96K:G6<:8DBBDCH=6G:HDJIHI6C9>C<JH:9>C6H>8), 	 	  	 	  	 	 
"C8G:B:CI6A8DBBDCH=6G:H;GDB
HHJB:9:M:G8>H:D;9>AJI>K:DEI>DCH6C9K:HI>C<D;9>AJI>K:+,.H6C9
),.H 	 	  	 	  	 	 
HHJB:98DCK:GH>DCD;I=:8DCK:GI>7A:9:7:CIJG:H 	 	  	 	  	 	 
0:><=I:96K:G6<:8DBBDCH=6G:HDJIHI6C9>C<JH:9>C>AJI:9), 	 	  	 	  	 	 
6H>8),;GDB8DCI>CJ>C<DE:G6I>DCH 	 	  	 	  	 	 
>AJI:9),;GDB8DCI>CJ>C<DE:G6I>DCH 	 	  	 	  	 	 


-- 136 of 162 --

#$) 	("#)#$'")$#
-=:DBE6CNDE:G6I:H6C9G:EDGIH>IHG:HJAIH>CI=G::H:E6G6I:7JH>C:HHH:<B:CIH8DCH>HI>C<D;I=:%>;:,8>:C8:H >6<CDHI>8H
6C9CK>GDCB:CI6AEEA>:9,DAJI>DCHH:<B:CIH 0=:C9:I:GB>C>C<I=:G:EDGI67A:H:<B:CIH I=:DBE6CN6<<G:<6I:9
DE:G6I>C<H:<B:CIH76H:9DCI=:>GH>B>A6G:8DCDB>86C9DE:G6I>C<8=6G68I:G>HI>8H (E:G6I>C<EGD;>IG:EG:H:CIHIDI6AG:K:CJ:H
A:HHDE:G6I>C<:ME:CH:H :M8AJ9>C<CDCDE:G6I>C<>C8DB:6C9:ME:CH: >CI:G:HI6C9>C8DB:I6M:H (E:G6I>C<EGD;>I6BDJCIH>C
I=:(I=:GH:<B:CI8DCH>HID;JC6AAD86I:98DGEDG6I:8DHIH6C9DI=:G8DHIHCDI8DCH>9:G:9E6GID;B6C6<:B:CIWH:K6AJ6I>DCD;
G:EDGI67A:H:<B:CIDE:G6I>C<E:G;DGB6C8: -=:>9:CI>;>67A:6HH:IH7NH:<B:CI6G:I=DH:JH:9>C:68=H:<B:CIWHDE:G6I>DCH 
"CI:GH:<B:CI6BDJCIH6G:CDIH><C>;>86CI6C96G::A>B>C6I:9ID6GG>K:6I8DCHDA>96I:9IDI6AH
:I6>A:9H:<B:CI96I6;DGI=:N:6GH:C9:9:8:B7:G>H6H;DAADLH>CB>AA>DCH
 	
,6A:H
%>;:,8>:C8:H 	 	  	 	  	 	 
>6<CDHI>8H 	 	  	 	  	 	 
CK>GDCB:CI6AEEA>:9,DAJI>DCH 	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	 
(E:G6I>C<EGD;>I
%>;:,8>:C8:H 	 	  	 	  	 	 
>6<CDHI>8H 	 	  	 	  	 	 
CK>GDCB:CI6AEEA>:9,DAJI>DCH 	 	 	 	  	 	
(I=:G 	 	  	  	
-DI6A 	 	  	 	  	 	 
"9:CI>;>67A:6HH:IH
%>;:,8>:C8:H 	 	  	 	  	 	 
>6<CDHI>8H 	 	  	 	  	 	 
CK>GDCB:CI6AEEA>:9,DAJI>DCH 	 	  	 	  	 	 
(I=:G 	 	  	 	  	 	 
>H8DCI>CJ:9DE:G6I>DCH 	 	T 	 	T 	 	 
-DI6A 	 	  	 	  	 	 
:EG:8>6I>DC6C96BDGI>O6I>DC
%>;:,8>:C8:H 	 	  	 	 	 	
>6<CDHI>8H 	 	 	 	 	 	
CK>GDCB:CI6AEEA>:9,DAJI>DCH 	 	 	 	 	 	
(I=:G 	 	 	 	 	 	
-DI6A 	 	  	 	  	 	 
6E>I6A:ME:C9>IJG:H <GDHH
%>;:,8>:C8:H 	 	 	 	 	 	
>6<CDHI>8H 	 	 	 	 	 	
CK>GDCB:CI6AEEA>:9,DAJI>DCH 	 	 	 	 	 	
(I=:G 	 	 	 	 	 	
-DI6A 	 	 	 	 	 	


-- 137 of 162 --

$?4A0C8>=B8=4>6A0?7820;A40B
.40A=343424<14A
>CB>AA>DCH 	 	
,6A:H
.C>I:9,I6I:H 	 	  	 	  	 	 
=>C6 	 	  	 	  	 	 
:GB6CN 	 	  	 	  	 	 
AADI=:G:68=8DJCIGN>C9>K>9J6AANA:HHI=6CD;IDI6AH6A:H 	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	 
)GDE:GIN EA6CI6C9:FJ>EB:CI C:I
.C>I:9,I6I:H 	 	  	 	  	 	 
,L:9:C 	 	 	 	 	 	
.C>I:9$>C<9DB 	 	 	 	 	 	
:GB6CN 	 	 	 	 	 	
AADI=:G:68=8DJCIGN>C9>K>9J6AANA:HHI=6CD;IDI6AEGDE:GIN EA6CI
6C9:FJ>EB:CI C:I 	 	 	 	 	 	
-DI6A 	 	  	 	  	 	 
(0;4B1H"09>A%A>3D2CA>D?
.40A=343424<14A
>CB>AA>DCH 	 	
C6ANI>86A6C9E=NH>86A>CHIGJB:CI6I>DC 	 	  	 	  	 	 
+:H:6G8=6C9B:9>86AEGD9J8IH 	 	  	 	  	 	 
)GD9J8I>9:CI>;>86I>DC 	 	  	 	  	 	 
-DI6A 	 	  	 	  	 	 


-- 138 of 162 --

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
Not applicable.
ITEM 9A. CONTROLS AND PROCEDURES
The Company’s management, with the participation of the Company’s President and Chief Executive Officer, and Executive
Vice President and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and
procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the Company’s President
and Chief Executive Officer, and Executive Vice President and Chief Financial Officer, have concluded that, as of the end of
such period, the Company’s disclosure controls and procedures were effective.
Management’s annual report on its internal control over financial reporting (as such term is defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act) and the independent registered public accounting firm’s audit report on the effectiveness of
Danaher’s internal control over financial reporting are included in the Company’s financial statements for the year ended
December 31, 2020 included in Item 8 of this Annual Report on Form 10-K, under the headings “Report of Management on
Danaher Corporation’s Internal Control Over Financial Reporting” and “Report of Independent Registered Public Accounting
Firm,” respectively, and are incorporated herein by reference.
There have been no changes in the Company’s internal control over financial reporting (as such term is defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the Company’s most recent completed fiscal quarter that
have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
ITEM 9B. OTHER INFORMATION
Not applicable.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Other than the information below, the information required by this Item is incorporated by reference from the sections entitled
Proposal 1–Election of Directors of Danaher, Corporate Governance and Other Information in the Proxy Statement for the
Company’s 2021 annual meeting of shareholders and from the information under the caption “Information About Our
Executive Officers” in Part I hereof. No nominee for director was selected pursuant to any arrangement or understanding
between the nominee and any person other than the Company pursuant to which such person is or was to be selected as a
director or nominee.
Code of Ethics
Danaher has adopted a code of business conduct and ethics for directors, officers (including Danaher’s principal executive
officer, principal financial officer and principal accounting officer) and employees, known as the Code of Conduct. The Code
of Conduct is available in the “Investors—Corporate Governance” section of Danaher’s website at www.danaher.com.
Danaher intends to disclose any amendment to the Code of Conduct that relates to any element of the code of ethics definition
enumerated in Item 406(b) of Regulation S-K, and any waiver from a provision of the Code of Conduct granted to any director,
principal executive officer, principal financial officer, principal accounting officer, or any of its other executive officers, in the
“Investors—Corporate Governance” section of its website, at www.danaher.com, within four business days following the date
of such amendment or waiver.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item is incorporated by reference from the sections entitled Director Compensation,
Compensation Discussion and Analysis, Compensation Committee Report, Compensation Tables and Information and
Summary of Employment Agreements and Plans in the Proxy Statement for the Company’s 2021 annual meeting of
shareholders (provided that the Compensation Committee Report shall not be deemed to be “filed”).
117

-- 139 of 162 --

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information required by this Item is incorporated by reference from the sections entitled Beneficial Ownership of Danaher
Common Stock by Directors, Officers and Principal Shareholders, Summary of Employment Agreements and Plans and
Compensation Tables and Information in the Proxy Statement for the Company’s 2021 annual meeting of shareholders.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this Item is incorporated by reference from the section entitled Director Independence and
Related Person Transactions in the Proxy Statement for the Company’s 2021 annual meeting of shareholders.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this Item is incorporated by reference from the section entitled Proposal 2–Ratification of
Independent Registered Public Accounting Firm in the Proxy Statement for the Company’s 2021 annual meeting of
shareholders.
118

-- 140 of 162 --

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
a) The following documents are filed as part of this report.
(1) Financial Statements. The financial statements are set forth under “Item 8. Financial Statements and Supplementary
Data” of this Annual Report on Form 10-K.
(2) Schedules. An index of Exhibits and Schedules is on page 120 of this report. Schedules other than those listed below
have been omitted from this Annual Report on Form 10-K because they are not required, are not applicable or the
required information is included in the financial statements or the notes thereto.
(3) Exhibits. The exhibits listed in the accompanying Exhibit Index are filed or incorporated by reference as part of this
Annual Report on Form 10-K.
ITEM 16. FORM 10-K SUMMARY
Not applicable.
119

-- 141 of 162 --

#'$'%$')$#
#-)$##!())"#)((*%%!"#)'.)###!())"#)(*!
 %064#D<14A8=
>A< 
,8=:9JA:
/6AJ6I>DC6C9*J6A>;N>C<88DJCIH 	 	
-)#-
G7818C#D<14A 	4B2A8?C8>=
  	FJ>IN6C9HH:I)JG8=6H:<G::B:CI96I:96HD;
:7GJ6GN  7N6C97:IL::C :C:G6AA:8IG>8
DBE6CN6C96C6=:GDGEDG6I>DC
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9:7GJ6GN 
  	>GHIB:C9:96C9+:HI6I:9FJ>IN6C9HH:I
)JG8=6H:<G::B:CI96I:96HD;&6G8=  7N
6C97:IL::C :C:G6AA:8IG>8DBE6CN6C96C6=:G
DGEDG6I>DC
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9DCEG>A 
  	+:HI6I:9:GI>;>86I:D;"C8DGEDG6I>DCD;6C6=:G
DGEDG6I>DC "C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWH*J6GI:GAN+:EDGIDCDGB
 *;DGI=:FJ6GI:G:C9:9#JC: 
  	:GI>;>86I:D;:H><C6I>DCHD;I=: &6C96IDGN
DCK:GI>7A:)G:;:GG:9,ID8@ ,:G>:H
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9&6G8= 
  	:GI>;>86I:D;:H><C6I>DCHD;I=: &6C96IDGN
DCK:GI>7A:)G:;:GG:9,ID8@ ,:G>:H "C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9&6N 
  	B:C9:96C9+:HI6I:9N A6LHD;6C6=:G
DGEDG6I>DC "C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9:8:B7:G 
  	,:C>DG"C9:CIJG:96I:96HD;:8:B7:G 7N
6C97:IL::C6C6=:GDGEDG6I>DC6C9-=:6C@D;
':L2DG@&:AADC-GJHIDBE6CN '  6HIGJHI::
U,:C>DG"C9:CIJG:V
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9DC:8:B7:G 
  	>GHI,JEEA:B:CI6A"C9:CIJG:ID,:C>DG"C9:CIJG: 
96I:96HD;,:EI:B7:G  7N6C97:IL::C
6C6=:GDGEDG6I>DC6C9-=:6C@D;':L2DG@
&:AADC-GJHIDBE6CN '  6HIGJHI::
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9,:EI:B7:G 
  	"C9:CIJG:96I:96HD;#JAN  7N6C97:IL::C
6C6=:GDGEDG6I>DC 6H<J6G6CIDG !JGDE:
>C6C8:, 6 G A 6H>HHJ:G 6C9-=:6C@D;':L
2DG@&:AADC-GJHIDBE6CN '  6HIGJHI::
U6C6=:G"CI:GC6I>DC6A"C9:CIJG:V
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9DC#JAN 
  	>GHI,JEEA:B:CI6A"C9:CIJG:ID6C6=:G
"CI:GC6I>DC6A"C9:CIJG: 96I:96HD;#JAN  7N
6C97:IL::C6C6=:GDGEDG6I>DC 6H<J6G6CIDG !
JGDE:>C6C8:,  6H>HHJ:G 6C9-=:6C@D;
':L2DG@&:AADC-GJHIDBE6CN '  6HIGJHI::
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9DC#JAN 
  	)6N>C<6C96A8JA6I>DC<:C8N<G::B:CI 96I:96H
D;#JAN  7N6C96BDC<6C6=:G
"CI:GC6I>DC6A 6C6=:GDGEDG6I>DC 6C9-=:6C@D;
':L2DG@&:AADC %DC9DCG6C8= 6HE6N>C<6C9
86A8JA6I>DC6<:CI
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9DC#JAN 
  	,:8DC9,JEEA:B:CI6A"C9:CIJG:ID6C6=:G
"CI:GC6I>DC6A"C9:CIJG: 96I:96HD;#JC:  
7N6C97:IL::C6C6=:GDGEDG6I>DC 6H<J6G6CIDG 
!JGDE:>C6C8:, 6 G A 6H>HHJ:G 6C9-=:6C@
D;':L2DG@&:AADC-GJHIDBE6CN '  6H
IGJHI::
"C8DGEDG6I:97NG:;:G:C8:;GDBM=>7>I ID
6C6=:GDGEDG6I>DCWHJGG:CI+:EDGIDCDGB $
;>A:9DC#JC: 


-- 142 of 162 --

4.7 Paying and Calculation Agency Agreement, dated as
of June 30, 2017, by and among Danaher
International, Danaher Corporation, The Bank of
New York Mellon Trust Company, N.A. as trustee
and The Bank of New York Mellon, London Branch,
as paying and calculation agent
Incorporated by reference from Exhibit 4.3 to
Danaher Corporation’s Current Report on Form 8-K
filed on June 30, 2017
4.8 Second Supplemental Indenture to Senior Indenture,
dated as of July 1, 2019 between Danaher
Corporation and The Bank of New York Mellon
Trust Company, N.A., as trustee
Incorporated by reference from Exhibit 4.2 to
Danaher Corporation’s Post-Effective Amendment
No. 1 to Registration Statement on Form S-3 filed
July 10, 2019
4.9 Third Supplemental Indenture to Senior Indenture,
dated as of March 30, 2020 between Danaher
Corporation and The Bank of New York Mellon
Trust Company, N.A., as trustee
Incorporated by reference from Exhibit 4.3 to
Danaher Corporation’s Current Report on Form 8-K
filed on March 30, 2020
4.10 Fourth Supplemental Indenture to Senior Indenture,
dated as of October 6, 2020 between Danaher
Corporation and The Bank of New York Mellon
Trust Company, N.A., as trustee
Incorporated by reference from Exhibit 4.4 to
Danaher Corporation’s Current Report on Form 8-K
filed on October 6, 2020
4.11 Third Supplemental Indenture to Danaher
International Indenture, dated as of July 1, 2019
among DH Europe Finance S.à r.l., as issuer,
Danaher Corporation, as guarantor and The Bank of
New York Mellon Trust Company, N.A., as trustee
Incorporated by reference from Exhibit 4.5 to
Danaher Corporation’s Post-Effective Amendment
No. 1 to Registration Statement on Form S-3 filed
July 10, 2019
4.12 Base Indenture, dated as of September 18, 2019,
among DH Europe Finance II S.à r.l., as issuer,
Danaher Corporation, as guarantor and The Bank of
New York Mellon Trust Company, N.A., as trustee
(“Danaher International II Indenture”)
Incorporated by reference from Exhibit 4.1 to
Danaher Corporation’s Current Report on Form 8-K
filed September 18, 2019
4.13 First Supplemental Indenture to Danaher
International II Indenture, dated as of September 18,
2019, among DH Europe Finance II S.à r.l., as
issuer, Danaher Corporation, as guarantor and The
Bank of New York Mellon Trust Company, N.A., as
trustee
Incorporated by reference from Exhibit 4.2 to
Danaher Corporation’s Current Report on Form 8-K
filed September 18, 2019
4.14 Specimen Certificate of the 4.75% Mandatory
Convertible Preferred Stock, Series A Included in Exhibit 3.2 above
4.15 Specimen Certificate of the 5.00% Mandatory
Convertible Preferred Stock, Series B Included in Exhibit 3.3 above
4.16 Description of Securities Registered Under Section
12 of the Exchange Act
10.1 Danaher Corporation 2007 Omnibus Incentive Plan,
as amended and restated* Incorporated by reference from Exhibit 10.1 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended June 30, 2017
10.2 Danaher Corporation Non-Employee Directors’
Deferred Compensation Plan, as amended, a sub-
plan under the 2007 Omnibus Incentive Plan*
Incorporated by reference from Exhibit 10.2 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2008
10.3 Amended Form of Election to Defer under the
Danaher Corporation Non-Employee Directors’
Deferred Compensation Plan*
Incorporated by reference from Exhibit 10.3 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2008
10.4 Form of Danaher Corporation 2007 Omnibus
Incentive Plan Stock Option Agreement for Non-
Employee Directors*
10.5 Form of Danaher Corporation 2007 Omnibus
Incentive Plan RSU Agreement for Non-Employee
Directors*
10.6 Form of Danaher Corporation 2007 Omnibus
Incentive Plan Stock Option Agreement*
121

-- 143 of 162 --

10.7 Form of Danaher Corporation 2007 Omnibus
Incentive Plan RSU Agreement*
10.8 Form of Danaher Corporation 2007 Omnibus
Incentive Plan PSU Agreement*
10.9 Danaher Corporation & Subsidiaries Amended and
Restated Executive Deferred Incentive Program* Incorporated by reference from Exhibit 10.8 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2018
10.10 Amendment to Danaher Corporation & Subsidiaries
Amended and Restated Executive Deferred Incentive
Program*
Incorporated by reference from Exhibit 10.14 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended September 27, 2019
10.11 Danaher Corporation Excess Contribution Program,
a sub-plan under the 2007 Omnibus Incentive Plan,
as amended and restated*
Incorporated by reference from Exhibit 10.9 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2018
10.12 Amendment to Danaher Excess Contribution
Program* Incorporated by reference from Exhibit 10.15 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended September 27, 2019
10.13 Amended and Restated Danaher Corporation
Deferred Compensation Plan* Incorporated by reference from Exhibit 10.12 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended September 27, 2019
10.14 Amendment to Amended and Restated Danaher
Corporation Deferred Compensation Plan* Incorporated by reference from Exhibit 10.13 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended September 27, 2019
10.15 Danaher Corporation Senior Leader Severance Pay
Plan* Incorporated by reference from Exhibit 10.1 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended March 29, 2013
10.16 Agreement Regarding Competition and Protection of
Proprietary Interests by and between Danaher
Corporation and Thomas P. Joyce, Jr., dated March
16, 2009*
Incorporated by reference from Exhibit 10.16 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2014
10.17 Amendment to Agreement Regarding Competition
and Protection of Proprietary Interests by and
between Danaher Corporation and Thomas P. Joyce,
Jr., dated September 11, 2014*
Incorporated by reference from Exhibit 10.1 to
Danaher Corporation’s Current Report on Form 8-K
filed on September 15, 2014
10.18 Agreement by and between Danaher Corporation
and Thomas P. Joyce, Jr., dated May 6, 2020* Incorporated by reference from Exhibit 10.1 to
Danaher Corporation’s Current Report on Form 8-K
filed May 6, 2020
10.19 Amended and Restated Agreement Regarding
Competition and Protection of Proprietary Interests
by and between Danaher Corporation and Rainer M.
Blair, dated May 6, 2020*
Incorporated by reference from Exhibit 10.2 to
Danaher Corporation’s Current Report on Form 8-K
filed May 6, 2020
10.20 Agreement Regarding Competition and Protection of
Proprietary Interests by and between Danaher
Corporation and Joakim Weidemanis, dated as of
May 15, 2020*
Incorporated by reference from Exhibit 10.3 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended July, 3, 2020
10.21 Agreement Regarding Competition and Protection of
Proprietary Interests by and between Danaher
Corporation and Matthew McGrew dated November
7, 2018*
Incorporated by reference from Exhibit 10.2 to
Danaher Corporation’s Current Report on Form 8-K
filed on November 8, 2018
10.22 Agreement Regarding Competition and Protection of
Proprietary Interests by and between Danaher
Corporation and Angela S. Lalor dated March 23,
2012*
Incorporated by reference from Exhibit 10.16 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2016
122

-- 144 of 162 --

10.23 Agreement Regarding Competition and Protection of
Proprietary Interests by and between Danaher
Corporation and Brian W. Ellis dated December 7,
2015*
Incorporated by reference from Exhibit 10.18 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2016
10.24 Letter Agreement by and between Danaher
Corporation and Angela S. Lalor, dated March 19,
2012*
Incorporated by reference from Exhibit 10.14 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2012
10.25 Letter Agreement by and between Danaher
Corporation and Brian W. Ellis, dated November 18,
2015*
Incorporated by reference from Exhibit 10.19 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2016
10.26 Description of compensation arrangements for non-
management directors* Incorporated by reference from Exhibit 10.22 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2019
10.27 Management Agreement dated February 23, 2012 by
and between FJ900, Inc. and Joust Capital III, LLC
(1)
Incorporated by reference from Exhibit 10.25 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2011
10.28 Interchange Agreement dated July 22, 2011 by and
between Danaher Corporation and Joust Capital III,
LLC (2)
Incorporated by reference from Exhibit 10.10 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended July 1, 2011
10.29 Aircraft Time Sharing Agreement by and between
Danaher Corporation and Rainer M. Blair, dated as
of August 3, 2020* (3)
Incorporated by reference from Exhibit 10.1 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended October 2, 2020
10.30 Amendment No. 1 to Aircraft Time Sharing
Agreement by and between Danaher Corporation
and Thomas P. Joyce, Jr., dated July 1, 2016*
Incorporated by reference from Exhibit 10.7 to
Danaher Corporation’s Quarterly Report on Form
10-Q for the quarter ended July 1, 2016
10.31 Form of Director and Officer Indemnification
Agreement Incorporated by reference from Exhibit 10.35 to
Danaher Corporation’s Annual Report on Form 10-
K for the year ended December 31, 2008
10.32 Second Amended and Restated Credit Agreement,
dated as of August 27, 2019, among Danaher
Corporation, certain of its subsidiaries party thereto,
Bank of America, N.A., as Administrative Agent and
a Swing Line Lender, and the lenders referred to
therein
Incorporated by reference from Exhibit 10.1 to
Danaher Corporation’s Current Report on Form 8-K
filed August 29, 2019
10.33 Amendment No. 1 to Second Amended and Restated
Credit Agreement, dated as of September 20, 2019,
among Danaher Corporation, Bank of America,
N.A., Bank of America, N.A. London Branch and
Citibank, N.A. , each in their respective roles as a
Swing Line Lender, Bank of America, N.A. as
Administrative Agent and the lenders referred to
therein
Incorporated by reference from Exhibit 10.8 to
Danaher Corporation’s Report on Form 10-Q for the
quarter ended September 27, 2019
10.34 Amendment No. 2 to Second Amended and Restated
Credit Agreement, dated as of October 7, 2019,
among Danaher Corporation, Bank of America,
N.A., Bank of America, N.A. London Branch and
Citibank, N.A. , each in their respective roles as a
Swing Line Lender, Bank of America, N.A. as
Administrative Agent and the lenders referred to
therein
Incorporated by reference from Exhibit 10.9 to
Danaher Corporation’s Report on Form 10-Q for the
quarter ended September 27, 2019
21.1 Subsidiaries of Registrant
22.1 Subsidiary guarantors and issuers of guaranteed
securities and affiliates whose securities collateralize
securities of the Registrant
23.1 Consent of Independent Registered Public
Accounting Firm
123

-- 145 of 162 --

31.1 Certification of Chief Executive Officer Pursuant to
Item 601(b)(31) of Regulation S-K, as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002
31.2 Certification of Chief Financial Officer Pursuant to
Item 601(b)(31) of Regulation S-K, as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002
32.1 Certification of Chief Executive Officer, Pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of Chief Financial Officer, Pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because
its XBRL tags are embedded within the Inline XBRL document. (4)
101.SCH Inline XBRL Taxonomy Extension Schema Document (4)
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document (4)
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document (4)
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document (4)
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document (4)
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Danaher is a party to additional long-term debt instruments under which, in each case, the total amount of debt authorized does
not exceed 10% of the total assets of Danaher and its subsidiaries on a consolidated basis. Pursuant to paragraph 4(iii)(A) of
Item 601(b) of Regulation S-K, Danaher agrees to furnish a copy of such instruments to the Securities and Exchange
Commission upon request.
+ The schedules have been omitted from this filing pursuant to Item 601 of Regulation S-K because they do not contain
information material to an investment or voting decision and that information is not otherwise disclosed in the exhibit or this
filing. Danaher will furnish copies of such schedules to the Securities and Exchange Commission upon request.
* Indicates management contract or compensatory plan, contract or arrangement.
(1) In accordance with Instruction 2 to Item 601(a)(4) of Regulation S-K, FJ900, Inc. (a subsidiary of Danaher) has entered into
a management agreement with Joust Capital II, LLC that is substantially identical in all material respects to the form of
agreement referenced as Exhibit 10.27, except as to the referenced aircraft and the name of the counterparty.
(2) In accordance with Instruction 2 to Item 601(a)(4) of Regulation S-K, Danaher Corporation or a subsidiary thereof has
entered into additional interchange agreements with each of Joust Capital II, LLC and Joust Capital III, LLC that are
substantially identical in all material respects to the form of agreement attached as Exhibit 10.28, except as to the referenced
aircraft and, in certain cases, the name of the counterparty.
(3) In accordance with Instruction 2 to Item 601(a)(4) of Regulation S-K, Danaher Corporation has entered into an aircraft time
sharing agreement with Thomas P. Joyce, Jr. and Matthew R. McGrew that is substantially identical in all material respects
to the form of agreement referenced as Exhibit 10.29.
(4) Attached as Exhibit 101 to this report are the following documents formatted in Inline XBRL (Inline Extensible Business
Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2020 and 2019, (ii) Consolidated Statements of
Earnings for the years ended December 31, 2020, 2019 and 2018, (iii) Consolidated Statements of Comprehensive Income
for the years ended December 31, 2020, 2019 and 2018, (iv) Consolidated Statements of Stockholders’ Equity for the years
ended December 31, 2020, 2019 and 2018, (v) Consolidated Statements of Cash Flows for the years ended December 31,
2020, 2019 and 2018 and (vi) Notes to Consolidated Financial Statements.
124

-- 146 of 162 --

(#)*'(
)JGHJ6CIIDI=:G:FJ>G:B:CIHD;,:8I>DCDG9D;I=:,:8JG>I>:HM8=6C<:8ID; I=:+:<>HIG6CI=6H9JAN86JH:9I=>H
G:EDGIID7:H><C:9DC>IH7:=6A;7NI=:JC9:GH><C:9 I=:G:JCID9JAN6JI=DG>O:9
#'$'%$')$#
6I: 	:7GJ6GN  	N 	 	H +"'+& %"+
 	+6>C:G& A6>G
 	)G:H>9:CI6C9=>:;M:8JI>K:(;;>8:G
)JGHJ6CIIDI=:G:FJ>G:B:CIHD;I=:,:8JG>I>:HM8=6C<:8ID; I=>H6CCJ6AG:EDGI=6H7::CH><C:97:ADL7NI=:;DAADL>C<
E:GHDCHDC7:=6A;D;I=:+:<>HIG6CI6C9>CI=:86E68>I>:H6C9DCI=:96I:>C9>86I:9
#0<4)8C;40=3(86=0CDA4 	0C4
H ,-/'& +%, 	:7GJ6GN 
,I:K:C& +6A:H
=6>GB6CD;I=:D6G9
H &"-!%%) +%, 	:7GJ6GN 
&>I8=:AA) +6A:H
=6>GB6CD;I=:M:8JI>K:DBB>II::
H %"'!'+"%%+ 	:7GJ6GN 
%>C96!:;C:G>AA:G
>G:8IDG
H +"'+& %"+ 	:7GJ6GN 
+6>C:G& A6>G
)G:H>9:CI =>:;M:8JI>K:(;;>8:G6C9>G:8IDG
H -+"%",- 	:7GJ6GN 
-:G>%>HI
>G:8IDG
H 0%-+ 	%(!+ #+ 	:7GJ6GN 
06AI:G 	%D=G #G
>G:8IDG
H #,,"% &  &  &)! 	:7GJ6GN 
#:HH>86% &:<6 &  &)!
>G:8IDG
H )+", ,-" &   )=>A 	:7GJ6GN 
)6G9>H ,67:I> &   )=>A
>G:8IDG
H #(!'- ,!0"-+, 	:7GJ6GN 
#D=C- ,8=L>:I:GH


-- 147 of 162 --

>G:8IDG
H %' 	,)((' 	:7GJ6GN 
A6C 	,EDDC
>G:8IDG
H +2&(' ,-/', )=  	:7GJ6GN 
+6NBDC9 ,I:K:CH )=  
>G:8IDG
H %", 3+!(.'" &  	:7GJ6GN 
A>6H 3:G=DJC> & 
>G:8IDG
H &--!0+ & +0 	:7GJ6GN 
&6II=:L+ &8 G:L
M:8JI>K:/>8:)G:H>9:CI6C9=>:;>C6C8>6A(;;>8:G
H +(+-, %.-3 	:7GJ6GN 
+D7:GI, %JIO
,:C>DG/>8:)G:H>9:CI6C9=>:;88DJCI>C<(;;>8:G


-- 148 of 162 --


 	 
&*".(&. ".0&#50%0
 	%2"."2&"3"!0%&/**1(",+.0+*+.) +#*%".+.,+.0&+*
 	/"!+*)5'*+3("!$"0%&/.",+.0!+"/*+0 +*0&**51*0.1"/00")"*0+#)0".&(# 0+.+)&00+/00")0".&(# 0
*" "//.50+)'"0%"/00")"*0/)!"&*(&$%0+#0%" &. 1)/0* "/1*!".3%& %/1 %/00")"*0/3".")!"*+0
)&/("!&*$3&0%."/," 00+0%",".&+! +2"."!50%&/.",+.0
 	/"!+*)5'*+3("!$"0%"#&** &(/00")"*0/*!+0%".#&** &(&*#+.)0&+*&* (1!"!&*0%&/.",+.0#&.(5,."/"*0&*
(()0".&(."/," 0/0%"#&** &( +*!&0&+*."/1(0/+#+,".0&+*/*! /%#(+3/+#0%"."$&/0.*0/+#*!#+.0%",".&+!/
,."/"*0"!&*0%&/.",+.0
 	%"."$&/0.*07/+0%". ".0&#5&*$+##& ".*!."."/,+*/&("#+."/0(&/%&*$*!)&*0&*&*$!&/ (+/1." +*0.+(/*!
,.+ "!1."//!"#&*"!&*4 %*$" 01("/ 	 	"*! 	! 	"*!&*0".*( +*0.+(+2".#&** &(.",+.0&*$/
!"#&*"!&*4 %*$" 01("/ 	 	#*! 	! 	##+.0%"."$&/0.*0*!%2"
 	"/&$*"!/1 %!&/ (+/1." +*0.+(/*!,.+ "!1."/+. 1/"!/1 %!&/ (+/1." +*0.+(/*!,.+ "!1."/0+"!"/&$*"!
1*!".+1./1,".2&/&+*0+"*/1."0%0)0".&(&*#+.)0&+*."(0&*$0+0%"."$&/0.*0&* (1!&*$&0/ +*/+(&!0"!
/1/&!&.&"/&/)!"'*+3*0+1/5+0%"./3&0%&*0%+/""*0&0&"/,.0& 1(.(5!1.&*$0%",".&+!&*3%& %0%&/.",+.0&/
"&*$,.",."!
 	"/&$*"!/1 %&*0".*( +*0.+(+2".#&** &(.",+.0&*$+. 1/"!/1 %&*0".*( +*0.+(+2".#&** &(.",+.0&*$0+"
!"/&$*"!1*!".+1./1,".2&/&+*0+,.+2&!"."/+*("//1.* "."$.!&*$0%"."(&&(&05+##&** &(.",+.0&*$*!0%"
,.",.0&+*+##&** &(/00")"*0/#+."40".*(,1.,+/"/&* 	+.!* "3&0%$"*".((5 	",0"! 	+1*0&*$,.&* &,("/
 	2(10"!0%""##" 0&2"*"//+#0%"."$&/0.*07/!&/ (+/1." +*0.+(/*!,.+ "!1."/*!,."/"*0"!&*0%&/.",+.0+1.
+* (1/&+*/+100%""##" 0&2"*"//+#0%"!&/ (+/1." +*0.+(/*!,.+ "!1."//+#0%""*!+#0%",".&+! +2"."!5
0%&/.",+.0/"!+*/1 %"2(10&+**!
! 	&/ (+/"!&*0%&/.",+.0*5 %*$"&*0%"."$&/0.*07/&*0".*( +*0.+(+2".#&** &(.",+.0&*$0%0+ 	1.."!!1.&*$0%"
."$&/0.*07/)+/0." "*0#&/ (-1.0".0%"."$&/0.*07/#+1.0%#&/ (-1.0".&*0%" /"+#***1(.",+.00%0%/
)0".&((5##" 0"!+.&/."/+*(5(&'"(50+)0".&((5##" 00%"."$&/0.*07/&*0".*( +*0.+(+2".#&** &(.",+.0&*$
*!
 	%"."$&/0.*07/+0%". ".0&#5&*$+##& ".*!%2"!&/ (+/"!/"!+*+1.)+/0." "*0"2(10&+*+#&*0".*( +*0.+(+2".
#&** &(.",+.0&*$0+0%"."$&/0.*07/1!&0+./*!0%"1!&0 +))&00""+#0%"."$&/0.*07/+.!+#!&." 0+./+.,"./+*/
,".#+.)&*$0%""-1&2("*0#1* 0&+*/
 	((/&$*&#& *0!"#& &"* &"/*!)0".&(3"'*"//"/&*0%"!"/&$*+.+,".0&+*+#&*0".*( +*0.+(+2".#&** &(
.",+.0&*$3%& %."."/+*(5(&'"(50+!2"./"(5##" 00%"."$&/0.*07/&(&050+." +.!,.+ "///1)).&6"*!
.",+.0#&** &(&*#+.)0&+**!
 	*5#.1!3%"0%".+.*+0)0".&(0%0&*2+(2"/)*$")"*0+.+0%"."),(+5""/3%+%2"/&$*&#& *0.+("&*0%"
."$&/0.*07/&*0".*( +*0.+(+2".#&** &(.",+.0&*$
0" ".1.5 	  	5 	/&*".(&.
)" 	&*".(&.
&0(" 	."/&!"*0*!%&"#4" 10&2"##& ".

-- 149 of 162 --


  	
 22'$5"0$5"$02(%72' 2
 	' 4$0$4($5$#2'(1,,3 *$.-02-,-0+ -% , '$0-0.-0 2(-,
 	 1$#-,+7),-5*$#&$2'(10$.-02#-$1,-2"-,2 (, ,73,203$12 2$+$,2-% + 2$0( *% "2-0-+(22-12 2$ + 2$0( *% "2
,$"$11 072-+ )$2'$12 2$+$,21+ #$(,*(&'2-%2'$"(0"3+12 ,"$13,#$05'("'13"'12 2$+$,215$0$+ #$,-2
+(1*$ #(,&5(2'0$1.$"22-2'$.$0(-#"-4$0$#!72'(10$.-02
 	 1$#-,+7),-5*$#&$2'$%(, ,"( *12 2$+$,21 ,#-2'$0%(, ,"( *(,%-0+ 2(-,(,"*3#$#(,2'(10$.-02% (0*7.0$1$,2(,
**+ 2$0( *0$1.$"212'$%(, ,"( *"-,#(2(-,0$13*21-%-.$0 2(-,1 ,#" 1'%*-51-%2'$0$&(120 ,2 1-% ,#%-02'$.$0(-#1
.0$1$,2$#(,2'(10$.-02
 	'$0$&(120 ,291-2'$0"$02(%7(,&-%%("$0 ,# 0$0$1.-,1(!*$%-0$12 !*(1'(,& ,#+ (,2 (,(,&#(1"*-130$"-,20-*1 ,#
.0-"$#30$1 1#$%(,$#(,6"' ,&$"23*$1 	 	$ ,# 	# 	$ ,#(,2$0, *"-,20-*-4$0%(, ,"( *0$.-02(,& 1
#$%(,$#(,6"' ,&$"23*$1 	 	% ,# 	# 	%%-02'$0$&(120 ,2 ,#' 4$
 	$1(&,$#13"'#(1"*-130$"-,20-*1 ,#.0-"$#30$1-0" 31$#13"'#(1"*-130$"-,20-*1 ,#.0-"$#30$12-!$#$1(&,$#
3,#$0-3013.$04(1(-,2-$,130$2' 2+ 2$0( *(,%-0+ 2(-,0$* 2(,&2-2'$0$&(120 ,2(,"*3#(,&(21"-,1-*(# 2$#
13!1(#( 0($1(1+ #$),-5,2-31!7-2'$015(2'(,2'-1$$,2(2($1. 02("3* 0*7#30(,&2'$.$0(-#(,5'("'2'(10$.-02(1
!$(,&.0$. 0$#
! 	$1(&,$#13"'(,2$0, *"-,20-*-4$0%(, ,"( *0$.-02(,&-0" 31$#13"'(,2$0, *"-,20-*-4$0%(, ,"( *0$.-02(,&2-!$
#$1(&,$#3,#$0-3013.$04(1(-,2-.0-4(#$0$ 1-, !*$ 1130 ,"$0$& 0#(,&2'$0$*( !(*(27-%%(, ,"( *0$.-02(,& ,#2'$
.0$. 0 2(-,-%%(, ,"( *12 2$+$,21%-0$62$0, *.30.-1$1(, ""-0# ,"$5(2'&$,$0 **7 ""$.2$# ""-3,2(,&.0(,"(.*$1
" 	4 *3 2$#2'$$%%$"2(4$,$11-%2'$0$&(120 ,291#(1"*-130$"-,20-*1 ,#.0-"$#30$1 ,#.0$1$,2$#(,2'(10$.-02-30
"-,"*31(-,1 !-322'$$%%$"2(4$,$11-%2'$#(1"*-130$"-,20-*1 ,#.0-"$#30$1 1-%2'$$,#-%2'$.$0(-#"-4$0$#!7
2'(10$.-02! 1$#-,13"'$4 *3 2(-, ,#
# 	(1"*-1$#(,2'(10$.-02 ,7"' ,&$(,2'$0$&(120 ,291(,2$0, *"-,20-*-4$0%(, ,"( *0$.-02(,&2' 2-""300$##30(,&2'$
0$&(120 ,291+-120$"$,2%(1" */3 02$02'$0$&(120 ,291%-302'%(1" */3 02$0(,2'$" 1$-% , ,,3 *0$.-022' 2' 1
+ 2$0( **7 %%$"2$#-0(10$ 1-, !*7*()$*72-+ 2$0( **7 %%$"22'$0$&(120 ,291(,2$0, *"-,20-*-4$0%(, ,"( *0$.-02(,&
,#
 	'$0$&(120 ,291-2'$0"$02(%7(,&-%%("$0 ,#' 4$#(1"*-1$#! 1$#-,-30+-120$"$,2$4 *3 2(-,-%(,2$0, *"-,20-*-4$0
%(, ,"( *0$.-02(,&2-2'$0$&(120 ,291 3#(2-01 ,#2'$ 3#(2"-++(22$$-%2'$0$&(120 ,291!- 0#-%#(0$"2-01-0.$01-,1
.$0%-0+(,&2'$$/3(4 *$,2%3,"2(-,1
 	**1(&,(%(" ,2#$%("($,"($1 ,#+ 2$0( *5$ ),$11$1(,2'$#$1(&,-0-.$0 2(-,-%(,2$0, *"-,20-*-4$0%(, ,"( *
0$.-02(,&5'("' 0$0$ 1-, !*7*()$*72- #4$01$*7 %%$"22'$0$&(120 ,291 !(*(272-0$"-0#.0-"$1113++ 0(8$ ,#
0$.-02%(, ,"( *(,%-0+ 2(-, ,#
! 	,7%0 3#5'$2'$0-0,-2+ 2$0( *2' 2(,4-*4$1+ , &$+$,2-0-2'$0$+.*-7$$15'-' 4$ 1(&,(%(" ,20-*$(,2'$
0$&(120 ,291(,2$0, *"-,20-*-4$0%(, ,"( *0$.-02(,&
 2$ $!03 07 	  	7 	1 22'$5"0$5
 +$  22'$5"0$5
(2*$ 	6$"32(4$("$0$1(#$,2 ,#'($%(, ,"( *%%("$0

-- 150 of 162 --

$!" "#
  
  
  
     
"*/&3-"*3$&35*':16346"/550 !&$5*0/ 	"4"%015&%16346"/550&$5*0/0'5)&"3#"/&49-&:$5
0'  5)"550.:,/08-&%(&"/")&303103"5*0/;4//6"-&10350/03. '035)&'*4$"-:&"3&/%&%&$&.#&3 	
 '6--:$0.1-*&48*5)5)&3&26*3&.&/540'&$5*0/ 	"03 	%0'5)&&$63*5*&49$)"/(&$50'  	"/%5)"5
*/'03."5*0/$0/5"*/&%*/46$)//6"-&10350/03. '"*3-:13&4&/54*/"--."5&3*"-3&41&$545)&'*/"/$*"-$0/%*5*0/"/%
3&46-540'01&3"5*0/40'"/")&303103"5*0/

"5& &#36"3: 	  	: 	4"*/&3-"*3
".& "*/&3-"*3
*5-& 	3&4*%&/5"/%)*&'9&$65*7&''*$&3
)*4$&35*'*$"5*0/"$$0.1"/*&45)&//6"-&10350/03. 16346"/550&$5*0/0'5)&"3#"/&49-&:$50'  
"/%4)"--/05#&%&&.&%'*-&%'03163104&40'&$5*0/ 0'5)&9$)"/(&$50305)&38*4&46#+&$5505)&-*"#*-*5:0'5)"5
4&$5*0/ )*4$&35*'*$"5*0/4)"--/05#&%&&.&%50#&*/$03103"5&%#:3&'&3&/$&*/50"/:'*-*/(6/%&35)&&$63*5*&4$5035)&
9$)"/(&$5&9$&15505)&&95&/55)"5"/")&303103"5*0/41&$*'*$"--:*/$03103"5&4*5#:3&'&3&/$&

-- 151 of 162 --

# !!"
    
  
  
     
$77+(:&5(:&(57,)<38568$1772 "  (&7,21 	$6$'237('38568$1772 (&7,212)7+( $5%$1(6;/(<
&72)  7+$7720<.12:/('*($1$+(525325$7,21=6118$/(325721250 )257+(),6&$/<($5(1'('
(&(0%(5 	  )8//<&203/,(6:,7+7+(5(48,5(0(1762) (&7,21 	$25 	'2)7+( (&85,7,(6;&+$1*(&72)  	$1'
7+$7,1)250$7,21&217$,1(',168&+118$/(325721250 )$,5/<35(6(176,1$//0$7(5,$/5(63(&767+(),1$1&,$/&21',7,21
$1'5(68/762)23(5$7,2162)$1$+(525325$7,21

$7( (%58$5< 	  	< 	6$77+(:&5(:
$0( $77+(:&5(:
!,7/( 	;(&87,9(#,&(5(6,'(17$1'+,(),1$1&,$/)),&(5
!+,6&(57,),&$7,21$&&203$1,(67+(118$/(325721250 38568$1772 (&7,212)7+( $5%$1(6;/(<&72)  
$1'6+$//127%('((0('),/(')25385326(62) (&7,21 2)7+(;&+$1*(&72527+(5:,6(68%-(&7727+(/,$%,/,7<2)7+$7
6(&7,21!+,6&(57,),&$7,216+$//127%('((0('72%(,1&25325$7('%<5()(5(1&(,172$1<),/,1*81'(57+( (&85,7,(6&7257+(
;&+$1*(&7(;&(37727+((;7(177+$7$1$+(525325$7,2163(&,),&$//<,1&25325$7(6,7%<5()(5(1&(

-- 152 of 162 --

Supplemental Reconciliation
of Non-GAAP Financial
Information to Corresponding
Financial Information
Presented in Accordance
with GAAP

-- 153 of 162 --

YEAR-OVER-YEAR CORE OPERATING MARGIN CHANGES
CORE REVENUE GROWTH BY SEGMENT
Life Sciences 	Diagnostics 	EAS 	Total Danaher
Total sales growth (decline) (GAAP) 	52.0% 	13.0% 	(2.0%) 	24.5%
Impact of:
Acquisitions/divestitures
Currency exchange rates
(46.5%)
–%
–%
0.5%
–%
0.5%
(18.0%)
–%
Core sales growth (decline) (Non-GAAP) 	5.5% 	13.5% 	(1.5%) 	6.5%
Impact of Cytiva sales growth
(net of divested product lines) 7.5% 	3.0%
Core sales growth including Cytiva (Non-GAAP) 	13.0% 	9.5%
% Change Year Ended 12/31/20 vs. Comparable 2019 Period
Total Danaher
Year Ended December 31, 2019 Operating Profit Margins from Continuing Operations (GAAP) 	18.30%
Full year 2020 impact from operating profit margins of businesses that have been owned for less
than one year or were disposed of during such period and did not qualify as discontinued operations 1.25
Full year 2020 acquisition-related fair value adjustments to inventory and deferred revenue, transaction
costs deemed significant and integration preparation costs, net of full year 2019 transaction costs
deemed significant and integration preparation costs, in each case related to the acquisition of Cytiva
(2.15)
Third quarter 2020 impairment charges related to trade names in the Environmental & Applied
Solutions segment (0.05)
First quarter 2020 impairment charges related to a facility in the Diagnostics segment and a trade
name and other intangible assets in the Environmental & Applied Solutions segment (0.05)
Year-over-year core operating profit margin changes for full year 2020 (defined as all year-over-year
operating profit margin changes other than the changes identified in the line items above)
(Non-GAAP)
1.70
Year Ended December 31, 2020 Operating Profit Margins from Continuing Operations (GAAP) 	19.00%
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
CYTIVA SALES
($ in billions) 	Year Ended 12/31/20
Cytiva April 1, 2020 to December 31, 2020
(subsequent to acquisition by Danaher Corporation) (GAAP) $>3.2
GE Biopharma Business January 1, 2020 to March 31, 2020
(prior to acquisition by Danaher Corporation) (GAAP) ~0.8
Cytiva January 1, 2020 to December 31, 2020 (Non-GAAP) 	$ >4.0

-- 154 of 162 --

Note: Management defines “Adjusted EBITDA” as GAAP operating income excluding (1) depreciation, (2) amortization, and (3) other adjustments, and defines “Adjusted EBITDA
Margin” as Adjusted EBITDA divided by sales.
($ in millions) 	Life Sciences 	Diagnostics 	EAS 	Other 	Total Danaher
Net Earnings from Continuing
Operations (GAAP) $3,646
Interest, net 	204
Other Nonoperating (Income) Expense 	(468)
Income Taxes 	849
Operating Profit (GAAP) 	$2,054 	$1,538 	$979 	$(340) 	$4,231
Operating Profit Adjustments 	509 	5 	17 	59 	590
Depreciation 	183 	397 	47 	10 	637
Amortization 	870 	205 	63 	– 	1,138
Adjusted EBITDA (Non-GAAP) 	$3,616 	$2,145 	$1,106 	$(271) 	$6,596
Interest, net 	(204)
Other Nonoperating (Income) Expense 	468
Income Taxes 	(849)
Operating Profit Adjustments 	(590)
Depreciation 	(637)
Amortization 	(1,138)
Net Income from Continuing
Operations (GAAP) $3,646
Net Sales 	$10,576 	$7,403 	$4,305 	$22,284
Adjusted EBITDA Margin (Non-GAAP) 	34.2% 	29.0% 	25.7% 	29.6%
ADJUSTED EBITDA MARGIN 	Year Ended 12/31/20

-- 155 of 162 --

1 Each of the per share adjustment amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of
common stock.
A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization
line item above):
Year Ended 12/31/20 	Year Ended 12/31/19
Pretax 	$1,138 	$625
After-tax 	915 	504
B Pretax costs incurred for fair value adjustments to inventory and deferred revenue, transaction costs deemed significant and integration preparation costs related to the
acquisition of Cytiva for the year ended December 31, 2020, ($568 million pretax as reported in this line item, $450 million after-tax) and pretax costs incurred for transaction
costs deemed significant and integration preparation costs related to the acquisition of Cytiva in the year ended December 31, 2019, ($93 million pretax as reported in this line
item, $84 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger
acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
C Loss on early extinguishment of debt resulting from “make-whole” payments associated with the retirement of the 2022 Euronotes ($26 million pretax as reported in this line
item, $20 million after-tax) in the year ended December 31, 2020 and the 2020 U.S. Notes and the 2020 Assumed Pall Notes ($7 million pretax as reported in this line item, $5
million after-tax) in the year ended December 31, 2019.
D Loss on partial settlement of a defined benefit plan resulting from the transfer of a portion of Danaher’s non-U.S. pension liabilities to a third party ($7 million pretax as reported
in this line item, $6 million after-tax) in the year ended December 31, 2019.
E Pretax impairment charges related to a facility in the Diagnostics segment, trade name and other intangible assets in the Environmental & Applied Solutions segment in the
first quarter of 2020 ($8 million pretax as reported in this line item, $6 million after-tax) and trade names in the Environmental & Applied Solutions segment in the third quarter
of 2020 ($14 million pretax as reported in this line item, $11 million after-tax).
F Pretax fair value (gains) and losses on the Company’s equity and limited partnership investments recorded in the year ended December 31, 2020 ($18 million pretax as reported in this line
item, $14 million after-tax).
G Pretax gain on the sale of certain product lines in the Life Sciences segment in the year ended December 31, 2020 ($455 million pretax as reported in this line item, $305 million after-tax).
H This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount
of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated effective tax rate to the pretax amount, unless the
nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is
estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact
of the MCPS dividends.
ADJUSTED DILUTED NET EARNINGS PER COMMON SHARE
FROM CONTINUING OPERATIONS 1
Year Ended 12/31/20 	Year Ended 12/31/19
Diluted Net Earnings Per Common Share from Continuing Operations (GAAP) 	$4.89 	$3.26
Pretax amortization of acquisition-related intangible assets A 	1.55 	0.85
Pretax acquisition-related fair value adjustments to inventory and deferred revenue,
incremental transaction costs deemed significant and integration preparation costs,
in each case related to the acquisition of Cytiva B
0.77 	0.13
Loss on early extinguishment of debt C 	0.04 	0.01
Loss on partial settlement of a defined benefit plan D 	– 	0.01
Pretax impairment charges related to a facility in the Diagnostics segment in the
first quarter of 2020, trade name and other intangible assets in the Environmental
& Applied Solutions segment in the first quarter of 2020 and trade names in the
Environmental & Applied Solutions segment in the third quarter of 2020 E
0.03 	–
Pretax fair value (gains) and losses on the Company’s equity and limited
partnership investments F 	(0.02) 	–
Gain on the sale of certain product lines in the Life Sciences segment in the
second quarter of 2020 G 	(0.62) 	–
Tax effect of all adjustments reflected above H 	(0.27) 	(0.17)
Discrete tax adjustments and other tax-related adjustments I 	(0.12) 	0.29
Declared dividends on the MCPS assuming “if-converted” method J 	0.06 	0.04
Adjusted Diluted Net Earnings Per Common Share from Continuing
Operations (Non-GAAP) $6.31 	$4.42

-- 156 of 162 --

I Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2020, include the impact of net discrete tax gains of $85 million (or $0.12 per diluted
common share), primarily related to the release of reserves for uncertain tax positions from audit settlements and expiration of statutes of limitation and excess tax benefits
from stock-based compensation, partially offset by a higher tax rate associated with the gain on the divestiture of certain product lines in the Life Sciences segment and changes
in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2019 include the
impact of net discrete tax charges of $215 million (or $0.29 per diluted common share). The discrete tax matters for the year ended December 31, 2019 relate primarily to changes
in estimates associated with prior period uncertain tax positions and audit settlements, net of the release of valuation allowances associated with certain foreign tax credits and
tax benefits resulting from a change in law. The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes
benefits in excess of this amount in the calculation of adjusted diluted net earnings per common share from continuing operations.
J In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS. In May 2020, the Company issued $1.72 billion in aggregate liquidation
preference of 5.0% MCPS. Dividends on the 4.75% and 5.0% MCPS are payable on a cumulative basis at an annual rate of 4.75% and 5.0%, respectively, on the liquidation
preference of $1,000 per share. Unless earlier converted, each share of 4.75% MCPS will automatically convert on April 15, 2022 into between 6.6563 and 8.1538 shares of
Danaher’s common stock, subject to further anti-dilution adjustments. Unless earlier converted, each share of 5.0% MCPS will automatically convert on April 15, 2023 into between
5.0081 and 6.1349 shares of Danaher’s common stock, subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable on conversion of the
MCPS will be determined based on the VWAP per share of the Company’s common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled
trading day immediately before April 15, 2022 and April 15, 2023 for the 4.75% and 5.0% MCPS, respectively. For the purposes of calculating adjusted earnings per share, the
Company has excluded the paid and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed
outstanding applying the “if-converted” method of calculating share dilution are referred to as the “Converted Shares”.)
FREE CASH FLOW FROM CONTINUING OPERATIONS
($ in millions) 	Year Ended 12/31/20 	Year Ended 12/31/19
Cash Flows from (used in) Continuing Operations:
Operating Cash Flows from Continuing Operations (GAAP) 	$6,215 	$3,657
Investing Cash Flows used in Continuing Operations (GAAP) 	$(21,239) 	$(1,166)
Financing Cash Flows from Continuing Operations (GAAP) 	$1,006 	$16,589
Free Cash Flow from Continuing Operations:
Operating Cash Flows from Continuing Operations (GAAP) 	$6,215 	$3,657
Less: payments for property, plant and equipment
(capital expenditures) from continuing operations (GAAP) 	(791) 	(636)
Plus: proceeds from sales of property, plant and equipment
(capital disposals) from continuing operations (GAAP) 2 	13
Free Cash Flow from Continuing Operations (Non-GAAP) 	$5,426 	$3,034
RATIO OF FREE CASH FLOW TO NET EARNINGS
($ in millions) 	Year Ended 12/31/20 	Year Ended 12/31/19
Free Cash Flow from Continuing Operations from Above (Non-GAAP) 	$5,426 	$3,034
Net Earnings from Continuing Operations (GAAP) 	$3,646 	$2,432
Free Cash Flow from Continuing Operations to Net Earnings
from Continuing Operations Conversion Ratio (Non-GAAP) 1.49 	1.25
We define free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital
expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).
1 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average
20 trading-day trailing volume weighted average price (“VWAP”) of $223.43 and $150.10 as of December 31, 2020 and December 31, 2019, respectively, for the years then ended.
ADJUSTED AVERAGE COMMON STOCK AND COMMON EQUIVALENT
DILUTED SHARES OUTSTANDING
(shares in millions) 	Year Ended 12/31/20 	Year Ended 12/31/19
Average common stock and common equivalent shares outstanding – diluted (GAAP) 	725.5
Converted shares 1 	17.1 	9.7
Adjusted average common stock and common equivalent shares outstanding –
diluted (Non-GAAP) 735.2
718.7
735.8

-- 157 of 162 --

AMONG DANAHER CORPORATION, S&P 500 INDEX, S&P 500 INDUSTRIALS INDEX
AND S&P 500 HEALTH CARE INDEX
The following graph compares the yearly percentage change in the cumulative total shareholder return in Danaher
common stock during the five years ended December 31, 2020 with the cumulative total return of the S&P 500 Index
(the equity index), the S&P 500 Industrials Index and the S&P 500 Health Care Index (the peer indices). The comparison
assumes $1.00 was invested on December 31, 2015 in Danaher common stock and in each of the above indices with
reinvestment of dividends. The graph is not deemed to be “soliciting material” or to be “filed” with the SEC or subject
to the SEC’s proxy rules or to the liabilities of Section 18 of the Securities Exchange Act of 1934, except to the extent
that Danaher specifically requests that such information be treated as soliciting material or specifically incorporates it by
reference into a filing under the Securities Act or the Securities Exchange Act.
Danaher
Corporation
S&P 500
(Equity Index)
S&P 500
Industrials Index
(Peer Index)
S&P 500
Health Care Index
(Peer Index)
12/31/15 	1.00 	1.00 	1.00 	1.00
12/31/16 	1.11 	1.12 	1.19 	.97
12/31/17 	1.34 	1.36 	1.44 	1.19
12/31/18 	1.49 	1.30 	1.25 	1.26
12/31/19 	2.23 	1.71 	1.61 	1.53
12/31/20 	3.25 	2.03 	1.79 	1.73
COMPARISON OF 5-YEAR CUMULATIVE
TOTAL SHAREHOLDER RETURN
Danaher Corporation
S&P 500 (Equity Index)
S&P 500 Industrials Index (Peer Index)
S&P 500 Health Care Index (Peer Index)
12/31/2015 	12/31/2016 	12/31/2017 	12/31/2018 	12/31/2019 	12/31/2020
1.00
1.40
1.80
2.20
2.60
3.00
3.40

-- 158 of 162 --

EXECUTIVE OFFICERS
STEVEN M. RALES
Chairman of the Board
MITCHELL P. RALES
Chairman of the
Executive Committee
RAINER M. BLAIR
President and
Chief Executive Officer
MATTHEW R. McGREW
Executive Vice President
and Chief Financial Officer
JENNIFER L. HONEYCUTT
Executive Vice President
JOAKIM WEIDEMANIS
Executive Vice President
BRIAN W. ELLIS
Senior Vice President
General Counsel
JOSE-CARLOS
GUTIERREZ-RAMOS
Senior Vice President
Chief Scientific Officer
WILLIAM H. KING
Senior Vice President
Strategic Development
ANGELA S. LALOR
Senior Vice President
Human Resources
ROBERT S. LUTZ
Senior Vice President
Chief Accounting Officer
DANIEL A. RASKAS
Senior Vice President
Corporate Development
DIRECTORS
RAINER M. BLAIR
President and
Chief Executive Officer
Danaher Corporation
LINDA HEFNER FILLER
Former President of
Retail Products and
Chief Merchandising Officer
Walgreen Co.
TERI LIST
Former Executive Vice President
and Chief Financial Officer
Gap Inc.
WALTER G. LOHR, JR.
Retired Partner
Hogan Lovells
JESSICA L. MEGA,
M.D., MPH
Chief Medical and
Scientific Officer
Verily Life Sciences LLC
MITCHELL P. RALES
Chairman of the
Executive Committee
Danaher Corporation
STEVEN M. RALES
Chairman of the Board
Danaher Corporation
PARDIS C. SABETI,
M.D., D.PHIL
Investigator
Howard Hughes Medical Institute
JOHN T. SCHWIETERS
Principal
Perseus TDC
ALAN G. SPOON
Former Managing General Partner
Polaris Partners
RAYMOND C. STEVENS,
PH.D.
Provost Professor of Biological
Sciences and Chemistry
Director of The Bridge Institute
The University of Southern California;
Chief Executive Officer, ShouTi
ELIAS A. ZERHOUNI, M.D.
Former President
Global Research and Development
Sanofi S.A.

-- 159 of 162 --

OUR TRANSFER AGENT
Computershare can help you with a variety of shareholder-related services, including
change of address, lost stock certificates, transfer of stock to another person and
additional administrative services. Computershare can be reached at:
P.O. Box 30170, College Station, TX 77842-3170
Toll-free: 800.568.3476 | Outside the U.S.: +1.312.588.4991 | www.computershare.com
INVESTOR RELATIONS
This annual report, along with a variety of other financial materials, can be viewed at
www.danaher.com. Additional inquiries can be directed to Danaher Investor Relations:
2200 Pennsylvania Avenue, NW, Suite 800W, Washington, DC 20037
Phone: 202.828.0850 | Fax: 202.828.0860 | E-mail: investor.relations@danaher.com
AUDITORS
Ernst & Young LLP, Tysons, Virginia
STOCK LISTING
New York Stock Exchange Symbol: DHR

-- 160 of 162 --



-- 161 of 162 --



-- 162 of 162 --